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 3 Abstract 
ABSTRACT 
In this Thesis several aspects related to the physiological effect of bioactive 
peptides on the digestive tract have been studied by a double approach. It has been 
investigated not only the modifications that food proteins and peptides undergo during 
the gastrointestinal digestion, but also the mechanisms of action involved in the 
biological function that bioactive peptides might exert due to their contact with digestive 
cells and receptors. Peptide lunasin, casein and whey proteins, and milk peptides were 
analyzed.  
Initially, the behavior of peptide lunasin under digestive conditions simulating 
the transit through the gastrointestinal tract in the absence or presence of soybean 
Bowman-Birk isoinhibitor 1 (IBB1), in both active and inactive states, was evaluated. 
IBB1 isoinhibitor exerted a protective effect on lunasin degradation during digestion. 
Protection against the action of pepsin was due to the presence of IBB1 and its higher 
size in comparison with that of peptide lunasin, independently of activity. However, an 
IBB1 dose-dependent protective effect was found at intestinal level, related to its 
inhibitory activity of pancreatic enzymes trypsin and chymotrypsin. The peptide profiles 
of gastric and gastrointestinal digests were characterized. It was demonstrated the 
notable resistance during the digestive process of some domains of peptide lunasin, 
especially regions 1SKWQHQQDSC10, 11RKQLQGVN18, 19LTPCEKHIME28 and 
29KIQGRGDDDDDDDDD43. The transepithelial transport of these four fragments and 
the precursor lunasin was evaluated using Caco-2 cell monolayers. While some 
regions of these peptides were susceptible to epithelial brush-border peptidases, a 
marked resistance was found for others, particularly for fragments 1SKWQHQQDSC10 
and 29KIQGRGDDDDDDDDD43. The transepithelial transport of lunasin and fragment 
11RKQLQGVN18 was mediated through diffusion via the paracellular pathway. 
Additionally, lunasin, as well as its gastrointestinal digests in presence/absence of 
IBB1, and some lunasin-derived fragments identified in these digests were evaluated 
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for their effect against the viability of gastric cancer AGS and colorectal cancer HT-29 
and Caco-2 cells. It is highlighted that the fragment 1SKWQHQQDSC10 was the main 
responsible for the demonstrated inhibitory effect of lunasin on cellular viability, 
particularly in HT-29 cells. The chemopreventive mechanisms of action of lunasin 
against the proliferation of bulk colorectal cancer HCT-116 cells and the expansion of 
their tumorsphere-derived cancer stem-like subpopulation were evaluated. Peptide 
lunasin inhibited the viability of bulk tumor cells, as well as the tumorsphere-forming 
capacity of HCT-116 cells. The inhibitory activity was mediated by inducing apoptosis 
and arresting cell cycle at G1 phase. These effects were associated to a stimulatory 
effect on molecular marker caspase-3 linked to a cleavage on PARP signal, and a 
modest activation of p21 protein expression. Upon chemical-induced oxidative stress, 
lunasin-treated liver HepG2 cells showed an increased cellular viability. This protective 
effect was mediated through raising intracellular glutathione levels, and decreasing 
oxygen reactive species production and glutathione peroxidase and catalase activities. 
In addition, lunasin protected proteins from oxidative damage and inhibited caspase-3 
mediated apoptosis. 
In the context of gastrointestinal mucus strengthening by food protein 
compounds, novel peptides derived from αs1-casein 
144YFYPEL149 and 144YFYPEL148 
and, to a lower extent, 144YFY146 and 143AYFYPEL149 were found, for the first time, to 
exert an opioid agonist activity. By molecular dynamics simulations of peptides binding 
with the µ-opioid receptor, it was proved that the carboxi-terminal proline residue from 
peptide 144YFYP147 affected to its interaction with opioid receptor and activity. On 
intestinal goblet cells, it was demonstrated that peptide 144YFYPEL149 was the minimum 
fragment able to stimulate expression of MUC5AC, the main secreted mucin gene in 
HT29-MTX cells. Later on, the protective effect of a peptic casein hydrolyzate 
containing these opioid peptides was studied in the rat intestinal mucus layer. This 
hydrolyzate stimulated the gene expression of mucins Muc2 and Muc3 in ileum and 
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colon, and the fecal mucin secretion after its oral administration during two and eight 
weeks, enhancing in vivo the intestinal mucus barrier.  
Finally, protein degradation and peptide formation in digests obtained after in 
vivo/in vitro gastrointestinal digestion of casein and whey protein were analyzed. With 
this purpose, the peptide profile of jejunal digests of 5 human volunteers was 
characterized and compared with peptides generated during in vitro gastrointestinal 
digestion of milk proteins following a standardized and internationally harmonized static 
digestion protocol. Whereas protein degradation through the gastrointestinal tract was 
observed, some protein domains showed resistance against the action of digestive 
enzymes. In vivo and in vitro protein degradation and digests peptidome were similar. 
Spearman correlation coefficients between in vivo and in vitro digests were within the 
range of that obtained between the different human volunteers of the study. Therefore, 
this in vitro method represented a suitable model to physiologically simulate the 
gastrointestinal digestion, at least in the case of milk proteins. 
Altogether, these results demonstrated the key role that digestive tract can play 
on the bioactivity of ingested compounds. Moreover, the results have allowed 
increasing the knowledge on the mechanisms of action involved in the beneficial 
effects of peptide lunasin, milk proteins, and derived peptides on digestive health.  
 
 
7 Resumen 
RESUMEN 
En la presente Tesis Doctoral se ha llevado a cabo el estudio de varios 
aspectos relacionados con el efecto fisiológico de los péptidos bioactivos sobre el 
tracto digestivo con un doble enfoque. Por un lado, se han estudiado las 
modificaciones que sufren las proteínas alimentarias durante la digestión 
gastrointestinal y, por otro, se han evaluado los mecanismos de acción implicados en 
la funcionalidad biológica que los péptidos bioactivos pueden ejercer en contacto con 
las células y los receptores del tracto digestivo. Como sustratos se estudiaron el 
péptido lunasina, las caseínas y proteínas de suero y distintos péptidos lácteos.  
Inicialmente, se estudió el comportamiento del péptido lunasina en condiciones 
de digestión que simulan el tránsito a través del tracto gastrointestinal, en ausencia o 
presencia de la isoforma 1 del inhibidor de proteasas Bowman-Birk (IBB1) derivado de 
la soja, tanto en su estado activo como inactivo. El isoinhibidor ejerció un efecto 
protector frente a la degradación del péptido lunasina durante la digestión. La 
presencia del IBB1 y su mayor tamaño con respecto al péptido lunasina, 
independientemente de su actividad, fueron responsables del efecto protector ejercido 
a nivel gástrico. Sin embargo, a nivel intestinal, la protección fue dependiente de la 
dosis de IBB1, relacionado con su actividad inhibitoria de las enzimas pancreáticas 
tripsina y quimiotripsina. Se caracterizó el perfil peptídico de los digeridos gástricos y 
gastrointestinales y se identificaron ciertos dominios del péptido lunasina con marcada 
resistencia durante el proceso digestivo, concretamente las regiones 
1SKWQHQQDSC10, 11RKQLQGVN18, 19LTPCEKHIME28 y 29KIQGRGDDDDDDDDD43. 
Asimismo, se evaluó el transporte transepitelial del péptido lunasina y de los cuatro 
fragmentos mencionados, empleando el modelo de células Caco-2 en monocapa. 
Aunque algunas regiones de estos péptidos fueron susceptibles a la acción de las 
enzimas del epitelio intestinal, se encontró una notable resistencia en otras zonas, 
especialmente los fragmentos 1SKWQHQQDSC10 y 29KIQGRGDDDDDDDDD43. El 
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transporte del péptido lunasina y del fragmento 11RKQLQGVN18 a través de la 
monocapa celular estuvo mediado por un mecanismo de difusión por la vía 
paracelular. Paralelamente, se ensayó el efecto del péptido lunasina, de los digeridos 
gastrointestinales obtenidos a partir de las mezclas con/sin IBB1 y de algunos de los 
fragmentos identificados en dichos digeridos sobre la viabilidad de células de cáncer 
gástrico AGS y colorrectal HT-29 y Caco-2. Se pudo concluir que el fragmento 
1SKWQHQQDSC10 es el principal responsable de la actividad inhibitoria del péptido 
lunasina sobre la viabilidad celular, especialmente en células HT-29. Se profundizó en 
los mecanismos de actividad quimiopreventiva del péptido lunasina frente a la 
proliferación de células nativas de cáncer colorrectal HCT-116 y la expansión de su 
subpoblación de células madre tumorales. El péptido lunasina inhibió la viabilidad de 
las células nativas tumorales así como la capacidad de formación de esferas 
tumorales de las células madre. La actividad inhibitoria estuvo mediada por un efecto 
inductor de la apoptosis celular y un bloqueo del progreso del ciclo celular en la fase 
G1. Estos eventos se asociaron a un aumento en la expresión proteica del 
biomarcador caspasa-3, con la consiguiente disminución de la señal PARP, y un 
moderado incremento de la expresión de la proteína p21. Frente al estrés oxidativo 
inducido químicamente en células hepáticas HepG2, las células tratadas con el 
péptido lunasina mostraron un incremento en la viabilidad. Este efecto estuvo mediado 
por un aumento del contenido intracelular de glutatión, una disminución en la 
generación de especies reactivas de oxígeno y de la actividad de las enzimas glutatión 
peroxidasa y catalasa, así como una recuperación frente al daño oxidativo a proteínas 
provocado por el agente químico y un bloqueo de la activación pro-apoptótica por 
caspasa-3. 
En el contexto del fortalecimiento del mucus gastrointestinal mediante 
compuestos alimentarios de naturaleza proteica, se describió por primera vez la 
actividad agonista opioide de los péptidos lácteos derivados de la αs1-caseína 
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144YFYPEL149 e 144YFYPE148 y, aunque con menor potencia, de los péptidos 144YFY146 y 
143AYFYPEL149. Mediante una modelización de la interacción molecular entre los 
péptidos y el receptor opioide tipo µ, se observó que la presencia de prolina en el 
extremo carboxi-terminal del péptido 144YFYP147 influía negativamente en su 
interacción con el receptor y actividad opioide. Adicionalmente, se demostró que el 
péptido 144YFYPEL149 constituye la mínima secuencia con capacidad estimulante de la 
expresión del gen MUC5AC, que codifica para la principal mucina en las células 
caliciformes intestinales HT29-MTX. Posteriormente, se estudió el efecto protector de 
un hidrolizado de caseínas con pepsina que contiene estos péptidos lácteos opioides, 
sobre la barrera mucosa del intestino de ratas. El hidrolizado aumentó la expresión 
génica de las mucinas Muc2 y Muc3 en íleon y colon, así como la secreción fecal de 
mucinas tras dos y ocho semanas de tratamiento, fortaleciendo in vivo la capa mucosa 
intestinal.  
Finalmente, se comparó la degradación proteica y el proteoma obtenido tras la 
digestión gastrointestinal in vivo/in vitro de caseínas y proteínas de suero lácteo. Para 
ello, se caracterizó el perfil peptídico de los digeridos obtenidos a partir del yeyuno 
humano en 5 voluntarios y se comparó con los péptidos liberados a partir de las 
proteínas lácteas tras ser sometidas a un protocolo estático de simulación de la 
digestión gastrointestinal recientemente consensuado a nivel internacional. Se puso de 
manifiesto la degradación que sufren las proteínas a su paso por el tracto 
gastrointestinal, mientras que algunos dominios mostraron resistencia al proceso 
digestivo. La degradación proteica y el peptidoma de los digeridos obtenidos in vivo e 
in vitro fueron similares entre ambas digestiones. Tras la comparación, los coeficientes 
de correlación de Spearman entre los digeridos in vivo e in vitro fueron del mismo 
orden a los encontrados al evaluar la variabilidad inter-individual entre los voluntarios 
del estudio. Por ello, el método empleado de simulación de la digestión gastrointestinal 
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in vitro, supuso una buena aproximación a la situación fisiológica, al menos en el caso 
de la digestión de las proteínas lácteas.  
En conclusión, se ha demostrado el papel determinante que desempeña el 
tracto digestivo sobre los compuestos bioactivos ingeridos y se ha avanzado en el 
conocimiento de los mecanismos involucrados en los efectos beneficiosos del péptido 
lunasina, de proteínas lácteas y de péptidos derivados sobre la salud digestiva.  
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LISTA DE ABREVIATURAS 
α-La: α-lactoalbúmina 
β-Lg: β-lactoglobulina  
BBI: inhibidor de proteasas Bowman-Birk 
BBIC: concentrado de inhibidor de proteasas Bowman-Birk 
CAT: catalasa 
CM: casomorfina 
CMP: caseinomacropéptido 
CN: caseína 
CPPs: caseinofosfopéptidos 
ECA: enzima convertidora de angiotensina 
EFSA: Agencia Europea de Seguridad Alimentaria 
FDA: Agencia Estadounidense de Alimentos y Medicamentos 
GPx: glutatión peroxidasa 
GSH: glutatión reducido 
H2O2: peróxido de hidrógeno 
HPLC-MS/MS: cromatografía de líquidos de alta eficacia acoplada a espectrometría de 
masas en tándem 
IBB1: isoinhibidor-1 de Bowman-Birk 
KTI: inhibidor de tripsina Kunitz 
LF: lactoferrina 
LPS: lipopolisacárido 
Mucn: gen correspondiente a la mucina de rata número “n” 
MUCn: gen correspondiente a la mucina humana número “n” 
qRT-PCR: reacción en cadena de la polimerasa cuantitativa con transcriptasa inversa 
ROS: especies reactivas de oxígeno 
SDS-PAGE: electroforesis en gel de poliacrilamida 
SOD: superóxido dismutasa 
t-BOOH: tert-butil hidroperóxido 
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15 Objetivos y plan de trabajo 
El tracto digestivo constituye la mayor superficie de intercambio entre el medio 
externo y el organismo. Se encuentra continuamente en contacto con los digeridos de 
los alimentos y con numerosos compuestos que pueden provocar desequilibrios 
oxidativos y alteraciones proliferativas en sus poblaciones celulares. Además, expresa 
una gran cantidad de receptores, p.e. receptores opioides, y desempeña un papel 
decisivo en las modificaciones de los componentes ingeridos. Por tanto, el tracto 
digestivo es considerado como una de las principales dianas de los compuestos con 
actividad biológica y es determinante en su posible relevancia fisiológica. 
Durante la digestión gastrointestinal se producen una gran cantidad de péptidos 
por hidrólisis de las proteínas alimentarias, los cuáles podrían desempeñar distintos 
efectos regulatorios sobre las funciones digestivas. Así, en el estudio de los efectos 
biológicos de los péptidos alimentarios, resulta esencial conocer cómo se digieren las 
proteínas alimentarias, identificar la forma activa en el organismo y evaluar los 
mecanismos de acción implicados en dichos efectos. Esta información es fundamental 
para establecer la relación entre el compuesto y la funcionalidad biológica. De este 
modo, estos estudios se presentan como una interesante estrategia para la mejora de 
la salud digestiva y la prevención de las enfermedades relacionadas. 
Objetivo general 
El principal objetivo de esta Tesis Doctoral es la “evaluación de los procesos 
relacionados con la digestión y la biodisponibilidad de diferentes péptidos de origen 
alimentario implicados en la salud digestiva, así como el estudio de sus propiedades 
beneficiosas, a través de su efecto opioide y modulador de la expresión de mucinas 
intestinales, y de su capacidad protectora frente a procesos de estrés oxidativo y de 
proliferación celular anormal”. Para cumplir este objetivo se plantearon los siguientes 
objetivos parciales y se diseñó el siguiente plan de trabajo: 
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Objetivo 1 
Estudio del comportamiento del péptido lunasina frente a la simulación in vitro de la 
digestión y la absorción gastrointestinal. Efectos sobre la viabilidad de células 
tumorales del tracto digestivo. 
1.1. Evaluación del efecto protector del isoinhibidor-1 de Bowman-Birk (IBB1) 
en la digestión in vitro del péptido lunasina. Estudio de la actividad de los 
digeridos gastrointestinales sobre la viabilidad de células de cáncer colorrectal. 
 
1.2. Evaluación del transporte transepitelial del péptido lunasina y de péptidos 
liberados a partir de su digestión gastrointestinal. Estudio de la actividad de los 
péptidos sobre la viabilidad de células de cáncer gástrico y colorrectal. 
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Objetivo 2 
Estudio de los mecanismos celulares protectores del péptido lunasina responsables de 
su actividad quimiopreventiva. 
2.1. Efecto del péptido lunasina sobre la proliferación de células de cáncer 
colorrectal. Evaluación de los mecanismos preventivos en células nativas y 
células madre tumorales.   
 
2.2. Evaluación de los mecanismos de defensa antioxidante ejercidos por el 
péptido lunasina en células hepáticas. 
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Objetivo 3 
Estudio de los mecanismos implicados en la actividad protectora de péptidos lácteos   
sobre la capa mucosa del tracto intestinal. 
3.1. Evaluación de la actividad opioide de péptidos lácteos con efecto en la 
expresión de mucinas en células caliciformes intestinales. 
 
3.2. Efecto modulador in vivo de un hidrolizado de caseínas lácteas sobre la 
producción de mucinas en el intestino de rata. 
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Objetivo 4 
Estudio comparativo de procesos de simulación in vitro de la digestión gastrointestinal 
de proteínas lácteas (caseínas y proteínas de suero) con digeridos intestinales 
obtenidos en individuos sanos.   
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Un gran número de las funciones del organismo se encuentran reguladas por 
proteínas y péptidos endógenos que pueden actuar como hormonas, 
neurotransmisores o reguladores enzimáticos. Durante la digestión gastrointestinal de 
las proteínas alimentarias se produce una amplia variedad de péptidos. Estos péptidos 
exógenos pueden ser estructuralmente similares a sus homólogos endógenos, lo que 
les permite interaccionar con los mismos receptores y, de esta forma, ejercer una 
determinada actividad biológica. El tracto digestivo se encuentra expuesto de forma 
continua y directa a los compuestos derivados de la digestión de los alimentos. 
Además, expresa en su superficie una gran diversidad de receptores, por lo que es en 
sí mismo una de las principales dianas de los compuestos bioactivos ingeridos. De 
este modo, la modulación ejercida por la dieta en las funciones fisiológicas del sistema 
digestivo ha sido reconocida como un elemento esencial para el mantenimiento 
general y la mejora de la salud (Shimizu, 2010). 
En las últimas dos décadas se han descrito varios estudios acerca de las 
múltiples actividades de los péptidos bioactivos. Sin embargo, los datos sobre la 
influencia que tiene el tracto digestivo en la relevancia fisiológica de los péptidos, así 
como los efectos biológicos ejercidos a este nivel son más reducidos. Por un lado, 
resulta necesario conocer los cambios ocurridos durante la digestión de las proteínas, 
a través del análisis, tanto de su degradación, como de la consecuente liberación de 
secuencias peptídicas. Asimismo, se debe considerar que los péptidos bioactivos 
pueden ejercer su efecto bien a través de interacciones locales con los receptores de 
la superficie gastrointestinal o bien a nivel sistémico, para lo cual deben resistir el 
proceso digestivo, atravesar la barrera intestinal y permanecer en estado activo 
durante su metabolismo y distribución hasta el órgano diana (Foltz y col., 2010). Por 
otro lado, para establecer una relación causa-efecto entre los péptidos bioactivos y la 
salud, es necesario evaluar los mecanismos de acción implicados e identificar la forma 
activa potencialmente responsable de los efectos biológicos observados.  
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Por todo ello, y en el ámbito de la funcionalidad de las proteínas alimentarias, 
se ha despertado el interés científico sobre las interacciones entre los componentes 
del sistema digestivo y los péptidos derivados de los alimentos. Estos estudios pueden 
proporcionar información muy valiosa y de relevancia fisiológica para la promoción de 
la salud digestiva y la prevención de las enfermedades crónicas asociadas. Además, 
pueden ser de utilidad para el avance en el diseño de nuevos ingredientes 
alimentarios. 
1.1. Composición proteica de la soja y la leche 
La soja presenta un contenido en proteína variable entre el 35 y el 45% 
(peso/peso). Las proteínas de almacenamiento globulinas son el componente proteico 
mayoritario (70-83%), principalmente formado por la β-conglicinina y la glicinina, 
también conocidas como globulina 7S y globulina 11S, respectivamente. Se presentan 
como proteínas poliméricas unidas mediante puentes disulfuro y uniones no 
covalentes (Hill y Breidencach, 1974). La fracción proteica de la soja, al igual que la 
presente en otras especies de leguminosas, está compuesta por una compleja mezcla 
de proteínas minoritarias y polipéptidos como lectinas, lipoxigenasas, α-amilasas, 
inhibidores de proteasas de las familias Bowman-Birk (BBI) y Kunitz (KTI), y péptidos 
bioactivos como la lunasina. Se ha descrito que la composición nutricional y proteica 
de la soja es variable en función de factores medioambientales, genéticos y de las 
condiciones de cultivo o del procesado (Zarkadas y col., 2007; Gomes y col., 2014). 
La leche tiene un contenido medio en proteína entre el 3,0 y el 3,5% 
(peso/volumen), variable según algunos factores como la especie, la alimentación o el 
estado de lactancia y/o salud del animal, entre otros (Dalgleish, 1993). Las proteínas 
lácteas se clasifican en dos grupos: caseínas y proteínas de suero. Las caseínas se 
caracterizan por precipitar en condiciones ácidas (pH 4,6 y 20 ºC), por su carácter 
anfipático y por poder estar fosforiladas en los residuos de serina. Las caseínas 
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representan un 80% del contenido proteico total y comprenden cuatro tipos de 
cadenas polipeptídicas: αs1-caseína (CN), αs2-CN, β-CN y κ-CN, en proporción 
aproximada 4:1:4:1, respectivamente. Por ejemplo, en la leche de vaca, el contenido 
en caseínas es de 29 g/L y estas proteínas se presentan en un 37,6-39,5% (αs1-CN), 
7,8-12,1% (αs2-CN), 33,4-44,6% (β-CN) y 9,5-19,7% (κ-CN) (Farrell y col., 2004). En la 
leche, las caseínas se encuentran estructuralmente en forma de micelas, formando 
complejos esféricos con sales inorgánicas, principalmente el fosfato cálcico. Además, 
pueden sufrir modificaciones por glicosilación y proteolisis, como las producidas sobre 
la β-CN por las propias enzimas presentes en la leche y que dan lugar a las 
denominadas γ-CN (Swaisgood, 1992). Las proteínas de suero lácteo permanecen 
solubles en condiciones ácidas (pH 4,6 y 20 ºC). Estas proteínas incluyen la β-
lactoglobulina (β-Lg), la α-lactoalbúmina (α-La), la seroalbúmina bovina, las 
inmunoglobulinas, y otros componentes minoritarios como lactoferrina (LF), 
lactoperoxidasa, y algunos péptidos de bajo peso molecular que provienen de la 
proteolisis de las caseínas. La β-Lg es predominante en la leche bovina, mientras que 
está ausente en la leche humana, en la que la α-La es mayoritaria. Las proteínas de 
suero tienen una estructura globular en la que predominan los motivos α-hélice. Son 
proteínas susceptibles a la desnaturalización por calentamiento, aunque disponen de 
puentes disulfuro intramoleculares que aportan estabilidad a su estructura (Madureira 
y col., 2007).  
La funcionalidad de las proteínas está influenciada por sus características 
estructurales y físico-químicas. Se ha demostrado que dichas características pueden 
ejercer un papel determinante en la digestión, biodisponibilidad y formación de 
secuencias peptídicas de relevancia fisiológica, tanto a partir de proteínas de soja 
(Carbonaro y col., 2015) como de proteínas lácteas (Dziuba y col., 2010).  
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1.2. Digestión y biodisponibilidad de proteínas de soja y lácteas  
 Las acciones ejercidas por los procesos fisiológicos del sistema digestivo han 
sido objeto de estudio en numerosas investigaciones científicas relativas a la nutrición, 
farmacología, toxicología y microbiología (Sambruy y col., 2001). Los alimentos, tras 
ser ingeridos, van a sufrir una serie de complejas modificaciones físicas y químicas 
propias de la digestión que finalmente darán lugar a la liberación y absorción de los 
nutrientes. Las proteínas alimentarias pueden comportarse de distintas maneras 
durante el proceso digestivo debido a las diferencias en sus características 
estructurales, de conformación y tamaño, o a la presencia de inhibidores de proteasas. 
Además, durante la digestión de las proteínas, se liberan una gran cantidad de 
péptidos que podrían tener implicaciones fisiológicas, actuando como señales 
regulatorias de las funciones del organismo (Sánchez-Rivera y col., 2014a), y 
toxicológicas, como la formación de epítopos con capacidad para inducir reacciones 
relacionadas con las alergias alimentarias (Jiménez-Saiz y col., 2015). Por ello, resulta 
fundamental conocer los cambios ocurridos en las proteínas alimentarias en relación a 
su degradación y a la identificación de regiones proteicas resistentes durante el 
proceso digestivo. Aunque los métodos de evaluación de la digestión in vivo, tanto en 
animales como en humanos, son los que aportan los resultados fisiológicamente más 
relevantes, por razones prácticas y éticas, ha sido necesario el desarrollo de modelos 
in vitro de simulación gastrointestinal. En los últimos años, se ha descrito una amplia 
diversidad de metodologías in vitro que difieren en cuanto a variables, como el número 
de fases de la digestión, fluidos y enzimas empleados, pH y tiempos de incubación, 
relación enzima:sustrato, adición y retirada de compuestos, mezcla del contenido y 
uso de co-factores de digestión, entre otros (Hur y col., 2011; Guerra y col., 2012). En 
este contexto, y en el ámbito de la Acción COST FA 1005 Infogest, recientemente se 
ha publicado un protocolo en el que se establecen las condiciones estándar para la 
simulación de la digestión in vitro (Minekus y col., 2014). Este método ha sido 
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aceptado mediante el consenso por parte de diferentes grupos de investigación 
internacionales, y su reproducibilidad se ha evaluado recientemente en ensayos inter-
laboratorio (Egger y col., 2016). Sin embargo, es necesario correlacionar y validar los 
resultados de estos métodos in vitro con aquellos obtenidos in vivo, para los que 
todavía existen muy pocos datos. 
 Se ha descrito que el tracto gastrointestinal juega un papel decisivo en la 
relevancia fisiológica de los compuestos bioactivos derivados de los alimentos. En el 
estudio de los péptidos bioactivos, uno de los primeros aspectos a evaluar es su 
resistencia a las enzimas digestivas. Asimismo, debe considerarse su estabilidad 
durante el tránsito digestivo, así como su capacidad de absorción, distribución, 
metabolismo y excreción (Segura-Campos y col., 2011; Sánchez-Rivera y col., 2014a). 
La presencia de péptidos bioactivos en el contenido intestinal no es suficiente si no se 
asegura su bioaccesibilidad y biodisponibilidad (Figura 1), es decir, es necesario que
 
           
Figura 1. Bioaccesibilidad y biodisponibilidad de los compuestos ingeridos (Adaptada de 
Guerra y col., 2012). 
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el péptido interaccione con receptores de la superficie gastrointestinal o, si su sitio de 
acción implica su absorción, que atraviese la barrera intestinal y alcance el órgano 
diana en su forma activa (Foltz y col., 2010; Nongonierma y FitzGerald, 2016). Por ello, 
en los últimos años, se han empleado modelos combinados de simulación in vitro de la 
digestión y absorción intestinal en monocapas de células Caco-2 (Picariello y col., 
2013a; 2015). Las células Caco-2 provienen de una línea de adenocarcinoma 
colorrectal humano. Al cultivarse en soportes adecuados y llegar a confluencia, son 
capaces de diferenciarse espontáneamente en una monocapa polarizada con 
microvellosidades, espacios intercelulares, enzimas y sistemas de transporte, 
presentando las características propias de las células epiteliales intestinales. Este 
modelo celular ha sido ampliamente utilizado para evaluar la degradación y absorción 
en el intestino de fármacos y otros compuestos administrados por vía oral (Hubatsch y 
col., 2007; Antunes y col., 2013). Además, este modelo ha permitido identificar las 
principales rutas implicadas en el transporte intestinal de proteínas y péptidos 
derivados (Segura-Campos y col. 2011), tal como se describe en la Figura 2. 
 
Figura 2. Representación esquemática de los principales mecanismos de transporte de 
péptidos a través de las células del epitelio intestinal: (1) Transporte paracelular a través 
de las uniones intercelulares, (2) Transporte transcelular mediante difusión pasiva, (3) 
Transcitosis, transporte transcelular mediante vesículas, (4) Transporte transcelular 
mediado por transportadores específicos. 
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1.2.1. Proteínas de soja. Péptido lunasina 
Los trabajos publicados sobre la digestión y/o biodisponibilidad de las proteínas 
de la soja en relación a sus efectos fisiológicos son escasos. Se ha descrito que la 
digestión in vitro de un aislado de proteínas de soja da lugar a la formación de 
péptidos antihipertensivos con capacidad inhibidora de la enzima convertidora de 
angiotensina (ECA) (Lo y Li-Chan, 2005). Siguiendo una estrategia similar, se ha 
observado como el producto de la digestión enzimática de la proteína β-conglicinina 
provoca una activación del receptor de colecistoquinina tipo-1, relacionado con la 
sensación de saciedad (Staljanssens y col., 2012). También se ha visto que la 
digestión de esta proteína, y de su forma deglicosada, genera péptidos con potencial 
efecto protector frente a radicales libres (Amigo-Benavent y col., 2014). En este trabajo 
se identificaron los péptidos presentes en los digeridos gastrointestinales, algunos de 
los cuáles fueron además biodisponibles en la monocapa intestinal de células Caco-2. 
En un trabajo reciente, Capriotti y col. (2015) han caracterizado el conjunto de péptidos 
presentes en digeridos in vitro de las proteínas extraídas de semillas y bebidas de 
soja. Estos autores observaron una intensa degradación de las proteínas durante el 
proceso digestivo, formándose un total de 2430 secuencias de tamaño variable entre 5 
y 49 aminoácidos. Además, se propuso que la longitud de algunos de los péptidos, 
generalmente más largos que aquellos encontrados en estudios similares con 
proteínas animales, se justificaba por la presencia de inhibidores de proteasas en las 
propias proteínas de origen vegetal (Capriotti y col., 2015).  
Se ha demostrado que el péptido de 43 aminoácidos lunasina, tanto de origen 
sintético como aislado de la soja, se digiere rápidamente en presencia de pepsina y 
pancreatina (Park y col., 2007). Sin embargo, en este trabajo se observó que cuando 
la lunasina se encuentra dentro del extracto proteico de la soja es capaz de resistir 
parcialmente la acción de las enzimas gastrointestinales. Estos resultados también se 
han visto en otros estudios con lunasina procedente de otras fuentes proteicas 
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vegetales, como trigo (Jeong y col., 2007a) y Solanum nigrum L. (Jeong y col., 2007b). 
Por ello, se ha sugerido que los inhibidores de proteasas presentes de forma natural 
en estos productos, como BBI y KTI, pueden ejercer un efecto protector sobre la 
digestión enzimática del péptido lunasina. En este sentido, se ha determinado la 
presencia de los péptidos lunasina y BBI en varios productos comerciales de soja 
(Hernández-Ledesma y col., 2009a). En este estudio se estableció que la relación de 
lunasina:BBI (peso:peso) presente en los productos se encontraba en el rango de 
1:0,7 – 1:3,9, y se sugirió la influencia de esta relación sobre la resistencia del péptido 
lunasina frente a la digestión gastrointestinal in vitro mediante pepsina y pancreatina. 
Además, se han publicado algunos estudios in vivo que confirman los hallazgos in vitro 
anteriormente mencionados. Hsieh y col. (2010) demostraron la biodisponibilidad de la 
lunasina en ratones y ratas, determinando su presencia en varios tejidos como hígado, 
riñón, pulmón, glándula mamaria y próstata. De forma similar, se ha determinado la 
presencia de este péptido en una forma intacta y bioactiva en el plasma e hígado de 
ratas alimentadas con dietas de soja (Jeong y col., 2007c), trigo (Jeong y col., 2007a), 
centeno (Jeong y col., 2009) y cebada (Jeong y col., 2010) enriquecidas en lunasina. 
Asimismo, Dia y col. (2009) determinaron la presencia de este péptido en el plasma de 
individuos sanos tras la ingesta de soja, estimando un porcentaje de absorción 
(intestino-plasma) del 4,5% del total de lunasina ingerida en 50 g de proteínas de soja. 
Sin embargo, y en el contexto de las modificaciones propias ejercidas durante el 
proceso digestivo de los péptidos bioactivos, no hay estudios que hayan evaluado en 
profundidad la influencia de la digestión sobre la secuencia de 43 aminoácidos del 
péptido lunasina ni la formación e identificación de fragmentos derivados de dicho 
péptido con posible actividad biológica. 
1.2.2. Proteínas lácteas 
La digestión de las proteínas lácteas ha sido evaluada en numerosos trabajos 
mediante métodos in vitro de simulación gastrointestinal, en los que mayoritariamente 
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se emplea como herramienta analítica técnicas de separación e identificación por 
cromatografía acopladas a espectrometría de masas (Picariello y col., 2013b; Capriotti 
y col., 2016). Estos estudios se han desarrollado con una amplia variedad de objetivos 
dirigidos, bien a la identificación de secuencias específicas con relevancia fisiológica, o 
al análisis general de las modificaciones ocurridas en las proteínas y sus péptidos 
liberados durante la digestión. Por ejemplo, se ha estudiado la formación de péptidos 
antioxidantes e inhibidores de la ECA en digeridos de leche humana y fórmulas 
infantiles (Hernández-Ledesma y col., 2007), de los péptidos opioides β-casomorfina 
(CM)-5 y β-CM-7 tras la digestión de varios productos lácteos comerciales (De Noni y 
Cattaneo, 2010) y de epítopos relacionados con la alergia a las proteínas lácteas β-Lg 
(Benedé y col., 2014a) y β-CN (Benedé y col., 2014b). Oshawa y col. (2008) 
observaron la resistencia de los péptidos antihipertensivos IPP y VPP, fragmentos 
f(74-76) y f(84-86) de la β-CN, respectivamente, tras una simulación de la digestión 
con enzimas gástricas, pancreáticas y del epitelio intestinal. Asimismo, se ha 
demostrado la biodisponibilidad de estos tripéptidos y se han estudiado sus 
parámetros farmacocinéticos en cerdos (van der Pijl y col., 2008) y humanos (Foltz y 
col., 2007). De un modo similar, se ha evaluado la estabilidad del péptido 
antihipertensivo LHLPLP, correspondiente al fragmento f(133-138) de la β-CN, durante 
la digestión (Quirós y col., 2009) y la biodisponibilidad del péptido derivado HLPLP, β-
CN f(134-138), en células Caco-2 (Quirós y col., 2008) y en ratas (Sánchez-Rivera y 
col., 2014b). Con un enfoque más amplio, recientemente se ha evaluado el conjunto 
de péptidos generados durante la fermentación y posterior digestión gastrointestinal de 
un yogur (Jin y col., 2016). También se ha comparado el perfil de péptidos formados 
en los digeridos de dos matrices alimentarias lácteas distintas, queso Valdeón y leche 
en polvo evaporada (Sánchez-Rivera y col., 2014c). Dupont y col. (2010) estudiaron el 
comportamiento de las proteínas β-CN y β-Lg sometidas a dos protocolos de digestión 
in vitro distintos acordes a las condiciones propias de la digestión de un organismo 
adulto o infantil. En el trabajo de Picariello y col. (2010), se demostró la influencia 
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ejercida por las peptidasas del borde del epitelio intestinal en la digestión mediante 
pepsina y pancreatina de las caseínas y las proteínas de suero. Estos autores trataron 
así de aproximar los protocolos in vitro de digestión simulada a las condiciones propias 
in vivo del entorno fisiológico del tracto digestivo. 
Hay pocos estudios que hayan evaluado la digestión gastrointestinal de las 
proteínas lácteas en humanos. Se ha descrito que las distintas proteínas lácteas 
presentan un comportamiento diferente durante la digestión gastrointestinal. Por 
ejemplo, se ha encontrado que un 64 y 44% de las proteínas β-Lg y α-La, 
respectivamente, llegan intactas a la parte superior del yeyuno (Mahé y col., 1991). En 
el caso de la proteína LF, Troost y col. (2001) observaron que más de un 60% no se 
degrada durante su digestión en el estómago. Se ha reconocido a las caseínas como 
proteínas de “digestión lenta” y a las proteínas de suero lácteo de “digestión rápida”, 
en función de la cinética de su hidrólisis y de la absorción de aminoácidos 
provenientes de su digestión (Boirie y col., 1997). Recientemente, se ha propuesto en 
un meta-análisis de estudios clínicos que estas diferencias podrían tener influencia 
sobre la utilización postprandial del nitrógeno proteico, la llegada de péptidos y 
aminoácidos al plasma sanguíneo, la secreción de hormonas y enzimas digestivas y 
sobre aspectos metabólicos relacionados con el apetito (Bendtsen y col., 2013). Estos 
autores vieron que las proteínas de suero tenían un mayor efecto sobre la saciedad a 
corto plazo mediante el estímulo de la secreción de hormonas incretinas (péptido 1 
similar al glucagón y péptido insulinotrópico-dependiente de glucosa), mientras que 
relacionaron a las caseínas con efectos a largo plazo.  
 Como se muestra en la Tabla 1, se han descrito algunos estudios in vivo 
acerca de la presencia de péptidos en el tracto gastrointestinal tras la digestión de 
proteínas lácteas en humanos y animales. Sin embargo, la diversidad de estos 
trabajos es bastante amplia en cuanto a la especie utilizada, el producto consumido 
Tabla 1. Estudios in vivo de la digestión de productos lácteos y presencia de péptidos derivados en el tracto gastrointestinal (Adaptada de 
Boutrou y col., 2015).  
Especie Dieta
 
Muestra Objetivo del estudio Referencia 
Humano Leche Intestino delgado β-CMs Svedberg y col., 1985 
 Leche, yogur Estómago, duodeno Péptidos de caseínas Chabance y col., 1998 
 Yogur, caseínas, proteínas de suero  Yeyuno, íleon CMP Ledoux y col., 1999 
 LF Estómago LF Troost y col., 2001 
 Caseínas, proteínas de suero  Yeyuno Péptidos de caseínas y suero Boutrou y col., 2013 
Mini cerdo Caseínas Intestino delgado β-CMs, CPPs Meisel y Frister, 1989 
 Leche desnatada Duodeno Péptidos de caseínas y suero Barbé y col., 2014 
Vaca Leche desnatada, caseínas Estómago Péptidos de caseínas Yvon y Pelissier, 1987 
 Leche desnatada Estómago Péptidos de caseínas Scanff y col., 1992 
Rata CPPs Duodeno, yeyuno, íleon CPPs Brommage y col., 1991 
 Caseínas, CPPs Intestino delgado, intestino grueso CPPs Kasai y col., 1995 
 Proteínas de suero, α-La Estómago, intestino delgado α-La, péptidos de suero Pantako y col., 2001 
 Dieta suplementada en Phe-CMP  Estómago, intestino delgado CMP Fosset y col., 2002 
LF: lactoferrina, CPPs: caseinofosfopéptidos, α-La: α-lactoalbúmina, CMP: caseinomacropéptido, β-CMs: β-casomorfinas 
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(desde matrices lácteas a proteínas aisladas), el segmento del tracto gastrointestinal 
evaluado y el análisis de las muestras a estudio. 
Con un enfoque particular a los trabajos publicados sobre el análisis de 
contenidos intestinales humanos, tras la ingesta de leche se ha detectado en el 
intestino delgado la presencia de los péptidos opioides β-CM-7, -6, y -4 mediante 
ensayos inmunológicos (Svedberg y col., 1985). Posteriormente, Chabance y col. 
(1998) caracterizaron los digeridos gástricos y duodenales de humanos que tomaron 
leche y yogur. A nivel gástrico, en el estudio de la leche se identificaron un total de 26 
péptidos derivados de la αs1-CN, αs2-CN, β-CN y κ-CN, mientras que del yogur se 
formaron 8 péptidos derivados de la αs1-CN, β-CN y κ-CN. Adicionalmente, se observó 
la degradación de las proteínas lácteas a su paso por el intestino delgado, así como la 
formación de péptidos de menor tamaño, entre los que destacan algunas secuencias 
para las que posteriormente se ha demostrado bioactividad, como el péptido inductor 
de mucinas intestinales YFYPEL, αs1-CN f(144-149) (Martínez-Maqueda y col., 2013a), 
y el péptido opioide YPVEPF, β-CN f(114-119) (Jinsmaa y Yoshikawa, 1999), ambas 
formadas 20 minutos tras la ingestión de leche. Además, se identificó la presencia y 
resistencia del caseinomacropéptido (CMP), correspondiente al fragmento f(106-169) 
de la κ-CN, y de varios fragmentos derivados durante el tránsito gastrointestinal. De la 
misma forma, Ledoux y col. (1999) confirmaron posteriormente la presencia de CMP a 
nivel de yeyuno e íleon. Con el avance de las técnicas analíticas de proteómica y 
peptidómica se ha conseguido mejorar la identificación de secuencias en muestras 
complejas como son los digeridos gastrointestinales. Así, en un estudio reciente 
realizado con muestras de aspirados de yeyuno, se han detectado y secuenciado un 
total de 356 y 146 péptidos tras la ingesta de caseínas y proteínas de suero, 
respectivamente (Boutrou y col., 2013). En el caso de las caseínas, la mayoría de los 
péptidos identificados pertenecían a la β-CN (61,2%) seguida de la αs1-CN (24,9%). 
Ciertas regiones de estas proteínas resistieron durante su tránsito digestivo hasta el 
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yeyuno dando origen a la mayoría de los péptidos encontrados, como son, las 
regiones 1-14, 57-70, 67-92, 128-140, 144-163 y el dominio C-terminal de la β-CN; y 
las regiones 23-33, 104-121 y 165-186 de la αs1-CN. De las proteínas de suero, la β-
Lg, y principalmente las regiones comprendidas entre los aminoácidos 40-58 y 122-
137, dieron lugar a la mayoría de los péptidos identificados (72,0%). Mientras que en 
las proteínas de suero no se observó la presencia de ningún fragmento con efecto 
biológico descrito, numerosos péptidos bioactivos se identificaron derivados de las 
caseínas, y en concreto de la β-CN, como por ejemplo el péptido con efecto 
inmunomodulante PGPIPN, f(63-68) (Gill y col., 2000) o los péptidos antihipertensivos 
EMPFPK, f(108-113) (Pihlanto y col., 1998) y LHLPLP, f(133-138) (Miguel y col., 
2006). Además, se identificaron 32 y 27 precursores de los tripéptidos 
antihipertensivos (Nakamura y col., 1995) VPP e IPP, respectivamente, y 15 
precursores que incluyen la conocida secuencia opioide YPFPGPI, f(60-66) β-CM-7. 
Dada la relevancia fisiológica y la alta frecuencia de estos últimos péptidos en los 
digeridos, se cuantificó la presencia de β-CM-7 estimándose una concentración de 17 
µM después de 2 horas tras la ingestión de caseínas, lo que sería compatible con la 
cantidad necesaria para ejercer su efecto fisiológico in vivo (European Food Safety 
Authority, EFSA, 2009; Boutrou y col., 2013).  
1.3. Péptidos alimentarios con efectos biológicos relacionados con la salud 
digestiva 
En las últimas dos décadas muchos estudios han establecido una relación 
entre las proteínas alimentarias, y los péptidos incluidos en sus secuencias, y diversos 
efectos beneficiosos sobre los principales sistemas del organismo, como son el 
sistema cardiovascular, digestivo, endocrino, inmunológico y nervioso (Hernández-
Ledesma y col., 2014). 
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Se ha considerado que el tracto gastrointestinal es el órgano endocrino más 
extenso del organismo, ya que presenta un amplio rango de receptores y de péptidos 
endógenos. Se ha demostrado que además de la regulación ejercida por factores 
internos sobre las funciones del sistema digestivo, los agentes externos también 
pueden actuar, existiendo un interés creciente sobre la funcionalidad biológica que 
proteínas y péptidos de origen alimentario pueden ejercer a este nivel (Shimizu y 
Hachimura, 2011; Martínez-Augustin y col., 2014). Actualmente, más del 70% de los 
productos comercializados como alimentos funcionales en Japón “Food for Specified 
Health Uses (FoSHU)” se encuentran relacionados con las funciones del sistema 
digestivo. Sin embargo, la mayoría de estos compuestos se refieren a bacterias 
probióticas y compuestos prebióticos como la fibra dietética y oligosacáridos no 
digestibles (Shimizu, 2012). Con respecto al grupo de compuestos de origen proteico, 
la EFSA, hasta el momento, tan solo ha aprobado el efecto de las proteínas 
alimentarias sobre el mantenimiento normal del sistema óseo, del crecimiento y de la 
masa muscular (EFSA, 2010a), mientras que no se han aprobado efectos a nivel 
digestivo. En relación con la salud digestiva, la EFSA ha aprobado la utilización de 
compuestos de naturaleza glucídica, como la fibra de salvado de trigo para aumentar 
el peso del bolo fecal y reducir el tiempo de tránsito intestinal (EFSA, 2010b), y de las 
bacterias vivas del yogur para mejorar la digestión de la lactosa en individuos con 
maladigestión de este azúcar (EFSA 2010c). Por lo tanto, resulta evidente la 
necesidad de más estudios que evalúen el efecto de las proteínas alimentarias y sus 
péptidos derivados sobre la fisiología del tracto digestivo y la prevención de las 
enfermedades asociadas. 
Dada la baja biodisponibilidad descrita para varios péptidos bioactivos, se ha 
sugerido que ciertos efectos fisiológicos pueden estar mediados a través de 
interacciones con receptores localizados a nivel de la superficie gastrointestinal 
(Moughan y col., 2007). Aunque generalmente la afinidad de estos péptidos por los 
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receptores celulares es relativamente baja, las altas concentraciones alcanzadas en el 
lumen durante el proceso digestivo podrían desencadenar propiedades remarcables. 
Algunas de las actividades relacionadas con la modulación gastrointestinal se han 
referido al efecto sobre la saciedad, la regulación del vaciado gástrico y de la motilidad 
intestinal, la capacidad secretora y de absorción de las células intestinales, el 
metabolismo de nutrientes y a propiedades inmunomodulantes (Pang y col., 2012). 
Muchos de los péptidos que ejercen un efecto modulador directo sobre la función 
digestiva presentan actividad opioide, agonista o antagonista (Rutherfurd-Markwick, 
2012). Además, pueden ejercer capacidad antioxidante, contrarrestando situaciones 
de estrés oxidativo e inflamación (Chakrabarti y col., 2014), así como efectos 
preventivos frente a la proliferación de células tumorales (Hernández-Ledesma y 
Hsieh, 2015), fenómenos íntimamente implicados en el origen, desarrollo y 
agravamiento de múltiples alteraciones patológicas digestivas. 
1.3.1. Actividad opioide. Efectos sobre la producción de mucinas intestinales 
Los receptores opioides se encuentran ampliamente distribuidos en el 
organismo, principalmente formando parte de los sistemas fisiológicos nervioso, 
endocrino, inmunológico y digestivo (Filizola y Devi, 2012). En 1975 se descubrió la 
actividad opioide de dos pentapéptidos endógenos, Met-encefalina y Leu-encefalina 
(Hughes y col., 1975). Posteriormente, se ha descrito actividad opioide para otras dos 
familias de péptidos endógenos, endorfinas y dinorfinas, y para diversos péptidos 
exógenos derivados de los alimentos. En relación a su estructura, ambos grupos de 
péptidos, endógenos y exógenos, muestran una secuencia conservada a nivel del 
extremo N-terminal con un residuo de tirosina en la primera posición acompañado de 
otro aminoácido aromático en la tercera o cuarta posición (Meisel, 1997). Se ha 
descrito que esta disposición estructural es un factor esencial para la interacción del 
péptido con el sitio de unión del receptor opioide (Teschemacher y col., 1997).  
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Los primeros péptidos exógenos derivados de proteínas alimentarias que 
demostraron actividad opioide se denominaron β-CMs, al encontrarse en un 
hidrolizado lácteo de β-CN (Brantl y col., 1979). Tal como se detalla en la Tabla 2, 
numerosos estudios posteriores han caracterizado péptidos alimentarios opioides 
entre los que destacan algunos derivados de las proteínas lácteas, y mayoritariamente 
de las caseínas. Sin embargo, los péptidos opioides también han sido identificados en 
otras proteínas animales, como las proteínas de suero lácteo y la hemoglobina, y en 
proteínas vegetales, como el trigo, el arroz, la espinaca, y la soja (Teschemacher, 
2003; Garg y col., 2016).  
Las primeras investigaciones sobre péptidos opioides alimentarios 
determinaron la presencia de compuestos con características “similares a la morfina” a 
partir de muestras de leche humana y bovina en un rango de concentración entre 200-
500 ng/L (Hazum y col., 1981), que fueron principalmente atribuidos a las secuencias 
YPFPGPI, β-CN f(60-66), denominada β-CM-7 (Brantl y col., 1981), RYLGYLE, αs1-CN 
f(90-96) (Loukas y col., 1983), y sus fragmentos derivados. Dependiendo de la 
proteína de origen y el efecto opioide, los péptidos lácteos han sido clasificados como 
agonistas opioides: α-exorfinas (derivados de la α-CN), β-CMs (derivados de la β-CN), 
α-lactorfinas (derivados de la α-La) y β-lactorfinas (derivados de la β-Lg), y 
antagonistas opioides: casoxinas (derivados de la κ-CN) y lactoferroxinas (derivados 
de la LF) (Tabla 2). El grupo de las β-CMs ha sido el más investigado dentro de los 
péptidos exógenos con actividad opioide (EFSA, 2009). La β-CM-7 bovina fue el 
primer ejemplo de péptido de origen natural en el que la sustitución de los residuos 
glicina-glicina (GG) de los péptidos endógenos por un residuo de prolina no producía 
un descenso de la actividad opioide en el ensayo en músculo longitudinal del plexo 
mientérico del íleon de cobaya (Brantl y col., 1979; 1981). Posteriormente, algunos 
péptidos derivados de esta secuencia, como la β-CM-5 (YPFPG) y β-CM-4 (YPFP), 
Tabla 2. Péptidos opioides derivados de proteínas alimentarias (Adaptada de Teschemacher, 2003; Garg y col., 2016).  
Origen Proteína
1 
 
Péptido opioide  Receptor opioide Referencia 
Denominación Secuencia Fragmento  A/AN
2
 Selectividad  
Animal α-CNB α-Exorfina (1-7) RYLGYLE f(90-96)  A κ > µ/δ  Loukas y col., 1983 
α-Exorfina (2-7) YLGYLE f(91-96)  A µ/δ 
α-CNH α-Casoxina D YVPFPPF f(158-164)  AN µ/δ Yoshikawa y col., 1994 
α-Casomorfina (1-5) YVPFP f(158-162)  A/AN κ > µ/δ Kampa y col., 1996 
α-Casomorfina (1-5)-NH2 YVPFP-NH2   A/AN κ/δ > µ 
β-CNB β-Casomorfina-8 YPFPGPIP f(60-67)  A µ > κ/δ Petrilli y col., 1984 
β-Casomorfina-7 YPFPGPI f(60-66)  A µ Brantl y col., 1979; 1981 
β-Casomorfina-6 YPFPGP f(60-65)  A µ Brantl y col., 1981 
β-Casomorfina-5 YPFPG f(60-64)  A µ 
β-Casomorfina-4 YPFP f(60-63)  A µ 
Morficeptina YPFP-NH2   A µ > δ > κ Chang y col., 1981 
Neocasomorfina-6 YPVEPF f(114-119)  A µ Jinsmaa y Yoshikawa, 1999 
β-CNH β-Casomorfina-8 YPFVEPIP f(51-58)  A µ > δ > κ Koch y col., 1985 
β-Casomorfina-7 YPFVEPI f(51-57)  A µ > δ > κ 
β-Casomorfina-5 YPFVE f(51-55)  A µ > δ > κ 
β-Casomorfina-4 YPFV f(51-54)  A µ > δ > κ 
Valmuceptina YPFV-NH2   A µ > δ Yoshikawa y col., 1986 
β-Casorfina YPSF-NH2 f(41-44)  A µ 
κ-CNB Casoxina A YPSYGLN f(35-41)  AN µ > κ/δ Chiba y col., 1989 
Casoxina B YPYY f(57-60)  AN µ 
Casoxina C YIPIQYYLSR f(25-34)  AN µ 
Casoxina-6 SRYPSY-OCH3 f(33-48)  AN µ > κ 
Casoxina-5 RYPSY-OCH3 f(34-48)  AN µ > κ 
α-LaBH α-Lactorfina YGLF f(50-53)  A µ Yoshikawa y col., 1986 
α-Lactorfina-NH2 YGLF-NH2   A µ 
β-LgB β-Lactorfina YLLF f(102-105)  A µ 
β-Lactorfina-NH2 YLLF-NH2   A µ 
  LFH Lactoferroxina A YLGSGY-OCH3 f(318-323)  AN µ Tani y col., 1990 
Lactoferroxina B RYYGY-OCH3 f(536-540)  AN µ 
Lactoferroxina C KYLGPQY-OCH3 f(673-679)  AN µ 
SeroalbúminaB Serorfina YGFQNA f(399-404)  A δ > µ Tani y col., 1994 
HemoglobinaB Hemorfina (1-4) YPWT β-cadena (34-47)  A µ/δ > κ Brantl y col., 1986 
Vegetal Glutenina Exorfina A5 GYYPT -  A δ > µ Fukudome y Yoshikawa, 
1992; 1993 Exorfina A4 GYYP -  A δ > µ 
Exorfina B5 YGGWL -  A δ  
Exorfina B4 YGGW -  A δ 
Exorfina C5 YPISL -  A δ > µ 
α-Gliadina Gliadorfina (1-7) YPQPQPF f(43-49)  A - Payan y col., 1987 
Alérgeno 
RA5B 
Oryzatensina (1-9) GYPMYPLPR f(47-55)  A µ Takahashi y col., 1994 
Oryzatensina (5-9) YPLPR f(51-55)  A µ 
Rubisco Rubiscolina-6 YPLDLF f(103-109)  A δ  Yang y col., 2001 
Rubiscolina-5 YPLDL f(103-108)  A δ 
β-Conglicinina Soymorfina-7 YPFVVNA f(323-329)  A µ Ohinata y col., 2007 
Soymorfina-6 YPFVVN f(323-328)  A µ 
Soymorfina-5 YPFVV f(323-327)  A µ 
1 
B: bovina, H: humana  
2 
A: agonista, AN: antagonista 
CN: caseína, α-La: α-lactoalbúmina, β-Lg: β-lactoglobulina, LF: lactoferrina 
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mostraron un mayor efecto opioide en este ensayo con valores de inhibición 
(concentración necesaria para disminuir en un 50% la actividad, IC50) de 0,5 y 3,6 µM, 
respectivamente, comparado con el valor de 5,1 µM, determinado para la β-CM-7 
(Koch y col., 1985). Con respecto a las β-CMs de origen humano, caracterizadas por la 
presencia de los residuos valina-ácido glutámico (VE) en la cuarta y quinta posición 
desde el extremo N-terminal, en vez de los residuos prolina-glicina (PG) propios de las 
bovinas, estos autores encontraron un efecto entre 3 y 30 veces menor en el mismo 
ensayo de íleon de cobaya. Por lo tanto, las β-CMs de la leche humana también 
mostrarían efecto opioide, aunque significativamente menor al descrito para sus 
homólogos bovinos (Koch y col., 1985).    
El mecanismo opioide ha sido determinado comúnmente por distintos 
métodos: (i) inhibición de la actividad de la enzima adenilato ciclasa, (ii) inhibición de la 
contracción inducida eléctricamente en preparaciones ex vivo de tejidos de íleon de 
cobaya, deferente de ratón y deferente de conejo, y (iii) estudios de unión con 
radioligandos. Las preparaciones animales ex vivo han sido ampliamente utilizadas 
debido a su mayor relevancia fisiológica, menor coste y mínimo impacto tóxico (Taylor, 
2011). Además, los efectos opioides en tejidos de íleon de cobaya, deferente de ratón 
y deferente de conejo están principalmente mediados por los subtipos µ-, δ- y κ-, 
respectivamente, del receptor opioide, lo que ha permitido el uso de este tipo de 
preparaciones para evaluar la selectividad de los péptidos opioides (Janecka y col., 
2004). Gracias a estos estudios se ha evidenciado que los péptidos exógenos de 
origen animal tienen una mayor selectividad por receptores del subtipo µ-opioide, y los 
de origen vegetal, con excepción de los descritos en soja y arroz, por el subtipo δ-
opioide (Tabla 2). Como ejemplos, los valores IC50 descritos para los péptidos 
vegetales exorfina A5, rubiscolina-5 y soymorfina-5 en preparaciones de deferente de 
ratón fueron 60, 51 y 50 µM, respectivamente, versus 1000, 1110 y 6 µM en el ensayo 
 
42 Introducción 
en íleon de cobaya (Fukudome y Yoshikawa, 1993; Yang y col., 2001; Ohinata y col., 
2007). 
Dependiendo de la localización de los sistemas opioides implicados, los 
efectos fisiológicos atribuidos a los péptidos opioides son diversos y pueden 
presentar actividad relacionada con numerosas funciones regulatorias y 
neuroendocrinas (Yoshikawa, 2015; Garg y col., 2016). Se han descrito efectos 
moduladores analgésicos, locomotores y sobre la conducta social de roedores tras la 
administración intraperitoneal o intracerebral de péptidos opioides (Teschemacher, 
2003). En diversos estudios in vivo, las β-CMs administradas por vía oral prolongaron 
el tiempo del tránsito gastrointestinal (Daniel y col., 1990; Defilippi y col., 1994) e 
inhibieron la motilidad y el vaciado gástrico (Froetschel, 1996), aumentaron la 
secreción de polipéptido pancreático, insulina y somatostatina (Schusdziarra y col., 
1983a; b; c), estimularon la ingesta vía enterostatina (White y col., 2000), e 
incrementaron la insulina plasmática y la actividad de las enzimas antioxidantes 
superóxido dismutasa (SOD) y catalasa (CAT) en ratas diabéticas (Yin y col., 2010). 
Además, se ha conseguido identificar la presencia de β-CMs en el contenido de 
digeridos intestinales de mini cerdos (Barbé y col., 2014) y humanos (Boutrou y col., 
2013) tras la ingesta de productos lácteos. Sin embargo, en individuos adultos, no ha 
sido posible demostrar la presencia de estos péptidos en el plasma tras la 
administración oral de sus precursores. Este hecho, junto a la baja permeabilidad 
intestinal mostrada en modelos in vitro del epitelio con células Caco-2 (Iwan y col., 
2008; Jarmolowska y col., 2013), sugiere que los efectos de estos péptidos pueden 
estar mediados por interacciones con receptores a nivel digestivo (Teschemacher, 
2003).  
Considerando los efectos locales producidos en el tracto gastrointestinal, varios 
estudios han evaluado una posible relación entre la activación de receptores opioides 
intestinales y la protección ejercida por la barrera mucosa digestiva. Usando el 
 
43 Introducción 
modelo ex vivo de yeyuno de rata, se ha descrito que la β-CM-7 tiene un potente 
efecto inductor sobre la secreción de mucinas intestinales a través de la activación del 
sistema nervioso entérico y los receptores opioides (Claustre y col., 2002; Trompette y 
col., 2003). Posteriormente, se demostró el efecto directo de este péptido sobre 
células caliciformes intestinales de rata (DHE) y humanas (HT29-MTX), con capacidad 
secretora de mucinas y presencia de receptores opioides (Zoghbi y col., 2006). Estos 
autores encontraron un aumento significativo en la secreción de mucinas y la 
sobreexpresión de los principales genes implicados en ambos modelos celulares 
(Muc2 en DHE, y MUC5AC en HT29-MTX). Igualmente, la aplicación de un agonista µ-
opioide, encefalina D-Ala(2),N-Me-Phe(4),glicinol(5), reprodujo estos efectos, mientras 
que el pretratamiento con un antagonista µ-opioide, cipromida, los anuló. Los péptidos 
lácteos µ-opioides α-lactorfina y β-lactorfina han demostrado efectos equiparables en 
células HT29-MTX (Martínez-Maqueda y col., 2012; 2013a). Por el contrario, otros 
péptidos a los que no se les atribuye actividad opioide y cuyas secuencias no 
presentan los requerimientos propios de los ligandos opiodes, como el fragmento de la 
β-CN f(94-123) (Plaisancié y col., 2013) y los péptidos derivados f(94-108) y f(117-123) 
(Plaisancié y col., 2015), también han manifestado efectos regulatorios en la 
producción de mucinas intestinales en células HT29-MTX y en el intestino delgado de 
rata. Además, Plaisancié y col. (2015) recientemente demostraron que el péptido 
opioide neocasomorfina-6, fragmento f(114-119) de la β-CN, inducía la sobreexpresión 
del gen que codifica para la mucina asociada a membrana MUC4 en células HT29-
MTX, mientras que no tenía ningún efecto sobre las mucinas secretadas MUC2 y 
MUC5AC, ni en la secreción de mucinas. En estos trabajos se ha sugerido que la 
activación de los mecanismos opioides podría tener influencia sobre la producción de 
mucinas intestinales. Sin embargo, los efectos demostrados son variables 
dependiendo del tipo de mucina analizada y se han evaluado escasamente en 
modelos animales. Además, no se ha conseguido establecer una relación directa entre 
ambas actividades, ni se ha descartado la implicación de otros posibles mecanismos. 
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1.3.2. Actividad antioxidante 
 En condiciones fisiológicas, en las células del organismo existe un equilibrio 
entre la formación de especies reactivas de oxígeno (comúnmente denominadas ROS 
por sus siglas en inglés “reactive oxygen species”) y su neutralización por parte de los 
mecanismos de defensa antioxidantes. Las ROS se originan en la célula 
fundamentalmente durante el metabolismo endógeno del oxígeno para la obtención de 
energía. También pueden tener origen externo por diversos factores como la radiación, 
la quimioterapia, los agentes contaminantes, el tabaco, el alcohol y los xenobióticos, 
entre otros. En situación de homeostasis, las ROS cumplen funciones esenciales 
como eficientes moléculas de señalización celular y componentes del sistema 
inmunológico. Las células presentan un eficaz sistema antioxidante, tanto enzimático, 
en el que destaca la actividad de las enzimas glutatión peroxidasa (GPx), glutatión 
reductasa, CAT y SOD, como no-enzimático, cuyo principal agente es el tripéptido 
ECG, denominado glutatión (GSH). Cuando se produce un desequilibrio debido a un 
aumento en la producción de ROS o a una reducción en los mecanismos de defensa 
antioxidante propia de situaciones patológicas (Ray y col., 2012), la célula entra en un 
estado anómalo conocido como estrés oxidativo. En este estado, las ROS pueden 
interaccionar con lípidos, proteínas, ácidos nucleicos, enzimas y otras moléculas 
celulares, y debido a su alta reactividad y carácter de radicales libres, pueden oxidar y 
alterar sus estructuras químicas (Figura 3).  
Se ha reconocido el papel que juegan los desequilibrios oxidativos celulares 
como agente causal subyacente en el desarrollo de numerosos procesos patológicos 
crónicos, como la inflamación, las enfermedades cardiovasculares, digestivas y 
neurodegenerativas, la diabetes, el envejecimiento y el cáncer (Reuter y col., 2010; 
Rains y Jain, 2011; Mittal y col., 2014). Además, las reacciones de oxidación participan 
en el origen de múltiples procesos relacionados con la pérdida de calidad y deterioro 
nutricional que se producen en el alimento. 
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Figura 3. Representación esquemática de la inducción del estado de estrés oxidativo y 
sus efectos patofisiológicos (Adaptada de Bhattacharyya y col., 2014).  
 
 
El tracto gastrointestinal se encuentra continuamente sometido al ataque 
oxidativo de altas concentraciones de ROS en el contenido luminal como 
consecuencia de ciertos compuestos pro-oxidantes de la dieta, fármacos o tóxinas, así 
como aquellas especies reactivas generadas de forma endógena en el metabolismo 
del propio organismo (Zhu y Li, 2012). Además, en íntima relación con el sistema 
digestivo, se considera que el hígado es particularmente sensible a los agentes tóxicos 
y oxidativos al estar directamente conectado con los órganos gastrointestinales y el 
bazo mediante la circulación portal hepática. Por todo ello, en numerosos estudios se 
han vinculado los desequilibrios del sistema redox con el inicio y la progresión de 
varias patologías digestivas, como las enfermedades inflamatorias intestinales, las 
disfunciones hepáticas y el cáncer colorrectal (Alzoghaibi, 2013; Bhattacharyya y col., 
2014).  
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Las estrategias actuales de intervención farmacológica están principalmente 
basadas en el uso de corticosteroides y otros agentes inmunosupresores. Sin 
embargo, estos fármacos presentan varios efectos adversos tras su administración 
prolongada, como alteraciones gastrointestinales, anemia, hepatotoxicidad, 
nefrotoxicidad y reacciones de hipersensibilidad (Rutgeerts y col., 2009). Además, el 
uso crónico de estos fármacos se ha asociado a una falta de efectividad de los mismos 
y/o una menor respuesta farmacológica (Barnes y Adcock, 2009). Por ello, y con el 
objeto de evitar estos inconvenientes, numerosas investigaciones se han centrado en 
la búsqueda e identificación de nuevos agentes de origen natural con potencial efecto 
antioxidante (Moura y col., 2015). Entre ellos, destacan las investigaciones 
relacionadas con los compuestos fenólicos derivados de frutas y vegetales (Goya y 
col., 2016; Umeno y col., 2016). Además, estos agentes se presentan como una 
alternativa más segura frente al uso de antioxidantes artificiales para retardar y evitar 
las alteraciones del propio alimento relacionadas con las reacciones de oxidación. 
Debido a la interacción directa y continua entre el tracto digestivo y los componentes 
alimentarios derivados de la digestión, como son los péptidos bioactivos, estos 
compuestos pueden representar una interesante estrategia preventiva para la 
protección del organismo a este nivel.  
Se han descrito numerosos métodos para evaluar la capacidad antioxidante de 
un compuesto. Inicialmente, la mayoría de las investigaciones se centraron en distintos 
métodos químicos in vitro, basados en la complejidad de las reacciones de oxidación 
que ocurren en los sistemas biológicos. Estos métodos químicos pueden clasificarse 
en ensayos basados en la transferencia de un átomo de hidrógeno, entre los que 
destacan el ensayo “oxygen radical absorbance capacity (ORAC)” y el ensayo “total 
radical trapping antioxidant parameter (TRAP)”; y los basados en la transferencia de 
electrones, como el ensayo “Trolox equivalent antioxidant capacity (TEAC)”, el ensayo 
“ferric ion reducing antioxidant parameter (FRAP)” y el ensayo “diphenyl-1-
 
47 Introducción 
picrylhydrazyl (DPPH) radical scavenging capacity assay”, entre otros (Huang y col., 
2005). Sin embargo, ninguno de estos métodos proporciona resultados inequívocos, 
existiendo además una falta de estandarización entre ellos, por lo que se ha 
recomendado aplicar una combinación de los mismos para evaluar conjuntamente 
diferentes condiciones de oxidación y mecanismos de acción de las sustancias 
(Carocho y Ferreira, 2013). Además, estas metodologías presentan varias limitaciones 
ya que solamente reflejan reactividad química, pero no demuestran evidencias de 
relevancia fisiológica (Sarmadi e Ismail, 2010). En este sentido, en los últimos años se 
han empleado los modelos in vitro en cultivos celulares ya que permiten evaluar la 
biodisponibilidad, el metabolismo y la bioactividad de los compuestos antioxidantes, y 
son una herramienta alternativa y previa a los modelos animales y a los ensayos 
clínicos que suponen un mayor tiempo, coste e implicaciones éticas (Power y col., 
2013; Wan y col., 2015). Por ello, únicamente los resultados obtenidos mediante 
ensayos en cultivos celulares o estudios in vivo se consideran a continuación. 
La actividad antioxidante de péptidos lácteos ha sido ampliamente evaluada 
mediante métodos químicos. Sin embargo, hay pocos estudios que hayan demostrado 
estos efectos en modelos celulares o in vivo (Power y col., 2013; Nongonierma y 
FitzGerald, 2015). Las proteínas de suero lácteo han sido las más estudiadas en 
cuanto a sus potenciales efectos antioxidantes. En el modelo celular de estrés 
oxidativo inducido por peróxido de hidrógeno (H2O2) en células de feocromocitoma de 
rata PC12, Jin y col. (2013) encontraron un efecto protector antioxidante para 
hidrolizados de proteínas de suero mediado por la actividad de las enzimas SOD y 
CAT y el marcador de daño oxidativo malondialdehído. Esta protección, además, se 
asoció a un efecto estabilizador de los niveles de ROS y Ca2+ y a una inhibición de la 
apoptosis (Jin y col., 2013). Posteriormente, Zhang y col. (2015) obtuvieron resultados 
similares, y propusieron que la naturaleza hidrofóbica de los hidrolizados se 
relacionaba con su potencial antioxidante. La hidrólisis enzimática de un concentrado 
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de proteínas de suero fue capaz de estimular el GSH intracelular y la actividad de la 
CAT, así como de regular la expresión de varios genes implicados en los mecanismos 
de defensa antioxidantes y de detoxificación de células endoteliales humanas 
HUVECs (O´Keeffe y FitzGerald, 2014). También se ha demostrado in vivo el efecto 
protector antioxidante de las proteínas de suero en modelos de ratas diabéticas (Ebaid 
y col., 2011), ratas con hepatotoxicidad inducida por tetracloruro de carbono (Gad y 
col., 2011) y ratas con envejecimiento inducido por suplementación en exceso de D-
galactosa (Peng y col., 2014). En un estudio clínico se observó como la ingesta de un 
aislado de proteínas de suero enriquecido en cisteína mejoraba la funcionalidad 
hepática, mediante un incremento del GSH plasmático y de la capacidad antioxidante 
total de pacientes con esteatosis hepática de origen no alcohólico (Chitapanarux y col., 
2009). Además, Lollo y col. (2014) demostraron que un hidrolizado de proteínas de 
suero inducía efectos reductores en los niveles de lactato deshidrogenasa y 
creatinquinasa, marcadores enzimáticos de daño oxidativo tisular, en individuos 
sometidos a esfuerzo físico.  
En cuanto a la fracción de caseínas de la leche, los caseinofosfopéptidos 
(CPPs) han mostrado efecto preventivo a nivel del epitelio digestivo usando células 
Caco-2 bajo estrés oxidativo inducido por H2O2 (García-Nebot y col., 2011). Estos 
autores vieron que las células pretratadas con CPPs estaban protegidas frente al daño 
oxidativo y mantenían la viabilidad y el progreso del ciclo celular, mediante un aumento 
del GSH intracelular y de la actividad de la CAT y una disminución de la peroxidación 
lipídica. Usando este mismo modelo de daño oxidativo en células hepáticas HepG2, se 
comprobó la actividad antioxidante de caseínas hidrolizadas mediante la acción de la 
enzima Alcalasa® y enzimas gastrointestinales (Xie y col., 2013). En este estudio, 
destacó el efecto llevado a cabo por la fracción biodisponible y menor de 1000 Dalton 
del hidrolizado de caseínas con Alcalasa®, aunque no se identificaron los péptidos 
potencialmente responsables de la actividad. Recientemente, Bessette y col. (2016) 
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han demostrado que el péptido β-CN f(94-123) es capaz de proteger in vivo frente a 
lesiones del epitelio intestinal inducidas por el anti-inflamatorio no esteroideo 
indometacina. Estos autores observaron como la administración oral de este péptido 
en ratas reducía la severidad del daño oxidativo a la mucosa intestinal, mejorando su 
capacidad de barrera y disminuyendo la apoptosis celular. 
La soja también ha sido descrita como una fuente natural de compuestos con 
capacidad antioxidante. Vernaza y col. (2012) demostraron que las harinas de soja 
germinadas durante 72 h e hidrolizadas con Alcalasa® tenían un efecto reductor sobre 
varios marcadores de estrés inflamatorio y oxidativo inducido por lipopolisacárido 
(LPS) en macrófagos murinos RAW 264.7. En este modelo celular, Dia y col. (2014) 
encontraron resultados similares para varios hidrolizados de productos comerciales de 
soja con pepsina y pancreatina. Recientemente, se ha visto en ratas que el consumo 
de una dieta normocalórica enriquecida en harinas de soja mejora los mecanismos 
antioxidantes enzimáticos y el contenido de GSH reducido hepáticos, en comparación 
con dietas basadas en caseínas (Razzeto y col., 2015). Además, Celec y col. (2013) 
observaron en un estudio clínico con individuos sanos como el consumo de soja (2 
g/Kg/día) durante 7 días aumentaba la capacidad antioxidante total en hombres y 
mujeres, y disminuía la oxidación de proteínas en mujeres. En estos estudios, además 
de las proteínas de la soja y sus péptidos derivados, otros componentes de naturaleza 
no proteica como polifenoles, isoflavonas, saponinas, oligosacáridos y fosfolípidos 
podrían contribuir a la actividad antioxidante observada. Sin embargo, hasta el 
momento, los agentes fitoquímicos responsables de estos efectos no han sido 
identificados.  
En relación a la fracción proteica de la soja, Hwang y col. (2011) han descrito 
que una mezcla de péptidos purificados puede ejercer efectos antioxidantes y de 
disminución de la muerte celular en miocitos C2C12 químicamente inducidos por H2O2, 
mediante la vía de quinasas reguladas por señales extracelulares. Además, esta 
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actividad se ha asociado con un efecto anti-trombótico en un modelo de rata (Hwang y 
col., 2011). En el estudio de Amigo-Benavent y col. (2014), se mostró que la 
deglicosilación de la proteína β-conglicinina mejoraba el estado oxidativo de células 
Caco-2 estimuladas con H2O2, facilitando además su digestión gastrointestinal y la 
absorción transepitelial de los péptidos generados. En un modelo in vivo de esteatosis 
hepática no alcohólica inducida por el consumo de una dieta grasa, Yang y col. (2011) 
determinaron que las ratas que habían recibido una suplementación con proteína de 
soja presentaban un mayor potencial antioxidante gracias a la activación de las 
enzimas CAT y SOD y a la disminución de la expresión del citocromo P450 2E1. La 
protección hepática observada en este trabajo se relacionó, además, con una 
disminución de los niveles de colesterol y triglicéridos y una mejora en la resistencia a 
la insulina. Young y col. (2012) observaron que un hidrolizado de proteínas de soja 
enriquecido en di- y tri-péptidos presentaba propiedades preventivas en un modelo de 
inflamación intestinal porcino. Este efecto se asoció, posteriormente, a la actividad del 
péptido VPY a través del transportador PepT1 (Kovacs-Nolan y col., 2012). Entre los 
péptidos bioactivos presentes en la soja con potencial antioxidante destacan los 
inhibidores de proteasas y el péptido lunasina. El inhibidor de proteasas BBI, en forma 
de un concentrado de proteína de soja enriquecido en BBI (BBIC), fue capaz de 
reducir los niveles de ROS en fibras musculares de ratón (Arbogast y col., 2007). 
Además, Li y col. (2011) demostraron su capacidad protectora frente al incremento de 
ROS y citoquinas pro-inflamatorias en macrófagos sometidos a estrés oxidativo por 
LPS. Paralelamente, el péptido lunasina ha mostrado efectos similares en diversos 
ensayos químicos y cultivos celulares. Se ha demostrado la actividad beneficiosa de 
este péptido al disminuir el estado oxidativo de macrófagos RAW 264.7 estimulados 
con LPS (Hernández-Ledesma y col., 2009b). Además, esta protección celular se ha 
vinculado con un potente efecto anti-inflamatorio mediado por mecanismos celulares 
del factor de transcripción nuclear-κB (Cam y de Mejia, 2012) y la expresión de la 
integrina αVβ3 (Cam y col., 2013). De una forma similar, García-Nebot y col. (2014) 
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observaron resultados equiparables en células intestinales Caco-2 sometidas a estrés 
oxidativo mediante los agentes químicos H2O2 y tert-butil hidroperóxido (t-BOOH). De 
todo ello, se concluye que la actividad protectora de estos péptidos frente a estadios 
de estrés oxidativo e inflamatorio podría contribuir a su potencial efecto 
quimiopreventivo (Hernández-Ledesma y Hsieh, 2015). 
1.3.3. Actividad antiproliferativa 
El cáncer es una enfermedad crónica reconocida como una de las principales 
causas de muerte a nivel mundial. A pesar de los avances médicos que se han 
alcanzado en los últimos años relativos a los tratamientos de quimioterapia, 
radioterapia y cirugía, recientemente se ha estimado que para el año 2030, 
aproximadamente 27 millones de nuevos casos de cáncer serán diagnosticados y 17 
millones de pacientes de cáncer morirán a causa de esta enfermedad (Ferlay y col., 
2015). Tan sólo un 5-10% de los casos de cáncer se han relacionado con factores 
genéticos, mientras que entre el 90-95% se han atribuido a agentes medioambientales 
externos y al estilo de vida (Anand y col., 2008). Entre ellos, los hábitos dietéticos 
podrían relacionarse con aproximadamente un 35% de los casos de cáncer (Davis y 
Milner, 2007). Además, numerosos estudios in vitro, in vivo y evidencias 
epidemiológicos han propuesto el papel preventivo que podrían tener los componentes 
encontrados en los alimentos (de Kok y col., 2008; Amin y col., 2009).  
La quimioprevención se ha definido como “el uso de sustancias químicas, 
naturales o sintéticas, que bloquean, retrasan o revierten el proceso de la 
carcinogénesis”. Un gran número de los agentes quimiopreventivos conocidos hasta el 
momento están presentes en los alimentos, pudiendo tener actividad antiproliferativa 
reduciendo el riesgo de cáncer e, incluso, sensibilizando a las células tumorales frente 
a las terapias anti-cancerígenas, además de evitar los efectos adversos propios de 
este tipo de tratamientos (Pratheeshkumar y col., 2012). Los polifenoles son uno de los 
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grupos de compuestos alimentarios más estudiados por sus propiedades 
quimiopreventivas, destacando algunos, como la quercetina, las catequinas, el 
resveratrol y la curcumina (Shay y col., 2015; Bimonte y col., 2016; Lewandowska y 
col., 2016), entre otros. En los últimos años, numerosos agentes quimiopreventivos se 
han descrito también dentro del grupo de las proteínas alimentarias y los péptidos 
derivados (Blanco-Míguez y col., 2016). Estos compuestos presentan ciertas ventajas 
con respecto a otros tipos de moléculas quimioterapéuticas, como su gran afinidad y 
especificidad por ciertas dianas celulares, su facilidad de penetración en los tejidos, 
así como su bajo coste, toxicidad y efectos adversos demostrados y su alta aceptación 
por parte de los consumidores (Bhutia y Maiti, 2008). 
Los estudios llevados a cabo para elucidar los mecanismos moleculares de la 
carcinogénesis han propuesto que las células cancerígenas presentan seis 
alteraciones esenciales que conjuntamente desembocan en el desarrollo del proceso 
tumoral (Hanahan y Weinberg, 2011). Tal como se representa en la Figura 4, las 
células cancerígenas son capaces de ignorar las señales de inhibición del crecimiento 
celular, presentan sus propias señales de proliferación, muestran un umbral de 
apoptosis muy elevado y capacidad de evadir la muerte celular programada, y son 
potencialmente capaces de replicarse sin límite, e invadir tejidos y capilares dando 
lugar a los procesos de angiogénesis y metástasis. 
Varios estudios han demostrado el efecto quimiopreventivo de los péptidos 
bioactivos como agentes moduladores del proceso tumoral mediante, la inducción de 
la apoptosis, el bloqueo de vías de señalización celular, la inhibición de la 
angiogénesis, así como mediante efectos anti-inflamatorios, antioxidantes e 
inmunomodulantes (Figura 5).  
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Figura 4. Representación esquemática de las alteraciones distintivas de las células 
tumorales (Adaptada de Hanahan y Weinberg, 2011).  
Figura 5. Representación esquemática de los mecanismos celulares implicados en la 
actividad quimiopreventiva de los péptidos antiproliferativos (Adaptada de de Mejia y 
Dia, 2010).  
 
En este sentido, se ha descrito que los péptidos bioactivos pueden regular la 
expresión de proteínas y genes implicados en los distintos estadios del inicio y 
progreso del desarrollo tumoral (de Mejia y Día, 2010; Blanco-Míguez y col., 2016). 
Numerosos trabajos han revisado la actividad antiproliferativa ejercida por proteínas y 
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péptidos lácteos y de soja frente a cultivos celulares de cáncer de mama, próstata, 
colorrectal, hepático, pulmonar, gástrico, ovárico, fibrosarcoma, leucemia y linfoma, 
entre otros (de Mejia y Día, 2010; Pepe y col., 2013; Clemente y Arqués, 2014; 
Hernández-Ledesma y Hsieh, 2015; Sah y col., 2015).  
En el contexto de la interacción directa entre los digeridos de compuestos de 
naturaleza proteica y el tracto digestivo, se ha establecido una evidencia creciente 
sobre los potenciales efectos quimiopreventivos ejercidos a este nivel (Half y Arber, 
2013; Khoogar y col., 2016). En la Tabla 3 se detallan aquellos efectos relacionados 
con la protección de la salud digestiva demostrados mediante estudios en cultivos 
celulares para proteínas y péptidos lácteos y de soja, así como los mecanismos de 
acción implicados en la actividad antiproliferativa. Dentro de las proteínas lácteas, 
destaca la actividad de la proteína de suero LF y del péptido lactoferricina, derivado de 
la proteína parental mediante digestión enzimática por pepsina. Se ha sugerido que el 
posible mecanismo de su acción quimiopreventiva podría relacionarse, por un lado, 
con su naturaleza catiónica, que le permite interaccionar con la superficie de la célula 
cancerígena caracterizada por su carga negativa, causando la desestabilización de la 
membrana tumoral (Hoskin y Ramamoorthy, 2008), y por otro, con su capacidad 
inhibitoria de la angiogénesis (Mader y col., 2006). Además se ha determinado que la 
unión de la LF con el ácido oleico da lugar a complejos proteína-ácido graso con 
efectos citotóxicos en varias líneas tumorales (Pepe y col., 2013; Fang y col., 2014), al 
igual que se ha demostrado para la proteína α-La. La α-La humana y bovina, en su 
unión al ácido oleico forma los complejos conocidos como “human alpha-lactalbumin 
made lethal to tumor cells (HAMLET)” y “bovine alpha-lactalbumin made lethal to tumor 
cells (BAMLET)”, respectivamente, que también han mostrado eficacia 
quimiopreventiva dependiente del tipo celular (Brinkmann y col., 2013). Una mezcla 
comercial de péptidos obtenidos a partir de proteínas de suero mediante digestión 
enzimática mostró capacidad inductora de la apoptosis y de condensación nuclear y 
Tabla 3. Proteínas y péptidos lácteos y de soja con actividad antiproliferativa a nivel digestivo.  
Proteína-
Péptido
1 
Tipo de 
cáncer
 
 
Línea 
celular 
Mecanismos de acción Referencia 
Citotoxicidad 
(IC50) 
Ciclo celular Apoptosis Otros 
LFL Colorrectal HCT-116 ~ 5,0 mg/mL - - Efectos antioxidantes Habib y col., 
2013 
LFcinL Carcinoma 
oral 
SAS ~ 1,0 mg/mL - Inducción vía caspasa-3 y 
PARP 
Fosforilación vías ERK1/2 y 
JNK/SAPK 
Sakai y col., 
2005 
 Colorrectal C26 111,0 µM - - Disrupción de la membrana 
celular 
Eliassen y 
col., 2002 
  HT-29 
Colo-35 
~ 0,1 mg/mL - Inducción de la apoptosis 
Fragmentación del ADN 
- Mader y col., 
2005 
  Caco-2 - Bloqueo en 
fase S 
- Descenso ciclina E1 Freiburghaus 
y col., 2009 
LFcinL-AO Colorrectal HT-29 5,0 µM - Inducción de la apoptosis - Fang y col., 
2014 
 Hepato-
carcinoma 
HepG2 4,9 µM - Inducción vía mitocondrial y 
receptor de muerte celular 
-  
α-LaL-AO Colorrectal HT-29 45,8 µM - Inducción de la apoptosis -  
 Hepato-
carcinoma 
HepG2 50,2 µM - Inducción de la apoptosis -  
CPPsL Colorrectal HT-29 - - Inducción vía caspasa-3/7 Activación de canales de 
voltaje dependientes de Ca
2+ 
Perego y col., 
2012 
LunasinaS Colorrectal HT-29 61,7 µM 
 
Bloqueo en 
fase G2/M 
Incremento 
p21 
Inducción vía mitocondrial 
Incremento Bax, nCLU y 
caspasa-3 
Descenso Bcl-2 
Efecto sinérgico con cisplatino Dia y de 
Mejia, 2010 
      
      
      
      
   KM12L4 13,0 µM Bloqueo en  
fase G2/M 
Incremento 
p21 y p27 
Inducción vía mitocondrial 
Incremento Bax, nCLU, 
citocromo c, caspasa-3/2/9 
Descenso Bcl-2 
Condensación nuclear y 
fragmentación del ADN 
Inhibición de las vías FAK/ERK 
y NF-κB 
Unión a integrina α5β1 
Modulación de angiogénesis y 
metástasis 
Efecto sinérgico con cisplatino 
Dia y de  
Mejia, 2011a; 
b 
HCT-116 26,3 µM - - Inhibición de las vías FAK/ERK 
y NF-κB  
RKO 21,6 µM - - Inhibición de las vías FAK/ERK 
y NF-κB 
Inhibición de la migración 
celular 
BBIS Hepato- 
carcinoma 
HepG2 140,0 µM - - - Ho y Ng, 
2008 
Colorrectal HT-29 46,0 µM (BBI) 
48,3 µM (IBB1) 
39,9 µM (IBBD2) 
Bloqueo en 
fase G0/G1 
 
- Actividad relacionada con la 
capacidad inhibitoria de 
proteasas 
Clemente y 
col., 2010 
KTIS Hepato- 
carcinoma 
HepG2 - - - Inducción de citoquinas Fang y col., 
2010 
> 25,0 µM  - - - Ye y Ng, 2009 
LectinaS Hepato- 
carcinoma 
HepG2 4,1 µM - - - Lin y col., 
2008 
1
 L: lácteo, S: soja 
LF: lactoferrina, LFcin: lactoferricina, AO: ácido oleico, α-La: α-lactoalbúmina, CPPs: caseinofosfopéptidos, BBI: inhibidor Bowman-Birk, KTI: inhibidor de 
tripsina Kunitz, IBB1 y IBBD2: iso-inhibidores Bowman-Birk, PARP: poli-ADP ribosa polimerasa, nCLU: cluster nuclear, ERK: quinasas reguladoras por 
señales extracelulares, JNK: quinasas c-Jun N-terminal, SAPK: quinasas activadas por estrés, FAK: quinasas de adhesión focal, NF: factor de transcripción 
nuclear  
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fragmentación del ADN en células de cáncer colorrectal HT-29 (Kreider y col., 2011). 
Sin embargo, estos autores no identificaron los péptidos responsables de dichos 
efectos. Las caseínas también representan una fuente de péptidos con propiedades 
antitumorales. Perego y col. (2012) determinaron el efecto pro-apoptótico de los CPPs 
en células HT-29 mediante su habilidad de unión al Ca2+, mientras que se ha 
propuesto que los péptidos β-CM-7 y β-CM-5 pueden bloquear el progreso del ciclo 
celular de células tumorales de cáncer de mama y colorrectal mediante su interacción 
con receptores opioides y de somatostatina (De Simone y col., 2009; Pepe y col., 
2013). El péptido lunasina es uno de agentes de la fracción proteica de la soja que 
más se ha estudiado por sus propiedades quimiopreventivas (Tabla 3). Este péptido 
ha demostrado efectos antiproliferativos en cultivos celulares de cáncer de mama, 
próstata, pulmón, colorrectal, leucemia y linfoma, mediante diversos mecanismos 
relacionados con el control del ciclo celular, la apoptosis y la metástasis, 
atribuyéndosele también una acción regulatoria de naturaleza epigenética (Hernández-
Ledesma y Hsieh, 2015). En el caso de los inhibidores de proteasas presentes en la 
soja, destaca la acción quimiopreventiva de las familias BBI y KTI, que se ha 
relacionado principalmente con su capacidad para inhibir la acción enzimática de las 
proteasas tripsina y quimiotripsina en el inicio de la carcinogénesis (Clemente y 
Arqués, 2014). Además, estos inhibidores son particularmente resistentes a las 
condiciones del tracto digestivo (Clemente y col., 2011). Adicionalmente, Rayaprolu y 
col. (2013) demostraron que la hidrólisis y fraccionamiento de aislados de proteína de 
soja daba lugar a la formación de compuestos resistentes a la digestión 
gastrointestinal in vitro y con actividad antitumoral dosis-dependiente en células de 
cáncer colorrectal (Caco-2 y HCT-116), hepático (HepG2) y pulmonar (NCL-H1299). 
Sin embargo, estos autores no identificaron la secuencia de los péptidos generados y 
potencialmente responsables de los efectos observados. 
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Los resultados demostrados en cultivos celulares han dado origen a algunos 
estudios con el objetivo de trasladar dichos efectos a evidencias in vivo. Mediante el 
uso de modelos animales de metástasis, se mostró que la actividad quimiopreventiva 
del péptido lactoferricina se relacionaba con su habilidad para suprimir la angiogénesis 
y la metástasis a los tejidos hepáticos y pulmonares (Eliassen y col., 2002; 2006; 
Mader y col., 2006). Paralelamente, se ha observado que la administración oral de 
este péptido induce un efecto quimiopreventivo, anti-metastásico e inmunomodulador 
en la mucosa intestinal mediante la activación de caspasa-1, interleuquina-18, 
interferón-γ y células de defensa T y “natural killer” (Kuhara y col., 2000; Iigo y col., 
2004). El péptido lunasina ha demostrado efectos in vivo en el modelo de metástasis 
hepática inducido por células de cáncer colorrectal KM12L4 (Dia y de Mejia, 2011b; 
2013). En estos estudios se observó una reducción del antígeno de proliferación 
celular, relacionado con el bloqueo del progreso del ciclo celular, y una inducción de la 
apoptosis mediante modulación de los marcadores Bcl-2:Bax. Sin embargo, se 
encontraron diferencias entre la administración por vía oral e intraperitoneal del 
péptido, que hicieron difícil obtener resultados definitivos sobre el potencial efecto in 
vivo de la lunasina frente a la metástasis del cáncer colorrectal (Dia y de Mejia, 2011b; 
2013). Utilizando modelos animales de lesiones intestinales inflamatorias y pre-
cancerígenas inducidas por los agentes químicos 1,2-dimetilhidrazina y sulfato de 
dextrano sódico, se ha evidenciado el papel protector del BBI derivado de la soja. Este 
péptido ha sido capaz de prevenir la formación de lesiones neoplásicas e inflamatorias 
y de reducir la incidencia y frecuencia de los tumores colorrectales y la tasa de 
mortalidad (St Clair y col., 1990; Ware y col., 1999; Kennedy y col., 2002; Carli y col., 
2012). En el año 1992, la Agencia Estadounidense de Alimentos y Medicamentos 
(FDA) aprobó la investigación del BBIC en ensayos clínicos. Desde entonces, se han 
llevado a cabo seis ensayos clínicos en pacientes de hiperplasia prostática benigna, 
leucoplasia oral y colitis ulcerativa (Clemente y Arqués, 2014). En concreto, en el 
estudio clínico de colitis ulcerativa, Lichtenstein y col. (2008) describieron que el 
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tratamiento durante 12 semanas (800 unidades/día) con BBIC presentaba notables 
beneficios en relación a la remisión de la sintomatología clínica (50,0%) y recuperación 
de la enfermedad (36,0%), comparado con el grupo placebo (respuesta 
sintomatológica parcial 29,0%, y recuperación 7,1%). En estos estudios se ha indicado 
el potencial efecto quimiopreventivo que pueden tener las proteínas alimentarias y sus 
péptidos derivados frente a diversos factores de riesgo relacionados con el inicio y 
progreso de enfermedades crónicas, como el cáncer (Hernández-Ledesma y Hsieh, 
2015). Sin embargo, todavía es necesario un mayor número de investigaciones para 
evidenciar cómo estos péptidos interaccionan con el organismo y poder demostrar 
científicamente su efectividad en estudios clínicos. 
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The protective role of the Bowman-Birk protease
inhibitor in soybean lunasin digestion: the eﬀect
of released peptides on colon cancer growth†
Elvia Cruz-Huerta,‡a Samuel Fernández-Tomé,‡a M. Carmen Arques,b
Lourdes Amigo,a Isidra Recio,a Alfonso Clementeb and
Blanca Hernández-Ledesma*a
Lunasin is a naturally-occurring peptide demonstrating chemopreventive, antioxidant and anti-inﬂamma-
tory properties. To exhibit these activities, orally ingested lunasin needs to survive proteolytic attack of
digestive enzymes to reach target tissues in active form/s. Preliminary studies suggested the protective
role of protease inhibitors, such as the Bowman-Birk inhibitor and Kunitz-trypsin inhibitor, against luna-
sin’s digestion by both pepsin and pancreatin. This work describes in depth the behaviour of lunasin
under conditions simulating the transit through the gastrointestinal tract in the absence or presence of
soybean Bowman-Birk isoinhibitor 1 (IBB1) in both active and inactive states. By liquid chromatography
coupled with tandem mass spectrometry (HPLC-MS/MS), the remaining lunasin at the end of gastric and
gastro-duodenal phases was quantiﬁed. Protection against the action of pepsin was independent of the
amount of IBB1 present in the analyzed samples, whereas an IBB1 dose-dependent protective eﬀect
against trypsin and chymotrypsin was observed. Peptides released from lunasin and inactive IBB1 were
identiﬁed by MS/MS. The remaining lunasin and IBB1 as well as their derived peptides could be responsible
for the anti-proliferative activity against colon cancer cells observed for the digests obtained at the end of
simulated gastrointestinal digestion.
1. Introduction
Lunasin is a naturally-occurring peptide corresponding to the
small subunit peptide of 2S albumin.1 Its amino acid sequence
(SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDD-
DD, National Center for Biotechnology Information, NCBI,
accession number AAP62458) is characterized by the presence
of a predicted α-helix structure, a tri-peptide RGD cell
adhesion motif and a continuous sequence of nine aspartic
acid residues at the C-terminus. A recent molecular dynamics
study of this peptide has suggested the important role played
by its α-helicity and highly negatively-charged C-terminal tail
in the recognition of and binding to the chromatin residue,
and thus, in the anti-mitotic activity of lunasin in several
mammalian cell lines.2
Recent studies have revealed the potential role of lunasin
against established breast, colon, and prostate cancer, and leu-
kemia cell lines, through its ability to inhibit cell proliferation
by arresting the cell cycle and inducing apoptosis.3 The
chemoprotective eﬀects of lunasin against skin,4 breast,5,6 and
colon cancer7,8 have also been evaluated in animal models.
Moreover, lunasin has been shown to restrain the oxidative
status caused by chemical agents in both intestinal Caco-2 and
hepatic HepG2 cells, and to inhibit inflammation in cultured
RAW 264.7 macrophages. These antioxidant and anti-inflam-
matory properties have been suggested to contribute to the
anti-cancer activity of lunasin.3
Food-derived peptides are expected to exhibit their health
beneficial properties after being orally taken. Even though
these peptides can elicit hormone-like functions locally in the
gastrointestinal tract, they are generally required to flow into
the blood to exhibit specific activities at a systemic level. In the
last few years, the number of studies evaluating bioavailability
aspects of dietary peptides, such as their resistance to digestive
enzymes and their absorption/distribution rates has notably
increased.9 In addition, the application of peptidomics tools
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c5fo00454c
‡Both authors equally contributed to this work.
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in these analyses has markedly emerged.10 It is increasingly
obvious that gastrointestinal digestion has an important influ-
ence on the biological activity of food-derived peptides, with
the release of new active fragments from their precursors or,
on the contrary, giving rise to fragments with less or null
activity.11–15
Park et al.16 reported that isolated lunasin, either synthetic
or soybean-purified, is easily digested after 2 min incubation
with simulated gastric or intestinal fluids. However, lunasin
survives, at least partially, the attack of digestive enzymes
when it is present in crude protein extracts purified from
soybean or other plant sources. By western-blot analysis, Jeong
et al.17 demonstrated that approximately 85% of the original
lunasin contained in Solanum nigrum L. crude protein extract
remained intact after 120 min digestion with simulated gastro-
intestinal fluids. In the case of lunasin present in soybean
crude protein extract, 60% and 80% of the initial lunasin was
detected by immunoblotting after proteolysis by pepsin and
pancreatin for 120 min, respectively.16 The results from these
studies suggested that the presence of naturally-occurring pro-
tease inhibitors in suﬃcient amounts, such as the Bowman-
Birk inhibitor (BBI) or the Kunitz-trypsin inhibitor, might
exert a protective eﬀect against lunasin’s proteolysis by diges-
tive enzymes. Hernández-Ledesma et al.18 also observed the
protective eﬀect exerted by BBI when lunasin present in
soybean-derived foods was subjected to a sequential digestion
with pepsin and pancreatin, suggesting the importance of the
lunasin : BBI ratio in this protection. However, to our knowl-
edge, the behavior of lunasin during its transit through the
gastrointestinal tract has not been previously evaluated. Thus,
the present study aims to simulate physiological conditions
using an in vitro digestion model for lunasin in the absence
and/or presence of a major soybean Bowman-Birk isoinhibitor
(IBB1). Liquid chromatography coupled with tandem mass
spectrometry (HPLC-MS/MS) analysis was carried out to quan-
tify the remaining intact lunasin and to identify the peptides
released during the digestive process. The anti-proliferative
eﬀect against colon cancer cells (HT-29 and Caco-2) of digests
obtained at the end of the digestive process was also
evaluated.
2. Materials and methods
2.1. Reagents
Peptide lunasin (>95% of purity) was synthesized by Chengdu
KaiJie Biopharm Co., Ltd (Chengdu, Sichuan, P. R. China). BBI
from soybean (T9777), N-α-benzoyl-DL-arginine-p-nitroanilide
(BAPNA), N-benzoyl-L-tyrosine ethyl ester (BTEE), porcine
pepsin (EC 3.4.23.1), pancreatic bovine trypsin (EC 232-650-8),
pancreatic bovine α-chymotrypsin (EC 232-671-2, Type I-S),
pancreatic porcine lipase (EC 232-619-9, Type VI-S), pancreatic
porcine colipase (EC 259-490-1), phosphatidylcholine (PC),
sodium taurocholate, sodium glycodeoxycholate, trifluoro-
acetic acid (TFA), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) were purchased from Sigma
Chemical Co. (Madrid, Spain). Other chemicals used were of
HPLC grade.
2.2. Purification of IBB1 isoinhibitor from soybean
IBB1 was purified from commercially available soybean BBI
following the protocol of Arques et al.19 Briefly, the sample
consisted of a mixture of protease inhibitors that was loaded
onto a MonoS 5/50 GL cation exchange column (GE Health-
care, Uppsala, Sweden) connected to an AKTA FPLC system
(GE Healthcare), using a linear gradient of 0–0.22 M NaCl in
25 mM sodium acetate buﬀer, pH 4.4, at a flow rate of 1 mL
min−1. The elution was monitored at 280 nm and 0.5 mL
fractions were collected. Measurements of trypsin inhibitory
activity of the eluted samples were carried out in flat-bottom
microtitre plates by using BAPNA as the specific substrate,
and assay products were measured at OD405 nm, as previously
described.20 The unbound sample, containing both trypsin
and chymotrypsin inhibitory activity – the latter measured
by using BTEE as the specific substrate21 – was dialyzed
extensively against distilled water and freeze-dried until
use. The identification of IBB1 was carried out by peptide
mass fingerprinting, as previously reported.22
To abolish the inhibitory activity of soybean IBB1, chemical
inactivation via reduction of disulphide bonds and subsequent
alkylation of the cysteinyl sulfhydryl groups was carried out.22
Ten milligrams of soybean IBB1 were dissolved in 50 mM Tris-
HCl (pH 8.2) and reduced with 100 µL 0.5 M dithiothreitol
(DTT) for 2 min at 100 °C, and alkylated with 500 µL of 0.25 M
iodoacetamide for 15 min at 50 °C under dark conditions.
In order to remove residual DTT and iodoacetamide, samples
were dialyzed extensively against distilled water and freeze-
dried.
2.3. Measurement of protease inhibitory activities
IBB1 and its inactive form were assessed for trypsin and
chymotrypsin inhibitory activities. Trypsin inhibitory activity
was measured using a modified small-scale quantitative assay
with BAPNA as the specific substrate using 50 mM-Tris pH 7.5
as enzyme assay buﬀer. A trypsin inhibitor unit is defined as
that which gives a reduction in absorbance at 410 nm of 0.01,
relative to trypsin control reactions, in 10 min in a defined
assay volume of 10 mL.23 Chymotrypsin inhibitory activity was
measured by using BTEE as the specific substrate. A chymo-
trypsin inhibitor unit is defined as that which gives a
reduction in absorbance at 256 nm of 0.01, relative to chymo-
trypsin control reactions, in 5 min in a defined assay volume
of 10 mL, as described previously.21 Specific trypsin and
chymotrypsin inhibitory activities, expressed as inhibitor units
per mg of protein, were calculated and used to assess the
chemical inactivation of IBB1.
2.4. In vitro simulated gastrointestinal digestion
The in vitro digestibility of lunasin in the presence or absence
of IBB1, either active or inactive, was evaluated by using an
in vitro model system mimicking in vivo gastric and duodenal
digestion according to Moreno et al.24 with some modifi-
Food & Function Paper
This journal is © The Royal Society of Chemistry 2015 Food Funct., 2015, 6, 2626–2635 | 2627
cations.25 The digestions were assessed under the following
conditions: lunasin in the absence of IBB1, lunasin in the
presence of IBB1 [lunasin : IBB1 ratios of 1 : 1 and 1 : 2 (w : w)]
and lunasin in the presence of chemically inactivated IBB1
[lunasin : IBB1 ratio of 1 : 2 (w : w)].
Lunasin and IBB1 were dissolved in simulated gastric fluid
(SGF, 35 mM NaCl, pH 2.0) containing phospholipid vesicles
at a total protein concentration of 1.5 mg mL−1. The solution
was adjusted to pH 2.0, preheated for 15 min at 37 °C, and
subjected to gastric digestion for 60 min at 37 °C by adding
182 units of porcine pepsin per mg of protein. Gastric reaction
was stopped by raising pH up to 7.0–7.5. For intestinal diges-
tion, the pH of the gastric digest was adjusted to 6.5–6.8 by
addition of 1 M CaCl2, 0.25 M Bis–Tris, and a 0.125 M bile salt
equimolar mixture of sodium glycodeoxycholate and sodium
taurocholate. The pancreatic bovine trypsin and α-chymo-
trypsin, and pancreatic porcine lipase were added to the
mixture at the enzyme : substrate ratios of 34.5, 0.4 and 24.8
units per mg of protein, respectively. Pancreatic porcine coli-
pase was added at an enzyme : substrate ratio of 1 : 895 (w : w).
Duodenal digestion was carried out for 60 min at 37 °C and
stopped by raising the temperature to 95 °C for 10 min.
Aliquots were taken before digestion at the end of both gastric
and duodenal phases. The simulated gastrointestinal digestion
was carried out in duplicate for each lunasin : IBB1 ratio.
2.5. Analysis of digests by RP-HPLC-MS/MS
Synthetic lunasin (at concentrations ranging from 0.125 to
1.50 mg mL−1) and samples collected during simulated gastro-
intestinal digestion were subjected to HPLC-MS/MS. The
samples were analyzed on an Agilent 1100 HPLC System
(Agilent Technologies, Waldbron, Germany) connected on-line
to an Esquire 3000 ion trap (Bruker Daltonik, Bremen,
Germany) and equipped with an electrospray ionization (ESI)
source. The analyses were carried out using a Mediterranea
Sea18 column (150 × 2.1 mm, Teknokroma, Barcelona, Spain).
The injection volume was 50 μL and the flow rate was set at
0.2 mL min−1. Peptides were eluted with a linear gradient
(0–70%) of solvent B [acetonitrile : TFA, 1000 : 0.27 (v : v)] in A
[water : TFA, 1000 : 0.37 (v : v)] in 75 min. Spectra were recorded
over the mass/charge (m/z) range 200–3000. Each sample was
analyzed in duplicate. Data obtained were processed and trans-
formed to spectra representing mass values using the Data
Analysis program (version 4.0, Bruker Daltonik). BioTools
(version 3.2, Bruker Daltonik) was used to process the MS/MS
spectra and to perform peptide sequencing.
2.6. Cell viability assay
Two human colorectal adenocarcinoma cell lines (Caco-2 and
HT-29) were obtained from the American Type Culture Collec-
tion (ATCC, Rockville, MD, USA). HT-29 and Caco-2 cells were
grown in McCoy’s medium (Lonza Group Ltd, Basel, Switzer-
land) and Dulbecco’s Modified Eagle Medium (DMEM, Sigma
Chemical), respectively, supplemented with 10% (v/v) fetal
bovine serum (FBS, Biowest, Nuaillé, France), and 1% (v/v)
penicillin/streptomycin/amphotericin B solution (Biowest). In
the case of Caco-2 cells, DMEM was also supplemented with
1% (v/v) non-essential amino acids (Lonza Group Ltd). Cell
cultures were grown in a humidified incubator containing 5%
CO2 and 95% air at 37 °C.
The eﬀect of digests on cell viability was evaluated by using
the MTT assay. Caco-2 and HT-29 cells were seeded in 48-well
plates (VWR International, Radnor, PA, USA) at a density of
7 × 104 cells per cm2, and incubated for 24 h. The cells were
treated with gastrointestinal digests (at total protein concen-
tration of 0.3, 0.2 and 0.1 mg mL−1) for 24 h, and washed with
phosphate buﬀer saline (PBS, Lonza Group Ltd). MTT solution
(0.5 mg mL−1 at the final concentration) was added to each
well, and cells were incubated for 2 h at 37 °C. The super-
natant was aspirated and insoluble formazan crystals formed
were solubilized in dimethylsulfoxide : ethanol (1 : 1, v : v),
measuring the absorbance at 570 nm in a FLUOstar OPTIMA
plate reader (BMG Labtech, Oﬀenburg, Germany). Experiments
were carried out in triplicate and the results were expressed as
a percentage of viable cells compared to the control, and as
IC50 values (protein concentration needed to inhibit 50% of
viable cells).
2.7. Statistics
Data were evaluated using one-way ANOVA followed by the
Bonferroni post hoc test, and expressed as the mean ± SD
of the diﬀerent experiments carried out. GraphPad Prism 5.0
software (San Diego, CA, USA) was used to perform statistical
analyses. Diﬀerences with a P value <0.05 (*) were considered
significant.
3. Results
3.1. Behavior of lunasin under gastric digestion
Commercial BBI consisted of a mixture of two major BBI iso-
inhibitors, IBB1 and IBBD2, diﬀering in potency and speci-
ficity against trypsin and chymotrypsin. While IBB1 shows the
ability to inhibit both trypsin and chymotrypsin, IBBD2 only
inhibits trypsin.22 By cation-exchange chromatography, both
forms were isolated, IBB1 being unbound to the Mono-S
column, whereas IBBD2 was eluted in the NaCl gradient. From
the functional point of view, the obtained IBB1 demonstrated
a high potency against both trypsin and chymotrypsin
showing Ki values at the nanomolar level (30 ± 4 and 3 ± 1 nM,
respectively). Its specific inhibitory activity against trypsin and
chymotrypsin was 3828 ± 209 trypsin inhibitor unit per mg of
protein and 2917 ± 292 chymotrypsin inhibitor unit per mg of
protein, respectively. Following the reduction of disulphide
bonds and further alkylation of the cysteinyl sulphydryl
groups, its inhibitory activities decreased in more than 95%.
In agreement with the inhibitory assays, the MS/MS analysis of
inactive IBB1 revealed the presence of a major peak corres-
ponding to reduced/alkylated IBB1, and a minor peak corres-
ponding to the active isoinhibitor that represented 2% of total
IBB1. This indicated that residual IBB1 remained active after
the inactivation process carried out in this study.
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In order to evaluate the resistance of lunasin to digestive
enzymes, mixtures of this peptide without and with IBB1 in
active or inactive states were prepared. The mixtures were sub-
jected to a two-stage hydrolysis process simulating gastrointes-
tinal digestion. Fig. 1A–D show the UV-chromatograms of the
diﬀerent digests obtained at the end of the gastric phase.
Chromatographic peaks (numbers or letters) corresponded to
the lunasin- and IBB1-derived peptides, respectively. Lunasin
(peak 20) eluted after 43 minutes, with ions confirming the
identity of this peptide (5028.3, experimental mass; 5028.0,
theoretical mass). Two peaks were visible for IBB1 (peak T).
One of them eluted after 53 minutes and corresponded to the
intact polypeptide (7858.6, experimental mass; 7858.8, theore-
tical mass). The additional peak was detected at a retention
time of 55 min, whose ions suggested the presence of IBB1
lacking the C-terminal tetrapeptide 68DKEN71 (7380.9, theore-
tical mass).
The percentage of intact lunasin after pepsin treatment was
calculated by using a lunasin’s standard curve (0.125–1.5 mg
mL−1) analyzed under the same conditions (Table 1). In the
absence of IBB1, only 2.6% of lunasin was resistant to the
action of pepsin, indicating the high susceptibility of this
peptide to the gastric enzyme. However, in the presence of
IBB1 at lunasin : IBB1 ratios of 1 : 1 and 1 : 2, more than 34%
of lunasin remained intact after pepsin digestion, without
observing statistical diﬀerences between both ratios. No sig-
nificant diﬀerences were observed when lunasin was mixed
with inactive IBB1 in comparison with the samples containing
active IBB1, with more than 28% of this peptide remaining
intact after the gastric phase. The higher size of IBB1 in com-
parison with that of lunasin could make this isoinhibitor act
as a “chaperone” encasing lunasin and preserving its integrity
during pepsin hydrolysis. In addition, it cannot be excluded
that the presence of a small percentage of active IBB1 during
the inactivation process was capable to protect lunasin from
the eﬀects of pepsin (Fig. 1D).
The peptidic profiles of gastric digests in the presence of
active IBB1 (Fig. 1B and C) were similar, but slightly diﬀerent
from that observed for lunasin’s digest in the absence of the
Table 1 Intact lunasin (expressed as % of the initial intact lunasin)
measured in the digests obtained after the gastric and the intestinal
phases of the digestion process simulating gastrointestinal conditions
from the lunasin : IBB1 mixtures at diﬀerent ratios. Digestion was carried
out in duplicate and two HPLC-MS/MS analyses were run for each
digesta
Lunasin : IBB1 ratio
(w : w)
Intact lunasin (%)
Gastric digest Gastric + intestinal
digest
1 : 0 2.6 ± 0.4a 0.1 ± 0.1a
1 : 1 34.3 ± 3.7b 1.8 ± 0.4b
1 : 2 35.1 ± 2.8b 5.3 ± 0.4c
1 : 2 (inactive IBB1) 28.4 ± 3.6b 1.5 ± 0.2b
aDiﬀerent superscript letters within the same column denote
statistically significant diﬀerences (p < 0.05).
Fig. 1 UV-chromatograms obtained after the gastric phase of the digestive process simulating the gastrointestinal digestion of lunasin :
IBB1 mixtures at ratios of (A) 1 : 0 (w : w), (B) 1 : 1 (w : w), (C) 1 : 2 (w : w), and (D) 1 : 2 (w : w) with inactive IBB1. Chromatographic peaks (numbers or
letters) corresponding to the lunasin- and IBB1-derived peptides, respectively, were identiﬁed by mass spectrometry in tandem, and shown in the
ESI, Table S1.†
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isoinhibitor (Fig. 1A). The HPLC-MS/MS analysis allowed iden-
tifying the peptides released from lunasin and inactive IBB1
during the simulated gastrointestinal digestive process
(Fig. 2A–D, Fig. 3A, and ESI Table S1†). It is remarkable that
no peptides derived from active IBB1 were identified in this
study. In the gastric digests, up to 22 peptides derived from
lunasin and 19 derived from inactive IBB1 were identified,
although the presence or absence of each one of these
peptides depended on the mixture digested (Fig. 2 and 3). As
expected, the higher number of fragments released from
lunasin was detected in the digest of sample in the absence
of IBB1, with 20 of the 22 total identified peptides. Five pep-
tides, whose sequences were 11RKQLQGVNLTPCEKHIME28,
17VNLTPCEKHIME28, 19LTPCE28, 20TPCEKHIME28, and
21PCEKHIME28, were identified in the digest without IBB1 but
not in those digests containing the isoinhibitor in its active state.
These fragments were released from the central region of lunasin
sited between amino acids 11 and 28, indicating that this area
could be predominantly enclosed and protected from the action
of pepsin when the protease isoinhibitor is present (Fig. 2A–D).
In the gastric digest of mixtures lunasin : inactive IBB1
(ratio 1 : 2), 19 peptides released from inactive IBB1 were
identified (Fig. 3A and ESI Table S1†), confirming the vulner-
ability of inactive IBB1 to the action of this gastric enzyme,
and the consequent release of an important number of IBB1-
derived fragments.
3.2. Eﬀects of pancreatic enzymes on lunasin
Once the gastric phase was complete, the mixtures were
digested with a combination of pancreatic enzymes, and the
resulting digests were analyzed by HPLC-MS/MS (Fig. 4) to
quantify the intact lunasin (Table 1). In the absence of IBB1,
the residual lunasin was almost completely degraded after the
action of pancreatic proteases (Table 1 and Fig. 4A). However,
active IBB1 exerted a protective eﬀect on lunasin against pan-
creatic hydrolysis that could be explained by its ability to
inhibit trypsin and chymotrypsin. The enzymatic inhibitory
properties of IBB1 together with its molecular structure sup-
ported by a network of seven disulphide bridges are respon-
sible for its resistance to duodenal digestion, thus the active
isoinhibitor was clearly visible at the end of simulated diges-
tion at lunasin : IBB1 ratios 1 : 1 and 1 : 2 (Fig. 4B and C,
respectively). It is remarkable that in contrast to the protection
against the action of pepsin, inhibitory eﬀects on duodenal
digestion were dose-dependent, the resistance of lunasin being
more evident when IBB1 was present at the higher concen-
tration (lunasin : IBB1 ratio 1 : 2). In this case, the residual
lunasin at the end of simulated gastrointestinal digestion was
5.3% while the residual value for mixtures lunasin : IBB1 at the
ratio 1 : 1 was 1.8%. The latter value was similar to that deter-
mined when mixtures lunasin : inactive IBB1 were subjected to
intestinal digestion (1.5% of residual lunasin, Table 1). As
indicated previously, inactive IBB1 did not show trypsin and
chymotrypsin inhibitory activities. However, lunasin was
slightly protected from the action of these pancreatic enzymes
when inactive IBB1 was present in the mixture. The small per-
centage of IBB1 remaining active during the inactivation
process could be responsible for this slight protection,
although it cannot be excluded that the presence of the isoin-
hibitor (in both the active and inactive state) could be enough
to encase lunasin and protect it from the proteolytic action of
trypsin and chymotrypsin. In addition, some of the IBB1-
derived peptides might contribute to the protective action
against lunasin’s digestion.
Of 20 lunasin-derived peptides identified in the gastric
digest of IBB1 free-sample, only three, corresponding to
24KHIME28, 28EKIQGR33, and 29KIQGRGDDDDDDDDD43,
appeared at the end of the whole digestive process, suggesting
their resistance to the action of trypsin and chymotrypsin
(Fig. 2E). The rest of peptides were not detected in the duo-
denal digest, indicating that without the protective role of
IBB1, pancreatic enzymes acted on those sequences released
during the gastric phase resulting in the liberation of shorter
peptides and/or free amino acids. Up to 15 new peptides
released from lunasin were identified in the hydrolyzate
obtained at the end of simulated gastrointestinal digestion
when IBB1 was not present (Fig. 2E and ESI Table S1†).
The release of eight of these peptides, corresponding to frag-
ments 4QHQQDSCR11, 15QGVNLTPCEK24, 16GVNLTPCEK24,
17VNLTPCEK24, 19LTPCEK24, 25HIME28, 29KIQGR33, and
34GDDDDDDDDD43, could be explained by the action of
trypsin on susceptible peptide bonds. The rest of them could
be released by the combined action of trypsin and chymo-
trypsin used during the simulated intestinal phase. None of
the peptides identified in the IBB1-free digest was identified in
digests containing active IBB1, suggesting the ability of this
isoinhibitor to protect both lunasin and derived peptides
against the action of trypsin and chymotrypsin. It was also
interesting to note the absence of those new peptides when
the digestion was carried out on a mixture containing inactive
IBB1. These results confirm that the presence of IBB1 in both
active and inactive forms was enough to protect lunasin and
derived fragments against digestion by duodenal enzymes.
Only four of the nineteen peptides released from inactive
IBB1 by the action of pepsin were degraded by trypsin and
chymotrypsin, which were not detected at the end of simulated
gastrointestinal digestion. The sequences of these peptides
were 24CSDMRLNSCHSA35, 43LSYPAQC49, 58CYEPCKPSEDD-
KEN71, and 61PCKPSEDDKEN71. The remaining peptides were
identified at the end of digestion, indicating their resistance to
the action of pancreatic enzymes (Fig. 3). Among them, the
presence of the trypsin inhibitory domain of IBB1 localized
between amino acids 14C and 22C was remarkable, which
could protect lunasin and its derived fragments from further
digestion by trypsin.22
3.3. Anti-proliferative action of gastrointestinal digests
against colon cancer cells
The digests at the end of the simulated digestive process were
assayed for their eﬀect against the cell viability of two colon
adenocarcinoma cell lines, HT-29 and Caco2, using the MTT
protocol. In order to evaluate the dose-response, the digests
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Fig. 2 Lunasin-derived peptides identiﬁed in the digests obtained after the (A–D) gastric and (E–H) intestinal phase of the simulated gastrointestinal digestion from lunasin : IBB1 mixtures at
ratios of (A and E) 1 : 0 (w : w), (B and F) 1 : 1 (w : w), (C and G) 1 : 2 (w : w), and (D and H) 1 : 2 (w : w) with inactive IBB1. Susceptible peptide bonds in the absence of IBB1 but resistant in the pres-
ence of this isoinhibitor are indicated with an arrow.
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were analyzed at the initial protein concentration (0.3 mg
mL−1) and after dilution in growth media 1.5 and 3-times.
Digestion media in the absence of lunasin and IBB1 were
assayed to evaluate whether any substances used to simulate
digestion were capable of decreasing the cell viability (Fig. 5).
An anti-proliferative eﬀect was observed when the non-diluted
digest was added to HT-29 and Caco2 cells, with values of
viable cells of 70.5 ± 8.0% and 86.6 ± 4.0%, respectively. The
anti-proliferative eﬀect was significantly higher when digests
from lunasin : IBB1 mixtures were assayed. As shown in
Fig. 5A, all the tested gastro-duodenal digests aﬀected the
HT-29 cell viability in a dose-dependent manner. The digests
obtained in the absence of IBB1 provoked a decrease of viable
cells of 52.4% at the highest protein concentration assayed.
The IC50 value calculated for this digest was 0.29 mg mL
−1.
Since the amount of lunasin in this hydrolyzate was practically
undetectable (0.1%), the anti-proliferative activity seems to be
mainly due to the peptides released during lunasin digestion.
However, these peptides did not exert any significant protec-
tive eﬀect against Caco2 cells (Fig. 5B), indicating that their
activity might be dependent on the cell line studied. Higher
anti-proliferative eﬀects in both the colon cancer cell lines
were observed when hydrolyzates obtained from the mixtures
containing lunasin and IBB1 were assayed, indicating that
both intact polypeptides lunasin and IBB1 and the peptides
released from them could cooperate to decrease the viability of
Fig. 3 IBB1-derived peptides identiﬁed in the digests obtained after the (A) gastric and (B) intestinal phase of the simulated gastrointestinal digestion
from the lunasin : IBB1 inactive mixture (1 : 2, w : w).
Fig. 4 UV-chromatograms obtained at the end of simulated gastrointestinal digestion of lunasin : IBB1 mixtures at ratios of (A) 1 : 0 (w : w), (B) 1 : 1
(w : w), (C) 1 : 2 (w : w), and (D) 1 : 2 (w : w) with inactive IBB1. Chromatographic peaks (numbers or letters) corresponding to the lunasin- and IBB1-
derived peptides, respectively, were identiﬁed by mass spectrometry in tandem, and shown in the ESI, Table S1.†
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colon cancer cells. The calculated IC50 values for these hydroly-
zates were lower (0.16–0.23 mg mL−1) when HT-29 cells were
treated with digests, suggesting the higher vulnerability of this
cell line to the action of lunasin, IBB1 and their derived-
peptides.
4. Discussion
Our findings indicate that, in the absence of IBB1, during the
simulated gastric phase, pepsin acts on lunasin hydrolyzing
more than 97% of the initial peptide and releasing a great
number of peptides. Previous studies have reported the ability
of pepsin to degrade lunasin, although the levels of the
residual peptide measured after incubation with this gastric
enzyme were diﬀerent in each study. Two immunological
studies revealed the complete disappearance of both synthetic
and soybean-isolated lunasin after 2-min incubation with the
SGF containing pepsin in the absence of BBI.16,17 However, in
BBI-free soymilk, a significant resistance (up to 60%) of
lunasin to pepsin treatment was reported.18 The discrepancies
among the studies could be due to multiple factors, such as
the occurrence of other protease inhibitors, such as Kunitz-
trypsin and the isoinhibitor IBBD2, diﬀerences in the lunasin :
BBI ratio present in products subjected to simulated pepsin
digestion as well as the methodology used to evaluate the per-
centage of residual lunasin after pepsin proteolysis. To quan-
tify lunasin, the MS analysis used shows some advantages in
Fig. 5 Eﬀect on proliferation of human colon adenocarcinoma (A) HT-29 and (B) Caco-2 cells shown by the digests obtained at the end of simu-
lated gastrointestinal digestion from digestion medium without lunasin and IBB1, and lunasin : IBB1 mixtures at diﬀerent ratios and protein concen-
trations, (■) 0.1 mg mL−1, ( ) 0.2 mg mL−1, and ( ) 0.3 mg mL−1. Cell viability was evaluated by the MTT assay. Experiments were carried out in
triplicate, and the results were expressed as a percentage of viable cells compared to control non-treated cells, considered as 100%. Diﬀerent letters
denote statistically signiﬁcant diﬀerences (p < 0.05) between digests at the same protein concentration and the corresponding dilution of digestion
medium without peptides.
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comparison with western-blotting and ELISA methods. On one
hand, this analysis allowed quantification of lunasin that
remained intact after gastric and gastro-duodenal diges-
tion.26,27 On the other hand, the application of MS to assess
digests allowed, for the first time, to identify the peptides
released from lunasin by the action of digestive enzymes.
The qualitative and quantitative data obtained confirm the
protective role of IBB1 against lunasin hydrolysis by both
gastric and pancreatic enzymes. In the presence of active IBB1
at both lunasin : IBB1 ratios, lunasin is partially resistant to
the action of pepsin, with more than 34% of the original
peptide being observed in the gastric digest. Lunasin pro-
tection is not likely associated with pepsin inhibition by
IBB1 given its null or extremely low inhibitory activity against
this gastric enzyme.28,29 The absence of peptides released from
IBB1 during the gastric phase indicated the extraordinary
resistance of this isoinhibitor to pepsin. It is well known that
this resistance to digestive proteases and thermal treatment is
due to its correct folding and functional structure maintained
by the disulphide bridge network.20,30,31 Conformational
changes resulting from the reduction of disulphide bridges
and alkylation of the cysteinyl sulfhydryl groups almost com-
pletely abolish both trypsin and chymotrypsin inhibitory activi-
ties of BBI, decreasing its resistance to enzymes and to high
temperatures.32 Our study confirms that after inactivation of
IBB1 by reduction/alkylation, no inactive IBB1 was visible after
gastric digestion, although the minimum quantity of IBB1
remaining active during the inactivation process was enough
to partly protect lunasin from pepsin action. IBB1-derived pep-
tides released by the action of pepsin might also contribute to
protect lunasin against this gastric enzyme.
In the case of the simulated duodenal phase, the trypsin
and chymotrypsin inhibitory activities of IBB1 were respon-
sible for the protective role on lunasin from digestion by these
enzymes. The absence of IBB1 in digested mixtures provoked
the almost complete disappearance of lunasin, as previously
reported by Hernández-Ledesma et al.18 when BBI-free soymilk
samples were digested with pancreatin over 60 min. However,
the presence of BBI has been suggested to provide protection
from lunasin’s digestion.33 These authors, by using immuno-
logical assays, reported that 3% of lunasin present in lunasin-
enriched soybean was detected at the end of a simulated
pepsin–pancreatin digestion. In our study, when lunasin :
IBB1 mixtures at 1 : 2 ratio were digested, more than 5% of
lunasin remained intact. The consumption of 25 g of soybean
protein per day of a diet low in saturated fat and cholesterol,
recommended by the US Food and Drug Administration to
reduce the risk of heart disease, leads to a total intake of
0.94 g of lunasin.33 Of this oral intake, 5% will survive gastro-
intestinal digestion resulting in 47 mg of biologically active
lunasin, with the ability to act at both local and systemic
levels.
Intact soybean lunasin and IBB1 have demonstrated to
exert anti-proliferative eﬀects against colon cancer using
diﬀerent cell culture models. Dia and de Mejia34,35 reported
the cytotoxic activity of soybean lunasin in colon cancer
HT-29, KM12L4, RKO, and HCT-116 cells. Treatment of HT-29
cells with IBB1 has been described to reduce the cell
proliferation in a concentration and time-dependent manner,
with an IC50 value of 39.9 μM.22 However, to our knowledge,
no information on the potential anti-proliferative eﬀects of
digests obtained from these two bioactive peptides during
their transit through the gastrointestinal tract was available.
In our study, a notable colon cancer HT-29 and Caco2 cell
proliferation inhibitory eﬀect was provoked after incubation
of cells for 24 hours with hydrolyzates obtained at the end
of simulated gastrointestinal digestion. The remaining
lunasin and IBB1 as well as shorter peptides released after the
action of pepsin and duodenal enzymes could be responsible
for the observed eﬀects. To date, only one fragment corres-
ponding to lunasin f(23–43), whose sequence is 23EKHIME-
KIQGRGDDDDDDDDD43, has demonstrated higher anti-
proliferative activity in human breast cancer MDA-MB-231 cells
than complete lunasin.36
A petition has been filed with the Food and Drug Adminis-
tration for a health claim that soy protein consumption as part
of a low fat diet may reduce the risk of certain cancers, includ-
ing colon cancer.37 Among the polypeptides contained in soy
protein, lunasin and naturally occurring protease inhibitors,
such as BBI and Kunitz-trypsin inhibitors, have become the
most extensively studied for their colon cancer preventive pro-
perties.38 Recently, a protein-enriched soybean meal hydro-
lyzate showing high resistance to simulated gastrointestinal
digestion was fractionated and evaluated for its eﬀects on cell
proliferation of colon cancer HCT-116 and Caco2 cells.39 The
highest potency was demonstrated for both the low molecular
weight peptide fraction (<5 kDa) and the fraction containing
polypeptides (10–50 kDa), although the sequences of the
responsible peptides were not elucidated. In our study, at the
end of the simulated gastrointestinal digestive process, 29
lunasin- and 24 IBB1-derived fragments have been identified,
although the presence of each one depended on the mixture
digested. Since the final digests have been found to exhibit
potent anti-proliferative properties against colon cancer HT-29
and Caco2 cells, the peptides liberated from lunasin and
IBB1 might be the main factor responsible for the observed
eﬀects. So far, this is the first study reporting that peptides
directly released from lunasin and IBB1, during their transit
through the gastrointestinal tract, possess anticancer activities.
Further studies are currently ongoing to synthesize these pep-
tides and confirm their potential anti-proliferative eﬀects.
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 75 Results / Resultados 
Supplementary Table S1. Peptides identified in the digests obtained from the lunasin:IBB1 mixtures at different ratios 
after the gastric and intestinal phases of digestive process simulating gastrointestinal conditions. The peak (number or 
letter) corresponds to the peptide peaks and sequences shown in Figures 1, 2, and 3 (number for lunasin-derived 
peptides and letter for IBB1-derived peptides). 
Peak Protein 
fragment 
 
Amino acid sequences 
 
Ion m/z 
(charge) 
Simulated  
gastric digests 
Simulated 
gastrointestinal 
digests 
1:0 1:1 1:2 1:2i 1:0 1:1 1:2 1:2i 
1 f(29-35) KIQGRGD 773.5(+1) + + + - - - - - 
2 f(29-36) KIQGRGDD 888.5(+1) + + + + - - + - 
3 f(29-37) KIQGRGDDD 1003.6(+1) + + - + - - + - 
4 f(29-38) KIQGRGDDDD 1118.6(+1) + + - + - - - - 
5 f(29-39) KIQGRGDDDDD 1233.7(+1) + + + + - - + - 
6 f(28-33) EKIQGR 729.7(+1) + + + + + + + + 
7 f(29-41) KIQGRGDDDDDDD 1463.7(+1) + + + - - + + - 
8 f(29-40) KIQGRGDDDDDD 1348.6(+1) - - + + - + + + 
9 f(29-43) KIQGRGDDDDDDDDD 1694.0(+1) + + + + + + + + 
10 f(11-18) RKQLQGVN 942.7(+1) + + + + - + + + 
11 f(24-28) KHIME  657.5(+1) + + + - + + + - 
12 f(1-8) SKWQHQQD 1056.6(+1) + + + - - + + - 
13 f(1-10) SKWQHQQDSC 1246.7(+1) + + + + - + + + 
14 f(19-23) LTPCE 562.3(+1) + - - - - - - - 
15 f(21-28) PCEKHIME 986.6(+1) + - - - - - - - 
16 f(20-28) TPCEKHIME 1087.6(+1) + - - - - - - - 
17 f(1-18) SKWQHQQDSCRKQLQGVN 1085.8(+2) + + + + - + + - 
18 f(19-28) LTPCEKHIME 1200.8(+1) + + + + - + + + 
19 f(11-19) RKQLQGVNL 1055.8(+1) + + + + - + + + 
20 LUNASIN: 
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGD
DDDDDDDD 
1677.2(+3) 
1258.0(+4) + + + + + + + + 
21 f(17-28) VNLTPCEKHIME 1413.9(+1) + - - - - - - - 
22 f(11-28) RKQLQGVNLTPCEKHIME 1062.8(+2) + - - + - - - + 
23 f(11-20) RKQLQGVNLT 1156.7(+1) - + + - - + + - 
24 f(28-37) EKIQGRGDDD 1133.4(+1) - - - - + - - - 
25 f(4-10) QHQQDSC 845.5(+1) - - - - + - - - 
26 f(34-43) GDDDDDDDDD 1111.4(+1) - - - - + - - - 
27 f(29-33) KIQGR 601.5(+1) - - - - + - - - 
28 f(4-11) QHQQDSCR 1001.6(+1) - - - - + - - - 
29 f(28-32) EKIQG 573.4(+1) - - - - + - - - 
30 f(28-34) EKIQGRG 786.6(+1) - - - - + - - - 
31 f(19-24) LTPCEK 690.5(+1) - - - - + - - - 
32 f(25-28) HIME 529.4(+1) - - - - + - - - 
33 f(29-34) KIQGRG 658.5(+1) - - - - + - - - 
34 f(27-38) MEKIQGRGDDDD 1378.7(+1) - - - - + - - - 
35 f(1-3) SKW 420.4(+1) - - - - + - - - 
36 f(17-24) VNLTPCEK 903.7(+1) - - - - + - - - 
37 f(16-24) GVNLTPCEK 960.6(+1) - - - - + - - - 
38 f(15-24) QGVNLTPCEK 1088.7(+1) - - - - + - - - 
39 f(28-43) EKIQGRGDDDDDDDDD 911.9(+2) - - - - - + - - 
40 f(31-43) QGRGDDDDDDDDD 1451.5(+1) - - - - - - + - 
A f(19-26) PPQCRCSD 1019.5(+1) - - - + - - - + 
B f(14-26) CTKSNPPQCRCSD 1609.8(+1) - - - + - - - + 
C f(1-13) DDESSKPCCDQCA 1571.7(+1) - - - + - - - + 
D f(1-15) DDESSKPCCDQCACT 1832.8(+1) - - - + - - - + 
E f(16-27) KSNPPQCRCSDM 1479.7(+1) - - - + - - - + 
F f(24-35) CSDMRLNSCHSA 719.3(+2) - - - + - - - - 
 76 Results / Resultados 
G f(30-42) NSCHSACKSCICA 1554.7(+1) - - - + - - - + 
H f(58-71) CYEPCKPSEDDKEN 885.9(+2) - - - + - - - - 
I f(58-66) CYEPCKPSE 1169.6(+1) - - - + - - - + 
J f(51-56) CVDITD 722.4(+1) - - - + - - - + 
K f(46-50) PAQCF 622.4(+1)  - - - + - - - + 
L f(43-49) LSYPAQC 838.4(+1) - - - + - - - - 
M f(57-71) FCYEPCKPSEDDKEN 959.5(+2) - - - + - - - + 
N f(61-71) PCKPSEDDKEN 1318.7(+1) - - - + - - - - 
O f(27-29) MRL 419.3(+1) - - - + - - - + 
P f(57-67) FCYEPCKPSED 1431.7(+1) - - - + - - - + 
Q f(57-66) FCYEPCKPSE 1316.7(+1) - - - + - - - + 
R f(43-50) LSYPAQCF 985.5(+1) - - - + - - - + 
S f(51-57) CVDITDF 869.4(+1) - - - + - - - + 
T IBB1: 
DDESSKPCCDQCACTKSNPPQCRCSDMRLNSCHSAC
KSCICALSYPAQCFCVDITDFCYEPCKPSEDDKEN 
1572.8(+5) 
1310.7(+6) - + + + - + + - 
U f(2-7) DESSKP 661.3(+1) - - - - - - - + 
V f(16-22) KSNPPQC 830.5(+1) - - - - - - - + 
W f(17-23) SNPPQCR 858.4(+1) - - - - - - - + 
X f(16-23) KSNPPQCR 986.6(+1) - - - - - - - + 
Y f(17-26) SNPPQCRCSD 1220.6(+1) - - - - - - - + 
Z f(31-42) SCHSACKSCICA 1440.7(+1) - - - - - - - + 
α f(28-42) RLNSCHSACKSCICA 912.5(+2) - - - - - - - + 
β f(46-49) PAQC 475.2(+1) - - - - - - - + 
γ f(54-57) ITDF 495.2(+1) - - - - - - - + 
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Transepithelial transport of lunasin and derived peptides with 
inhibitory effects on the viability of gastrointestinal cancer cells   
S. Fernández-Tomé,
a
 J. Sanchón,
a
 I. Recio
a 
and B. Hernández-Ledesma
a,
† 
Lunasin is a soybean peptide with demonstrated chemopreventive properties. Upon its oral intake, studies dealing with 
the effect of the digestive process on lunasin’s properties are crucial. The present study describes, for the first time, the 
behavior of lunasin and fragments derived from its digestion in the Caco-2 cell monolayer. The sequences SKWQHQQDSC 
and KIQGRGDDDDDDDDD showed a notable resistance against the epithelial brush-border peptidases, although some 
fragments were generated as cellular hydrolysis products. Lunasin and RKQLQGVN were absorbed intact across the 
intestinal epithelium. The tight junction disruptor cytochalasin D, increased their transport, suggesting that the 
paracellular passive diffusion was the main mechanism involved. The study on the cancer cells viability showed that 
lunasin and SKWQHQQDSC exerted the highest effects on colorectal cancer HT-29 cells. The stability of lunasin during the 
activity assay suggested that the cell line type might be determinant for the different effect of lunasin-derived sequences. 
1. Introduction 
The gastrointestinal epithelium acts not only as a physical 
barrier against the external environment, but also is the place 
where food digestion and absorption of nutrients occur. The 
gastrointestinal tract is known to play a key role on the 
physiological relevance of orally administered bioactive 
components.
1
 Firstly, the resistance of bioactive peptides to 
pepsin and pancreatic enzymes in gastric and intestinal fluids, 
respectively, must be one of the primary aspects to be 
addressed before their potential application into functional 
foods or drugs.
2
 Moreover, other factors such as the epithelial 
brush-border membrane peptidases, the absorption rate 
through the intestinal barrier, the possibility of active 
intracellular peptidases in case of transcellular transport, as 
well as the potential action of serum peptidases can be 
determinant leading to the formation and/or degradation of 
bioactive peptides upon oral administration. These peptides 
might be absorbed and reach the target tissues acting at 
systemic level or exert their effects locally in the 
gastrointestinal tract. 
In the last years, several studies have employed in vitro 
gastrointestinal digestion and Caco-2 cell absorption models to 
estimate the bioavailability of bioactive peptides.
3
 The human 
Caco-2 cells are able to spontaneously differentiate into 
enterocyte-like monolayers with morphological polarity with 
an apical and basolateral side, and develop feature 
characteristics such as apical microvillus and brush-border 
hydrolases, intercellular tight junctions (TJs), and active 
receptors and transport systems, including those for peptide 
transport.
4
 Among the several routes described for the 
transport of peptides in the gut, the main mechanisms include 
the PepT1, a proton-coupled membrane transporter,
5
 the 
paracellular passive pathway through intercellular TJs, the 
transcellular passive diffusion, and the vesicle-mediated 
transcytosis.
6
 For oligopeptides, susceptibility to brush-border 
peptidases has been recognized as the primary factor affecting 
to the apical-to-basolateral transport rate, with both the 
paracellular and transcytosis transports identified as the 
principal involved mechanisms.
7 
Lunasin is a 43-amino acid peptide naturally present in 
soybean and other legumes, with a variety of biological 
functions demonstrated by in vitro cell cultures and animal 
models.
8
 In vitro studies simulating the gastrointestinal 
digestion have proposed that this peptide was able to resist 
the action of digestive enzymes due to naturally present 
protease inhibitors in foods, such as Bowman-Birk protease 
inhibitor (BBI) and Kunitz trypsin inhibitor.
9, 10
 Moreover, Hsieh 
and co-workers
11
 showed that lunasin was bioavailable when 
orally administered to mice and rats, and Dia et al.
12
 reported 
the presence of this peptide in human plasma after 
consumption of soy protein. These findings suggest that 
lunasin is absorbed in the intestine and reaches the 
bloodstream. Although brush-border intestinal peptidases are 
key factors limiting the half-life and leading to the 
transformation of dietary peptides in the digestive tract,
13
 to 
our knowledge, the behaviour of the lunasin sequence in 
contact with this epithelial membrane has not been previously 
evaluated. 
Our group has recently identified the peptide patterns of 
gastric and gastrointestinal digests of lunasin by in vitro 
digestion and reverse phase-high liquid chromatography 
coupled with tandem mass spectrometry (HPLC-MS/MS) 
analysis, confirming the protective role played by the major 
Bowman-Birk family isoinhibitor (IBB1) on the digestion of this 
peptide. Moreover, the final digests were found to exhibit 
anti-proliferative properties against the growth of colorectal 
cancer HT-29 and Caco-2 cells.
14
 Thus, the present study aims 
to investigate whether lunasin and selected lunasin-derived 
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fragments arising from its digestion are resistant to brush-
border peptidases and susceptible to intestinal transepithelial 
transport in Caco-2 monolayers. Selective inhibitors of 
different transepithelial routes were evaluated to identify the 
potential mechanism involved in the intestinal absorption. 
Additionally, the anti-proliferative effect of these peptides on 
human adenocarcinoma gastric (AGS) and colorectal (HT-29 
and Caco-2) cells was assessed.  
 
2. Experimental 
2.1. Reagents and peptides 
Hanks´ balanced salt solution (HBSS), trifluoroacetic acid, Lucifer 
yellow, cytochalasin D, wortmannin, dimethylsulfoxide (DMSO) and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) were purchased from  Sigma Chemical Co. (Madrid, Spain). 
The rest of chemicals used were of HPLC grade. 
 Lunasin and lunasin-derived peptides used in this study (Table 
1) were provided by Chengdu KaiJie Biopharm Co., Ltd (Chengdu, 
Sichuan, P. R. China) that synthesized them by the conventional 
Fmoc solid-phase synthesis method.  
 
Table 1. Synthetic lunasin and lunasin-derived peptides released after an in 
vitro simulated digestion model 
 
 
2.2. Cell cultures 
The human gastric adenocarcinoma cell line (AGS) and two human 
colorectal adenocarcinoma cell lines (HT-29 and Caco-2) were 
obtained from the American Type Culture Collection (ATCC, 
Rockville, MD, USA). AGS, HT-29 and Caco-2 cells were grown in 
RPMI medium (Biowest, Nuaillé, France), McCoy´s medium (Lonza 
Group Ltd, Basel, Switzerland), and Dulbecco´s Modified Eagle 
Medium (DMEM, Biowest), respectively, supplemented with 10% 
(v:v) fetal bovine serum (FBS, Biowest) and 1% (v:v) 
penicillin/streptomycin/amphotericin B solution (Biowest). A non-
essential amino acid solution (Lonza Group Ltd) was also added to 
DMEM medium (1%, v:v) for the culture of Caco-2 cells. Cells were 
maintained in plastic 75-cm
2
 culture flasks at 37 ºC in a humidified 
incubator containing 5% CO2 and 95% air. The culture medium was 
changed every two days, and cells were kept sub-confluent by using 
trypsin/EDTA (Lonza Group Ltd) weekly. 
 
2.3. Transport studies  
2.3.1. Culture of Caco-2 monolayers 
Caco-2 cells were used to evaluate the transepithelial transport of 
peptides following the recommendations described by Hubatsch et 
al.
15
 Cells were seeded onto 12-well Transwell polycarbonate 
permeable membrane supports (12 mm diameter, 0.4 μm pore size, 
1.12 cm
2
 growth surface area, Costar, Corning, NY, USA) at a density 
of 1.5 × 10
5
 cells/filter, with 0.5 mL of suspended cells in the apical 
chamber and 1.5 mL of DMEM in the basolateral side. Filters were 
pre-wet with 0.1 mL of DMEM before seeding. Medium was 
replaced at days four and seven after seeding, and 24 h before the 
experiment. To allow transport studies, cells were used nine days 
after seeding. Previous to the assay, the integrity of the monolayer 
of differentiated cells was evaluated by measuring the 
transepithelial electrical resistance (TEER) value with an EVOM 
epithelial volt/ohm meter (World Precision Instruments, Sarasota, 
FL, USA). Cells monolayers with values higher than 400 Ω × cm
2
 
were considered confluent and used in the assays.
16
  
 
2.3.2. Transepithelial transport of peptides 
Transport experiments were performed as described by Quirós and 
co-workers,
17
 with some modifications. Filters were rinsed by 
transferring cell monolayers in DMEM into new 12-well plates 
(Costar) containing HBSS (1.5 mL) in the basolateral side, and by 
carefully adding HBSS (0.5 mL) to the apical side. Filters were 
equilibrated at 37 ºC for 20 min. Then, peptides were dissolved in 
HBSS *lunasin at 10 μM, and fragments f(1-10), f(11-18), f(19-28), 
and f(29-43) at 1000 μM+, and added to the apical chamber. 
Transwell cultures were incubated at 37 ºC for 60 min, and apical 
and basolateral samples were withdrawn, freeze-dried, and kept at 
– 20 ºC until analysis by HPLC-MS/MS. At the end of transport 
experiments, TEER values were measured again and the flux of 
Lucifer Yellow (a marker for paracellular permeability) was 
monitored. Chambers were rinsed with HBSS and incubated at 37 
ºC for 30 min. Afterwards, Lucifer Yelow in HBSS (50 μM) was added 
to the apical compartment and incubated at 37 ºC for 60 min. 
Aliquots from both the apical and the basolateral sides were taken, 
and fluorescence levels were determined (excitation 485 nm and 
emission 520 nm) in a FLUOstar OPTIMA plate reader (BMG 
Labtech, Offenburg, Germany). The post-assay TEER values and the 
Lucifer Yellow transport (<1% added to apical chamber) were used 
as parameters to confirm the Caco-2 monolayer integrity during 
experiments.
18
 At least, three independent replicates per peptide 
were evaluated, and the apparent permeability coefficient (Papp, 
cm/s) was calculated according to Contreras et al.
19
 as Papp = 
 ; where  is the transport rate (μmol/s), A is the 
surface area of the membrane (1.12 cm
2
), and C0 is the initial 
peptide concentration in the apical chamber (μmol/mL). 
To study the mechanism involved in the transepithelial 
transport of peptides, prior to the experiments described above, 
cell monolayers were incubated with cytochalasin D (a TJs 
disruptor, 0.5 μg/mL) and wortmannin (a transcytosis inhibitor, 500 
nM) for 30 min before addition of peptides.
17
 Cytochalasin D and 
wortmannin were dissolved in DMSO (final concentration in HBSS 
0.044%). As control, DMSO supplementation was used. Experiments 
were carried out in duplicate, and peptide quantification in the 
basolateral side was expressed as relative percentage of control. 
 
2.4. Analysis by HPLC-MS/MS 
Analysis of synthetic peptides and samples from apical and 
basolateral solutions was carried out as previously described,
14
 with 
minor modifications. Peptides were eluted with a linear gradient of 
solvent B (acetonitrile:trifluoroacetic acid, 1000:0.27, v/v) in solvent 
A (water:trifluoroacetic acid, 1000:0.37, v/v) going from 0% to 45% 
in 60 min. Spectra were recorded over the mass/charge (m/z) 200-
2000, selecting the molecular ion of peptides as the target mass, 
m/z 1258 (lunasin), m/z 1247 [f(1-10)], m/z 943 [f(11-18)], m/z 1201 
[f(19-28)], and m/z 1694 [f(29-43)]. Peptides were identified by 
their retention times and fragmentation profiles. Data obtained 
were processed and transformed to spectra representing mass 
values using the Data Analysis program (version 4.0, Bruker 
Peptide  Amino acid sequence Purity 
(%, by HPLC) 
Lunasin (1-43) SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD 98.9 
f(1-10)a SKWQHQQDSC 87.6 
f(11-18)a RKQLQGVN 89.6 
f(19-28)a LTPCEKHIME 75.7 
f(29-43)a KIQGRGDDDDDDDDD 68.7 
f(17-28)a VNLTPCEKHIME 73.0 
f(29-41)a KIQGRGDDDDDDD 76.1 
f(34-43)a GDDDDDDDDD 86.1 
   
a Lunasin-derived fragments were identified by Cruz-Huerta et al.14  
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Daltonik). To process the MS/MS spectra and to perform peptide 
sequencing BioTools (version 3.2, Bruker Daltonik) was used. 
 Previous to the analysis, for lunasin transport experiments (10 
µM), freeze-dried samples from apical and basolateral solutions 
were reconstituted in the initial volume, or concentrated twenty 
times, respectively, in Milli-Q water. In the case of the four lunasin-
derived peptides (1000 µM), apical samples were reconstituted in 
the initial volume and then diluted 1:24 (v:v), and basolateral 
samples were concentrated ten times. Five-point external 
calibration curves were prepared with synthetic lunasin (from 0.5 to 
10.0 µM), and lunasin-derived fragments (from 0.9 to 46.4 µM). 
Duplicate injections were performed for each point of the 
calibration curve. The area under the curve of the extracted 
molecular ions of peptides and their sodium and potassium 
adducts, when formed, was measured and linear or polynomial 
regression curves were estimated depending on the fit: lunasin, 
 (R
2
=0.998); f(1-10), 
 (R
2
=0.994); f(11-18),  (R
2
=0.976); 
f(19-28),  (R
2
=0.992); and f(29-43), 
 (R
2
=0.996). 
 
2.5. Cell viability experiments 
2.5.1. MTT assay 
The MTT assay was performed to evaluate the effect of peptides on 
the viability of AGS, Caco-2 and HT-29 cells. Cells were seeded in 96-
well plates (Costar) at a density of 5 × 10
3
 cells/well (AGS),
20
 and 5 × 
10
4
 cells/well (Caco-2 and HT-29).
21 
After 24 h incubation, cells were 
treated with lunasin and all lunasin-derived fragments (Table 1) at 
different concentrations (10, 50, 100, and 200 μM) for 24, 48, and 
72 h. After the different treatment times, cells were washed with 
phosphate buffer saline (PBS, Lonza Group Ltd), and incubated for 2 
h with a MTT solution (0.5 mg/mL final concentration). The 
supernatants were discarded and insoluble formazan crystals 
formed were dissolved in DMSO:ethanol (1:1, v:v). After gently 
mixing, the absorbance was measured at 570 nm in a FLUOstar 
OPTIMA plate reader (BMG Labtech). Experiments were carried out 
in triplicate and results were expressed as percentage of the 
control, non-treated cells.   
 
2.5.2. Morphological analysis 
AGS, Caco-2 and HT-29 cells were plated in 6-well plates (Costar) at 
a density of 5.0 × 10
5
, 3.5 × 10
4
 and 6.7 × 10
5
 cells/well, 
respectively. After 24 h incubation, cells contained in four of six 
wells were treated with lunasin (100 and 200 μM) for 48 h. Two 
wells were used as control (untreated) cells. Afterwards, cell images 
were taken by using an optical microscope Leica DM2500 (Leica 
Lasertechnik GmbH, Mannheim, Germany) at 10X magnification, 
coupled to a camera Leica DFC420 C (Leica Lasertechnik GmbH). 
This assay was carried out in duplicate. 
 
2.5.3. Stability of lunasin 
AGS, Caco-2 and HT-29 cells were plated as described above for 
morphological analysis, and treated with 10 μM lunasin for 72 h, 
taking aliquots of the medium at 0, 2, 24, 48, and 72 h of 
incubation. Aliquots of cultures with non-treated medium were also 
taken at these times. Samples were evaluated in duplicate and 
analysed by HPLC-MS/MS as indicated above for transepithelial 
transport experiments. 
 
2.6. Statistics 
Data were analyzed using GraphPad Prism 5.03 software (San 
Diego, CA, USA) by a one-way ANOVA, followed by the Bonferroni 
post hoc test. Differences with a P value < 0.05 were considered 
significant.  
 
3. Results and Discussion 
3.1. Effect of epithelial peptidases on lunasin and lunasin-
peptides  
In a previous study, our group had demonstrated that more than 
5% of synthetic lunasin resisted at the end of an in vitro simulated 
pepsin-pancreatin digestion when IBB1 was present (lunasin:IBB1 
ratio of 1:2, w:w). Moreover, the peptides released in the gastric 
and gastrointestinal digests of lunasin were identified by HPLC-
MS/MS.
14 
Therefore, in this transepithelial study, the lunasin-
derived peptides f(1-10), f(11-18), f(19-28), and f(29-43) arising 
from its digestion were selected according to their proved 
resistance to the gastrointestinal enzymes. In order to evaluate a 
possible structure/activity relationship, peptide lunasin and these 
four digestion fragments integrating the complete 43-amino acid 
sequence were assessed in Caco-2 monolayers for their resistance 
to brush-border peptidases and intestinal transport. 
 The integrity of the Caco-2 monolayers was confirmed by 
measuring TEER values and the flux of Lucifer Yellow before and 
after the experiments. Cell monolayers maintained intact along the 
incubation with lunasin-derived peptides at 1000 μM. However, 
lunasin at 50-1000 μM affected the integrity of the monolayers 
showing a reduction effect on the TJs strength. Lunasin at 10 μM 
did not exert a drop on TEER values. Previous studies carried out in 
our group had demonstrated that lunasin at concentrations ranged 
from 0.5 to 25 M did not damage cell integrity during the period of 
incubation of this peptide with differentiated human Caco-2,
16
 and 
liver HepG2 cells.
22
 Thus, 10 M was the concentration selected to 
carry out the following transport studies. As illustrated in Figure 1A, 
lunasin was shown to reduce its concentration in a 42.8% ± 1.3, 
while lunasin-peptides f(11-18) and f(19-28) remained intact in a 
79.7 ± 2.1 and 78.7% ± 8.4 of the initial peptide added, respectively. 
However, peptides f(1-10) and f(29-43) maintained nearly intact 
after 60 min incubation with Caco-2 peptidases. This confers further 
resistance for these peptides in the intestine epithelium, beyond 
that was previously shown against pepsin and pancreatic 
proteases.
14
 Similarly, some food-derived antihypertensive peptides 
from milk caseins which sequences were VPP and IPP,
23
 and 
HLPLP,
17
 and from egg white QIGLF,
24
 and the immunomodulatory 
peptide β-casein f(193-209)
25 
have shown remarkable resistance 
against intestinal brush-border peptidases. As shown in Figure 1B, 
when lunasin was added to the apical side of Caco-2 monolayers, 
brush-border intestinal peptidases were found to cleave at the 
central region at the peptide bonds 
15
Q-G
16
, 
18
N-L
19
, 
19
L-T
20
, 
22
C-E
23
, 
and 
23
E-K
24
. These findings suggest a higher susceptibility to 
epithelial peptidases for the central region of lunasin sequence than 
the N- and C-terminal domains. Interestingly, this central region 
sited between amino acids 11 and 28 was also described to be 
predominantly cleaved by pepsin and pancreatin when lunasin was 
subjected to a two-stages hydrolysis process simulating 
gastrointestinal digestion in absence of IBB1, but enclosed and 
protected from the enzymatic action when the protease inhibitor 
was present.
14 
In the case of the lunasin-derived peptides, the fragments found 
were mostly formed as consequence of cleavages at the N-terminus 
(Figure 1B). Caco-2 cells have been demonstrated to express up to 
eight membrane peptidases on the apical side. Among them, the 
serine protease dipeptidyl peptidase IV (DPPIV) that predominantly 
cleaves at the N-terminal position has shown to have the highest
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Figure 1. Behaviour of lunasin and lunasin-fragments added to Caco-2 
monolayers. Analysis by HPLC-MS/MS of peptides in apical solutions after 
incubation of lunasin 10 µM and lunasin-fragments 1000 µM with Caco-2 
monolayers for 60 min. (A) Remaining intact peptide in apical solutions was 
evaluated by the extracted molecular ions of lunasin mass/charge (m/z) 
1258.0 (charge +4) and m/z 1677.2 (charge +3), f(1-10) m/z 1246.3 (charge 
+1), f(11-18) m/z 942.3 (charge +1), f(19-28) m/z 1200.7 (charge +1), and 
f(29-43) m/z 1694.0 (charge +1). Sodium and potassium adducts were 
considered, when formed. Data are represented as relative percentage of 
initial peptide added to the chamber, and expressed as mean ± standard 
error of the mean (SEM) of at least three independent replicates. (B) Intact 
peptides presented in the apical chamber and derived fragments released 
by brush-border intestinal peptidases are shown. Sequence of peptide 
added to the apical solution is marked with an arrow: Lunasin, 
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD; f(1-10), 
SKWQHQQDSC; f(11-18), RKQLQGVN; f(19-28), LTPCEKHIME; and f(29-43), 
KIQGRGDDDDDDDDD. 
 
 
activity, especially when Caco-2 cells are completely 
differentiated.
26
 Besides, N-terminal hydrophobic or basic amino 
acid residues represented a preferred substrate for the enzymatic 
action of DPPIV, while proline residue was fairly resistant.
27
 
Degradation by DPPIV presumably occurred at the peptide bonds 
1
S-K
2
 in f(1-10), 
11
R-K
12 
in f(11-18), 
19
L-T
20 
in f(19-28), and 
29
K-I
30 
in 
f(29-43), while the peptide bond 
20
T-P
21 
maintained its integrity. The 
effect of DPPIV enzyme had been also suggested to be responsible 
for the N-terminal degradation of bioactive peptides LHLPLP,
17
 
FRADHPFL,
28
 RYLGY and AYFYPEL,
19
 and RVPSL,
29
 in Caco-2 
monolayers. 
 These results imply the relevance of the resistance to the 
epithelial brush-border membrane to evaluate the bioavailability of 
bioactive peptides. Despite the enzymatic attack shown on lunasin 
and derived fragments prior to their possible transport, these 
peptides have shown a notable resistance against Caco-2 
peptidases, especially f(1-10) and f(29-43), when compared to other 
bioactives peptides such as the µ-opioid receptor agonists β-
casomorphin-5 and -7 from both bovine,
30
 and human
31
 origins that 
nearly disappeared after incubation in the apical side of Caco-2 
monolayers. 
  
3.2. Transepithelial transport of lunasin and lunasin-
fragment f(11-18) 
Analysis by HPLC-MS/MS of standard curves prepared with five-
point dilutions of synthetic peptides allowed the quantification of 
peptides in the basolateral solutions. Only peptides lunasin and 
f(11-18) were absorbed through the cell monolayer, while the rest 
of lunasin-fragments were not detected at the basolateral side. Any 
of the released fragments by the action of brush-border peptidases 
were able to flux across the Caco-2 monolayer. After 60 min 
incubation in the apical compartment, the Papp values calculated for 
the apical-to-basolateral transport of lunasin and f(11-18) were 3.32 
× 10
-7
 cm/s and 2.50 × 10
-7
 cm/s, respectively (Figure 2A). These 
values were similar to those found for other bioactive peptides on 
this transepithelial model such as AYFYPEL (2.60 × 10
-7
 cm/s) and 
RYLGY (2.20 × 10
-7
 cm/s),
19
 and VLPVP (2.78 × 10
-7 
cm/s).
32
 Several 
studies have been focused on the in vitro transport of bioactive 
peptides through Caco-2 monolayers, with different permeability 
values reported for peptides VPP and IPP (0.50 and 1.00 × 10
-8
  
cm/s, respectively),
33
 RVPSL (6.97 × 10
-6
 cm/s),
29
 and SRYPSY 
(casoxin-6, 9.21 × 10
-6
 cm/s).
30
  
Further experiments were conducted in order to evaluate the 
mechanism involved in the transepithelial transport of intact 
peptides lunasin and f(11-18). Three main mechanisms have been 
described for the flux of peptides across intestinal epithelium, the 
PepT1-mediated transport, the TJs-mediated paracellular pathway, 
and the vesicle-mediated transcytosis route.
34
 Peptides longer than 
three amino acids residues have been described as not substrates 
for the PepT1 transporter.
35
 Therefore, in this study, Caco-2 
monolayers were pre-incubated with wortmannin (a transcytosis 
inhibitor), and cytochalasin D (a TJs disruptor) for 30 min before the 
transepithelial experiments.
17
 As illustrated in Figure 2B, the 
presence of wortmannin hardly modified the intensity of neither 
peptides lunasin nor f(11-18) in the basolateral chamber, suggesting 
that the vesicle-mediated mechanism was not involved on the 
transport of these peptides, in disagreement with other peptides 
such as the β-casein f(193-209).
25
 However, cytochalasin D was 
shown to induce an approximately 1.5-fold increase in the presence 
of both lunasin and f(11-18) compared to controls. The enhanced 
transport was accompanied by a TEER value decrease (21.2% 
average), which also pointed toward the involvement of an 
expanded intercellular effect on the peptides flux.
25
 The 
paracellular route is characterized by the passive diffusion of 
molecules between adjacent cells, and is regulated by the 
intercellular TJs forming a biological barrier with selective 
permeation function.
2
 The aqueous nature of this pathway makes it 
favourable for the absorption of water-soluble substances including 
oligopeptides,
36
 and allows the flux to the basolateral side avoiding 
the enzymatic role of intracellular peptidases. Together these 
findings suggested that the paracellular pathway via TJs was the 
mainly route for the transepithelial transport of lunasin and f(11-
18), consistent with the transport of many peptides, such as VPP,
37
 
GGYR,
7
 HLPLP,
17
 QIGLF,
24
 RVPSL,
29
 TNGIIR,
38
 and VLPLP.
32
 In 
addition, the permeability of paracellular-transported compounds 
has been considered to be underestimated in Caco-2 monolayers 
because of the colonic origin of these cells that present a relatively 
higher TJs tightness in comparison with human or animal small 
intestinal epithelial cells,
39
 which ultimately might imply a higher in 
vivo transepithelial transport for the peptides lunasin and derived 
fragment f(11-18), than that found in this study. 
 
 
 
 
Assayed 
peptide 
 Peptides detected in the apical chamber 
Lunasin   S  K  W Q  H  Q  Q  D  S  C  R  K  Q  L  Q  G  V  N  L  T  P  C  E  K  H  I  M  E  K  I  Q  G  R  G  D  D  D  D  D  D  D  D  D  
 S  K  W  Q  H  Q  Q  D  S  C  R  K  Q  L  Q      T  P  C  E  K  H  I  M  E  K  I Q  G  R  G  D  D  D  D  D  D  D  D  D  
 S  K  W  Q  H  Q  Q  D  S  C  R  K  Q  L  Q  G V N     E  K  H  I  M  E  K  I  Q  G  R  G  D  D  D  D  D  D  D  D  D  
 S  K  W  Q  H  Q  Q  D  S  C  R  K  Q  L  Q  G V N L     K  H  I  M  E  K  I  Q  G  R  G  D  D  D  D  D  D  D  D  D  
f(1-10)  S  K  W  Q  H  Q  Q  D  S  C                                   
  S  K  W  Q  H  Q  Q  D                                     
   K  W  Q  H  Q  Q  D  S  C                                   
f(11-18)          
 
 R  K  Q  L  Q  G  V  N                           
             K  Q  L  Q  G  V  N                           
f(19-28)                  
 
 L  T  P  C  E  K  H  I  M  E                 
                     T  P  C  E  K  H  I  M  E                 
                       C  E  K  H  I  M  E                 
f(29-43)                            
 
 K  I  Q  G  R  G  D  D  D  D  D  D  D  D D 
                               I  Q  G  R  G  D  D  D  D  D  D  D  D D 
 
(B) 
(A) 
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Figure 2. Transepithelial transport of peptides lunasin and f(11-18), 
RKQLQGVN. (A) Peptides were analyzed by HPLC-MS/MS in the basolateral 
solutions after incubation of 10 µM lunasin and 1000 µM lunasin-fragment 
f(11-18). The apparent permeability coefficient (Papp) was calculated as 
described in Materials and methods section, and represented as mean ± 
standard error of the mean (SEM) of at least three independent replicates 
per assayed peptide. (B) Effects of cytochalasin D and wortmannin on the 
transepithelial transport of peptides. Cells were pre-incubated with 
cytochalasin D (0.5 μg/mL) and wortmannin (500 nM) for 30 min, or Hanks’ 
Balanced Salt Solution (HBSS) with 0.044% dimethylsulfoxide (DMSO) 
(control), before addition of 10 µM lunasin and 1000 µM lunasin-fragment 
f(11-18). Experiments were carried out in duplicate, and results were 
represented as relative peptide intensity in the basolateral chamber (% of 
control, mean ± SEM). (*, P < 0.05) denotes statistically significant 
differences versus control by a one-way ANOVA followed by the Bonferroni 
post hoc test. 
 
This is the first study that evaluates the behaviour of lunasin 
and some digestion-fragments on the Caco-2 monolayer. Artursson 
and Karlsson
40 
established an association between the Papp 
coefficient in Caco-2 cells and the oral drug in vivo absorption. Later 
on, numerous studies on this cellular model have also found a high 
correlation for several compounds compared to the human 
intestinal transport.
41, 42
 In this sense, Dia et al.
12
 estimated in 
humans an average of 4.5% lunasin absorption from the total 
lunasin ingested in 50 g of soy protein, which is in agreement with 
the Papp coefficient found in this study (3.32 × 10
-7 
cm/s). Regarding 
the absorption of lunasin, a relative long 43-amino acid peptide, it is 
worthy to mention that other polypeptides in this size range such as 
the therapeutics 32-amino acid calcitonin, and 51-amino acid insulin 
have been also reported to be transportable in the Caco-2 model.
39
 
This is similar to the flux found for some dietary whey protein-
derived peptides in the β-lactoglobulin sequence f(114-146).
43
 The 
lunasin f(11-18) was the only fragment in this study resembling the 
transepithelial behaviour of the parent peptide. The RGD-motif 
found in lunasin sequence at amino acids 33-35 had been 
demonstrated to allow the attachment of this peptide to the 
extracellular matrix, suggesting its role in the internalization into 
mammalian cells.
44
 Besides, RGD-motif was suggested as the 
recognizing sequence for the α5β1 integrin-mediated 
antiproliferative activity of lunasin on colorectal cancer cells.
45
 
Nevertheless, in this study, the RGD-containing peptide f(29-43) 
was not transported across the Caco-2 monolayer. It may be 
hypothesised whether peptide f(11-18) was the presumable target 
sequence for the intact absorption of complete lunasin across the 
intestinal epithelium. However, more studies by modifying this 
region of the sequence are thus required to confirm these findings. 
 
3.3. Effects of lunasin and derived peptides on the viability 
of gastric and colorectal cancer cells  
Several food-derived peptides have been described to exert 
potential chemo-preventive properties against the proliferation of 
malignant cells.
46
 Peptide lunasin has demonstrated anti-
proliferative activity in colorectal cancer HCT-116, HT-29, KM12L4, 
and RKO cells.
21, 45
 Cruz-Huerta et al.
14
 recently showed an 
inhibitory effect for the gastrointestinal digests of lunasin:IBB1 
mixtures in colorectal cancer HT-29 and Caco-2 cells, suggesting 
that remaining intact peptides and derived fragments directly 
released after their enzymatic digestion could be the responsible 
agents for the observed protective effects. In this study, lunasin and 
some new derived fragments (Table 1) were thus evaluated for 
their potential anti-proliferative effect in the gastrointestinal tract 
by the MTT protocol.  
As shown in Figure 3, peptide lunasin affected the viability of 
the three cell lines, with relatively higher effects on HT-29 cells. 
After 24 h treatment, lunasin provoked a ca. 10% significative 
induction of non-viable cells at all concentrations assessed (Figure 
3A). However, after 48 and 72 h treatment, a dose-dependent 
statistical trend was found for lunasin activity with the maximum 
inhibitory effect found at 200 µM (19.1 and 23.8%, respectively). 
Moreover, a time-dependent lunasin´s effect was revealed, showing 
a significant enhanced activity for this peptide at 50-200 µM from 
24 to 72 h (12.4% average). Dia and de Mejia
21
 had previously found 
that lunasin induced a cytotoxic effect ranging from 19.3% (10 µM) 
to 62.8% (100 µM) on HT-29 cells. While these authors assessed the 
activity of purified lunasin (~90%) from defatted soybean flour, we 
have evaluated the effect of the synthetic peptide. The lower 
activity found in this study might be due to differences in the 
secondary and tertiary structures between plant-purified lunasin 
and the synthetic peptide. In Caco-2 cells, lunasin 50-200 µM, and 
10-200 µM was able to induce an average ca. 10% significant 
increase on the number of non-viable cells after 24 and 48 h 
treatment, respectively (Figure 3B). In these cells, a dose-
dependent trend was not clearly shown, however a notable time-
dependent difference was demonstrated at 72 h. At this time no 
anti-proliferative outcome was shown, suggesting that lunasin´s 
effects at 24 and 48 h were insufficient to induce a marked 
inhibition on treated cells, which were found to recover and growth 
at the same ratio as control cells after 72 h. As shown in Figure 3C, 
lunasin showed a significant dose-dependent activity in AGS cells. 
At 10 and 50 µM, this peptide did not present any statistical 
difference from control cells. However, lunasin 100 and 200 µM 
modestly induced an average inhibitory effect ca. 7% and 15%, 
respectively. Figure 4 illustrates the morphological analysis of non-
treated and lunasin-treated cells, which showed a visual change in 
viable cells as compared with the homogenous growth of control 
cells over the plate. With these results, it is not possible to know 
the mechanisms responsible for the effects of lunasin on MTT, thus 
additional experiments would be required. Together these findings 
indicated the higher susceptibility of HT-29 cells than both Caco-2
ARTICLE Food & Function 
6 | This journal is © The Royal Society of Chemistry 20xx 
  
Figure 3. Effects of lunasin on cancer cells viability. Cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay after treatment of human adenocarcinoma colorectal (A) HT-29 and (B) Caco-2 cells and (C) gastric cancer AGS cells with lunasin (10-200 µM, 24-72 h). 
Results were expressed as percentage of non-viable cells compared to control, considered as 0% (% of control, mean ± standard error of the mean, SEM). 
Experiments were carried out in triplicate, and analysed by a one-way ANOVA followed by the Bonferroni post hoc test. Lower case letters denote 
statistically significant differences (P < 0.05) between doses and control, considered as (a). Capital letters denote statistically significant differences (P < 0.05) 
for the same dose between treatment times. 
 
 
Figure 4. Morphological analysis. Representative images, taken by using an optical microscope at 10X magnification, of HT-29, Caco-2, and AGS (A-C, 
respectively) non-treated cells, and (D-F, respectively) lunasin-treated cells (200 µM, 48 h). Lunasin-treated cells showed areas with minor cellular density 
(arrows), compared to non-treated control cells presenting a continuous growth over the plate. 
 
and AGS cells to peptide lunasin, in agreement with previous results 
that found a more evident anti-proliferative effect for lunasin:IBB1 
gastrointestinal digests on the former colorectal cancer cells.
14
 
Likewise, the cytotoxic activity of this peptide has been proposed to 
be dependent on the type of cell line treated with inhibitory 
concentration (IC50) values ranging from 13 µM in colorectal cancer 
KM12L4 cells
45
 to 181 µM in breast cancer MDA-MB-231 cells.
47 
Following the same methodology, gastric and colorectal cancer 
cells were treated with seven lunasin-derived peptides (10-200 µM, 
24-72 h). In HT-29 cells, peptide f(1-10) induced a time-dependent 
trend on the percentage of non-viable cells compared to control 
non-treated cells (Figure 5A). This peptide showed an increasing 
effect with the dose at 24 h from 9.4% to 15.1% inhibition, while no 
statistical differences between concentrations were demonstrated 
at 48 and 72 h. The highest effect, 25.8% inhibition, was found at 72 
h for the dose of 200 µM. As shown in Figure 5B, peptide f(17-28) 
reproduced these anti-proliferative properties, but to a lower 
extent, with a dose-dependent trend (10-100 µM) at 24 and 48 h, 
and an enhanced activity along the treatment time. The maximum 
inhibitory effect found for this fragment was observed at 72 h for all 
the concentrations evaluated (17.3% average). Lunasin-peptides 
f(19-28), f(29-41), and f(29-43) (10-200 µM) showed a ca. 10% 
inhibitory activity at 48 and 72 h, while f(11-18) and f(34-43) did not 
cause significant effect at any condition evaluated in HT-29 cells 
(data not shown). In Caco-2 cells, f(1-10) and f(17-28) were also the 
most active peptides among all lunasin-fragments assessed. 
Lunasin-peptides f(1-10) exhibited the highest effect after 24 h 
treatment with 200 µM (18.6%) (Figure 5C), and f(17-28) after 48 h 
treatment with 200 µM (22.8%) with a marked dose-dependent 
statistically different activity at this time, but not at 24 h (Figure 
5D). As it was shown for lunasin treatment on Caco-2 cells, the 
activity of both fragments was notably decreased after 48 h, with 
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Figure 5. Effects of lunasin-derived fragments on cancer cells viability. Cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay after treatment of human adenocarcinoma colorectal (A and B) HT-29 and (C and D) Caco-2 cells with (A and C) 
peptide SKWQHQQDSC, f(1-10) and (B and D) peptide VNLTPCEKHIME, f(17-28) at concentrations ranging from 10 to 200 µM for 24-72 h. Results 
were expressed as percentage of non-viable cells compared to control, considered as 0% (% of control, mean ± standard error of the mean, SEM). 
Experiments were carried out in triplicate, and analysed by a one-way ANOVA followed by the Bonferroni post hoc test. Lower case letters denote 
statistically significant differences (P < 0.05) between doses and control, considered as (a). Capital letters denote statistically significant differences (P 
< 0.05) for the same dose between treatment times. 
 
any statistical difference from control cells at 72 h. While 
peptide f(29-41) showed a ca. 8% inhibitory activity at 24 and 
48 h, none of the rest lunasin-peptides induced cytotoxic 
effects on these cells (data not shown). Therefore, in colorectal 
HT-29 cells, peptide f(1-10) might be the main contributor to 
the anti-proliferative activity proven for the complete lunasin. 
Despite the inhibitory activity exerted by lunasin and its 
fragments f(1-10) and f(17-28), the functionality of these 
peptides on Caco-2 cells was not absolutely established due to 
the higher resistance of these cells, showing weaker effects 
that lead to a recovery to control levels after 72 h treatment. 
Similarly to that was observed for lunasin in gastric AGS cells, 
all derived fragments showed modest results in the range of 
10-15% inhibition, especially at 100 and 200 µM (data not 
shown). Thus, the effect of lunasin on these cells seems to be 
unspecific and independent of the assessed region within the 
complete 43-amino acid peptide. The chemo-preventive 
properties of lunasin had been attributed to its C-terminal 
domain that presents: (i) a predicted helix with structural 
homology to a conserved region of chromatin-binding 
proteins, (ii) an RGD cell adhesion motif, and (iii) a poly-D tail, 
with a high negatively charge, known to preferentially bind to 
positively charged deacetylated histones and hypoacetylated 
chromatin.
44
 To date, to the best of our knowledge, only one 
study had evaluated a possible structure-activity relationship 
with different lunasin fragments on breast cancer MDA-MB-
231 cells.
47
 Whereas peptide lunasin inhibited the malignant 
growth with an IC50 value of 181 µM, these authors proved 
that the C-terminal region was more active than the complete 
peptide with IC50 values of 175 and 138 µM for lunasin-
fragments 
23
EKHIMEKIQGRG
34
 and 
23
EKHIMEKIQGRGDDDDDDDDD
43
, respectively, while the 
fragment 
1
SKWQHQQDSCRKQLQGVNLTPC
22 
at the N-terminal 
domain was less potent (IC50: 323 µM). Therefore, this is the 
first study suggesting a protective role for the N-terminal 
region of lunasin, especially for f(1-10) in HT-29 cells. In this 
line, Chang et al.
48
 recently found that a truncated peptide 
lacking the RGD-motif and the poly-D was equally active than 
the complete lunasin sequence on the immunomodulatory 
activation of natural killer cells. However, in the present study, 
neither lunasin nor lunasin-derived peptides exerted the 
protective activity previously shown for lunasin:IBB1 digests.
14
 
Therefore, the inhibitory properties of other compounds in the 
digests or a possible synergistic effect between the peptides 
identified could not be discarded in this study. Moreover, it 
should be highlighted that culture conditions have been 
recently found to notably modulate the anti-proliferative 
activity of lunasin on non-small cell lung cancer cells.
49
 These 
authors demonstrated that anchorage-independent growth 
conditions, more closely mimicking the in vivo tumor 
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environment, increased the sensitivity of cancer cells to 
lunasin. In our study under anchorage-dependent growth 
conditions, the moderate biological MTT-activity would be 
presumably meaningful in a more physiological state. 
 
3.4. Stability of lunasin on gastric and colorectal cancer cells  
As shown in Table 2, by HPLC-MS/MS analysis, the residual intact 
lunasin in the cell cultures was quantified and the derived 
fragments released by cellular enzymatic action were identified. 
 
Table 2. Stability of peptide lunasin in medium added to AGS and HT-
29 cells, and identification of lunasin-derived fragmentsa 
 
 
 
In AGS cells, lunasin remained intact for up to 24 h incubation, 
and showed a 13.2% and 27.0% reduction in its content after 48 
and 72 h, respectively. Furthermore, at 48 h incubation, the lunasin 
fragments 
23
EKHIMEKIQGRGDDDDDDDDD
43
, 
25
HIMEKIQGRGDDDDDDDDD
43
, and 
29
KIQGRGDDDDDDDDD
43
 were 
generated and remained in the culture after 72 h. In HT-29 cells, a 
relatively higher cellular enzymatic activity was evidenced, with 
residual lunasin percentages being decreased in a time-dependent 
manner from 2 h (97.3%) to 72 h (68.0%), and the identification of 
the same three lunasin-derived peptides from 24 h incubation, as 
well as the new fragment 
32
GRGDDDDDDDDD
43
 at 72 h. In addition 
to peptide hydrolysis, degradation by the enzymatic response of 
cells to incubation with peptide explained the decrease in lunasin 
concentration. It might be also due to peptide´s internalization into 
AGS and HT-29 cells, as it has been demonstrated in murine 
fibroblast C3H10T1/2 cells,
44
 and human THP-1 macrophages,50 
colorectal cancer KM12L4 cells,
45
 and prostate epithelial RWPE-2 
cells.
51
 Four lunasin-derived fragments were formed corresponding 
to the C-terminal region of the sequence from the amino acid 
residue 23. Among them, fragment 
29
KIQGRGDDDDDDDDD
43
 
coincided with the sequence of one lunasin-peptide that showed a 
ca. 10% inhibitory activity on AGS and HT-29 cells in this study, and 
had been identified in in vitro gastrointestinal digests of lunasin.
14
 In 
this sense, it is worthy to mention that the lunasin-derived peptide 
1
SKWQHQQDSC
10
 was not formed during the stability assay, 
although it was the most active in the MTT assay. The enzymatic 
action of digestive peptidases would be thus required to release 
this fragment. Moreover, the fragments 
25
HIMEKIQGRGDDDDDDDDD
43
, 
29
KIQGRGDDDDDDDDD
43
 and 
32
GRGDDDDDDDDD
43
 had been already identified in a previous 
study of lunasin´s stability in human liver HepG2 cells,
22
 which 
suggested that these cultures might share enzymatic activities upon 
incubation with lunasin peptide. However, further studies with 
these peptides are required to definitively elucidate whether this C-
terminal region is, at least partially, involved in the protective 
properties showed for the intact lunasin. In contrast, neither 
lunasin decrease nor derived fragments were demonstrated in 
Caco-2 cells along the incubation time. Lunasin degradation in this 
culture was thus not the cause of the anti-proliferative activity loss 
showed after 72 h treatment. García-Nebot et al.
16
 had previously 
conducted the study of lunasin´s stability on differentiated Caco-2 
cells, as an in vitro model of the human intestine, and also found 
that this peptide mostly remained intact after 24 h incubation, with 
no derived fragments identified. Therefore, it might be suggested 
that the cell line type is determinant in the behavior of lunasin 
added to the culture medium. 
 
4. Conclusions 
The present study has been focused on the analysis of peptides 
lunasin and lunasin-digestion fragments at the gastrointestinal 
tract. The results pointed out for the first time a notable resistance 
against the epithelial brush-border membrane of Caco-2 
monolayers, especially for peptides f(1-10) and f(29-43). Lunasin 
and f(11-18) were demonstrated to cross the intestinal epithelial 
barrier, with the paracellular route found as the main transport 
mechanism involved. The f(11-18) might be proposed as preferred 
target sequence for the transepithelial transport of lunasin peptide. 
These findings might imply biological relevance, suggesting 
potential to exert bioactive effects both locally in the 
gastrointestinal tract as well as at a systemic level. Lunasin and 
lunasin-released peptides after simulated in vitro digestion were 
shown to play moderate protective properties against the growth of 
gastric and colorectal cancer cells, with the maximum inhibitory 
effects shown for lunasin and f(1-10) in HT-29 cells. Therefore, this 
is the first study that postulates a preventive role for the N-terminal 
region of lunasin. It has been suggested that the cell line type is 
determinant for the different behaviour of lunasin-derived 
sequences. 
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ABSTRACT  
The involvement of cancer stem-like cells (CSC) in the tumor pathogenesis has profound 
implications for cancer therapy and chemoprevention. Lunasin is a bioactive peptide with proved 
protective activities against cancer and other chronic diseases. The present study focused on the 
cytotoxic effect of peptide lunasin in colorectal cancer HCT-116 cells, both the bulk tumor and the 
CSC subpopulations. Lunasin inhibited the proliferation and the tumorsphere-forming capacity of 
HCT-116 cells. Flow cytometry results demonstrated that the inhibitory effects were related to an 
induction of apoptosis and cell cycle-arrest at G1 phase. Moreover, lunasin caused an increase in 
the sub-GO/G1 phase of bulk tumor cells, linked to the apoptotic events found. Inmunoblotting 
analysis further showed that lunasin induced apoptosis evidenced by activation of caspase-3 and 
cleavage of PARP, and modestly controlled cell cycle progress by increasing the protein expression 
of the cyclin-dependent kinase inhibitor p21. Together these results provide new evidence on the 
chemopreventive activity of peptide lunasin on colorectal cancer by modulating both the parental 
and the CSC tumorigenic subsets of HCT-116 cells. 
 
KEYWORDS: colorectal cancer, cancer stem cells, chemoprevention, bioactive peptide, lunasin 
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1. INTRODUCTION 
Current statistics on colorectal cancer (CRC) have ranked this disease as the third leading 
cause of cancer-related deaths and the third most common diagnosed cancer in both men and 
women in the United States (Siegel and others 2014). In recent years, a great deal of research has 
been focused on CRC pathogenesis. Meanwhile, the existence of tumor-initiating cells or cancer 
stem-like cells (CSC) in this solid tumor has been established (O’Brien and others 2007; Ricci-
Vitiani and others 2007; Anderson and others 2011). According to the CSC theory, a minor 
population of tumor cells is responsible for the driving of tumorigenesis (Reya and others 2001). 
These stem cells, like those in adult tissue, undergo unlimited proliferation and asymmetrically 
division into more differentiated cells leading to the neoplastic growth and maintenance (Visvader 
and Lindeman 2008). In addition, it has been suggested that this CSC subpopulation might be 
potentially responsible for the tumor invasion, metastasis, recurrence, and resistance to therapy 
(Zhou and others 2009; Clevers 2011). Therefore, the potential of preventive strategies need to be 
evaluated not only against CRC cells, representing the bulk of the tumor mass (non-CSC), but also 
against colon CSC. 
Accumulating evidence and epidemiological studies have revealed an inverse correlation 
between soybean consumption and the risk of CRC development (Spector and others 2003; Yang 
and others 2009), that can be in part due to the chemopreventive effects of the bioactive 
compounds described in this legume. Several soybean components including isoflavones (Kim and 
others 2012), saponins (Tsai and others 2010), and bioactive proteins and peptides, such as lectins 
and protease inhibitors (de Mejia and others 2003; Clemente and others 2010) have been shown to 
exert protective activities against the growth of CRC cells. Identified in soybean, lunasin is a 43-
amino acid peptide which chemopreventive properties have been recently reviewed (Fernández-
Tomé and Hernández-Ledesma 2016). It has been demonstrated that lunasin is able to cause 
cytotoxicity in four different human CRC cell lines, HCT-116, HT-29, KM12L4, and RKO, and their 
oxaliplatin-resistant variants (Dia and de Mejia 2011a). Studies on the mechanisms of action 
involved in this antiproliferative activity have been mostly carried out in HT-29 and KM12L4 cells, in 
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which Dia and de Mejia (2010, 2011a, b) evaluated lunasin´s effects on apoptosis-induction, cell 
cycle progression and CRC-related biomarkers. Moreover, García-Nebot and others (2014) have 
demonstrated the protective role played by lunasin in differentiated Caco-2 cells, as a model of 
human enterocytes, exposed to oxidizing agents through promoting cell viability and counteracting 
the rise in reactive oxygen species levels. This notably antioxidant protection at intestinal level is 
also a noteworthy aspect, pointing lunasin as a promising chemopreventive agent against CRC. 
The emergence of the CSC model has profound implications on cancer chemoprevention 
and the search of natural components targeting these cells has been markedly prompted (Kawasaki 
and others 2008). Some dietary compounds and phytochemicals have been shown to potentially 
interact toward the pathways involved in the renewal and proliferation of CSC (Li and others 2011; 
Kim and others 2012; Oh and others 2016). Despite the fact that food proteins and peptides have 
received increasing attention for their efficacy preventing the different stages of cancer, including 
initiation, promotion, and progression (de Mejia and Dia 2010; Hernández-Ledesma and Hsieh 
2015), their protective role against CSC has been scarcely studied. 
Accordingly, this study aimed to evaluate the cytotoxicity of peptide lunasin in human CRC 
HCT-116 cells, and to investigate its potential chemoprotective activity against colon CSC. 
Antiproliferative and tumorsphere forming inhibitory activities were evaluated, as well as lunasin´s 
effects on apoptosis induction, cell cycle progression, and carcinogenesis-related protein 
biomarkers. 
 
2. MATERIALS AND METHODS 
2.1. Materials 
Peptide lunasin was synthesized by Chengdu KaiJie Biopharm Co., Ltd. (Chengdu, 
Sichuan, P. R. China). Its purity (>95%) was confirmed by liquid chromatography (HPLC) coupled to 
mass spectrometry (HPLC-MS). 
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2.2. Cell lines 
  The human CRC cell line HCT-116 was obtained from American Type Cell Collection 
(ATCC, Manassas, VA, USA), and maintained in RPMI medium (ATCC) supplemented with 5% 
heat inactivated fetal bovine serum (FBS; Mediatech, Herndon, VA, USA), 100 units/mL penicillin, 
and 0.1 mg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA). Cells were grown in a humidified 
incubator containing 5% CO2 and 95% air at 37 ºC, kept sub-confluent, and medium was changed 
every other day. All cells were assayed within 5-25 passages. Enrichment culture of tumor-derived 
colon CSC was performed by incubating parental HCT-116 cells in serum-free medium (SFM) 
composed of DMEM/F-12 medium supplemented with 2% B-27 supplement, 20 ng/mL recombinant 
human epidermal growth factor, 10 ng/mL fibroblast growth factor-basic (Life Technologies, Grand 
Island, NY, USA), 100 units/mL penicillin, 0.1 mg/mL streptomycin, and 10 μg/mL insulin (Sigma-
Aldrich) in ultra low-attachment plates (Corning, Lowell, MA, USA) at 37 ºC. Plated under these 
anchorage-independent conditions in supplemented-SFM, tumor cells form floating spheres 
reported to represent the growth of CSC (Kanwar and others 2010; O’Brien and others 2012).  
 
2.3. Cell proliferation assay 
HCT-116 cells were seeded in 96-well plates (11  10
3
 cells/mL). After 24 h incubation, 
cells were treated with different concentrations of lunasin ranging from 5 to 80 μM. After 72 h 
treatment, cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay. Treatment medium was replaced by 200 μL of fresh medium containing 0.5 
mg/mL MTT (Sigma-Aldrich). After 1 h incubation at 37 ºC, MTT-containing medium was removed 
and the reduced formazan dye was solubilized by adding 100 μL of dimethyl sulfoxide to each well. 
After gently mixing, the absorbance was read at 570 nm using a microplate reader (Elx800TM, 
BioTek Instrument, Winooski, VT, USA). The results were expressed as percentage of the control, 
considered as 100%. Experiments were carried out in triplicate with at least three replicates per 
concentration. 
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2.4. Tumorsphere formation assay 
To examine the effect of lunasin on the formation of tumorspheres, HCT-116 cells were 
grown in SFM and plated as single cells in ultra low-attachment 24-well plates (6  10
3
 cells/mL). 
Right after seeding, cells were treated with different concentrations of lunasin ranging from 5 to 80 
μM, and incubated at 37 ºC for 10 days. After that time, tumorspheres were formed and transferred 
to 6-well dishes in differentiating medium (RPMI supplemented with 5% FBS and 1% antibiotics). 
Under these conditions, tumorspheres were adhered after 24 h incubation. Then, cells were stained 
with crystal violet solution (0.2% crystal violet in 2% ethanol) for 20 min at room temperature, 
photographed and counted. Results were presented as percentage of tumorspheres forming cells 
compared to control, considered as 100%. Analyses were performed in triplicate with at least three 
replicates per concentration. 
 
2.5. Detection of apoptosis 
Apoptotic cells were quantified by Annexin V/propidium iodide (PI) double staining using an 
apoptotic detection kit (BioVision, Mountain View, CA, USA) according to manufacturer’s instruction, 
followed by flow cytometry. HCT-116 cells (4  10
4
 cells/mL) and colon CSC (3  10
3 
cells/mL) were 
seeded in 6-well plates and treated (20-80 μM lunasin) as described above. After 72 h treatment, 
HCT-116 cells were collected as described by Qiu and others (2010). In the case of colon CSC, 
after 7 days treatment, floating tumorspheres in medium were collected in ice-cold flow cytometry 
tubes. After centrifugation (2000 × g, 2 min), single-cell suspensions were generated by incubation 
with 0.5 mL trypsin (0.25% trypsin-ethylenediaminetetraacetic acid, Sigma-Aldrich) and 1 mL 
medium for 5 min at 37 ºC, and gentle pippeting. Afterwards, in both cell cultures, cell suspensions 
were centrifuged (2000 × g, 2 min) and washed twice with 0.5 mL ice-cold phosphate buffer saline 
(PBS). Then, cells were suspended in 0.3 mL binding buffer containing Annexin V and PI, and 
incubated for 15 min at room temperature in the dark. Apoptotic cells were identified using a BD 
LSR II cell analyzer (BD Biosciences, San Jose, CA, USA) as Annexin V-positive cells, being 
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Annexin V-positive/PI-negative and Annexin V-positive/PI-positive cells identified as early apoptotic 
and late apoptotic cells, respectively. At least 10000 events were recorded to assess the 
percentage of apoptotic cells. Analyses were performed in duplicate with at least three replicates 
per concentration, and results were presented as the increased number in apoptotic cell 
populations, compared to control cells. 
 
2.6. Cell cycle analyses 
HCT-116 cells and colon CSC were treated as described for the apoptosis detection assay. 
After 72 h treatment, HCT-116 cells were collected as described by Qiu and others (2010). In the 
case of colon CSC, after 7 days treatment, cells were collected as described for apoptosis detection 
assay with some modifications. Briefly, floating tumorspheres in medium were collected, 
centrifuged, and single-cell suspensions were generated, washed with ice-cold PBS, and then fixed 
in 1 mL of 70% ethanol and kept at -20 ºC overnight. After centrifugation (2000 × g, 2 min), cells 
were washed with 0.5 mL PBS, and incubated with 0.3 mL PBS solution containing RNAse (10%; 
Sigma-Aldrich) and PI (1%; BioVision) for 25 min at room temperature in the dark. Cell cycle 
distribution was analyzed with at least 8000 events recorded using a BD LSR II cell analyzer (BD 
Biosciences), and data were processed using ModFit LT software. Analyses were performed in 
duplicate with at least three replicates per concentration, and results were presented as percentage 
of cells in G1, S, and G2-phases. 
 
2.7. Immunoblotting  
HCT-116 cells (3.5  10
4
 cells/mL) were seeded in 10-cm cell culture dishes. Colon CSC 
were seeded exactly same as described for apoptosis assay. After 72 h treatment (20-80 μM 
lunasin), HCT-116 cells were collected and whole-cell lysates were prepared as previously 
described (Xiao and others 2009). In the case of colon CSC, after 7 days-treatment (20-80 μM 
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lunasin), cells were collected following the same procedure with some modifications. Briefly, floating 
tumorspheres in medium were collected, centrifuged, and washed with ice-cold PBS. Then, cells 
were incubated on ice for 30 min in RIPA lysis buffer containing a protease inhibitor cocktail (Boston 
BioProducts, Ashland, MA, USA), and processed as previously described (Xiao and others 2009). 
Supernatants were collected and protein content was quantified by the bicinchoninic acid method 
(Pierce, Rockford, IL, USA) using bovine serum albumin as standard protein. Equal amount of 
proteins (50-70 μg) were resolved over 12% SDS-polyacrylamide gel electrophoresis and 
transferred to nitrocellulose membranes. After blocking, membranes were incubated with different 
monoclonal primary antibodies overnight at 4 ºC, according to manufacturer’s instructions. Primary 
antibodies for cleaved caspase-3 (Asp175), full-length PARP, p21
Waf1/Cip1
, and p27
Kip1
 were from 
Cell Signaling Technology (Beverly, MA, USA). Antibody for β-actin was from Sigma-Aldrich. After 1 
h incubation with the appropriate secondary antibodies [goat anti-mouse IgG, and goat anti-rabbit 
IgG IRDye (LI-COR Biosciences, Lincoln, NE, USA)], proteins of interest were visualized using 
enhanced chemiluminescence (Boston Bioproducts). Analyses were conducted for three 
independent replicates.  
 
2.8. Statistical analysis  
Data were evaluated using one-way ANOVA followed by Bonferroni post hoc test, and 
expressed as the mean ± standard variation (SD) of the different experiments carried out. 
GraphPad Prism 5.0 software (San Diego, CA, USA) was used to perform statistical analyses. 
Differences with a P value < 0.05 (*), P value < 0.01 (**) or P value < 0.001 (***) were considered 
significant. 
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3. RESULTS AND DISCUSSION 
3.1. Inhibitory effect of lunasin on cell viability and tumorsphere formation  
 A growing amount of evidence asserts that epithelial cancers, including CRC are driven by 
a small subset of self-renewing CSC different from the cellular bulk of the tumor (Anderson and 
others 2011). In this study, the effect of lunasin was thus assessed against both non-CSC and CSC 
populations. As shown in Figure 1, the human HCT-116 cell line was grown in monolayer as 
parental CRC cells (Figure 1A) and used for the expansion of tumor-derived CSC as colonspheres 
(Figure 1B).  
 We first examined the growth of HCT-116 cells exposed to lunasin. HCT-116 cells were 
treated with serial concentrations of lunasin (5-80 μM) for 72 h and the number of viable cells was 
assessed by the MTT assay. As shown in Figure 1C, lunasin caused a dose-dependent inhibition of 
proliferation. Treatment with 10 µM lunasin was able to induce a significant reduction on cellular 
growth (12.9%, P < 0.01) compared to control cells. The cytotoxic effect increased up to the highest 
concentration used (37.3%, P < 0.001). However, to calculate the IC50 value, expressed as the 
peptide concentration needed to inhibit 50% cell number, an additional experiment was carried out 
with lunasin at 160 µM. This concentration showed a 64.1% inhibition (P < 0.001), being the IC50 
value of 107.5 µM. It had been previously demonstrated that lunasin is able to induce cytotoxicity to 
HCT-116, HT-29, KM12L4, and RKO CRC cells, with IC50 values of 26.3 µM, 61.7 µM, 13.0 µM, 
and 21.6 µM, respectively (Dia and de Mejia 2011a). While these authors used purified lunasin (~ 
90%) from defatted soybean flour, in our study we have assessed the effects of synthetic lunasin. 
The higher IC50 value found in our study might be due to differences in the secondary and tertiary 
structures between plant-purified lunasin and the synthetic peptide. Additionally, other compounds 
present in the natural preparation could be responsible for the observed change in the inhibitory 
potency. In this regard, synthetic lunasin has been shown to suppress the growth of breast cancer 
MDA-MB-231 cells with a reported IC50 value of 181.0 µM (Hernández-Ledesma and others 2011).
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Figure 1. Cell culture and cytotoxic effect of lunasin on colorectal cancer (CRC) cells. Representative images 
of (A) HCT-116 cells in adherent conditions and (B) enrichment culture of tumor-derived colon stem-like cells 
(CSC) formed from the parental HCT-116 cell line under anchorage-independent conditions. (C) HCT-116 cells 
were treated with lunasin (5-80 μM) for 72 h, and cell viability was determined by the MTT assay. (D) Colon 
CSC were treated with lunasin (5-80 μM) for 10 days, and tumorspheres were stained with crystal violet 
solution and counted. Results, expressed as percentage of control cells, are means ± SD of the replicates of 
experiments carried out. ** (P < 0.01), *** (P < 0.001) significantly different from control. 
 
 
 
 
Since colonsphere subpopulations were demonstrated to exert a key role in the CRC 
pathogenesis, the culture of tumor-derived spheroids has been widely used for the evaluation of 
chemotherapy drugs and chemopreventive agents (Anderson and others 2011). The sphere 
formation assay is extensively applied as in vitro method for the derivation and characterization of 
stem-like cancer cells with intrinsic self-renewal and tumorigenic properties (Kanwar and others 
2010). To evaluate whether lunasin protects against colon CSC, we first determined its effect on the 
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proliferation of colonspheres. Colon CSC were cultured as non-adherent spheres under 
anchorange-independent conditions and treated with lunasin for 10 days. As shown in Figure 1D, 
lunasin at the lowest range assessed (5-10 µM) was not able to suppress tumorsphere-forming 
capacity. Likewise, Pabona and others (2013) have showed that while isoflavone genistein (40 nM) 
reduces the number of mammosphere-forming units in malignant breast cancer MCF-7 cells, 
peptide lunasin (2 µM) is not able to recapitulate this inhibitory protection. However, as represented 
in Figure 1D, this peptide in the range of 20-80 µM exerted an inhibitory effect ca. 30%. Lunasin´s 
IC50 value on HCT-116-derived CSC was 161.0 µM, indicating that colonspheres are less sensitive 
to this peptide than parental HCT-116 cells. These results are in agreement with the reported higher 
resistance of CSC to anti-cancer therapies (Zhou and others 2009; Kim 2014). Similarly, Yang and 
others (2013) have recently showed that fatty acid DHA exerts higher antiproliferative potency on 
adherent CRC SW620 cells than on their tumorspheres-derived CSC subpopulation. Nevertheless, 
in the study of McConnell and others (2015), it has been recently found that peptide lunasin 
presents a higher anti-proliferative activity against non-small cell lung cancer cells when they were 
assessed under anchorage-independent growth conditions, compared to anchorage-dependent 
conditions. Therefore, lunasin´s modulatory chemoprevention might notably depend on the culture 
conditions and the cell line used.  
 
3.2. Apoptosis analysis of lunasin-treated CRC cells  
 
 Tumor cell populations expand in number through several molecular processes such as the 
capability of evading programmed cell death by presenting an elevated apoptotic threshold 
(Hanahan and Weinberg 2011). In order to determine whether the inhibitory effect of lunasin on 
HCT-116 cells was through interacting with the apoptotic pathways, adherent and colonspheres-
derived cells were incubated with lunasin, and apoptosis detection was assessed by flow cytometry-
based Annexin V/PI assay. Based on the lunasin´s inhibitory effects on HCT-116 cell viability and 
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colonsphere forming-frequency, the range of 20-80 µM for this peptide was chosen as the optimal 
treatment concentration for subsequent experiments. 
 Figure 2 presents the apoptotic state of adherent HCT-116 cells after control- or lunasin-
treatment for 72 h. The apoptotic populations of cells treated with the peptide were significantly 
increased with a dose-dependent trend (Figure 2A). Lunasin at 20, 40 and 80 µM induced a 1.3-
fold, 1.7-fold and 1.8-fold increase of total apoptotic cells, respectively, compared to controls. In the 
case of lunasin at 40 and 80 µM, both the late and the early apoptotic populations were also 
significantly enhanced. These findings might be explained by a weak apoptosis-induction effect in 
20 µM cells, corresponding to the lower MTT activity found at this dose. The apoptosis-involved 
inhibitory role of lunasin against CRC HCT-116 cells was further addressed by the immunoblotting 
study of the molecular proteins PARP and caspase-3. PARP is responsible for the regulation of 
many cellular functions, such as key events supporting cell viability and DNA repair (Satoh and 
Lindahl 1992). PARP degradation has been shown to facilitate cellular disassembly and serve as a 
marker of cells undergoing apoptosis, with this protein being the main cleavage target on the 
activity of the apoptotic trigger caspase-3 (Oliver and others 1998). As shown in Figure 2B, lunasin 
activated the cleavage of caspase-3 up to 190% (40 µM), a hallmark of apoptosis, and 
consequently decreased the protein level of full-length PARP by 30% (40 µM) and 60% (80 µM). In 
this line, Dia and de Mejia (2010, 2011a) found that lunasin was able to activate the apoptotic 
mitochondrial pathway in CRC HT-29 and KM12L4 cells, as evidenced by the modulation of Bcl-
2/Bax family of proteins, nuclear clusterin, cytochrome c, and caspases-activity. Similar apoptosis- 
related properties have been reported for this peptide against the growth of leukemia L1210 cells 
(de Mejia and others 2010), and breast cancer MCF-7 (Pabona and others 2013) and MDA-MB-231 
(Hsieh and others 2011) cells.  
  
Figure 2. Effect of lunasin on the apoptosis state of HCT-116 cells. Cells were treated with lunasin at the indicated concentrations for 72 h, and harvested for 
apoptosis analyses and Western immunoblotting. (A) Flow cytometry-based Annexin V/PI double labelling of apoptotic cells. Apoptotic cells were identified as 
Annexin V-positive cells, being Annexin V-positive/PI-negative and Annexin V-positive/PI-positive cells identified as early apoptotic and late apoptotic cells, 
respectively. Results, presented as the increased number in apoptotic cell populations compared to control cells, are means ± SD of the replicates of experiments 
carried out. * (P < 0.05), ** (P < 0.01), *** (P < 0.001) significantly different from control. (B) Expression of full length PARP and cleaved caspase-3 proteins 
determined by Western Blot. The numbers underneath of the blots represent band intensity (normalized to β-actin), measured by Image J software. β-actin was 
served as an equal loading control. The immunoblots are shown as representative images of different experiments with similar results.
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 We next aimed to determine whether this apoptosis-inducing property was also involved in 
the suppression of the spheroid-forming capacity of HCT-116 cells. Colonspheres were treated with 
lunasin for 7 days and apoptosis detection was examined as shown in Figure 3. Results from the 
flow cytometry study after staining of colon CSC with Annexin-V/PI showed that lunasin led to an 
induction in the cellular apoptotic state (Figure 3A and 3B). The raise in the number of apoptotic 
cells was not significantly promoted at lunasin 20 µM, however lunasin at 40 and 80 µM exerted a 
2.0-fold apoptosis-induction effect, mostly in the late apoptotic cellular subset. As shown in Figure 
3C, the implication of an apoptosis mechanism responsible for the inhibitory effect of lunasin 
peptide against the expansion of the HCT-116-derived CSC subpopulation was further 
demonstrated by immunobloting. Cleaved caspase-3 activity was induced by lunasin treatment, with 
this activation being markedly companied by a down-regulation of PARP level in a dose-dependent 
manner. Therefore, in the present study, it has been suggested that lunasin has similar effects in 
the apoptosis-induction of both CRC HCT-116 parental and tumor-derived colonsphere cells. In this 
sense, other food/natural compounds and phytochemicals have been demonstrated to exert similar 
inhibitory effects against the cellular expansion of the CSC subpopulation of CRC (Lin and others 
2011; Yang and others 2013; Massey and others 2014), and pancreatic and prostate cancer cells 
(Ottinger and others 2012; Soner and others 2014) by induction of the apoptotic pathways.  
 
3.3. Effect of lunasin on cell cycle progression of CRC cells 
 To provide further insights into the growth inhibitory effects exerted by lunasin in HCT-116 
cells, analyses on cell cycle distribution were performed on both parental and colonspheres stem 
cells after treatment with lunasin for 72 h and 7 days, respectively. Deregulation of cell cycle control 
and potential to replicate without limit are one of the hallmarks of cancer, with all these events being 
highly regulated by internal checkpoints that ensure the proper cellular division (Hanahan and 
Weinberg 2011).
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of lunasin on the apoptosis state of colon CSC. Cells were treated with lunasin at the indicated concentrations for 7 days, and harvested for 
apoptosis analyses and Western immunoblotting. (A) Flow cytometry-based Annexin V/PI double labelling of apoptotic cells. (B) Apoptotic cells were identified as 
Annexin V-positive cells, being Annexin V-positive/PI-negative and Annexin V-positive/PI-positive cells identified as early apoptotic and late apoptotic cells, 
respectively. Results, presented as the increased number in apoptotic cell populations compared to control cells, are means ± SD of the replicates of experiments 
carried out. * (P < 0.05) significantly different from control. (C) Expression of full length PARP and cleaved caspase-3 proteins determined by Western Blot. The 
numbers underneath of the blots represent band intensity (normalized to β-actin), measured by Image J software. β-actin was served as an equal loading control. 
The immunoblots are shown as representative images of different experiments with similar results.
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As shown in Figure 4A, control adherent HCT-116 cells (G1: 66.5 ± 1.7%) were found to 
significantly increase their G1-cellular phase after lunasin´s treatment (20 µM lunasin: 70.2 ± 0.3%, 
P < 0.05; 40 µM lunasin: 70.5 ± 0.7%, P < 0.05; 80 µM lunasin: 72.0 ± 1.2%, P < 0.01). 
Interestingly, as represented in Figure 4B, lunasin-treated cells also resulted in a marked 
accumulation of the sub-G0/G1 cell population, compared to control cells. Cells at the sub-G0/G1 
fraction contain less amount of DNA than G1 cells, suggesting DNA degradation potentially caused 
by apoptotic events (Nagata and others 2003). This effect had also been demonstrated for peptide 
lunasin in leukemia L1210 cells (de Mejia and others 2010), and is in agreement with our results on 
apoptosis-induction in HCT-116 cells (Figure 2). On the other hand, our findings differ with other 
studies showing the capability of this peptide to arrest cell cycle at S-phase in breast cancer MDA-
MB-231 cells (Hsieh and others 2011), and at G2-phase in leukemia L1210 cells (de Mejia and 
others 2010) and CRC HT-29 and KM12L4 cells (Dia and de Mejia 2010, 2011a). However, other 
arginine-glycine-aspartic acid (RGD-motif)-containing peptides, such as lunasin, have been also 
reported to result in a G0/G1-phase arrest in cancer cells (Yang and others 2006). Moreover, 
regarding to the colon CSC subpopulation (Figure 5A), lunasin at 80 µM also led to an 
enhancement of G1-arrest (74.0 ± 0.6%, P < 0.001), accompanied with a reduction in the S-cellular 
subset (14.3 ± 0.9%, P < 0.05), compared to control cells (G1: 69.4 ± 0.6%; S: 16.4 ± 0.9%). This 
effect might be related to the antiproliferative and pro-apoptotic activities above indicated, however 
20-40 µM-treated colonspheres showed a similar trend but in a weaker manner lacking of statistical 
significance.  
To further explain lunasin´s effect on cell cycle progression, evaluation of the expression of 
the cyclin-dependent kinase (CDK) inhibitors p21
Waf1/Cip1
 and p27
Kip1
 was performed by Western 
Blot. While treatment of CRC cells with lunasin showed no effect on the level of p27 marker (data 
not shown), it resulted in a modest increase in the molecular expression of p21 protein up to 140% 
and 120% in adherent HCT-116 cells (Figure 4C) and colonspheres CSC (Figure 5B), respectively. 
Dia and de Mejia (2010, 2011a) also reported lunasin´s capability to induce the expression of the 
CDK- inhibitor p21 in the CRC HT-29 and KM12L4 cells, and linked this effect with a decreased cell 
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Figure 4. Effect of lunasin on cell cycle progression of HCT-116 cells. Cells were treated with lunasin at the 
indicated concentrations for 72 h, and harvested for cell cycle analyses and Western immunoblotting. (A) Cell 
cycle distribution was assessed by flow cytometry using PI staining. Results, presented as percentage of cells 
in G1, S, and G2 phases, are means ± SD of the replicates of experiments carried out. * (P < 0.05), ** (P < 
0.01) significantly different from control. (B) Representative images of lunasin-induced increase in the sub-
GO/G1 cell population (black arrow). (C) Expression of p21
Waf1/Cip1
 protein determined by Western Blot. The 
numbers underneath of the blots represent band intensity (normalized to β-actin), measured by Image J 
software. β-actin was served as an equal loading control. The immunoblots are shown as representative 
images of different experiments with similar results. 
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Figure 5. Effect of lunasin on cell cycle progression of colon CSC. Cells were treated with lunasin at the 
indicated concentrations for 7 days, and harvested for cell cycle analyses and Western immunoblotting. (A) 
Cell cycle distribution was assessed by flow cytometry using PI staining. Results, presented as percentage of 
cells in G1, S, and G2 phases, are means ± SD of the replicates of experiments carried out. * (P < 0.05), *** (P 
< 0.001) significantly different from control. (B) Expression of p21
Waf1/Cip1
 protein determined by Western Blot. 
The numbers underneath of the blots represent band intensity (normalized to β-actin), measured by Image J 
software. β-actin was served as an equal loading control. The immunoblots are shown as representative 
images of different experiments with similar results. 
 
proliferation, cell cycle arrest, and up-regulation of the pro-apoptotic markers caspase-3 and nuclear 
clusterin isoform.  
 In order to provide more evidence on the cancer-preventive role of bioactive peptide lunasin 
against the CRC malignancy some studies have been carried out. In the highly metastatic KM12L4 
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cell line, Dia and de Mejia (2011a, b) demonstrated that lunasin is able to internalize into the cell 
and sit within the nucleus, to modify the expression of human extracellular matrix and cell adhesion 
genes by binding to α5β1 integrin, and also to inhibit the FAK/ERK/NF-κB signaling pathway. The in 
vivo effect of this peptide was suggested in the CRC liver metastasis mice model by Dia and de 
Mejia (2013), although disagreements between intraperitoneally- and orally-administered findings 
made it hard to establish a definitive lunasin´s role on preventing the CRC liver metastasis. 
Additionally, several studies have already demonstrated the chemopreventive properties of lunasin 
peptide by modulating expression of different proteins and genes involved in signaling pathways 
related to the complex pathogenesis of tumor cells (Fernández-Tomé and Hernández-Ledesma 
2016).  
 
4. CONCLUSION 
In the present study, our cellular model allowed us accomplishing the ideal approach for the 
evaluation of cancer-preventive agents by targeting both the parental and the stem-like tumorigenic 
populations. The protective mechanisms on lunasin-treated cells can be postulated in terms of 
inhibition of cell growth and tumorsphere-forming activity, induction of apoptosis, and regulation of 
cell cycle progression. The recent CSC hypothesis has supposed a challenge on the search of 
chemotherapeutic agents that efficiently target fast diving cancer cells as well as CSC responsible 
for the growth and maintenance of the tumorigenic bulk mass. The protective potential of bioactive 
peptides against the CSC subpopulation deserves additional studies. The promising results of this 
work clearly need to be further addressed to elucidate the molecular basis of the chemopreventive 
activity of this peptide on CSC, to study its potential on stem-related markers and signaling 
pathways, such as Wnt/β-catenin, Hedgehog and Notch, and especially to confirm this role by using 
in vivo models of CSC self-renewal. 
 
 
 
108 Results / Resultados 
ACKNOWLEDGMENTS 
This work has received financial support from project AGL2015-66886-R from the Spanish Ministry 
of Economy and Competitiveness (MINECO). S. F. -T. and B. H. -L. acknowledge MINECO for their 
FPI fellowship (AGL2011-24643) and “Ramón y Cajal” post-doctoral contract, respectively. 
REFERENCES 
Anderson EC, Hessman C, Levin TG, Monroe MM, Wong MH. 2011. The role of colorectal cancer 
stem cells in metastatic disease and therapeutic response. Cancers 3:319-39. 
Clemente A, Moreno FJ, Marín-Manzano MC, Jiménez E, Domoney C. 2010. The cytotoxic effect of 
Bowman-Birk isoinhibitors, IBB1 and IBBD2, from soybean (Glycine max) on HT29 human 
colorectal cancer cells is related to their intrinsic ability to inhibit serine proteases. Mol Nutr Food 
Res 54:396-405. 
Clevers H. 2011. The cancer stem cell: premises, promises and challenges. Nat Med 17:313-19. 
de Mejia EG, Bradford T, Hasler C. 2003. The anticarcinogenic potential of soybean lectin and 
lunasin. Nutr Rev 61:239-46. 
de Mejia EG, Dia VP. 2010. The role of nutraceutical proteins and peptides in apoptosis, 
angiogenesis, and metastasis of cancer cells. Cancer Metast Rev 29:511-28. 
de Mejia EG, Wang W, Dia VP. 2010. Lunasin, with an arginine-glycine-aspartic acid motif, causes 
apoptosis to L1210 leukemia cells by activation of caspase-3. Mol Nutr Food Res 54:1-9. 
Dia VP, de Mejia EG. 2010. Lunasin promotes apoptosis in human colon cancer cells by 
mitochondrial pathway activation and induction of nuclear clusterin expression. Cancer Lett 295:44-
53. 
Dia VP, de Mejia EG. 2011a. Lunasin induces apoptosis and modifies the expression of genes 
associated with extracellular matrix and cell adhesion in human metastatic colon cancer cells. Mol 
Nutr Food Res 55:623-34. 
Dia VP, de Mejia EG. 2011b. Lunasin potentiates the effect of oxaliplatin preventing outgrowth of 
colon cancer metastasis, binds to α5β1 integrin and suppresses FAK/ERK/NF-κB signaling. Cancer 
Lett 313:167-80. 
 
109 Results / Resultados 
Dia VP, de Mejia EG. 2013. Potential of lunasin orally-administered in comparison to intraperitoneal 
injection to inhibit colon cancer metastasis in vivo. J Cancer Ther 4:34-43. 
Fernández-Tomé S, Hernández-Ledesma B. 2016. An update on lunasin research, a bioactive seed 
peptide for health promotion. In: Govil JN, editor. Recent Progress in Medicinal Plants. Vol. 43 
Phytotherapeutics II, Studium Press LLC, New Dehli, India. p 331-352.   
García-Nebot MJ, Recio I, Hernández-Ledesma B. 2014. Antioxidant activity and protective effects 
of peptide lunasin against oxidative stress in intestinal Caco-2 cells. Food Chem Toxicol 65:155-61. 
Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144:646-74. 
Hernández-Ledesma B, Hsieh CC, de Lumen BO. 2011. Relationship between lunasin´s sequence 
and its inhibitory activity of histones H3 and H4 acetylation. Mol Nutr Food Res 55:989-98. 
Hernández-Ledesma B, Hsieh CC. 2015. Chemopreventive role of food-derived proteins and 
peptides: A review. Crit Rev Food Sci. In press. DOI: 10.1080/10408398.2015.1057632 
Hsieh CC, Hernández-Ledesma B, de Lumen BO. 2011. Cell proliferation inhibitory and apoptosis-
inducing properties of anacardic acid and lunasin in human breast cancer MDA-MB-231 cells. Food 
Chem 125:630-6. 
Kanwar SS, Yu YJ, Nautiyal J, Patel BB, Majumdar APN. 2010. The Wnt/beta-catenin pathway 
regulates growth and maintenance of colonospheres. Mol Cancer 9:212. 
Kawasaki BT, Hurt EM, Mistree T, Farrar WL. 2008. Targeting cancer stem cells with 
phytochemicals. Mol Interv 8:174-84. 
Kim GN, Song JH, Kim ES, Choi HT, Jang HD. 2012. Isoflavone content and apoptotic effect in HT-
29 cancer cells of a soy germ extract. Food Chem 130:404-7. 
Kim TI. 2014. Chemopreventive drugs: Mechanisms via inhibition of cancer stem cells in colorectal 
cancer. World J Gastroentero 20:3835-46. 
Kim YS, Farrar W, Colburn NH, Milner JA. 2012. Cancer stem cells: potential target for bioactive 
food components. J Nutr Biochem 23:691-8. 
Li Y, Wicha MS, Schwartz SJ, Sun D. 2011. Implications of cancer stem cell theory for cancer 
chemoprevention by natural dietary compounds. J Nutr Biochem 22:799-806. 
 
110 Results / Resultados 
Lin L, Liu Y, Li H, Li PK, Fuchs J, Shibata H, Iwabuchi Y, Lin J. 2011. Targeting colon cancer stem 
cells using a new curcumin analogue, GO-Y030. Brit J Cancer 105:212-20. 
Massey AR, Reddivari L, Vanamala J. 2014. The dermal layer of sweet sorghum (Shorgum bicolor) 
stalk, a byproduct of biofuel production and source of unique 3-deoxyanthocyanidins, has more 
antiproliferative and proapoptotic activity than the pith in p53 variants of HCT116 and colon cancer 
stem cells. J Agr Food Chem 62:3150-9. 
McConnell EJ, Devapatla B, Yaddanapudi K, Davis KR. 2015. The soybean-derived peptide lunasin 
inhibits non-small cell lung cancer cell proliferation by suppressing phosphorylation of the 
retinoblastoma protein. Oncotarget 6:4649-62. 
Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H. 2003. Degradation of chromosomal DNA 
during apoptosis. Cell Death Differ 10:108-16. 
O’Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang YD, Tsatsanis A, Gallinger S, Dick JE. 
2012. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through 
p21. Cancer Cell 21:777-92. 
O’Brien CA, Pollett A, Gallinger S, Dick JE. 2007. A human colon cancer cell capable of initiating 
tumor growth in immunodeficient mice. Nature 445:106-10. 
Oh J, Hlatky L, Jeong YS, Kim D. 2016. Therapeutic effectiveness of anticancer phytochemicals on 
cancer stem cells. Toxins 8:199. 
Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Menissier-de Murcia J. 1998. 
Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis - Lesson from an 
uncleavable mutant. J Biol Chem 273:33533–9. 
Ottinger S, Klöppel A, Rausch V, Liu L, Kallifatidis G, Gross W, Gebhard MM, Brümmer F, Herr I. 
2012. Targeting of pancreatic and prostatic cancer stem cell characteristics by Crambe crambe 
marine sponge extract. Int J Cancer, 130:1671-81. 
Pabona JMP, Dave B, Su Y, Montales MTE, de Lumen BO, de Mejia EG, Rahal OM, Simmen RCM. 
2013. The soybean peptide lunasin promotes apoptosis of mammary epithelial cells via induction of 
tumor suppressor PTEN: similarities and distinct actions from soy isoflavone genistein. Genes Nutr 
8:79-90. 
Qiu P, Dong P, Guan H, Li S, Ho CT, Pan MH, McClements DJ, Xiao H. 2010. Inhibitory effects of 
5-hydroxy polymethoxyflavones on colon cancer cells. Mol Nutr Food Res 54:S244-52. 
 
111 Results / Resultados 
Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. 
Nature 414:105-11. 
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. 2007. 
Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-5. 
Satoh MS, Lindahl T. 1992. Role of poly(ADP-ribose) formation in DNA repair. Nature 356:356-8. 
Siegel R, DeSantis C, Jemal A. 2014. Colorectal cancer statistics, 2014. CA-A Cancer J Clin 
64:104-17. 
Soner BC, Aktug H, Acikgoz E, Duzagac F, Guven U, Ayla S, Cal G, Oktem G. 2014. Induced 
growth inhibition, cell cycle arrest and apoptosis in CD133
+
/CD44
+
 prostate cancer stem cells by 
flavopiridol. Int J Mol Med 34:1249-56. 
Spector D, Anthony M, Alexander D, Arab L. 2003. Soy consumption and colorectal cancer. Nutr 
Cancer 47:1-12. 
Tsai CY, Chen YH, Chien YW, Huang WH, Lin SH. 2010. Effect of soy saponin on the growth of 
human colon cancer cells. World J Gastroentero 16:3371-6. 
Visvader JE, Lindeman GJ. 2008. Cancer stem cells in solid tumors: accumulating evidence and 
unresolved questions. Nat Rev Cancer 8:755-68. 
Xiao H, Yang CS, Li S, Jin H, Ho CT, Patel T. 2009. Monodemethylated polymethoxyflavones from 
sweet orange (Citrus sinensis) peel inhibit growth of human lung cancer cells by apoptosis. Mol Nutr 
Food Res 53:398-406. 
Yang G, Shu XO, Li HL, Chow WH, Cai H, Zhang XL, Gao YT, Zheng W. 2009. Prospective cohort 
study of soy food intake and colorectal cancer risk in women. Am J Clin Nutr 89:577-83. 
Yang T, Fang S, Zhang HX, Xu LX, Zhang ZQ, Yuan KT, Xue CL, Yu HL, Zhang S, Li YF, Shi HP, 
Zhang Y. 2013. N-3 PUFAs have antiproliferative and apoptotic effects on human colorectal cancer 
stem-like cells in vitro. J Nutr Biochem 24:744-53. 
Yang W, Meng L, Wang H, Chen R, Wang R, Ma X, Xu G, Zhou J, Wang Y, Lu Y, Ma D. 2006. 
Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic 
acid peptide in vitro. Oncol Rep 15:113-7. 
Zhou BBS, Zhang HY, Damelin M, Geles KG, Grindley JC, Dirks PB. 2009. Tumor-initiating cells: 
challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806-23.
 
Food Research International 62 (2014) 793–800
Contents lists available at ScienceDirect
Food Research International
j ourna l homepage: www.e lsev ie r .com/ locate / foodresIn vitro chemo-protective effect of bioactive peptide lunasin against
oxidative stress in human HepG2 cellsSamuel Fernández-Tomé a, Sonia Ramos b, Isabel Cordero-Herrera b, Isidra Recio a,
Luis Goya b,⁎, Blanca Hernández-Ledesma a,⁎⁎
a Departamento de Bioactividad y Análisis de Alimentos, Instituto de Investigación en Ciencias de la Alimentación (CIAL, CSIC-UAM, CEI UAM+ CSIC), Nicolás Cabrera, 9, 28049 Madrid, Spain
b Departamento de Metabolismo y Nutrición, Instituto de Ciencia y Tecnología de Alimentos y Nutrición ICTAN (CSIC), José Antonio Novais, 10, 28040 Madrid, Spain⁎ Corresponding author. Tel.: +34 915445607; fax: +3
⁎⁎ Corresponding author. Tel.: +34 910017970; fax: +3
E-mail addresses: luisgoya@ictan.csic.es (L. Goya), b.he
(B. Hernández-Ledesma).
http://dx.doi.org/10.1016/j.foodres.2014.04.054
0963-9969/© 2014 Elsevier Ltd. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 24 February 2014
Accepted 13 April 2014
Available online 30 April 2014
Keywords:
Antioxidant defenses
Biomarkers for oxidative stress
Dietary antioxidants
Peptide lunasinLunasin is a peptide with proven properties against cancer and cardiovascular diseases. Relevant amounts of
lunasin have been found in liver of rats fed lunasin-enriched diets, indicating its potential bioactive effect in
this tissue. This study investigated the stability of lunasin in human liver HepG2 cells, and its chemoprotective ef-
fect against oxidative stress induced by tert-butylhydroperoxide. Pre-treatment of cells with lunasin (0.5–10 μM)
signiﬁcantly prevented the increased reactive oxygen species (ROS) generation (122% compared to 190% in
stressed cells), and glutathione peroxidase and catalase activities, as well as the depletion of reduced glutathione.
By restraining ROS overproduction, lunasin evoked a decline in carbonyl groups, and a signiﬁcant recovery from
cell death by apoptosis. These ﬁndings suggest that lunasin, at physiological concentrations,might confer a signif-
icant chemoprotective effect against oxidative stress-associated liver disorders. In addition, fragments released
after hydrolysis of lunasin by cell enzymes might contribute to the observed antioxidant effects.
© 2014 Elsevier Ltd. All rights reserved.Introduction
Cells are naturally providedwith an extensive array of protective en-
zymatic and non-enzymatic antioxidants that counteract the potentially
injurious oxidizing agents. But even this multifunctional protective
system cannot completely prevent the deleterious effects of reactive oxy-
gen species (ROS), and consequently, molecules damaged by oxidation
accumulate in cells. Large amounts of ROS have been shown to participate
in the pathogenesis of several human degenerative diseases, including
inﬂammation, cardiovascular and neurodegenerative disorders, and
cancer (Ramos, 2008). Restoration or activation of improperly working
or repressed antioxidant machinery as well as suppression of abnormally
ampliﬁed inﬂammatory signaling can provide important strategies for
chemoprevention. Therefore, determination of anti-inﬂammatory and/
or antioxidant properties has been proposed as a good indicator for
screening anti-cancer agents (Federico, Morgillo, Tuccillo, Clardiello, &
Loguercio, 2007).
There is substantial evidence that antioxidant food components
have a protective role against oxidative stress-induced atherosclerosis,
degenerative and age-related diseases, cancer and aging. Food-
derived peptides are promising natural antioxidants withoutmarked
adverse effects. In addition to their potential as safer alternatives to4 915493627.
4 910017905.
rnandez@csic.essynthetic antioxidants used to avoid or retard oxidation reactions
in foods, antioxidant peptides can also act reducing the risk of numerous
oxidative stress-associated disorders (Meisel, 2004). Lunasin is a
43-amino acid peptide identiﬁed in soybean and other seeds and plants
which chemopreventive properties have been recently reviewed
(Hernández-Ledesma, Hsieh, & de Lumen, 2013). This peptide has
demonstrated, by using cell cultures and animal models, to act as an
anticarcinogenic agent against skin, prostate, colon, and breast cancer
(Hernández-Ledesma, de Lumen, & Hsieh, 2013). Recently, lunasin has
been commercialized in the US by its beneﬁts on the cardiovascular sys-
tem through reduction of low density lipoprotein cholesterol concen-
tration (Gálvez, 2012). Moreover, its promising anti-inﬂammatory and
antioxidant activities reported in the recent years might contribute to
lunasin chemoprotective action. Lunasin has been shown to inhibit in-
ﬂammation in cultured RAW 264.7 macrophages through suppression
of the nuclear factor (NF)-κB pathway (Cam, Sivaguru, & González de
Mejia, 2013; González de Mejía & Dia, 2009; Hernández-Ledesma,
Hsieh, & de Lumen, 2009a). Additionally, in vitro assays have revealed
the ability of this peptide to scavenge peroxyl radicals, and to block
Fenton reaction by chelating iron ferrous ions, protecting DNA from ox-
idative damage (García-Nebot, Recio, & Hernández-Ledesma, 2014;
Hernández-Ledesma et al., 2009a; Jeong, de Lumen, & Jeong, 2010).
Studies on bioavailability carried out in mice and rats have demon-
strated that, after its oral ingestion, lunasin appears in an intact and ac-
tive form in different organs and tissues, such as blood, liver, and kidney,
among others (Hsieh, Hernández-Ledesma, Jeong, Park, & de Lumen,
2010; Jeong et al., 2009). In humans, the presence of lunasin has been
794 S. Fernández-Tomé et al. / Food Research International 62 (2014) 793–800also reported in plasma, indicating that this peptide might reach differ-
ent target tissues, and exert its biological activity (Dia, Torres, de Lumen,
Erdman, & González de Mejía, 2009).
The liver is particularly susceptible to toxic and oxidative insults
since the portal vein brings blood to this organ after intestinal absorp-
tion. Therefore, studies dealing with the effects of chemopreventive
compounds at a cellular level in cultured hepatic cells are essential.
Human HepG2, a well differentiated transformed cell line, is a reliable
model for cultured hepatocyte-type cells used for biochemical, pharma-
cological and nutritional studies since it retains hepatocyte morphology
and most of its functionality in culture (Alía, Ramos, Mateos, Bravo, &
Goya, 2006; Mateos, Goya, & Bravo, 2006).
The aims of the study were to evaluate the stability of lunasin in
human liver HepG2 cells as a model for cultured hepatocytes, and to
investigate the potential chemo-protective effect of this peptide against
oxidative stress chemically induced by a potent pro-oxidant, tert-butyl
hydroperoxide (t-BOOH). Cell integrity and several biomarkers of
oxidative damage were evaluated to estimate the effect of lunasin on
cell survival and on the response of the antioxidant defense systems of
HepG2 cells to t-BOOH.Materials and methods
Reagents
Peptide lunasin (N95% of purity) was synthesized by Chengdu
KaiJie Biopharm Co., Ltd. (Chengdu, Sichuan, P. R. China). t-BOOH,
glutathione reductase, reduced glutathione (GSH), nicotine adenine
dinucleotide phosphate reduced salt (NADPH), o-phthalaldehyde
(OPT), dichloroﬂuorescin (DCFH), dinitrophenylhydrazine (DNPH),
triﬂuoroacetic acid (TFA), ethylenediaminetetraacetic acid (EDTA),
β-mercaptoethanol, gentamicin, penicillin G, streptomycin, Triton-
X100, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)
and dithiothreitol (DTT) were purchased from Sigma Chemical
Co. (Madrid, Spain). Sodium dodecyl sulfate (SDS) was from Panreac
Química (Madrid, Spain). N-acetyl-Asp-Glu-Val-Asp-7-amino-4-
methylcoumarin (Ac-DEVD-AMC) was from BD Pharmingen (Madrid,
Spain). Bradford reagent was from BioRad Laboratories S.A. (Madrid,
Spain). The rest of the chemicals used were of HPLC grade.Cell culture
Human HepG2 cells were grown in a humidiﬁed incubator contain-
ing 5% CO2 and 95% air at 37 °C. They were grown in Dulbecco's
Modiﬁed Eagle Medium (DMEM)–F12 medium from Biowhittaker
(Lonza, Madrid, Spain), supplemented with 2.5% (v/v) Biowhittaker
fetal bovine serum (FBS) and 50 mg/L of each of the following antibi-
otics: gentamicin, penicillin G, and streptomycin. Cells were changed
to FBS-free medium the day before the assay (Mateos et al., 2006).Cell treatment conditions
Cells were incubated for 20 h with peptide lunasin dissolved in
FBS-free DMEM–F12 at ﬁnal concentrations ranging from 0.5 to
10 μM. To evaluate both direct and protective effects against oxidative
stress, the incubation period was followed by a 3 h treatment with cul-
ture medium (direct effect) or oxidant chemical t-BOOH (400 μM).
Crystal violet (CV) staining, GSH concentration, ROS generation and
glutathione peroxidase (GPx) and catalase (CAT) activities were evalu-
ated in both direct and protective experiments. Besides, the protective
effect of lunasin against t-BOOH-induced oxidative damage to proteins
and apoptotic cellular signals was evaluated by carbonyl groups and
caspase-3 assays, respectively.Crystal violet assay
Cell viability was evaluated following the CV assay described by
Granado-Serrano and co-workers (Granado-Serrano et al., 2007).
HepG2 cells were seeded in 96-well plates (1 × 104 cells per well) and
incubated overnight. Then, cells were treated with lunasin for 20 h as
described above, washed with PBS, and incubated with CV (0.2% in
ethanol) for 20 min at room temperature. Finally, cell lysis was carried
outwith 1% SDS, and the absorbancewas read at 570 nm in amicroplate
reader (FL600, Bio-Tek, Winooski, VT, USA). Results were pooled from
different plates to obtain an average of n = 12, and presented as
percentage of viable cells compared to control, considered as 100%.
Morphological analysis
HepG2 cells were exposed to increasing concentrations (0.5–10 μM)
of lunasin for 20 h, then treated with DMEM (controls) or DMEM
supplemented with t-BOOH for 3 h, and cell images were taken using
an inverted phase contrast microscope at 20× magniﬁcation.
Determination of intracellular ROS levels
Intracellular ROS levels were quantiﬁed following the method
described by Alía and co-workers, using DCFH as ﬂuorescent probe
(Alía, Ramos, Mateos, Bravo, & Goya, 2005). HepG2 cells were cultured
in 24-wellmultiwell plates (2× 105 cells perwell), incubated overnight,
and then, treated with lunasin as described above. After 19.5 h incuba-
tion with the peptide, a solution of DCFH was added to each well
(5 μM ﬁnal concentration), and cells were incubated in the dark for
30 min at 37 °C. Afterwards, cells were washed with PBS, incubated
with culture medium (direct effects), or subjected to chemical-
induced oxidative stress with t-BOOH (protective effects). The produc-
tion of intracellular ROS was followed over 3 h measuring the ﬂuores-
cence intensity at λexcitation and λemission of 485 nm and 530 nm,
respectively, in a microplate reader (FL600, Bio-Tek). The results were
pooled from different plates to obtain an average of n = 8, and
expressed as percentage of the control (cells in a basal state), considered
as 100%.
Quantiﬁcation of concentration of GSH and determination of GPx and CAT
activity
Cells were seeded onto 100-mm Petri dishes, incubated overnight,
treated with lunasin (for both direct and protective assays), exposed
to t-BOOH (for protective assays), and then, collected following the
methodology described by Quéguineur and co-workers (Quéguineur
et al., 2012). The obtained supernatants, corresponding to the cellular
content of HepG2 cells, were subjected to the determination of the con-
centration of GSH and the activity of GPx and CAT enzymes. The content
of GSH was evaluated by a ﬂuorometric assay as previously described
(Quéguineur et al., 2012). Brieﬂy, 50 μL of each sample were transferred
in triplicate to a 96-multiwell plate, and the reactionmixture containing
15 μL of 1 M NaOH, 175 μL of PBS/EDTA, and 10 μL of a solution of OPT
(10 mg/mL) was added. After 20 min incubation, the ﬂuorescence was
read (λexcitation/λemission = 340/460 nm) in a microplate reader
(FL600, Bio-Tek). Results were pooled from different plates to obtain
an average of n = 6, and interpreted considering those of a standard
GSH curve similarly prepared within each of the experiments run.
GPx catalyzes the oxidation of GSH to oxidized glutathione, using t-
BOOH as a substrate, reaction coupled to the decomposition of NADPH
to β-nicotinamide adenine dinucleotide by glutathione reductase.
Thus, disappearance of NADPH reliably estimates GPx activity, which
can be measured by following the decrease in absorbance at 340 nm
(Alía et al., 2006). CAT activity was determined by following the break-
down of the peroxide H2O2 to H2O, monitored as a decrease in absor-
bance at 240 nm (Granado-Serrano et al., 2007). Results for both GPx
and CAT activities were pooled from different plates to obtain an
average of n = 6, and 4, respectively, and referred to the total protein
concentration of the cytosolic samples, measured by the Bradford
reagent (Bio-Rad).
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Oxidative damage to proteins by reactive species, particularly ROS,
was evaluated by measuring the content of carbonyl groups in cell su-
pernatants according to the method of Richert and co-workers
(Richert, Wehr, Stadtman, & Levine, 2002). Absorbance was measured
at 360 nm, and carbonyl content results (experiments run to obtain an
average of n = 4) were expressed as nmol of carbonyl groups per mg
of total protein, using an extinction coefﬁcient of 22,000 nmol/L/cm.
Determination of caspase-3 activity
Caspase-3 activitywasmeasured according to theﬂuorometric assay
previously described (Herrera et al., 2001). After treatmentwith lunasin
for 20 h and chemical induction with t-BOOH for 3 h, cells were
collected, and lysed in a buffer containing 5 mM Tris, 20 mM EDTA,
and 0.5% Triton-X100. Then, the reaction mix containing 30 μg cell pro-
tein, 20 mMHEPES, 10% glycerol, 2 mMDTT, and 20 μMAc-DEVD-AMC
was incubated in the dark for 2 h. Fluorescence was measured at
λexcitation and λemission of 380 nm and 440 nm, respectively, in a
microplate reader (FL600, Bio-Tek), and enzymatic activity results
(experiments run to obtain an average of n = 4) were expressed as
units of caspase-3 per μg of total protein.
Stability of lunasin
HepG2 cells were plated in 60 mm-diameter plates at a density of
1.5 × 106 cells per plate, and incubated at 37 °C overnight. Then, cells
were treated with 10 μM lunasin dissolved in FBS free DMEM–F12,
and incubated at 37 °C for 20 h, taking aliquots of the medium at 0, 2,
6, 12, and 20 h of incubation. These aliquots were subjected to liquid
chromatography (HPLC) coupled to tandem mass spectrometry
(HPLC–MS/MS) on an Agilent 1100 HPLC System (Agilent Technologies,
Waldbronn, Germany) connected on-line to an Esquire 3000 ion trap
(Bruker Daltonik GmbH, Bremen, Germany), and equipped with an
electrospray ionization source as previously described (Contreras
et al., 2010). The column used was a Mediterranea Sea18 column
(150 × 2.1 mm, Teknokroma, Barcelona, Spain), the injection volume
was 50 μL, and the ﬂow was set at 0.2 mL/min. Peptides were eluted
with a linear gradient of solvent B (acetonitrile:TFA 1000:0.27 v/v) in
A (water:TFA 1000:0.37 v/v) going from 0% to 45% in 130 min. Data
obtained were processed and transformed to spectra representing
mass values using the Data Analysis program (version 4.0, Bruker
Daltonik). To process the MS/MS spectra and to perform peptide se-
quencing BioTools (version 3.1, Bruker Daltonik) was used.
Statistics
Data were analyzed by a one-way ANOVA followed by the
Bonferroni Multiple Comparison test, and expressed as the mean ±
standard variation (SD). GraphPad Prism 5.0 software (San Diego, CA,
USA) was used to perform statistical analyses. Differences with a
P value b 0.05 (*,#), P value b 0.01 (**,##) or P value b 0.001 (***,###)
were considered signiﬁcant.
Results and discussion
Chemoprotective effects of lunasin on cell viability and redox status
In order to evaluate the effect of lunasin at a physiological level, in
the present study, a range of concentrations between 0.5 and 10 μM
was selected. Previous studies on lunasin's bioavailability have demon-
strated that, because of the protection against gastric and pancreatic
enzymes exerted by naturally occurring protease inhibitors such as
the Bowman–Birk inhibitor (BBI), a high percentage of daily ingested
peptide remains intact during its passage through the gastrointestinal
tract, reaching target organs and tissues in an active form (Hsieh et al.,
2010). The presence of lunasin and BBI has been conﬁrmed in differentsoybean products, such as soymilk, tofu, soybean cake and fermented
soybean products (Hernández-Ledesma, Hsieh, & de Lumen, 2009b).
Daily consumption of 25 g of soy protein, recommended by the Food
and Drug Administration (FDA) to reduce coronary disease (FDA,
1999), supplies lunasin in quantity ranged from 110 mg (21.9 μmol)
to 1760 mg (350.2 μmol). Selected concentrations in our study were
not far from reality since steady-state concentrations of 99.3 μg/g
tissue were isolated from liver of rats fed lunasin-enriched rye
diets for 4 weeks, and lunasin extracted from those livers has been
demonstrated to be active (Jeong et al., 2009).
Before testing the chemo-protective effect of lunasin, it was impor-
tant to evaluate the effect of this peptide per se, in basal conditions,
ensuring that no direct damage is caused to the cell by the compound.
Thus, the direct effect of lunasin on HepG2 cell viability was evaluated.
The CV assay, based on the growth rate reduction reﬂected by the color-
imetric determination of the stained cells, was used to determine the
cell viability. As shown in Fig. 1A, treatment of HepG2 cells with lunasin
for 20 h evoked no decreases in CV staining, indicating that the concen-
trations selected for the study (0.5–10 μM) did not damage cell integrity
during the period of incubation. Higher concentrations of lunasin
were also assessed, observing that the percentage of viable cells was
not affected by 25 μM lunasin (111.20% ± 4.80) and 50 μM lunasin
(111.07% ± 6.19).
The cell damage caused by ROS and other reactive species plays a
crucial role in the induction and progression of several liver diseases
such as hepatocarcinoma, viral and alcoholic hepatitis, and non-
alcoholic steatosis. Consequently, there is an increasing interest in
new therapeutic agents protecting the liver from such oxidative
damage, with natural antioxidants being considered one of the most
effective alternatives (Vitaglione, Morisco, Caporaso, & Fogliano,
2004). t-BOOH, a short-chain analog of lipid peroxide, is often used to
induce acute oxidative stress in different in vitro and in vivo systems,
and to evaluate the protective effects of antioxidants (Mersch-
Sundermann, Knasmuller, Wu, Darroudi, & Kassie, 2004). In the case
of hepatocytes, these cells metabolize t-BOOH to toxic peroxyl and
alkoxyl radicals, initiating peroxidation ofmacromolecules, and thus, af-
fecting the cell integrity and leading to chemical-induced hepatic oxida-
tive damage. Therefore, treatment of HepG2 cells with t-BOOH is an
excellent model of oxidative stress in cell culture systems (Alía et al.,
2005). To evaluate whether lunasin protects HepG2 from oxidative
stress induced by t-BOOH, we ﬁrst determined its effect on the cell
viability. As shown in Fig. 1A, the percentage of viable cells in HepG2 in-
duced by 400 μM t-BOOH was 67.5% (compared to non-stressed cells),
indicating that this chemical showed remarkable cytotoxicity
(P b 0.001) on these cells. However, incubation of the cells with 0.5–
10 μM lunasin for 20 h, prior to chemical oxidant treatment, signiﬁcantly
restored cell viability up to 99.8% (P b 0.001), although dose-dependent
effects were not observed.
As shown in Fig. 2A and B, HepG2 cells treated with t-BOOH showed
reduction in cell numbers and loss of cell-to-cell contact. Thesemorpho-
logical changes in t-BOOH-induced HepG2 cells were attenuated by
pre-treatment with lunasin at 0.5 μM (Fig. 2C), and 5 μM (Fig. 2D).
In order to understand whether the cytoprotective effect of lunasin
might be attributed to the reduction of oxidative stress, the intracellular
ROS generation was evaluated in HepG2 cells exposed to t-BOOH with
and without pre-treatment with lunasin for 20 h. As shown in Fig. 1B,
the level of intracellular ROS in HepG2 cells treated with t-BOOH
alone was 190.0% compared to the non-treated cells (considered as
100%), indicating that 400 μM t-BOOHhad a strong effect on ROS gener-
ation. When the cells were pre-treated with lunasin, intracellular ROS
levels were signiﬁcantly decreased up to 122% (compared to control)
(P b 0.001), but no dose-dependent activity was observed. These results
suggest that ROS generated during the period of oxidative stress were
more efﬁciently quenched in cells pre-treated 20 h with lunasin,
which could be a ﬁrst explanation for the reduced cell damage and
death shown. The intracellular ROS levels of non-stressed cells were
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Fig. 1.Direct and protective effects of peptide lunasin on cell viability and intracellular ROS and GSH levels. HepG2 cells were pre-incubatedwithmedium or medium supplementedwith
lunasin (ﬁnal concentration ranged from 0.5 to 10 μM) for 20 h before treatmentwithmedium (□: non-stressed cells) ormedium supplementedwith 400 μM t-BOOH for 3 h (■). (A) Cell
viability was measured by the CV assay. Results are expressed as percent of viable cells, n= 12. (B) Intracellular ROS generation. Fluorescence units corresponding to intracellular ROS
production are expressed as percent of data from non-stressed cells, n= 8. (C) Intracellular GSH levels. Results of ﬂuorescent analysis are calculated as nmoles of GSH per mg of protein,
and represented as percentage of non-stressed cells, n= 6. ⁎(P b 0.05), ⁎⁎⁎(P b 0.001), signiﬁcantly different from control non-stressed cells, and ###(P b 0.001), signiﬁcantly different
from control t-BOOH-induced cells.
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C D
10µm
Fig. 2.Morphological analysis of HepG2 cells. HepG2 cells were pre-incubatedwithmedium ormedium supplementedwith lunasin (ﬁnal concentration 0.5–10 μM) for 20 h before treat-
ment withmedium (non-stressed cells) ormedium supplementedwith 400 μM t-BOOH for 3 h. Representative images of (A) non-stressed cells pre-incubatedwithmedium, (B) t-BOOH-
induced cells pre-incubated with medium, and t-BOOH-induced cells pre-incubated with (C) 0.5 μM lunasin and (D) 5 μM lunasin. HepG2 cells pre-incubated with medium and treated
with t-BOOH showed reduction in cell numbers and loss of cell-to-cell contact (arrows), compared with non-stressed cells pre-incubated with medium, and t-BOOH-induced cells
pre-incubated with lunasin. Size bar: 10 μm.
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Fig. 3. Protective effects of lunasin on enzymes GPx and CAT activity. HepG2 cells were
pre-incubated with medium or medium supplemented with lunasin (ﬁnal concentration
ranged from 0.5 to 10 μM) for 20 h before oxidation induction with 400 μM t-BOOH for
3 h (■). Results of enzymes (A) GPx and (B) CAT activities are calculated as mUnits per
mg of protein and represented as percentage of data from non-stressed cells (□). Repre-
sented values aremeans± SD of n=6 (GPx) and n=4 (CAT). ⁎⁎⁎(P b 0.001), signiﬁcant-
ly different from control non-stressed cells, and #(P b 0.05), ##(P b 0.01), and
###(P b 0.001), signiﬁcantly different from control t-BOOH-induced cells.
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control cells) when 5 μM lunasin was used (Fig. 1B). These ﬁndings
conﬁrm the ability of this peptide as an effective scavenger of ROS in
cell cultures. Previous studies have demonstrated that lunasin is a
potent antioxidant in different in vitro assays, including reducing
power, and ABTS, peroxyl and superoxide radical scavenging activities
(García-Nebot et al., 2014; Hernández-Ledesma et al., 2009a; Jeong
et al., 2010).
Lunasin at concentrations higher than 1 μM signiﬁcantly increased
the cytosolic levels of GSH (P b 0.05) (Fig. 1C). GSH is a tripeptide
found in all mammalian cells and considered the main non-enzymatic
antioxidant defense within the cell. It appears in high concentration in
the liver where it plays a crucial role protecting against oxidative stress
through elimination of toxic ROS, and mitigation of macromolecule
peroxidation and cell injury (Mari, Morales, Colell, García-Ruiz, &
Fernández-Checa, 2009). It is usually assumed that enhanced levels of
GSH prepare the hepatocytes against a potential oxidative insult,
whereas its depletion reﬂects an intracellular oxidation state (Alía
et al., 2005). The effect of lunasin on GSH levels, together with the de-
creased ROS generation, reﬂects a diminished intracellular oxidation
which could be expected to place the cell in favorable conditions to
face a potential oxidative insult. Treatment of HepG2 cells with
t-BOOH induced a signiﬁcant decrease in the concentration of GSH
(P b 0.001), as it was previously demonstrated (Goya, Mateos, &
Bravo, 2007). However, this depletion of the GSH store was partly
prevented by pre-treatment with lunasin (Fig. 1C). These ﬁndings indi-
cate that increased levels of GSH in the lunasin-treated cells before
exposure to the oxidative damage greatly helped to prevent the dramatic
depletion of intracellular GSH during the oxidative stress, an effect of
lunasin that hadnot been reported previously.MaintainingGSH concen-
tration above a critical threshold while facing a stressful situation repre-
sents an enormous advantage for cell survival.
Inﬂuence of lunasin on antioxidant enzyme activity
In non-stressed HepG2 cells, lunasin did not provoke any change in
the activity of GPx and CAT (data not shown). These results indicate
that in spite of the direct effects of lunasin on ROS levels and GSH
content, the enzymatic defense system in the cellswas balanced. The in-
crease in the activity of GPx and CAT observed after exposure to t-BOOH
(Fig. 3A and B), clearly indicates a positive response of the cell defense
system to face the increasing generation of ROS evoked by the oxidative
insult (Alía et al., 2006; Goya, Martín, Ramos, Mateos, & Bravo, 2009). It
has been demonstrated that GPx and CAT play a crucial role as the ﬁrst
line of the antioxidant defense systemagainst ROS generated during ox-
idative stress (Ray & Husain, 2002). However, a rapid return of the anti-
oxidant enzyme activities to basal values once the challenge has been
surmounted will place the cell in a favorable condition to deal with a
new insult. Therefore, changes in their activity are considered as bio-
markers of the antioxidant cellular response. It has been previously
shown that ﬂavonoid quercetin (Alía et al., 2006), olive oil phenol
hydroxytyrosol (Goya et al., 2007), organic selenium derivatives
(Cuello et al., 2007), and seaweed metabolite phloroglucinol
(Quéguineur et al., 2012), among others, protect HepG2 cell integrity
by preventing the severely increased activity of antioxidant enzymes in-
duced by t-BOOH. In the present study,we show, for theﬁrst time, that a
20 h treatment of human HepG2 cells with lunasin prevents the perma-
nent increase in the activity of both glutathione-related GPx and
glutathione-independent CAT induced by oxidative stress (Fig. 3A and
B). Thus, the restrained ROS production during the stressful challenge
in lunasin-treatedHepG2 cells reduces the need for peroxide detoxiﬁca-
tion through GPx and CAT. Although a potential direct effect of lunasin
on antioxidant enzymes gene expression throughout the antioxidant
response element cannot be ruled out, the protective mechanism of
lunasin can be illustrated in terms of regulation of the speciﬁc activity
of antioxidant defense enzymes.Lunasin-induced reduction of protein oxidation
Since protein carbonyl concentration has been found elevated in
various diseases thought to be related to free radical damage, it has
been widely used as an index of protein oxidation in biological and
medical sciences (Mateos & Bravo, 2007). Fig. 4A shows that 3 h-
treatment of HepG2 with 400 μM t-BOOH evoked a signiﬁcant increase
in the cellular concentration of protein carbonyl groups of about 3-times
compared to non-stressed cells, indicating an intense oxidative damage
to cell proteins. However, pre-incubation of the cells with lunasin at
concentrations ranged from 0.5 to 10 μM for 20 h reduced the protein
carbonyl levels down to levels measured in non-stressed cells. This
fact indicates the ability of this peptide to diminish the level of protein
oxidation resulting from chemical induction with t-BOOH. Other food
compounds including plant polyphenols, beta carotene, lutein, seaweed
metabolite phloroglucinol and biscuit melanoidins have been also
reported to prevent protein oxidation (Alía et al., 2006; Goya et al.,
2007; Martín et al., 2010; Murakami, Hirakawa, Inui, Nakano, &
Yoshida, 2002; Quéguineur et al., 2012). However, to date, no dietary
peptide had demonstrated to exert this protective effect.Lunasin prevents apoptosis by reducing stress-induced caspase-3
Oxidative stress-induced hepatic cell injury results not only from
direct chemical interactions by altering cellular macromolecules such
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Fig. 4. Protective effects of lunasin on protein carbonyl content and caspase-3 activity.
HepG2 cells were pre-incubated with medium or medium supplemented with lunasin
(ﬁnal concentration ranged from 0.5 to 10 μM) for 20 h before oxidation induction with
400 μM t-BOOH for 3 h (■). (A) Protein carbonyl content. Results are expressed as nmol
permg protein and represented as percentage of non-stressed cells (□). (B) Caspase-3 ac-
tivity. Results are calculated as Units per μg of protein and expressed as percent of control
data. Values are means ± SD of 4 different samples per condition. ⁎⁎⁎(P b 0.001), signiﬁ-
cantly different from control non-stressed cells, and ###(P b 0.001), signiﬁcantly different
from control t-BOOH-induced cells.
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stress signals and stress-dependent apoptosis reactions (Singh & Czaja,
2008). In this regard, ROS generation has been described as a critical
upstream activator of the caspase cascade that ends up with stimulation
of downstream key effectors such as caspase-3 and subsequent develop-
ment of apoptosis (Singh & Czaja, 2008). Besides, GSH depletion is a
common feature of apoptotic cells, and its role as a critical regulator in
the signaling pathways leading to the progression of apoptosis has
been reported (Franco & Cidlowski, 2009, 2012). As shown in Fig. 4B,
the caspase-3 activity was signiﬁcantly increased after 400 μM t-BOOH
treatment for 3 h (P b 0.001), comparedwith the non-stressed cells. Pre-
vious studies had also demonstrated this pro-apoptotic effect of chemical
t-BOOH on HepG2 cells through activation of caspase-3 and, ultimately,
cell death (Martín et al., 2010). Consistent with the above-mentioned
ROS scavenging effect of lunasin, this peptide in the range of 1–10 μM
effectively reduced caspase-3 activity in t-BOOH-induced HepG2 cells
(P b 0.001) although no dose–response relationship was observed, indi-
cating that increases in lunasin's concentration did not improve the
caspase-3 activity reduction caused by this peptide. The demonstrated
effects indicated the preventive capacity of lunasin against apoptotic ef-
fects induced by disruption of the redox steady-state.
Stability of peptide lunasin in HepG2 cultures
In order to study the stability of lunasin after its addition to HepG2
cells and incubation for 20 h, the medium without and with lunasin(10 μM) at different incubation hours (0, 2, 6, 12, and 20 h) was ana-
lyzed by HPLC–MS/MS. As an example, Fig. 5A shows the extracted
ion chromatograms of the molecular ion of lunasin m/z 1257.5
(charge +4) obtained after 6, 12, and 20 h-incubation of cells
with lunasin. The lunasin's peak area was measured (Fig. 5B), and it was
observed that the content of this peptide in the medium notably de-
creased with the incubation time. After 12 h-incubation, only 29% of ini-
tial lunasin remained in the medium, and after 20 h, less than 1% was
observable. In the present study, the analysis by HPLC–MS/MS also
allowed the identiﬁcation of lunasin-derived fragments that could be re-
leased during incubation of lunasin with HepG2 cells (Fig. 5A). Five
lunasin-fragments were observed; all of them corresponding to the C-
terminal region of the peptide, from the amino acid residue 25. The iden-
tiﬁedpeptides' peak areaswere alsomeasured (Fig. 5B). After 2 h-incuba-
tion, fragments f(25-43) and f(26-43) were already detectable in the
medium. Other three peptides were released at 6 and 12 h-incubation.
It has to be highlighted that after 20 h, extracellular lunasin only repre-
sented the 0.6% of total identiﬁed peptideswhereas peptide f(25-43) rep-
resented 76.5%. Therefore, it can be postulated that the most abundant
fragment, f(25-43), can be, at least, in part, responsible for the activity ob-
served, and further studies with this lunasin-derived peptide are already
in progress. In spite the important hydrolysis observed, it cannot be ex-
cluded that part of the lunasin could also internalize into HepG2 cells. It
is also important to note that all the identiﬁed fragments contain the C-
terminal part of the lunasin, which had previously been proposed as the
active site of lunasin (Hernández-Ledesma, de Lumen, & Hsieh, 2013).
The hydrolysis of lunasin observed in contact with the HepG2 cells was
different to that observed in our previous study with differentiated
human intestinal Caco-2 cells (García-Nebot et al., 2014), where most of
lunasin added to the culture medium remained intact after 24 h incuba-
tion with these cells.
In the present study, analyses, focused on evaluating the antioxidant
activity of peptide lunasin in HepG2 cells, were carried out after 20 h
pre-treatment with this peptide. The protective mechanism on cells
submitted to an oxidative stress that can be illustrated in terms of regu-
lation of the cellular redox status, i.e. peptide treatment restrained ROS
production and maintained GSH concentration during the stress which
reduced the necessity of peroxide detoxiﬁcation through GPx and CAT
was demonstrated. Additionally, a controlled ROS generation reduced
oxidative damage to proteins and restrained activity of the apoptotic
pathway resulting in improved cell viability. The ﬁnal ﬁndings found
on lunasin's stability in HepG2 cells indicated that this peptide was
markedly hydrolyzed at the selected time (20 h), and thus, in addition
to the remaining peptide, the fragments released during its hydrolysis
might be the actual fragments responsible for the observed effects. All
the peptides identiﬁed at 20 h corresponded to the active sequence of
lunasin described to date. Also, they contained the motif RGD known
to be crucial for the interaction of proteins or peptides with its cell
surface receptor (Ruoslahti & Pierschbacher, 1986). Therefore, these
structural characteristics make these ﬁve peptides promising chemo-
protective peptides against oxidative stress in liver HepG2 cells. In
conclusion, our results point out for the ﬁrst time a direct antioxidant
action of lunasin or its derived fragments on hepatocytes exposed to
oxidizing species. It indicates the possibility that these peptides may
signiﬁcantly contribute to preserve the integrity of liver tissues against
oxidative damage related disorders. Since this study has been carried
out with synthetic lunasin which secondary and tertiary structures
could differ to that of plant-puriﬁed lunasin, conﬁrmation of the effects
should be needed to demonstrate the chemo-protective potential of
natural lunasin.
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Supplementary Figure. (A) UV-chromatogram (black line) of the serum free DMEM-F12 medium incubated with 10 
micromolar (µM) lunasin and collected at the starting point of incubation, and extracted ion chromatogram (EIC) (grey 
line) of the molecular ion of lunasina m/z 1257.5 (charge +4). (B) Mass spectrum of the selected chromatographic 
peak in (A). Other peaks showed in (A) correspond to DMEM-F12 medium components. 
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A B S T R A C T
The opioid effect of αs1-casein fragments related to 143AYFYPEL149 and 144YFYPEL149, which
had previously shown mucin-stimulatory activity in human goblet cells, was investigated.
Peptides 144YFYPEL149 and 144YFYPE148 showed opioid agonistic activity in guinea pig ileum,
and in mouse vas deferens but to a lower extent. Peptides were partly hydrolysed during
the assay and several of the resulting fragments lost the N-terminal Tyr residue. Docking
of peptides 144YFYPEL149 (active) and 144YFYP147 (inactive) into the active site of the opioid re-
ceptor model showed remarkable differences regarding the flexibility at the third intracellular
loop of the receptor and the interaction with Pro at the peptide C-terminus that forced resi-
dues Arg148 and Glu166 from the receptor to move towards the interior of the binding pocket.
The study on human cells HT29-MTX has shown that 144YFYPEL149 is the minimum frag-
ment able to stimulate MUC5AC expression.
© 2016 Elsevier Ltd. All rights reserved.
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1. Introduction
During food digestion, proteins render a large variety of dif-
ferent peptides. Some of these sequences are structurally similar
to endogenous physiologically active peptides, and therefore
these food-derived sequences can interact with the same re-
ceptors in the organism, exerting an agonist or antagonist
activity. One of the best examples where this applies, are food-
derived opioid peptides, i.e., exogenous opioid receptor ligands
with agonistic activity. From milk, peptides derived from
β-casein, referred as β-casomorphins,were the first food protein-
derived opioid receptor ligands whose sequences were identified
(Brantl, Teschemacher, Henschen, & Lottspeich, 1979).They have
been found in in vivo digestion products from humans and
minipigs (Barbé et al., 2014; Boutrou et al., 2013). The common
structural characteristics of both exogenous and endogenous
opioid peptides are the presence of a tyrosine residue at the
N-terminus and the presence of other aromatic residue, phe-
nylalanine or tyrosine in the third or fourth position (Meisel,
* Corresponding author. Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC-UAM, CEI UAM+CSIC), Nicolás Cabrera, 9,
28049 Madrid, Spain.
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1997). In case of the αs1-casein derived peptides or α-casein
exorphins, the active sequence can contain an additional ar-
ginine residue at the N-terminus. Although caseins are source
of many peptides showing agonist or antagonist action on dif-
ferent opioid receptors, opioid peptides from other protein
sources have been also described, such as whey proteins (Antila
et al., 1991) and haemoglobin (Zhao, Garreau, Sannier, & Piot,
1997) from animal sources, and gluten, rice, or soy from plant
proteins (Yoshikawa, 2015).
Biological activities observed for these food-derived opioid
sequences include analgesia andmodulation of social behaviour
after parenteral or intracerebral administration to animals.
Orally administered food-derived opioid peptides have dem-
onstrated to influence postprandial metabolism by stimulating
secretion of insulin and somatostatin, prolongation of
gastrointestinal transit time, stimulation of food intake, and
effects on the immune system, among others (for reviews re-
garding biological activity, see Meisel & Fitzgerald, 2000;
Rutherfurd-Markwick, 2012; Teschemacher, 2003; Teschemacher,
Koch, & Brantl, 1997). Moreover, it was found that the opioid
peptide β-casomorphin-7 (60YPFPGPI66) induced intestinal mucin
release through a nervous pathway and opioid receptor acti-
vation in ex-vivo preparations of rat jejunum (Claustre et al.,
2002; Trompette et al., 2003). In human (HT29-MTX) and rat
(DHE) intestinal mucin-producing cells, this peptide in-
creased secretion and expression of mucin, and these effects
were prevented with the µ-opioid antagonist cyprodime (Zoghbi
et al., 2006). Similar effects were reported for the µ-opioid
ligands, α-lactorphin (Martínez-Maqueda et al., 2012) and
β-lactorphin (Martínez-Maqueda, Miralles, Ramos, & Recio,
2013b). However, other β-casein-derived peptides whose struc-
tures do not fulfil the requirements of opioid ligands have also
demonstrated regulation ofmucin production in HT29-MTX cells
and in animals, such as the peptide β-casein f(94–123) found
in yogurts and the derived fragments (94–108) and (117–123)
(Plaisancié et al., 2013, 2015).
Our group had shown themucin secretory activity of various
bovine αs1-casein-derived peptides with favourable struc-
tures to bind opioid receptors due to the presence of Tyr at the
N-terminus or in the second position and other Tyr in the third
or fourth position. From these peptides, fragments 143AYFYPEL149,
144YFYPEL149 and a casein hydrolysate containing both se-
quences produced an increased mucin secretion and MUC5AC
gene expression in HT29-MTX cells (Martínez-Maqueda,
Miralles, Cruz-Huerta, & Recio, 2013a). Interestingly, these two
peptides had been identified in in vivo gastric and duodenal
human digests after milk ingestion (Chabance et al., 1998).
However, despite the favourable structure of these sequences
and their potential to interact with opioid receptors located
at the intestinal tract, the opioid activity of these peptides has
not been previously demonstrated. The objective of this work
was to investigate the opioid effect of the bovine αs1-casein frag-
ment 143AYFYPEL149, and four derived peptides comprising the
core structure for opioid activity YFY in guinea pig ileum and
mouse vas deferens preparations. A molecular docking of two
peptides into the active site of the µ-opioid receptor was carried
out to identify the key residues responsible for the affinity to
the receptor. In addition, a preliminary study of these se-
quences on MUC5AC gene overexpression in HT29-MTX cells
is shown.
2. Materials and methods
2.1. Peptides
αs1-casein fragments 143AYFYPEL149, 144YFYPEL149, 144YFYPE148,
144YFYP147 and 144YFY146, and the β-casein fragment 60YPFPGPI66
were synthesized in house using conventional solid-phase
FMOC synthesis with a 433A peptide synthesizer (Applied
Biosystems, Warrington, UK). In the peptide purification pro-
tocol, the treatment with acetic acid was included to replace
trifluoroacetic acid which affects the pH of the peptide solu-
tions in the bioassays. Their purity (>90%) was verified in our
laboratory by reverse phase high performance liquid chroma-
tography and tandem mass spectrometry (HPLC–MS/MS).
2.2. Isolated preparations from guinea pig ileum and
mouse vas deferens
Female guinea pigs weighing 300–450 g and male CD-1 mice
weighing 25–30 g were used. Myenteric plexus–longitudinal
muscle strips (MP–LM) from guinea pig ileum and the mouse
vas deferens were isolated as described by Ambache (1954) and
Hughes et al. (1975), respectively. Tissues were suspended in
a 10 mL organ bath containing 5 mL of Krebs solution (NaCl
118, KCl 4.75, CaCl2 2.54, KH2PO4 1.19, MgSO4 1.2, NaHCO3 25,
glucose 11 mM). This solution was continuously gassed with
95% O2 and 5% CO2. Tissues were kept under 1 g (guinea pig
ileum) or 0.5 g (mouse vas deferens) of resting tension at 37 °C
andwere electrically stimulated through two platinum ring elec-
trodes. MP–LM strips were stimulated with rectangular pulses
of 70 V, 0.1 ms duration and 0.3 Hz frequency, and mouse vas
deferens with trains of 15 rectangular pulses of 70 V, 15 Hz and
2 ms duration each minute. The isometric force was moni-
tored by computer using a MacLab data recording and analysis
system. In both assays the interval between applications of in-
creasing concentrations was optimized to obtain a stable signal,
and it was 9min for αs1-casein peptides and 3min when control
opioid agonists were tested. To evaluate the opioid-agonistic
activity of peptides in the guinea pig ileum, cumulative
concentration–response curves with five doses in the range
6.1 × 10−8–1.0 × 10−5M were constructed in a step by step manner
as follows: after 15-min stabilization of MP–LM strips in organ
bath, electrical stimulation was applied, and the peptide’s effect
on the electrically induced contractions was evaluated once
the response reached a plateau. Morphine was used as µ-opioid
agonist positive control.To corroborate that the inhibitory effect
of the peptides was mediated through interaction with opioid
receptors, one dose of naloxone (1.0 × 10−6M, Sigma, St. Louis,
MO, USA), a non-selective opioid antagonist, was added to the
organ bath at the end of each experiment. In mouse vas def-
erens preparations, non-cumulative concentration–response
curves with four doses in the range 5.5 × 10−7–1.0 × 10−5M were
tested. Once tissue stabilization was achieved, the first peptide
dose was added and evaluated. The tissue was then washed,
and subsequent doses were applied. In this preparation, [D-
Pen(2),D-Pen(5)]-enkephalin (DPDPE) was used as δ-opioid
agonist, and one dose of naltrindole (1.0 × 10−9–1.0 × 10−7 M,
Sigma), a δ-selective opioid antagonist, was added after the ex-
periments to evaluate selective interaction with δ-opioid
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receptors. Results were expressed as % of inhibition, taking the
mean amplitude of the last five contractions before the addi-
tion of the peptides as 100%. In guinea pig ileum, when the
effect of peptidase inhibitors (captopril, amastatin and
phosphoramidon 1.0 × 10−6 M, Sigma) was evaluated, they
were added 5 min before the beginning of the peptide’s
concentration–response curve (Akahori et al., 2008). Each tissue
was employed only once, with at least six biological repli-
cates per condition. Experimental protocols used in this
investigation were approved by the Ethical Committee of Rey
Juan Carlos University. Data were analysed using GraphPad
Prism 5.03 software by a one-way ANOVA, followed by the
Bonferroni multiple comparison test. Differences between each
dose with a P value < 0.05 were considered significant.
2.3. Analysis by HPLC–MS/MS
In order to evaluate the stability of the peptides during the ac-
tivity assay on MP–LM preparations, they were added at
5.0 × 10−6M to the organ bath solution, and aliquots were with-
drawn at time 0, 4, and 9 min, frozen immediately and kept
at –20 °C until analysis. Analysis of the peptides was per-
formed using an Acquity ultrahigh performance liquid
chromatography system (Waters, Milford, MA, USA) con-
nected to microToF II Quadrupole-Time-of-Flight mass
spectrometer (Bruker Daltonik, Bremen, Germany). A Waters
Acquity UPLC BEH C18 column 100 mm length, 2.1 mm inter-
nal diameter, 1.7 µm packing was used. A binary elution
gradient, based on water (solvent A) and acetonitrile (solvent
B), both containing 0.1% formic acid (v/v), and operated at a
flow rate of 0.2 mL/min, was adopted. A gradient elution pro-
gramme based on solvent B increase from 0% to 70% in 30 min
was used. Column reconditioning at the initial mobile phase
composition was accomplished in 15 min. ESI-MS acquisi-
tions were carried out in positive ion mode.The LC–MS system
was controlled by the HyStar 3.2 software (Bruker). The main
parameters of the ESI interface and of the quadrupole were:
dry temperature 180 °C; dry gas flow 4.0 L/min; nebulizer gas
pressure 0.4 bar; capillary voltage 4.5 kV; quadrupole ion energy
5.0 eV. The ToF analyser was calibrated on a daily basis in MS
mode, using the m/z ratios of adduct ions arising from sodium
formate as reference.
2.4. Molecular modelling receptor-peptide
Homology model of the µ-opioid receptor (UniProtKB – P35372
(OPRM_HUMAN)) was built by standard homology modelling
techniques using MODELER version 9.7. (Eswar et al., 2006), as
described in the Supplementary material. The structure of the
human δ- and µ-opioid receptors (Protein Data Bank entries
4RWA and 5C1M) (Fenalti et al., 2015; Huang et al., 2015) was
used as template.The structure of the bifunctional δ-opioid an-
tagonist and µ-opioid agonist tetrapeptide Dmt-Tic-Phe-Phe-
NH2 (Protein Data Bank entry 4RWA) was used as template for
docking the peptides 144YFYPEL149 and 144YFYP147 into the active
site of the opioid receptor model.
2.5. Cell culture
HT29-MTX, a human colon adenocarcinoma-derived mucin-
secreting goblet cell line, was provided by Dr.Thécla Lesuffleur
(Lesuffleur et al., 1993). The cell line was grown in plastic 75-
cm2 culture flasks in Dulbecco’s Modified Eagle’s medium
supplemented with 10% foetal bovine serum and 10 mL/L
penicillin–streptomycin solution (all from Gibco, Paisley, UK)
at 37 °C in a 5% CO2 atmosphere in a humidified incubator. Cells
were passaged weekly using trypsin/EDTA 0.05% (Gibco). The
culture medium was changed every two days. To study the
effect of peptides, cells were seeded at a density of 5 × 105 cells
per well in 12-well culture plates (Nunc, Roskilde, Denmark).
The cell line was used between passages 12 and 19. Experi-
ments were performed 21 days after confluence. The culture
medium was replaced, 24 h before the studies, by serum- and
antibiotic-free medium to starve the cells and to eliminate any
interference from extraneous proteins or hormones. After
serum-free medium removal, the monolayer was washed twice
with PBS. Serum-free medium with or without peptide
(5.0 × 10−5, 1.0 × 10−4, and 5.0 × 10−4M) was added to the cells and
incubated at 37 °C for 2 to 24 h in a 5% CO2 humidified atmo-
sphere. The supernatants were collected, frozen and stored at
−80 °C. The total RNA was isolated with Nucleospin® RNA II
(Macherey-Nagel, Düren, Germany) according to manufactur-
er’s instruction.
2.6. Quantitative RT-PCR assays (qRT-PCR)
qRT-PCR amplification was carried out using a Lightcycler 480
(Roche, Mannheim, Germany) in 384 wells microplates (Roche).
RNA (375 ng) was reverse transcribed using a High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Carls-
bad, CA, USA) according to the manufacturer’s instruction. For
MUC5AC (accession no. AJ001402), target gene, primers 2870–
2889/3109–3091 were used. For reference genes human
cyclophilin (accession no. Y00052) and human β-actin (acces-
sion no. NM_001101) primers 280–304/445–421 and 879–896/
1076–1053, respectively, were used (Tai et al., 2008; Zoghbi et al.,
2006). The SYBR Green method was used and each assay was
performed with cDNA samples in triplicate. Each reaction tube
contained 5 µL 2x SYBR Green real-time PCRMaster Mix (Roche),
0.25 µL of a 10 µM of gene-specific forward and reverse primers,
0.27 µL of cDNA (5.06 ng), and 4.23 µL of water. Amplification
was initiated at 95 °C for 5 min, followed by 45 cycles of 95 °C
for 10 s, 60 °C for 10 s and 72 °C for 10 s. Control PCRs were in-
cluded to confirm the absence of primer dimer formation
(no-template control) and to verify that there was no DNA con-
tamination (without RT enzyme). All real-time PCR assays
amplified a single product as determined by melting curve
analysis. Amplification efficiencies of the target and refer-
ence genes were performed, and the relative expression levels
of the target gene were calculated according to the 2-ΔΔCt method
(Livak & Schmittgen, 2001). Human cyclophilin and human
β-actin were tested as reference gene. Human cyclophilin gene
was then chosen to calculate the threshold cycles because it
had previously been shown to be constant under all condi-
tions used.All experiments were performed at least three times
in triplicate. Data were analysed using GraphPad Prism 5.03 soft-
ware by a two-way ANOVA. For a better comparison of the
concentration versus control data for each time, data were
analysed by one-way ANOVA, followed by the Newman–
Keuls test. Differences between means and controls with a P
value < 0.05 (*) or P value < 0.01 (**) were considered significant.
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3. Results
3.1. Activity of αs1-casein fragment 143AYFYPEL149 and
derived peptides on guinea pig ileum and mouse vas
deferens preparations
As illustrated in Fig. 1, the inhibition of the electrically induced
contractions in MP–LM preparations in cumulative curves of
five doses showed a significant increase upon addition of the
αs1-casein peptides 144YFYPEL149 and 144YFYPE148 between the
first and the third dose but the curve did not show any further
increase. The other peptides, 143AYFYPEL149, 144YFYP147 and
144YFY146, did not show inhibitory effect on this preparation.
Themaximum inhibition responses for 144YFYPEL149 (35.1 ± 5.6%)
and 144YFYPE148 (31.8 ± 2.5%) were reached at a dose 5.5 × 10−7M
and it was followed by a smooth decrease. As positive con-
trols, β-casomorphin-7 (YPFPGPI) and morphine were used.
β-casomorphin-7 showed an increasing trend up to 1.0 × 10−5M
with a maximum response of 23.3 ± 5.1%, while the mor-
phine inhibition curve increased up to 1.6 × 10−6M reaching a
60.6 ± 5.8% of inhibition on the electrically stimulated con-
tractions of the MP–LM preparations. In this latter case, the
plateau observed for the highest concentration (5.0 × 10−6M)
could be due to receptor saturation. However, the decreasing
trend of the curves obtained for the αs1-casein-derived pep-
tides from the third dose led us to consider the possibility of
peptide degradation in the organ bath. In order to check peptide
stability during the experiments, aliquots of the organ bath were
withdrawn at time 0, 4 and 9 min and analysed by HPLC–MS/
MS.The chromatographic areas of the extracted molecular ion
corresponding to the assayed peptides showed a decrease with
the time (Supplementary Fig. S1).The observed decrease in the
area of intact peptide was accompanied with the increase of
derived peptide fragments, which could be also identified by
their fragmentation pattern. In this way, from peptide
143AYFYPEL149 increasing concentrations of fragments
144YFYPEL149, 145FYPEL149, and 146YPEL149 were detected over time;
from peptide 144YFYPEL149, fragments 145FYPEL149, 146YPEL149, and
144YFYP147 were found; and from 144YFYPE148, the formation of
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Fig. 1 – Inhibition of the electrically induced contractions in guinea pig ileum preparations at increasing concentrations
(cumulative curve) of αs1-casein fragment 143AYFYPEL149 (A), αs1-casein fragment 144YFYPEL149 (B), αs1-casein fragment
144YFYPE148 (C), αs1-casein fragment 144YFYP147 (D), αs1-casein fragment 144YFY146 (E), β-casein fragment (β-casomorphin-7,
60YPFPGPI66) (F), and morphine (G). For clarity, food-derived peptides and morphine results are represented in the Y-axis up
to 40 and 80% inhibition, respectively. Each point represents the mean % ± SEM (n = 6). Different letters denote statistically
significant differences between concentrations (P < 0.05).
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145FYPE148 could be followed. No peptide fragments were de-
tected for 144YFYP147 or 144YFY146, although a concentration
decrease ca. 34% and 29% was found from 0 to 9 min, respec-
tively. For these two short peptides, it is possible that although
peptide degradation could occur, the derived peptide frag-
ments could not be detected due to the short size of the
fragments. It has to be noted that some of the new peptide frag-
ments generated by the action of tissue peptidases preserved
the cluster 144YFY146, but in other cases the N-terminal Tyr
residue was lost, and therefore presumably their potential opioid
effect. Since the lost in opioid effect along the accumulative
dose–response curve could be attributed to the peptide deg-
radation over time, the assays were repeated in the presence
of three peptidase inhibitors.
Fig. 2 shows the inhibition curves for peptides 143AYFYPEL149,
144YFYPEL149, 144YFYPE148, 144YFYP147 and 144YFY146 when pepti-
dase inhibitors captopril, amastatin and phosphoramidon were
used. The inhibition curves for all peptides, except 144YFYP147,
showed an increasing trend with the peptide concentration and
a significant dose-effect was found for various peptides, such
as 144YFYPEL149 and 144YFY146. Peptide 144YFYPE148 reached the
highest mean inhibitory value, 31.6 ± 4.6%, although the inhi-
bition percentages determined for 143AYFYPEL149, 144YFYPEL149,
and 144YFY146 were not significantly different from this, being
22.2 ± 4.1, 26.2 ± 4.9 and 25.5 ± 5.3%, respectively. The suppres-
sive effect of these peptides on the electrically stimulated
contractions in MP–LM preparations was reverted by the use
of naloxone at 1.0 × 10−6M, once the maximum concentration
of the peptide was tested. In addition, the stability of the pep-
tides over time in the presence of peptidase inhibitors was also
evaluated, as previously. As expected, derived peptide frag-
ments were not detected or their intensities were considerably
lower (data not shown).
In the mouse vas deferens preparation, αs1-casein-derived
peptides showed lower activity. Peptides 143AYFYPEL149,
144YFYPEL149 and 144YFYPE148 induced a maximum inhibitory
effect of the contractions of 8.8 ± 3.4, 6.9 ± 1.6 and 13.4 ± 2.8%,
respectively, at the highest dose assayed (1.0 × 10−5M), with a
dose-effect trend only found for 144YFYPE148.The positive control,
DPDPE, also showed a dose-dependent activity, with the
maximum inhibitory effect found at 6 × 10−8M (55.3 ± 10.2%).
By the addition of naltrindole (1 × 10−9M), a selective δ-opioid
receptor antagonist, DPDPE effect was partly reversed
(36.0 ± 7.9%), while the weak activity found for the peptides was
not affected.
3.2. Molecular modelling of the µ-opioid receptor bound
to αs1-casein peptides
To better understand the opioid activity of these αs1-casein pep-
tides and aiming to elucidate a structure–activity relationship,
molecular dynamics simulations of peptides binding at µ-opioid
receptor were performed. As representative examples, pep-
tides 144YFYPEL149 and 144YFYP147 were chosen for these
experiments to explain the lack of activity of the shorter form,
according to the results on guinea pig ileum preparations.
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Fig. 2 – Inhibition of the electrically induced contractions in guinea pig ileum preparations in the presence of the peptidase
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The structural stability of the complex receptor-peptide was
evaluated by monitoring the Root-Mean-Square Deviation
(RMSD) between different structures sampled along the simu-
lation. The fluctuations of the individual residues from the
receptor and the peptides were studied. In both cases, intra
and extra loops of the receptor exhibited the greatest vari-
ability, most noteworthy loops between residues 145–150, 195–
200, 240–250 and the C-terminal domain of the receptor (Fig. 3A).
However, when peptide 144YFYP147 was assayed the loop between
residues 195–200 started the simulation with a retracted loop
but it became stretched maintaining this position for the rest
of the simulation (Fig. 3B).While peptide 144YFYPEL149 stays stable
at the active site at its first three residues and fluctuates due
to the repositioning of its last two residues, movements of
peptide 144YFYP147 are mainly due to residues Tyr at the third
position and Pro at the C-terminus, as consequence of the new
C-terminal group.
As shown in Table 1 and Supplementary Fig. S2 the inter-
action energy of the different amino acid residues of the
peptides at the active site of µ-receptor was calculated.The po-
sition of peptide 144YFYPEL149 at the base of active site is
stabilized by strong van derWaals, hydrogen bond, and charge–
charge interactions.This is clearly seen at the final model where
the interactions of the residues of the receptor Asp84, Tyr263,
His234, and Trp230 interact with Tyr at the peptide N-terminus
stabilizing this position (Fig. 4A). Peptide Phe and Tyr resi-
dues, at the second and third position, respectively, showed
strong hydrogen bonds and van derWaals interactions between
their aromatic rings and compatible µ-receptor residues that
also help N-terminal Tyr to maintain its right configuration
(Fig. 4B and 4C). At the top of the cavity, peptide Glu and Leu
establish charge–charge and hydrogen bond interactions, build-
ing a network of electrostatic interactions between the peptide,
some water molecules, and the last residues of the cavity
(Fig. 4D). In the case of peptide 144YFYP147, the behaviour of the
N-terminal Tyr at the right side of the binding pocket re-
sembles that described above for 144YFYPEL149 (Fig. 4E). However
the interaction between the Tyr at the third position and the
Gln61 residue from the receptor changes from van der Waals-
type to hydrogen bond-type (Table 1). Moreover, an additional
hydrogen bond is established with Tyr85, instead of Tyr12 as
before. Consequently, as shown in Fig. 4G, the orientation of
the second Tyr residue from 144YFYP147 differs from that of
peptide 144YFYPEL149. In addition, the C-terminal Pro residue from
144YFYP147 played a remarkable role in receptor-peptide rela-
tion, not described in the case of 144YFYPEL149, by establishing
a strong charge–charge-type interaction withArg148, whichmodi-
fies the configuration of this location (Table 1 and Fig. 4H).
The interactions of peptide-receptor residues were moni-
tored during the simulation time (45 ns). In case of peptide
144YFYPEL149, interactions with N-terminalTyr were stable during
the simulation, whereas for the rest of residues interactions
became stronger as the simulation progressed (Supplemen-
tary Fig. S3). However, main interactions of peptide 144YFYP147
seem to follow a different behaviour.WhereasTyr at the peptide
N-terminus and Asp84 maintained a quite stable interaction,
this peptide residue lost interaction strength with Tyr85 after
10 ns, and with Tyr263 and His234 at the last steps of the simu-
lation. It is remarkable that the second peptideTyr residue began
to show a tough interaction with Tyr85, Asp84, and Ile81 at the
opioid receptor after 20 ns. Similarly, C-terminal Pro in-
creased interaction with Arg148 and Thr155 at the end of the
simulation. All these modifications might be most likely due
to a change in the peptide-receptor orientation.
3.3. Activity of bovine αs1-casein-derived peptides
144YFYPE148, 144YFYP147 and 144YFY146 on MUC5AC expression
Because peptides 143AYFYPEL149 and 144YFYPEL149 had previ-
ously demonstrated stimulatory effect on mucin secretion and
MUC5AC gene expression (Martínez-Maqueda et al., 2013a), the
effect of the shorter derived peptides on HT29-MTX cells was
also evaluated.The relative expression of MUC5AC was deter-
mined by qRT-PCR after exposure of HT29-MTX cells to the
peptides. Table 2 shows the maximum relative MUC5AC
Fig. 3 – Mean residue fluctuations of the µ-opioid receptor
and the αs1-casein fragment 144YFYPEL149 (A) and the αs1-
casein fragment 144YFYP147 (B). Structures of opioid receptor
and peptides are represented as ribbons where the most
moving regions are thicker and coloured in red-orange,
while static regions are thinner and coloured in blue. Third
loop between receptor residues 195–200 is marked with an
arrow. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of
this article.)
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expression level along 24 h of treatment with 144YFYPE148,
144YFYP147, and 144YFY146 at three concentrations (5.0 × 10−5,
1.0 × 10−4, and 5.0 × 10−4M). Although treatment with 144YFY146
showed increased levels of MUC5AC after 24 h at the three con-
centrations, these values did not reach significance due to the
high variability between replicates. For the other two pep-
tides 144YFYPE148 and 144YFYP147, no significant MUC5AC over-
expression was observed compared with controls (untreated
cells). From these two latter peptides, only 144YFYPE148, but not
144YFYP147, had demonstrated the ability to inhibit electrically
stimulated contractions in MP–LM. According to these results,
the assayed shorter forms exhibited different behaviour on the
mucin gene expression in HT29-MTX cells than the longer pep-
tides 143AYFYPEL149 and 144YFYPEL149.
4. Discussion
β-casomorphins were the first food-derived opioid peptides and
were found in a casein hydrolysate in 1979 (Brantl et al., 1979).
Table 1 – Binding free energy for µ-opioid receptor-peptides 144YFYPEL149 and 144YFYP147 complexes decomposed by
protein and peptide residues (vdW: Van der Waals; HB: hydrogen bond; q–q: charge–charge).
Peptide
(YFYPEL)
µ-Opioid
receptor
E
(kcal/mol)
Interaction
type
Peptide
(YFYP)
µ-Opioid
receptor
E
(kcal/mol)
Interaction
type
Tyr ASP84 −13,75 q-q Tyr ASP84 −15,69 q–q
TYR263 −5,35 HB TYR263 −5,43 HB + vdW
HIS234 −4,12 HB HIS234 −3,05 HB
ILE233 −1,79 vdW ILE259 −1,75 vdW
TRP230 −1,65 vdW (π-π) ILE233 −1,54 vdW
MET88 −1,63 vdW MET88 −1,50 vdW
ILE259 −1,62 vdW TRP230 −1,33 vdW
Phe TRP255 −3,36 HB TYR85 −1,05 vdW
LYS170 −1,44 vdW Phe VAL237 −2,23 vdW
VAL237 −1,32 vdW TRP255 −1,75 vdW
ILE259 −1,12 vdW LYS170 −1,69 vdW
TYR85 −0.91 VdW ILE259 −1,07 vdW
Tyr TYR12 −2,34 HB VAL173 −1,07 vdW
GLN61 −2,18 vdW Tyr GLN61 −3,58 HB
TRP255 −1,87 vdW ILE81 −2,94 vdW
ILE259 −1,64 vdW TYR85 −2,07 HB
HIS256 −1,10 vdW LEU156 −1,25 vdW
Pro GLU247 −1,68 vdW VAL80 −1,16 vdW
Glu LYS170 −10,65 HB + q–q ASP84 −1,11 vdW
GLU166 −1,28 vdW CYS154 −1,10 vdW
Leu ARG148 −3,38 HB + q–q Pro ARG148 −15,86 q–q
THR155 −6,20 HB
LEU156 −2,65 vdW
GLU166 −1,13 vdW
Fig. 4 – Final molecular dynamics structure of peptides 144YFYPEL149 (A–D) and 144YFYP147 (E–H) bound the µ-opioid receptor.
Main residues involved in the interaction (showed as sticks) are highlighted in blue in the protein receptor, and those from
the peptides in green. Interactions are shown by amino acid residue of each peptide 144YFYPEL149 and 144YFYP147,
respectively: N-terminal Tyr (A and E); Phe (B and F); Tyr at third position (C and G); Pro-Glu-Leu from 144YFYPEL149 (D) and
C-terminal Pro from 144YFYP147 (H). (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)
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Since then, different opioid peptides derived from milk pro-
teins and other food proteins have been described.The present
study was undertaken to examine if two αs1-casein-derived se-
quences, 143AYFYPEL149 and 144YFYPEL149, which share some
structural characteristics with previously described opioid pep-
tides, could also exert this effect. These two sequences, found
in a peptic casein hydrolysate, had also demonstrated to stimu-
late mucin secretion and gene expression in HT29-MTX cells
(Martínez-Maqueda et al., 2013a), and it had been suggested
that this effect could be mediated by interaction with µ-opioid
receptors (Zoghbi et al., 2006).The results of this study showed,
for the first time, opioid activity in the guinea pig MP–LM
preparation for various related αs1-casein sequences, espe-
cially 144YFYPEL149 and 144YFYPE148. Other related fragments,
143AYFYPEL149 and 144YFY146, were able to exert this effect, but
only when peptidase inhibitors were added to the preparation.
In view of their structures, opioid peptides have been divided
into two groups designated as “typical” and “atypical”
(Teschemacher et al., 1997). “Typical” opioid peptides exhibit
the definite N-terminal sequence YGGF, characteristic of the
endogenous opioid peptides: enkephalins, endorphins, and
dynorphins. “Atypical” peptides are characterized by the pres-
ence of Tyr at the N-terminus which is a structural motif
important in ligand-receptor binding, although this N-terminal
residue is not present in nociception/orphanin FQ (Reinscheid
et al., 1995).The αs1-casein derived peptides studied in this work
share some structural characteristics with previously de-
scribed αs1-casein exorphins. Loukas, Varoucha, Zioudrou,
Streaty, and Klee (1983) identified various αs1-casein opioid pep-
tides, 90RYLGYLE96, 90RYLGYL95 and 91YLGYLE96, from a digest of
casein with pepsin. Similarly to αs1-casein exorphins, pep-
tides in this work were identified in a peptic casein hydrolysate
and also possess two Tyr residues, in our case separated by a
Phe residue instead by the dipeptide LG, as occurs in the
peptides previously described. In addition, some αs1-casein
exorphins are characterized by the presence of an additional
Arg residue at the N-terminus. Our results show by compari-
son of the activity of 143AYFYPEL149 and 144YFYPEL149 that the
presence of an additional Ala residue at the N-terminus di-
minishes the effect on the guinea pig ileum preparation, when
no peptidases inhibitors were used. However, in the presence
of peptidases inhibitors 143AYFYPEL149 exerted certain activ-
ity, and therefore the lack of activity in the absence of peptidase
inhibitors might be explained by a rapid peptide degradation.
Peptides in this study, especially 144YFYPEL149 and 144YFYPE148,
showed naloxone-antagonizable inhibitory effect in the elec-
trically stimulated guinea pig ileum preparation.This isolated
tissue possesses both µ- and κ-opioid receptors that regulate
the contractile response when stimulated by inhibiting ace-
tylcholine release during electrical stimulation of the myenteric
plexus neurons. Although this preparation also contains can-
nabinoid, adenosine and adrenergic receptors (Taylor, 2011), the
reversion of the effect by naloxone, a competitive antagonist
at µ, δ, and κ-opioid receptors, proved the participation of these
receptors on the effect of the assayed peptides. However, lower
effects were found in the mouse vas deferens. This tissue can
be used to study all three opioid receptor subtypes, but the ex-
pression of µ- and κ-opioid receptors is lower in this preparation
than in guinea pig ileum (Taylor, 2011), the δ-opioid being the
predominant receptor subtype (Lord, Waterfield, Hughes, &
Kosterlitz, 1977).The activity of the assayed peptides in mouse
vas deferens was not reverted by the use of naltrindole, which
suggests poor affinity for δ-opioid receptors. Likewise, bovine
β-casomorphins have been also demonstrated to exert a higher
opioid activity in the guinea pig ileum than in the mouse vas
deferens assay (Brantl, Teschemacher, Bläsig, Henschen, &
Lottspeich, 1981). On the contrary, the previously described αs1-
casein exorphins demonstrated amoderated effect on inhibition
of adenyl cyclase in neuroblastoma × glioma hybrid cells, as
well as inhibition of contractions in mouse vas deferens, sug-
gesting selectivity for δ-opioid receptors (Loukas et al., 1983).
The assayed peptides show structural homologies with
β-casomorphins, with an aromatic residue at the first and third
positions and a proline residue at the fourth position from the
N-terminal.This is in agreement with the higher activity found
in the guinea pig ileum preparation.Therefore, further studies
with selective opioid antagonists such as β-funaltrexamine,
naltrindole, and nor-binaltorphimine for µ-, δ-, and κ-opioid re-
ceptors, respectively, are required to evaluate the selectivity of
the active peptides found in this study on different receptor
subtypes.
Regarding activity, these peptides containing the tripep-
tideYFY were found to exert an agonist opioid effect on guinea
pig ileum preparations, althoughmoderate in strength. However,
Table 2 – qRT-PCR analysis of MUC5AC mRNA level in HT29-MTX cells after addition of αs1-casein peptides 143AYFYPEL149,
144YFYPEL149, 144YFYPE148, 144YFYP147, and 144YFY146.
Peptide Relative MUC5AC expression level Time
(h)αs1-casein
fragment
Sequence 5.0 × 10−5M 1.0 × 10−4M 5.0 × 10−4M
143–149a AYFYPEL 1.6 ± 0.1 1.7 ± 0.3* 1.5 ± 0.2 4
144–149a YFYPEL 1.2 ± 0.1 1.4 ± 0.2 1.8 ± 0.2** 4
144–148 YFYPE 0.9 ± 0.1 1.5 ± 0.4 1.3 ± 0.2 8
144–147 YFYP 1.2 ± 0.2 1.0 ± 0.1 0.7 ± 0.1 24
144–146 YFY 1.3 ± 0.6 1.8 ± 0.8 1.9 ± 1.0 24
a Martínez-Maqueda et al. (2013a).
Cells were treated at different concentrations (5.0 × 10−5, 1.0 × 10−4, and 5.0 × 10−4M) and times (2, 4, 8, and 24 h), and the maximum relative
MUC5AC expression level is shown. Data are normalized to control (untreated cells) expression level, using cyclophilin as reference gene. The
results represent the mean ± SEM of three biological replicates in triplicate. Significant differences of each concentration versus control were
determined by two-way ANOVA applying the Bonferroni test: *P < 0.05, **P < 0.01.
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it has to be pointed that under our experimental conditions,
i.e., application of increasing concentrations at 9 min inter-
vals, peptide β-casomorphin-7, which was used as positive
control, did not reach the activity values previously reported
in guinea pig ileum preparations, with IC50 values between
3.2 × 10−6 and 6.9 × 10−6M (Jinsmaa & Yoshikawa, 1999; Koch,
Wiedemann, & Teschemacher, 1985; Yoshikawa, Fumito,
Takashi, & Hideo, 1986). The time intervals used in this study
were optimized to ensure signal stability. In addition, the sta-
bility of the assayed peptides in the organ bath was studied
by HPLC–MS/MS. It was demonstrated that these peptides were
partly hydrolysed by the action of ileum peptidases within 9min
and some of the generated fragments lost the N-terminal Tyr
residue characteristic of opioid peptides. In fact, it has been
reported that endogenous opioid peptides, with homologous
structure than the assayed peptides, are particularly sensi-
tive to rapid hydrolysis by a number of peptidases that are
present in the guinea pig ileum, as well as in other tissues
(McKnight, Corbett, & Kosterlitz, 1983). From our results, it was
also shown that the shape of the inhibition curve changed by
the use of the three peptidase inhibitors but the maximum in-
hibitory activity did not significantly increase (Fig. 1 vs. Fig. 2).
The change in the accumulative inhibition curves compared
to experiments conducted in the absence of peptidase inhibi-
tors confirmed that the decrease observed at higher doses in
the absence of peptide inhibitors is caused by the peptide deg-
radation during the assay.The combination of these peptidase
inhibitors (captopril, amastatin and phosphoramidon
1.0 × 10−6M) was not able to change the activity of morphine,
DAMGO and metabolically stable synthetic opioid peptides in
this preparation (Hiranuma et al., 1998). Aoki, Kajiwara, and
Oka (1984) and McKnight et al. (1983) demonstrated that the
peptidase inhibitor mixtures captopril 1.0 × 10−6, bestatin
10.0 × 10−6, and thiorphan 1.0 × 10−6M, and captopril 10.0 × 10−6,
bestatin 10.0 × 10−6, thiorphan 0.3 × 10−6, and L-Leu-L-Leu
2.0 × 10−3M, respectively, did not affect, alone nor in combina-
tion, the contraction of the guinea pig MP–LM.
In order to explain the different opioid activity found for
these structurally similar peptides, molecular dynamic simu-
lations were performed with 144YFYPEL149 which showed opioid
activity in guinea pig ileum, and 144YFYP147 which was inac-
tive.The homologymodel of µ-opioid receptor with the peptides
docked at the active site was evaluated by the study of the
energy stability and the identification of those responsible
binding-residues at the cavity.The simulations with both pep-
tides showed a notably energy variability in intra- and extra-
cellular loops of the receptor at positions 145–150, 195–200, 240–
250 and the C-terminal domain.This structural flexibility is in
agreement with previous studies with the µ-opioid receptor
(Serohijos et al., 2011). Similarly, it has been found that mor-
phine leads to a greater flexibility of the third intra-cellular loop
of the receptor, which is consistent with the critical role of this
loop as the docking site of G-proteins binding (Waldhoer,
Bartlett, & Whistler, 2004). Due to the flexibility observed in
our simulation, it can be suggested that peptide 144YFYPEL149
behaves as an opioid agonist. For peptide 144YFYP147, the flex-
ible areas of the receptor were similar, but a remarkable
difference was found at the movement of the loop 195–200,
which is related to the activity of the receptor. In addition, while
peptide 144YFYPEL149 evoked a continuous change in this loop
during the simulation, with peptide 144YFYP147 it became fixed.
Moreover, it has been found that both peptides establish two
strong hydrogen bonds and a charge–charge interaction, in the
same way as the morphinan agonist BU72 (Huang et al., 2015),
between the N-terminal Tyr at the peptide andTyr263, His234, and
Asp84 residues. However, and in contrast with the 144YFYPEL149
simulation, the secondTyr residue and Pro from 144YFYP147 were
found to create different interactions with the receptor, re-
sulting in a clear change between the locations of both peptides
at the active binding site. Besides, another fact that might con-
tribute to the different behaviour is the orientation of Arg148
and Glu166 receptor residues.When peptide 144YFYP147 was bound
to the receptor, Arg148 and Glu166 residues had to move towards
the interior of the binding pocket to interact with C-terminal
Pro of 144YFYP147. This process would require a large amount
of energy due to their charged character, and when exposed
to the solvent, would be highly solvated. The energy needed
to remove this solvation shell might render peptide 144YFYP147
inactive.
Previously, Zoghbi et al. (2006) had reported the activity of
β-casomorphin-7 on mucin production in HT29-MTX cells via
µ-opioid interactions. Given the effect observed in guinea pig
ileum preparations, it was expected that in addition to
143AYFYPEL149 and 144YFYPEL149, peptide 144YFYPE148 could also
induce MUC5AC gene expression. However, although this
peptide at 1.0 × 10−4 and 5.0 × 10−4M showed increased expres-
sion levels over the control, it did not reach significance.There
is sufficient literature that illustrates the lack of correlation
between µ-opioid potency and effect onmucin secretion or gene
overexpression. For instance, in a screening of several pep-
tides with proved or probable µ- and δ-opioid activity, six out
of eight peptides induced mucin secretion in HT29-MTX cells
(Martínez-Maqueda et al., 2012). The evaluation of the effect
on MUC5AC expression by α-lactorphin-amide and human
β-casomorphin-5 revealed that only the first provoked a sig-
nificant gene overexpression, despite both behaving as mucin
secretors (Martínez-Maqueda et al., 2012), β-casomorphin-5
beingmore potent than α-lactorphin-amide in guinea pig prepa-
rations (IC50 values of 14 × 10−6 and 50 × 10−6M, respectively)
(Yoshikawa et al., 1986). Similarly, a recent report has shown
that the µ-opioid peptide neocasomorphin-6 (YPVEPF) induced
a significant rise in the transmembrane-associated mucin gene
MUC4 but without effect on neither the expression of se-
creted MUC2 and MUC5AC nor the release of mucin-like
glycoprotein (Plaisancié et al., 2015). The effect on mucin pro-
duction by food protein hydrolysates and peptides appears to
be mediated by more than one type of mechanism. It remains
to be clarified whether any of these αs1-casein peptide frag-
ments might stimulate mucin secretion and/or induce mucin
gene overexpression other than MUC5AC.
In conclusion, various αs1-casein fragments containing the
tripeptide YFY, especially 144YFYPEL149 and 144YFYPE148, have
shown for the first time opioid activity in guinea pig ileum
preparations. Other related fragments, 143AYFYPEL149 and
144YFY146, were able to exert this effect, but only when pepti-
dase inhibitors were added to the preparation.This effect was
antagonized by naloxone, which demonstrates the implica-
tion of opioid receptors. The susceptibility of these peptides
to be hydrolysed by peptidases found in this tissue was dem-
onstrated by HPLC–MS/MS. Several of the resulting fragments
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lost the N-terminal Tyr residue, and therefore the potential
ability to interact with opioid receptors. Similar to
β-casomorphins, the assayed peptides exerted opioid activity
on mouse vas deferens to a lower extent than in guinea pig
ileum. The lack of activity of peptide 144YFYP147 can be ex-
plained by the different position of the third intracellular loop
at the receptor. In addition, it was found that interactions of
Pro residue at 144YFYPEL149 and 144YFYP147 were established at
different places of the receptor active site. The study of the
MUC5AC expression in human goblet cells HT29-MTX has
shown that bovine αs1-casein 144YFYPEL149 is the minimum frag-
ment able to stimulate mucin production, whereas the smaller
fragments 144YFYPE148, 144YFYP147 and 144YFY146 had no effect on
MUC5AC expression, although activity on other mucin mRNA
levels or on mucin secretion cannot be discarded.
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Supplementary Materials and Methods  
Molecular modelling receptor-peptide 
Using the Membrane Builder module (Jo, Kim, & Im, 2007; Jo, Lim, & Im, 2009) in 
CHARMM-GUI (www.charmm-gui.org) (Jo, Kim, & Im, 2008), each protein was inserted in a pre-
equilibrated box containing a POPC lipid bilayer, POPE lipid bilayer, cholesterol molecules and 
water, and a 0.15 M concentration of Na
+
 and Cl
−
 ions. We performed molecular dynamics 
simulations using AMBER, the protocol was as followed: (i) energy minimization to relax the initial 
model (20 ps), (ii) heating (100k), holding lipid  molecules and Cα carbons fixed (100 ps), (iii) 
heating (303k), holding lipid molecules and Cα carbons fixed (100 ps), (iv) holding, to equilibrate the 
simulation box (5 x 300 ps), (v) production at constant temperature and pressure (45 ns). All the 
simulations were performed at constant pressure (1 atm) and temperature (300 °K) with an 
integration time step of 2 fs. The SHAKE algorithm
 
(Ryckaert, Ciccotti, & Berendsen, 1977) was 
used to constrain all the bonds involving H atoms at their equilibrium distances. Periodic boundary 
conditions and the particle mesh Ewald methods were applied to treat long-range electrostatic 
effects (Darden, York, & Pedersen, 1993). AMBER ff03 (Duan et al., 2003), Lipid11
 
(Skjevik, Madej, 
Walker, & Teigen, 2012), Lipid14 (Callum et al., 2014) and TIP3P
 
(Jorgensen, Chandrasekhar, 
Madura, Impey, & Klein, 1983) force fields were used in all cases. Finally, the effective binding free 
energies were estimated with the MM-GBSA (Still, Tempczyk, Hawley, & Hendrickson, 1990) 
approach that calculates the free energy of binding as a sum of a molecular mechanics (MM) 
interaction term, a solvation contribution through a generalized Born (GB) model, and a surface 
area (SA) contribution to account for the nonpolar part of the desolvation. A 12-6 Lennard-Jones 
term was used to model the MM contribution. For GB, the solute dielectric constant was set to 4, 
whereas that of the solvent was set to 80. The dielectric boundary was calculated using a solvent 
probe radius of 1.4 Å. The SA contribution was approximated as a linear relationship to the change 
in solvent accessible surface area (SASA). All the trajectories and analysis were performed using 
the AMBER 12 computer program and associated modules (Case et al., 2012).
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decomposition interaction matrices, obtained from the same snapshots, were represented in an 
energy-dependent color gradient using Matrix2png (Pavlidis & Noble, 2003). 
 
 
Supplementary Results  
Supplementary Figure 1 
 
Supplementary Figure 1. Time course stability of αs1-casein fragments 
143
AYFYPEL
149
, 
144
YFYPEL
149
, 
144
YFYPE
148
, 
144
YFYP
147
, and 
144
YFY
146
. Peptides were added
 
at 5.0 × 10
-6
 M to the organ bath and aliquots 
were withdrawn at time 0    , 4      and 9     minutes. Relative area (expressed as % of initial peptide, 
considered as 100%) was determined by RP-HPLC-MS/MS from the extracted ion chromatogram of the 
molecular ion of 
143
AYFYPEL
149 
m/z 902.4 (charge +1), 
144
YFYPEL
149
 m/z 831.4 (charge +1), 
144
YFYPE
148
 m/z 
718.3 (charge +1), 
144
YFYP
147
 m/z 589.3 (charge +1), and 
144
YFY
146 
m/z 492.2 (charge +1).  
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Supplementary Figure 2 
 
 
Supplementary Figure 2. Per residue interactions of peptides (A) 
144
YFYPEL
149
 and (B) 
144
YFYP
147
 with the 
μ-opioid receptor. X axis shows the name and number of the μ-opioid receptor residues and Y axis the name 
and number of peptide residues. The color scale is based on the energy value from red (most favorable) to 
blue (less favorable). 
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Supplementary Figure 3. Per residue interactions of peptides 
144
YFYPEL
149
 and 
144
YFYP
147
 with the μ-opioid 
receptor. X axis shows the name of the peptide residue at each step of the molecular dynamic simulation. Y 
axis shows the name and number of the receptor residues interacting with the peptide. The color scale is 
based on the energy value from red (most favorable) to blue (less favorable). For each peptide 
144
YFYPEL
149 
and 
144
YFYP
147
, respectively: N-terminal Tyr (A and G); Phe (B and H); Tyr at third position (C and I); Pro (D 
and J); Glu from 
144
YFYPEL
149
 (E) and C-terminal Leu from 
144
YFYPEL
149 
(F). 
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ABSTRACT 
The effect of a peptic casein hydrolysate on the relative gene expression level of mucins Muc2, 
Muc3 and Muc4 in the intestine of obese rats was investigated by quantitative reverse 
transcription-PCR. In addition, secretion of fecal mucins at the 2
nd
 and 8
th
 week and of luminal 
mucins at the end of the experimental period (8 weeks) was also evaluated by a fluorimetric 
assay. This casein hydrolysate induced a significant increase in ileal and colonic mucin mRNA 
expression. Concretely, it was found an increased expression for the genes that codifies for the 
secreted Muc2 and the membrane-bound Muc3. In agreement with this gene overexpression, it 
was found a significant rise of O-linked glycoproteins in feces after 2 and 8 weeks of 
administration of the casein hydrolyzate. Mucus material in the small intestine lumen of rats fed 
the casein hydrolyzate was higher than that found in control rats (124%), however the change 
did not reach statistical difference. This hydrolyzate had been previously shown a mucin 
stimulatory effect in human goblet cells (HT29-MTX) and this study confirms in vivo the potential 
effects on mucus gastrointestinal protection. 
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The mucus gel layer covering the gastrointestinal surface is a major component of 
physiological defense mechanisms. This protective capacity is mainly attributed to its principal 
component, mucins, high molecular weight glycoproteins secreted by goblet cells. Interestingly 
some dietary compounds can positively modulate the dynamics of mucus, proving thus potential 
to prevent the gastrointestinal barrier-related disorders (Bischoff et al., 2014). Obesity is 
associated with several metabolic and inflammatory pathologies. The impact of intestinal 
permeability in the inflammatory-obese disorders has been postulated, via an increase in the 
circulating levels of bacterial lipopolysaccharide (Cani et al., 2007). Interestingly, dietary 
administration of prebiotics has shown positive effects in intestinal integrity, reducing 
inflammation and improving metabolic conditions (Cani et al., 2009).    
The specific effect of food proteins on intestinal mucus production was first 
demonstrated for milk casein and α-lactalbumin hydrolyzates by using an isolated ex-vivo 
preparation of rat jejunum (Claustre et al., 2002). Similarly, the opioid peptide β-casomorphin-7, 
β-casein f(60-66), also gave rise to a marked increase on mucin discharge in this tissue 
(Trompette et al., 2003). Later on, Zoghbi et al. (2006) found that this peptide induced mucin 
secretion and gene overexpression in rat (DHE) and human (HT29-MTX) goblet cells though 
activation of µ-opioid intestinal receptors. Likewise, the peptide β-casein fragment (94-123) 
increased mucin release and mRNA transcripts in HT29-MTX cells (Plaisancié et al., 2013), and 
similar results were shown for some fragments comprised within its 30-amino acid sequence 
(Plaisancié et al., 2015). However, just a few animal studies have been carried out to reveal in 
vivo evidence on mucus protection by dairy components. 
Recently, our group found that a peptic casein hydrolyzate (CH) and the contained αs1-
casein peptides 
143
AYFYPEL
149
 and 
144
YFYPEL
149 
exerted stimulatory effect on mucin secretion 
in human HT29-MTX cells and on the expression of MUC5AC, the major secreted mucin gene 
in this cell line (Martínez-Maqueda et al., 2013). Therefore, the aim of the present study was to 
investigate the in vivo effect of this CH on the expression of various intestinal mucin genes. In 
rodent intestine the main mucins are the secreted Muc2 confined to goblet cells, and the 
transmembrane Muc3 and Muc4 detectable in both goblet cells and enterocytes (Trompette et 
al., 2004). Zucker rats were used in order to evaluate the potential effect of the hydrolyzate to 
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improve intestinal integrity. In addition, the influence on mucin secretion in fecal and gut luminal 
contents was also evaluated. Based on previous animal studies, the relevance of dairy 
compounds on mucus gastrointestinal protection is briefly discussed. 
The study protocol was approved by the Institutional Animal Ethics Committee of La 
Paz University Hospital (Madrid, Spain) and procedures were performed in accordance with the 
EU Directive 2010/63/EU and the Spanish law RD 53/2013 regarding the protection of 
experimental animals. Eighteen male 8-week-old zucker rats, weighing 426-521 g were 
purchased from Charles River Laboratories (Barcelona, Spain) and were randomly assigned to 
the control or the experimental group (n = 9 per group). Rats were placed in separate cages 
holding 3 animals per cage, and during 1 week of acclimation period they had access to water 
and commercial standard rodent diet (Scientific Animals Food & Engineering A04, Augy, 
France) ad libitum. After acclimation period, experimental group received a diet supplemented 
with 0.7% CH, providing approximately 0.4 g CH/kg of animal per day. Blood pressure, weight 
gain and food intake were monitored weekly.  
Following the experimental feeding period (8 weeks), rats were anaesthetized using 
1.5% isoflurane and subjected to complete intracardiac exsanguination. Plasma was 
separated out by centrifugation (10 min at 2500 g) in pre-treated EDTA tubes with complete 
peptidase inhibitor cocktail (Roche Applied Science, Madrid, Spain), and immediately frozen 
at – 20 ºC. Plasma biochemical analysis were performed in a COVAS Autoanalyzer (Roche 
Applied Science) and circulating levels of glucagon-like peptide-1, leptin, insulin and 
proinflamatory cytoquines (interleukin-6 and tumor necrosis factor-
immunoassay in a Luminex LX200 analyzer using the Rat Adipokine multiplex kit (RADPK-
81K, Milliplex® Map Kit, Rat Serum Adipokine Panel, Millipore, Billerica, MA, US), according 
to manufacturer´s instructions.  
Duodenum, jejunum, ileum and colon samples were removed and immediately stored 
in RNAlater
®
 (Applied Biosystems, Carlsbad, CA, USA), according to manufacturer’s 
instructions. Total RNA from the gut sections (20 mg) was isolated with Nucleospin® RNA II 
(Macherey-Nagel, Düren, Germany). The RNA concentration and purity were determined by 
NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and 
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Bioanalyzer 2100 (Agilent Technologies, Waldbronn, Germany). RNA (375 ng) was reverse 
transcribed using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-
time quantitative PCR amplification was performed using the ViiA™ 7 Real-Time PCR System 
in 384 wells microplates with TaqMan® Gene Expression Assays (FAM™ dye-labeled MGB 
probe), according to manufacturer’s instructions (all from Applied Biosystems). For each 
sample, PCR amplification was carried out in a reaction volume of 10 µL with cDNA samples 
(1:5 dilution, 5.06 ng) in triplicate. No-template controls were also included. Based on previous 
experiments, β-actin (accession no. 116659) was used as reference gen. The relative 
expression levels of the target genes, Muc2, Muc3 and Muc4 (accession no. 24572, 687030 
and 303877, respectively) were calculated according to the 2
-ΔΔCt
 method (Livak and 
Schmittgen, 2001). Data were analyzed with DataAssist 3.01 software (Applied Biosystems). 
Significant differences were determined by a two-tailed Mann-Whitney test, and P values were 
adjusted using Benjamini-Hochberg false discovery rate procedure. 
Feces were collected from cages at weeks 2 and 8. Luminal contents of small intestine 
(jejunum to ileum) at the end of the experimental period (8 weeks) were collected by flushing 
with 20 mL of ice-cold PBS (sodium azide 0.02 M, pH 7.4) and the same volume of air. Feces 
and luminal contents were kept at – 20 ºC and freeze-dried. Mucin fraction from feces (Sprong 
et al., 2010) and luminal contents (Lien et al., 1996) were isolated as previously described, and 
measured using a fluorimetric assay (Crowther and Wetmore, 1987). Standard solution of 
commercial porcine stomach mucins (Sigma–Aldrich Química, Madrid, Spain) was used to 
calculate the total amount of fecal and luminal mucins. Data were analyzed using GraphPad 
Prism 6.01 software, and significant differences were determined by a two-tailed Mann-Whitney 
test. 
Animals tolerated well the experimental conditions and gained weight during the feeding 
period, being similar the weight gained in both experimental groups. Plasma lipid profile, 
glucose, hormones and cytokines levels were not significantly different in treated rats, compared 
to control rats. Our results are in line with the safety data reported for this CH after acute and 
repeated dose (4 weeks) oral toxicity studies in rats (Anadón et al., 2010). 
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Figure 1 shows the modulatory effect of the CH on the relative gene expression level of 
mucins Muc2, Muc3 and Muc4 in the rat intestine, determined by quantitative reverse 
transcription-PCR. In duodenum tissue, the CH inhibited the expression of Muc2 (0.70 ± 0.06-
fold change) and Muc4 (0.81 ± 0.04-fold change), while any statistical variation compared to 
control rats was found in the jejunum. However, the hydrolyzate induced an increase in ileal and 
colonic mucin mRNA expression. Transcription level of both the secreted Muc2 and the 
transmembrane Muc3 mucins were significantly raised in the ileum (1.31 ± 0.07- and 1.20± 
0.06-fold change, respectively) and colon (1.51 ± 0.10- and 1.47 ± 0.06-fold change, 
respectively). Although the transmembrane Muc4 mucin gene expression was also enhanced 
with respect to control rats in the colonic tissue, it was not statistically different. Interestingly, the 
CH revealed an increasing trend in the modulatory effect along the intestine location, i.e., 
mucins mRNA transcripts, mainly Muc2, tended to be below or within control levels at proximal 
sections (duodenum and jejunum) and over control levels at distal sections (ileum and colon). 
Mucus thickness in the rat intestine has been shown to vary depending on the gut section, being 
the colonic layer, and to a lower extent the ileal, up to four times thicker compared to other 
regions (Atuma et al., 2001). This situation might imply a worthy biological relevance for the CH 
regulatory effect on the intestinal mucus layer. Strong evidence about the protective implication 
of mucins at intestine, especially in colon, was demonstrated when spontaneous colitis (Van der 
Sluis et al., 2006) and colorectal cancer (Velcich et al., 2002) were developed in mice 
genetically deficient in the mucin Muc2. Moreover, Shigeshiro et al. (2012) reported that rats 
subjected to water immersion-stress were found to decrease their colonic Muc2 gene relative 
expression and goblet cell population. 
The mucus component in the fecal and small intestine luminal contents was determined 
and quantified by a fluorimetric assay of O-linked glycoproteins (mucins). As shown in Figure 2, 
compared to control rats, the CH induced a significant rise in the fecal mucin excretion after 2- 
(129%) and 8-weeks (147%) of experimental feeding. Sprong et al. (2010) showed the 
protective role played by a dietary cheese whey protein in the dextran sulfate sodium-induced 
model of rat colitis. Despite these authors did not find Muc2 gene overexpression in colon, it 
was showed that the dairy protein ameliorated the colitis markers with an enhanced fecal mucin 
secretion.  
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Figure 1. Effect of casein hydrolyzate on the mRNA expression of Muc2, Muc3 and Muc4 in the rat (A) duodenum, (B) jejunum, (C) ileum and (D) colon. Results (mean ± SEM, 
n = 9) were expressed as relative gene expression level of control (fold change value 1), using β-actin as reference gene. Significant differences versus control were 
determined by Mann-Whitney analysis of variance: P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). 
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Figure 2. Effect of casein hydrolyzate on fecal mucin content after (A) 2 weeks and (B) 8 weeks of 
experimental feeding period. Results (mean ± SEM, n = 9) were represented as total amount of mucins 
(µg) per mg of freeze-dried feces. Significant differences versus control were determined by Mann-Whitney 
analysis of variance: P < 0.05 (*). 
 
As illustrated in Figure 3, the CH also suggested an increased mucin synthesis at the 
gut luminal content. Mucus material in the small intestine lumen of rats fed the CH was higher 
than that found in control rats (124%), however the change did not reach statistical difference (P 
= 0.15). Nevertheless, this is the first study that evaluates the in vivo influence of dairy proteins 
in the mucus component of the gut lumen, while other food-compounds such as dietary fiber 
had already proved this protective modulation (Ito et al., 2009). In our study, the different results 
between mucus secretions at fecal and luminal contents might correspond to the variations 
shown in mucin gene expression levels between the small and large intestine sections. 
However, the regulatory mechanisms involved in mucus production and the intricate 
functionality of the gastrointestinal gel layer are still largely understood (Kim and Ho, 2010). 
The results of our study might be explained by the previously demonstrated mucin 
stimulatory effect of this CH in human intestinal HT29-MTX cells (Martínez-Maqueda et al., 
2013). It was found that this CH increased the expression of the secreted mucin MUC5AC (1.8-
fold change) and the mucin-like glycoprotein production (210%). It was also proposed that the  
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Figure 3. Effect of casein hydrolyzate on small intestine mucin luminal content. Results (mean ± SEM, n = 
9) were represented as total amount of mucins (µg) per mg of freeze-dried luminal content. Significant 
differences versus control were determined by Mann-Whitney analysis of variance: P < 0.05 (*). 
 
peptides αs1-casein fragment 
143
AYFYPEL
149 
and its derived-fragment 
144
YFYPEL
149
, at 
concentrations between 0.05 and 0.5 mM, were the main contributors to the activity. In the 
present study, the rat standard diet was supplemented with 0.4 g/kg/day of the hydrolyzate, 
which contained 4.1 mg of 
143
AYFYPEL
149
 per g of hydrolysate, quantified by HPLC-tandem 
mass spectrometry. The concentration of peptide that can be reached with this dosage is within 
the range that proved activity in human intestinal goblet cells. However, it cannot be discarded 
the contribution of other peptides or components of the CH on the activity.  
 To date, only few in vivo studies have also pointed to the modulatory effect of dairy 
proteins, and hydrolyzates and peptides thereof, on the dynamics of the intestinal mucus layer. 
Interestingly, our findings are consistent with the study of Han et al. (2008) showing that 
pancreatin-hydrolyzed casein enhanced the ileal endogenous nitrogen flow and stimulated the 
transmembrane Muc3 and Muc4 mRNA expression in the rat small intestine and colon, 
respectively. Similarly, Plaisancié et al. (2013) found that the peptide β-casein fragment (94-
123) supported the gut mucosa by inducing the expression of small intestine Muc2 and Muc4, 
the number of goblet and Paneth cells and the antimicrobial factors rat defensing 5 and 
lysozyme. Recently, oral administration of this peptide to rats has also shown protective benefits 
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against indomethacin-induced lesions and markers of enteritis, being these effects associated 
with increased recount of goblet cells replenished with mucin content and lower epithelial 
apoptosis (Bessette et al., 2016). 
The emerging potential of natural compounds that can regulate the functionality of 
mucins and ultimately exert influence on health and disease has been recently stated (Macha et 
al., 2015). In the present study, the assayed CH induced the expression of mucin genes Muc2 
and Muc3 in the distal segments of the rat intestine, i.e. the ileum and colon. Because of the 
physiological relevance of Muc2, coding at goblet cells for the main secreted mucin in rat 
intestine, and Muc3, coding for the membrane-located mucins at goblet as well as absorptive 
cells, a double-level of improved mucosal protection can be thus proposed. Besides, the CH 
enhanced the secretion of mucins by increasing the total mucins in the feces during the 
experimental period. However, no significant changes were shown on the mucin luminal content 
of rats fed the CH, although the average amount was higher than in control rats. Additional 
studies that further evaluate at a molecular level the CH effect on markers of gut health status 
would benefit from above findings. This study has allowed better knowledge of the promising 
role of dairy proteins as functional components that promote the mucus gel barrier and prevent 
the gastrointestinal-related diseases.  
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ABSTRACT 
In this study, protein degradation and peptide formation during in vitro gastrointestinal digestion 
of casein and whey protein were compared with data obtained from human jejunal digests. In 
vitro digestion was performed by using a standardised static digestion method proposed in the 
context of the COST Action INFOGEST and jejunal digests after oral ingestion of the same 
substrates were collected by a nasogastric tube located at the proximal jejunum. By SDS-
PAGE, no intact casein could be detected in any of the jejunal samples, nor in the in vitro 
samples taken during the intestinal phase. β-lactoglobulin was detected in the jejunal effluents 
taken 1 h after ingestion of whey protein, although with different intensity depending on 
volunteers. Similarly, β-lactoglobulin resisted the in vitro gastric phase and it was hydrolysed 
after 1 h into contact with the simulated pancreatic juice. In vivo and in vitro digests were 
analysed by HPLC-MS/MS under equal conditions. In addition, a selective precipitation step 
was performed to enrich and identify phosphorylated peptides. Comparable peptide profiles 
were observed in the in vivo and in vitro digests. Based on these peptide profiles, it was shown 
that the correlation coefficients found between in vitro digests and the jejunal effluents were 
within the range found for the different volunteers of the study. Similar resistant regions to 
digestion were identified after in vitro and in vivo digestion and the formation of certain peptides 
is discussed. 
 
KEYWORDS: in vitro/in vivo digestion, peptidomic, mass spectrometry, milk protein digestion 
  
  
161 Results / Resultados 
1. INTRODUCTION 
 Digestion is an intricate process that food undergoes upon oral ingestion. Proteins are 
known to be extensively hydrolysed throughout the digestive tract by gastrointestinal enzymes 
and brush border membrane peptidases, leading to the release of numerous peptides and free 
amino acids. However, some specific regions of proteins have demonstrated a particular 
resistance against the digestive phenomena. Food protein-derived peptides present in the gut 
lumen might be biologically and metabolically relevant for different physiological functions, 
exerting not only beneficial properties (Rutherfurd-Markwick, 2012) but also deleterious effects, 
such as, those produced by epitopes involved in food allergies (Jiménez-Saiz et al., 2015). 
Because of the growing evidence on the health implications of dietary peptides, there has also 
been an interest to elucidate the factors that influence protein degradation and lead peptide 
release and stability in the gastrointestinal tract (Picariello et al., 2013; Sánchez-Rivera et al., 
2014a). 
 Although animal and human digestion studies obviously provide the most meaningful 
results, they imply ethical, technical and financial issues. Thus, a large variety of in vitro 
methods simulating the digestion process have been applied to study the gastrointestinal 
behaviour of food and pharmaceuticals (Kaukonen et al., 2004; Versantvoort et al., 2005; 
Dupont et al., 2010; Martos et al., 2010; Kopf-Bolanz et al., 2012; Ménard et al., 2014). To 
overcome the wide variation between the individual parameters used on these methodologies 
(Guerra et al., 2012), in the context of the COST Action INFOGEST FA1005 network (Dupont et 
al., 2011), a static in vitro digestion method was proposed (Minekus et al., 2014). The 
consistency and validation of this model has been recently published (Egger et al., 2016). 
However, these authors emphasized the difficulty to fully mimic the kinetic behaviour of the 
complex in vivo digestion process by a static model, and prompted further experiments to 
directly compare the in vitro results towards in vivo data. 
 Milk proteins are one of the main sources of biologically active peptides (Hernández-
Ledesma et al., 2014; Nongonierma & Fitzgerald, 2015). Moreover, these proteins represent a 
stable and complex food matrix commonly used as a suitable model in digestion experiments. 
Few in vivo studies have been performed on the presence of milk-derived peptides in the 
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gastrointestinal lumen of humans (Svedberg et al., 1985; Chabance et al., 1998; Boutrou et al., 
2013) and animals (Bouzerzour et al., 2012; Barbé et al., 2014) after ingestion of dairy products. 
Despite these studies are essential to test the interaction between dietary proteins and the 
digestive tract and to shed light on the physiological-derived consequences (Foltz et al., 2010), 
the data are still scarce and a notable diversity has been recently stated (Boutrou et al., 2015). 
 Accordingly, the objective of this work was to compare the peptidome of samples 
obtained after gastrointestinal digestion of milk casein and whey protein by the harmonized 
INFOGEST in vitro digestion method, with in vivo digests collected from human jejunum. Nine 
different time combinations of the in vitro gastric and intestinal phases were carried out and 
evaluated against in vivo jejunal samples obtained 1, 2, 3 and 4 h after protein ingestion. 
Protein degradation was determined by SDS-PAGE, and the characterization at a peptide level 
of the digestion products was evaluated by HPLC-MS/MS. Moreover, an enrichment selective 
precipitation was performed on in vivo casein samples to study the caseinphosphopeptide 
(CPP) fraction. 
 
2. MATERIALS AND METHODS 
2.1 Human jejunal effluents 
Human jejunal effluents were obtained as previously described (Boutrou et al., 2013). 
Briefly, individuals were fed with 30 g of milk protein powder, casein or whey, dissolved in 500 
mL of water. Samples were obtained by a nasogastric tube that migrated to the proximal 
jejunum by aspiration of jejunal effluents at 1, 2, 3 and 4 hours after oral administration of the 
protein solution. Jejunal effluents were collected on ice and freeze-dried and kept at -80 °C until 
analysis. Nitrogen content in freeze-dried samples was determined by elemental analysis and 
further analyses were performed on protein basis. In this study, 9 jejunal samples were 
analysed: 5 of them obtained after feeding with casein and 4 after feeding with whey protein. 
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2.2 In vitro simulated gastrointestinal digestion 
Casein and whey commercial milk protein powders were digested according to the in 
vitro harmonized protocol (Minekus et al., 2014). Briefly, freeze-dried casein or whey protein 
samples were dissolved in simulated saliva fluid at 30 mg of protein/mL without amylase 
because of the absence of starch in the samples. Then, the mix was diluted at a ratio of 50:50 
(v/v) in simulated gastric fluid containing pepsin from porcine gastric mucosa (2000 U/mL of 
digesta, EC 3.4.23.1, Sigma-Aldrich, St. Louis, MO, USA). Samples were withdrawn at 10, 20, 
30, 60 and 120 min during gastric digestion and the reaction was stopped by adjusting the pH at 
7.0 with NaOH 1 M and snap freezing in liquid nitrogen. Intestinal phase was carried out by 
mixing the gastric phase with the same volume of simulated intestinal fluid containing 
pancreatin from porcine pancreas (100 U trypsin activity/mL of final mixture, Sigma-Aldrich) and 
bile extract porcine (10 mM in the final mixture, Sigma-Aldrich). All simulated fluids were 
tempered at 37 °C before use. Digestions were performed in duplicate by incubating at 37 °C in 
an orbital shaker at 150 rpm. Intestinal phases were started from 20 and 120 min of gastric 
phase digests, performed during 60 and 120 min and the digestion was stopped with Pefabloc
®
 
SC (5 mM, Sigma-Aldrich) and snap freezing. Samples were freeze-dried and kept at -20 °C 
until analysis. A digestion blank consisting of the mix of enzymes used in digestions at the same 
concentration without substrate protein was prepared. Enzyme activities and bile concentration 
were measured according to the assay described in the protocol (Minekus et al., 2014). 
 
2.3 SDS-PAGE 
Samples were dissolved at 1 mg of protein/mL in sample buffer that contains Tris-HCl 
(0.05 M, pH 6.8, Sigma-Aldrich), SDS (1.6%, w:v, Merck, Darmstadt, Germany), glycerol (8%, 
v:v, PanreacQuímica SAU, Castellar del Vallés, Barcelona, Spain), β-mercaptoethanol (2%, v:v, 
Sigma-Aldrich) and bromophenol blue indicator (0.002%, w:v, Merck), heated at 95 °C for 5 min 
and loaded on 12% Bis-Trispolyacrilamide gels (Criterion_XT, Bio-Rad, Hercules, CA, USA). 
Electrophoretic separations were run at 100 V for 5 min and then at 150 V, using the XT MES 
running buffer (Bio-Rad) in the criterion cell (Bio-Rad). A molecular weight marker (Precision 
Plus Protein™ Unstainend standard, Bio-Rad) was used on each gel. Gels were stained with 
Coomasie Blue (Instant blue, Expedeon, Swavesey, UK) and images were taken with a 
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Molecular Imager
®
 VersaDoc™ MP 5000 system (Bio-Rad) and processed with Quantity One
® 
1-D analysis software (Bio-Rad). 
 
2.4 Analysis by HPLC-tandem mass spectrometry 
Freeze-dried samples were reconstituted in solvent A (water:formic acid, 100:0.1, v:v) 
and centrifuged at 13000 × g, 10 min, before injection of the supernatant. From in vivo casein 
samples, an enrichment selective precipitation of CPP was performed by adding calcium 
chloride (1%, w:v) and ethanol (50%, v:v) as described by Sánchez-Rivera et al. (2014b). Whey 
samples were treated for 60 min at 37 °C with 1,4-dithiothreitol 70 mM (Sigma-Aldrich) to 
reduce samples in order to improve the identification of disulfide-linked fragments (Martínez-
Maqueda et al., 2013a). 
Samples were analyzed by HPLC-MS/MS using an Agilent 1100 HPLC system (Agilent 
Technologies, Waldbron, Germany), equipped with a Mediterranea Sea18 column (150 x 2.1 
mm, Teknokroma, Barcelona, Spain). HPLC system was connected to an Esquire 3000 linear 
ion trap mass spectrometer (Bruker Daltonics GmbH, Bremen, Germany) equipped with an 
electrospray ionization source. The injection volume was 50 µL and the flow was set at 0.2 
mL/min. Peptide elution was performed with a linear gradient from 0 to 45% of solvent B 
(acetonitrile:formic acid, 100:0.1, v:v) in 115 min. Same gradient and solvents were used for 
CPP, however the elution time was 60 min. Injections were analyzed in duplicate, being the 
spectra recorded over the mass/charge (m/z) range 100-1300 and 100-1700, selecting 500 and 
1200, respectively, as the target mass. For CPP, spectra was recorded over the m/z range 100-
2100 with a target mass of 1200. The results were processed by using Data Analysis (version 
4.0, Bruker Daltonics). Homemade database of cow’s casein and whey protein were used for 
the peptide sequencing in MASCOT v2.4 software (Matrix Science). Moreover, Biotools version 
3.2 was used for the interpretation of the matched MS/MS spectra. No specific enzyme 
cleavage was used. Peptide mass tolerance was set to 0.1% and 0.5 Da for MS and MS/MS 
analysis, respectively. Each identified peptide spectrum was revised manually, regardless of its 
P value. 
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3. RESULTS AND DISCUSSION 
3.1. Protein degradation during in vitro and human gastrointestinal digestion 
Protein patterns obtained by SDS-PAGE of the jejunal effluents collected at 1, 2, 3 and 
4 h after oral administration of casein and whey protein are shown in Figure 1 (A and C, 
respectively). To obtain similar protein loadings in all lanes, samples were dissolved in the 
treatment buffer taking into account the protein content of each sample determined by 
elemental analysis. In all the jejunal digests from casein (Figure 1 A), there was a clear band 
with molecular weight (MW) 50 kDa, which likely corresponds to human pancreatic lipase, as 
previously described by other authors (Iizuka et al., 1991). In addition, there were several light 
bands with mobilities between 25 and 37 kDa, close to those of intact casein. However, no 
differences were observed at different sampling times or between volunteers and they did not 
react with antibodies against casein by immunoblotting (data not shown), thus, these bands 
could probably correspond to endogenous proteins. In a previous report, the nitrogen 
composition, endogenous and exogenous, in the upper jejunum of human volunteers after 
ingestion of casein or whey protein was investigated (Mahé et al., 1996). It was found that 
casein was slowly recovered in the jejunum and mainly in the form of degraded peptides which 
is consistent with our results where no intact protein is detected. Similarly, other in vivo studies 
in minipigs cannulated at duodenum have shown that after ingestion of non-heated liquid milk, 
intact casein can be detected during the first minutes of digestion, but they are rapidly digested 
in the next 20 min (Barbe et al., 2013). 
When applying the standardised in vitro digestion conditions on the same casein 
substrate (Figure 1 B), a gradual degradation of the casein fraction with the digestion time was 
observed in the gastric phase. Electrophoretic bands corresponding to casein were observed up 
to 30 min peptic digestion but they were absent in the samples obtained in the gastric phase at 
60 and 120 min. In the samples withdrawn during the intestinal phase an intense band 
corresponding to porcine pancreatic lipase could be observed ca. 50 kDa, as well as, other 
minor bands corresponding to other pancreatic enzymes between 20 and 35 kDa, which is 
compatible with the MW of the porcine pancreatic enzymes trypsin (23.3 kDa), chymotrypsin 
(25.5-29.10 kDa) or elastase (25.9 kDa), as previously shown (Ménard et al., 2014). The rapid  
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Figure 1. SDS-PAGE of jejunal digests (A and C) and in vitro simulated gastrointestinal digestion (B and 
D). A and B corresponded to casein and C and D to whey protein as substrate. Each lane in A and C 
corresponded to different subjects (referred to with capital letters from A to I) and times of jejunal sampling 
(1, 2, 3 and 4 h). Each lane in B and D correspond to different times (min) of gastric (G) and intestinal (I) 
digestion. MM, molecular weight marker; CN, casein; WP, whey protein; Blank, gastrointestinal digestion 
enzymes without milk protein; HPL, human pancreatic lipase; PPL, porcine pancreatic lipase; β-Lg, β-
lactoglobulin; α-La, α-lactalbumin. 
 
degradation of the casein fraction of milk during in vitro gastric digestion is in agreement with 
previous reports using this standardised method at different laboratories (Egger et al., 2016) 
where the casein bands were not detected at the end of the gastric phase (120 min) and by 
other authors using slightly different in vitro conditions (Picariello et al., 2010; Kopf-Bolanz et al., 
2012; Ménard et al., 2014). 
Figure 1C shows the SDS-PAGE analyses of the jejunal contents of different volunteers 
at different times when whey protein was orally administered. The electrophoretic band 
corresponding to β-lactoglobulin was visible in the samples taken at 1 h in all volunteers with 
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variations in intensity, and in some of them, this protein was also detected in the sample taken 2 
h after oral administration of the whey protein (volunteers H and I). Again, this is in agreement 
with previous results on nitrogen content at jejunum where β-lactoglobulin could be recovered, 
mostly in the form of intact protein (Mahé et al., 1996). From Figure 1C, it can be seen that in 
volunteer I an important amount of α-lactalbumin could be found 1 hour after administration. As 
expected, during in vitro digestion of whey protein (Figure 1D) β-lactoglobulin was resistant to 
digestion by pepsin but it disappeared completely after 60 min of intestinal digestion regardless 
the duration of the gastric phase (20 or 120 min). The resistance of this protein to peptic 
digestion has been largely documented in vivo (Bouzerzour et al., 2012) and in vitro assays 
(Dupont et al., 2010; Kopf-Bolanz et al., 2012), as well as, the effect of heat treatment on the 
susceptibility of this protein to gastric digestion (Barbé et al., 2013; Sánchez-Rivera et al., 
2015). 
 
3.2. Peptidomic characterisation of in vivo and in vitro digests 
Jejunal digests obtained at four different time points and in vitro digests withdrawn 
under gastric and intestinal conditions were analysed under equal conditions by HPLC-MS/MS. 
From the casein-jejunal samples, a total of 465 different peptides were unequivocally identified, 
most of them belonging to β-casein (176), followed by αs1-casein peptides (131) and αs2- and κ-
casein-derived peptides (74 and 84, respectively). However, under the same analytical 
conditions, a total of 338 different peptides were identified from the in vitro digests (97 from β-
casein; 78 from αs1-casein; 97 from κ-casein; and 66 from αs2-casein) although a higher number 
of time points were considered (4 vs 9). As an example, Table 1 shows the peptides derived 
from β-casein and αs1-casein from a representative volunteer in the jejunal sample taken 2 h 
after the oral administration of casein, and peptides from these major two proteins obtained 
after in vitro digestion (20 min gastric phase+60 min intestinal phase). Under our analytical 
conditions, most of the identified peptides ranged 5 to 26 amino acid long, with masses between 
500 and 3000 Da, although several phosphorylated peptides up to 30 amino acids were also 
identified (see Section 3.3).  
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Table 1: Identified peptides derived from β- and αs1-casein in the jejunal digests of a representative 
volunteer 2 hour after oral administration of casein, and peptides from these two proteins identified in the 
in vitro simulated gastrointestinal digestion after 20 min of gastric phase and 60 min of intestinal phase 
(G20+I60 min). 
JEJUNAL DIGESTS
a
 
β-casein-derived peptides  αs1-casein-derived peptides 
Range Sequence  Range Sequence 
1 5 RELEE  1 15 RPKHPIKHQGLPQEV 
5 15 ELNVPGEIVES  11 15 LPQEV 
6 14 LNVPGEIVE  12 21 PQEVLNENLL 
45 57 LQDKIHPFAQTQS  24 31 FVAPFPEV 
45 58 LQDKIHPFAQTQSL  24 32 FVAPFPEVF 
59 70 VYPFPGPIPNSL  25 31 VAPFPEV 
59 80 VYPFPGPIPNSLPQNIPPLTQT  25 33 VAPFPEVFG 
60 69 YPFPGPIPNS  26 30 APFPE 
69 80 SLPQNIPPLTQT  39 47 ELSKDIGSE 
71 80 PQNIPPLTQT  57 63 IKQMEAE 
81 89 PVVVPPFLQ  80 89 HIQKEDVPSE 
81 91 PVVVPPFLQPE  112 119 VPNSAEER 
81 92 PVVVPPFLQPEV  125 137 EGIHAQQKEPMIG 
81 93 PVVVPPFLQPEVM  126 137 GIHAQQKEPMIG 
85 92 PPFLQPEV  143 148 AYFYPE 
85 93 PPFLQPEVM  143 149 AYFYPEL 
115 119 PVEPF  157 164 DAYPSGAW 
115 121 PVEPFTE  159 163 YPSGA 
115 123 PVEPFTESQ  165 172 YYVPLGTQ 
115 124 PVEPFTESQS  165 173 YYVPLGTQY 
122 126 SQSLT  168 172 PLGTQ 
128 132 TDVEN  174 178 TDAPS 
128 139 TDVENLHLPLPL  180 190 SDIPNPIGSEN 
128 140 TDVENLHLPLPLL  180 191 SDIPNPIGSENS 
129 139 DVENLHLPLPL  180 193 SDIPNPIGSENSEK 
130 139 VENLHLPLPL  180 196 SDIPNPIGSENSEKTTM 
135 139 LPLPL  180 198 SDIPNPIGSENSEKTTMPL 
157 163 FPPQSVL  182 186 IPNPI 
158 162 PPQSV  185 196 PIGSENSEKTTM 
164 168 SLSQS  194 198 TTMPL 
164 182 SLSQSKVLPVPQKAVPYPQ  
164 189 SLSQSKVLPVPQKAVPYPQRDMPIQA  
171 175 LPVPQ  
172 189 PVPQKAVPYPQRDMPIQA  
174 183 PQKAVPYPQR  
177 189 AVPYPQRDMPIQA  
185 189 MPIQA  
192 209 LYQEPVLGPVRGPFPIIV  
193 199 YQEPVLG  
193 207 YQEPVLGPVRGPFPI  
193 208 YQEPVLGPVRGPFPII  
193 209 YQEPVLGPVRGPFPIIV  
196 201 PVLGPV  
196 205 PVLGPVRGPF  
199 209 GPVRGPFPIIV  
200 208 PVRGPFPII  
200 209 PVRGPFPIIV  
203 207 GPFPI  
205 209 FPIIV  
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a
 Only data for one volunteer is shown; 
b
 Only data from one duplicate is shown. 
 
It is also worthy to mention that certain regions, especially those rich in proline residues, 
were resistant to gastrointestinal digestion and reached jejunum. For instance, the opioid 
peptide β-casomorphin-7 (β-casein 
60
YPFPGPI
66
) and various peptides containing the same 
IN VITRO DIGESTION G20 +I60 min
b
 
β-casein-derived peptides  αs1-casein-derived peptides 
Range Sequence  Range Sequence 
1 5 RELEE  8 13 HQGLPQ 
1 6 RELEEL  9 13 QGLPQ 
6 14 LNVPGEIVE  17 28 NENLLRFFVAPF 
7 14 NVPGEIVE  24 28 FVAPF 
9 14 PGEIVE  24 30 FVAPFPE 
39 45 QQTEDEL  24 31 FVAPFPEV 
57 66 SLVYPFPGPI  25 31 VAPFPEV 
58 66 LVYPFPGPI  25 33 VAPFPEVFG 
59 66 VYPFPGPI  27 31 PFPEV 
59 68 VYPFPGPIPN  29 33 PEVFG 
60 66 YPFPGPI  35 41 EKVNELS 
61 68 PFPGPIPN  37 41 VNELS 
62 66 FPGPI  53 57 AMEDI 
69 76 SLPQNIPP  53 58 AMEDIK 
69 82 SLPQNIPPLTQTPV  70 74 EIVPN 
73 77 NIPPL  84 90 EDVPSER 
73 82 NIPPLTQTPV  102 107 KKYKVP 
75 82 PPLTQTPV  106 114 VPQLEIVPN 
83 87 VVPPF  134 138 PMIGV 
83 91 VVPPFLQPE  136 140 IGVNQ 
83 92 VVPPFLQPEV  139 143 NQELA 
85 91 PPFLQPE  155 161 QLDAYPS 
85 92 PPFLQPEV  157 161 DAYPS 
92 99 VMGVSKVK  174 178 TDAPS 
92 100 VMGVSKVKE  174 186 TDAPSFSDIPNPI 
100 105 EAMAPK  182 186 IPNPI 
101 105 AMAPK  194 198 TTMPL 
108 113 EMPFPK     
114 119 YPVEPF     
115 119 PVEPF     
125 129 LTLTD     
126 132 TLTDVEN     
128 132 TDVEN     
134 138 HLPLP     
144 154 MHQPHQPLPPT     
147 154 PHQPLPPT     
150 154 PLPPT     
156 162 MFPPQSV     
157 161 FPPQS     
164 168 SLSQS     
177 182 AVPYPQ     
193 201 YQEPVLGPV     
194 201 QEPVLGPV     
196 201 PVLGPV     
203 207 GPFPI     
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were found at jejunum after consumption of casein. These peptides had been previously 
quantified in jejunal contents and it was estimated that the amount considering β-casomorphin-7 
and its precursors could reach a concentration ca. 17 μmol/L (Boutrou et al., 2013). However, 
the in vitro gastric digestion samples contained several precursors of β-casomorphin-7 but in 
any of the samples the active form starting with tyrosine at the N-terminus was found. It has 
been described that pepsin cleaves the 
58
Leu-Val
59
 peptide bond at β-casein and leucine 
aminopeptidase removes the Val
59
, rendering the tyrosine residue at the N-terminus (Jinsmaa 
and Yoshikawa, 1999). In our study, the enzymatic action of the pancreatic extract employed in 
the in vitro simulation was needed to release the peptide β-casomorphin-7. Other β-casein 
regions especially resistant and found in jejunum and in vitro digests contained the clusters 
74
IPPLT
78
, 
83
VVPP
86
, 
134
HLPLP
138
, 
150
PLPP
153
, 
157
FPP
159
, 
172
PVP
174
, 
204
PFPI
207
. In the case of 
αs1-casein, for example the bioactive peptide 
143
AYFYPEL
149
 was found in both the in vitro and 
in vivo digests. This αs1-casein peptide had been previously identified in in vivo gastric human 
digests after milk ingestion (Chabance et al., 1998), and it is known for its proved 
antihypertensive effects in spontaneously hypertensive rats (Contreras et al., 2009), intestinal 
mucin stimulatory properties in human goblet HT29-MTX cells (Martínez-Maqueda et al., 
2013b), and opioid activity in the guinea pig ileum assay (Fernández-Tomé et al., 2016). A more 
detailed comparison between peptides found in vitro and in vivo digests is shown in Section 3.4. 
In order to compare the peptide profile obtained from the analysis of the jejunal digests 
and in vitro digests, a heat map was built (Figure 2). This graph represents the appearance 
frequency of each amino acid identified as part of different peptides for a given protein. This 
graph gives qualitative information about the protein coverage and about those protein regions 
where peptides were identified, although it does not provide quantitative information or relative 
abundancies. Each line in the heat map corresponds to a human volunteer (Figures 2A and 2C) 
or a different duplicate in the in vitro assays (Figures 2B and 2D). In the in vivo digests, there is 
a common pattern at the different time points and for the different volunteers, although certain 
inter-individual variability can be inferred. For instance, there are regions, such as β-casein 157-
161 where peptides were commonly found but this region was absent in some individuals. 
Comparing the in vivo and in vitro peptide profiles for β-casein, it can be seen that jejunal 
digests at any time point are comparable to the intestinal phase of the in vitro simulated
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Heat map built with the frequency of appearance of each amino acid on the β- and αs1-casein protein chain. A and C corresponds to profiles obtained from human 
jejunal digests obtained at 1, 2, 3 and 4 h after oral administration of casein and B and D corresponds to profiles obtained from simulated in vitro digestion of the same 
substrate. The green colour represents low frequency and red high frequency, being the maximum 24, 9, 18 and 8 in A, B, C, and D, respectively. G, gastric; I, intestinal. 
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gastrointestinal digestion. The β-casein N-terminal region and the region 57-99 is highly 
represented in both cases, but the peptides in the central region of the protein (from residue 115 
to 175) were more abundant in the jejunal digests. 
For αs1-casein (Figures 2C and 2D), the peptide profile was much more complex in the 
in vivo digests that in the in vitro ones. While in the simulated in vitro digestions peptides were 
mainly found in the N- and C-terminal regions, in the jejunal digests, peptides were found along 
the whole protein chain. Thus, many peptides belonging to the central domain of the αs1-casein 
protein chain could be identified in the jejunal digests which were absent in the in vitro digests. 
The frequency of appearance of each amino acid for β-casein was used to compare the 
in vitro and the in vivo digestion. Table 2 shows the Spearman correlation coefficients obtained 
for each time point. As expected from the peptide profile, the average correlation coefficient was 
higher when comparing the human jejunal digests with the intestinal phase from the in vitro 
digests (average 0.59 ± 0.09) than with the gastric phase (average 0.16 ± 0.12). In general, the 
correlation coefficients obtained between the in vivo data and the in vitro intestinal phase 
ranged from 0.39 to 0.67. All the in vitro intestinal time points correlated better with the human 
jejunal samples taken at 1 h, since they varied from 0.60 to 0.67. The correlation matrix for β-
casein-derived peptides comparing the profile obtained from the 5 different subjects was also 
built. The coefficients varied from 0.51 to 0.77, which are within the range obtained for the in 
vivo/in vitro comparison. 
Figure 3 shows the peptide pattern of the two major proteins, β-lactoglobulin (Figure 3A 
and 3B) and α-lactalbumin (Figure 3C and 3C), obtained when whey protein was used as 
substrate. In this case, β-lactoglobulin-derived peptides were only found in the intestinal phase 
during in vitro gastrointestinal simulation, and only few α-lactalbumin peptides were identified at 
the end of the gastric phase, in agreement with the results obtained by SDS-PAGE. The 
resistance of β-lactoglobulin to the action of pepsin is well documented (Miranda and Pelissier, 
1983). Other in vitro digestion studies have reported the release of certain peptides sequences 
from β-lactoglobulin during gastric digestion (Benedé et al., 2014; Egger et al., 2016), but it is 
known that the susceptibility of this protein to peptic hydrolysis may vary with the denaturation 
degree of β-lactoglobulin by heating or other treatments (Peram et al., 2013; Singh et al., 2014;  
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Table 2: Spearman correlation coefficients calculated for β-casein peptide profiles found in jejunal digests 
and in vitro simulated gastrointestinal digests when casein was used as substrate. 
 IN VIVO 
IN VITRO jejunum 1h jejunum 2h jejunum 3h jejunum 4h 
G10 min 
-0.09 -0.02 -0.13 -0.08 
G20 min 
-0.03 0.00 -0.06 -0.04 
G30 min 
0.06 0.09 0.01 0.01 
G60 min 
0.12 0.18 0.13 0.08 
G120 min 
0.24 0.40 0.27 0.24 
G20+I60 min 
0.67 0.61 0.64 0.54 
G20+I120 min 
0.60 0.42 0.47 0.39 
G120+I60 min 
0.62 0.45 0.50 0.41 
G120+I120 min 
0.62 0.49 0.54 0.44 
 
 
Sánchez-Rivera et al., 2015). During the in vitro intestinal phase, 46 different β-lactoglobulin 
sequences were released mainly from regions comprised between 42 and 68 and 107 and 135 
with few peptides from the N- and C- terminal regions of the protein. The peptidic profile 
obtained from jejunal digests was more complex than the in vitro one, with 112 different 
peptides along the whole protein chain. A considerable number of β-lactoglobulin peptides 
found in jejunum belonged to regions which were also overrepresented in the intestinal in vitro 
profile (40-60; 120-140). It has to be noted that the ability of peptides to be ionized can influence 
the final appearance of these peptidic profiles, i.e., peptides easily ionized are highly detected 
and may be overrepresented in these heat maps. Previous studies have also shown a higher 
abundancy of β-lactoglobulin peptides from region 40-60 in human jejunal contents after 
ingestion of whey protein (Boutrou et al., 2013), in piglet jejunum after administration of infant 
formula (Bouzerzour et al., 2012) and after the incubation of β-lactoglobulin with human 
gastrointestinal fluids (Benedé et al., 2014). 
In the case of the α-lactalbumin protein, both peptidic profiles, in vitro and in vivo were 
coincident in several regions: 40-52, 63-68, 80-90 (Figure 3C). Interestingly, peptides were 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Heat map built with the frequency of appearance of each amino acid on the β-lactoglobulin and α-lactalbumin protein chain. A and C corresponds to profiles obtained 
from human jejunal digests obtained at 1, 2, 3 and 4 h after oral administration of whey proteins and B and D corresponds to profiles obtained from simulated in vitro digestion 
of the same substrate. The green colour represents low frequency and red high frequency, being the maximum 32, 12, 8 and 9 in A, B, C, and D, respectively. G, gastric; I, 
intestinal.
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found in jejunal digests at samples withdrawn during the first two hours, but only few α-
lactalbumin peptides were identified at 3 and 4 h. In this sense, casein-derived peptides tended 
to maintain their presence along the digestion times evaluated (Figure 2), while the number of 
whey-derived peptides started to decrease after 3 h of ingestion. Similarly, Boutrou et al. (2013) 
also found these differences between casein and whey protein, regarding the kinetics of dietary 
nitrogen flux and the detection and size distribution of peptides in the jejunum after human 
ingestion. 
A correlation matrix for the in vitro/in vivo comparison of β-lactoglobulin-derived 
peptides was also calculated (Table 3). In this case, the in vitro gastric phase was not included 
since no peptides were released from this protein by the action of pepsin and neither jejunal 
samples at 4 h due to the low number of identified peptides. The average correlation coefficient 
was 0.64 ± 0.05 with correlation coefficients ranging between 0.55 to 0.71. Again, these values 
were comprised within the range found when assessing inter-individual variability after whey 
protein consumption (from 0.28 to 0.77). The highest correlation coefficients were found for the 
human jejunal samples obtained after 1 h with any of the in vitro samples from the intestinal 
phase. This higher correlation could be due to the higher number of peptides found in vivo 
samples at short times and because they might be less affected by the absorption process. 
 
Table 3: Spearman correlation coefficients calculated for β-lactoglobulin peptide profiles found in jejunal 
digests and in vitro simulated gastrointestinal digests when whey protein was used as substrate. 
 IN VIVO 
IN VITRO jejunum 1h jejunum 2h jejunum 3h 
G20+I60 min 
0.69 0.65 0.66 
G20+I120 min 
0.71 0.64 0.58 
G120+I60 min 
0.71 0.62 0.67 
G120+I120 min 
0.66 0.55 0.64 
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3.3. Identification of in vivo phosphorylated peptides 
In vivo digests were subjected to a selective precipitation procedure with CaCl2 in order 
to identify phosphorylated regions. Various phosphorylated fragments belonging to the region β-
casein 1-24 were identified in all jejunal digests, but especially, in the samples taken at 1 and 2 
h where phosphorylated peptides were found in all volunteers (Figure 4). However, after the 
same enrichment procedure, no peptides belonging to the phosphorylated N-terminal region of 
β-casein were found. Similar results were obtained for αs1-casein (Figure 5), for which several 
fragments from the region 42-52, in addition to other peptides phosphorylated at serine cluster 
64-68 or Ser
115
, were found. Some of the peptides identified in jejunum are similar to fragments 
previously identified in ileum of rats fed with CPP (Brommage et al., 1991; Hirayama et al., 
1992) or in duodenal digests from mini-pigs fed with different dairy matrices (Barbé et al., 2014).  
 
 
Figure 4: Phosphorylated peptides derived from β-casein identified in jejunal digests. Each grey colour 
denotes a different subject. In those peptides marked with an asterisk, the position of the phosphorylated 
residues may vary. 
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Figure 5: Phosphorylated peptides derived from αs1-casein identified in jejunal digests. Each grey colour 
denotes a different subject. In those peptides marked with an asterisk, the position of the phosphorylated 
residues may vary. 
 
 
3.4. Analysis of peptide homology in vivo vs in vitro 
In vitro and in vivo identified peptides resulting from the HPLC-MS/MS analyses of 
digests were assessed for homology of their sequences by Venn diagrams (Figure 6). A total of 
465 peptides were obtained from human jejunal effluents fed with casein and 338 were found by 
the in vitro protocol, being 101 of these sequences (14.4%) common between both digestions 
(Figure 6A). β-casein and αs1-casein were compared separately but the percentages of 
homology found were similar than that in whole casein. Around 23% of β-casein and 16% of αs1-
casein peptides were identical between in vitro and in vivo results (Figure 6C and 6E). In the 
case of whey protein, 179 and 117 peptides were identified in vivo and in vitro, respectively. The 
percentage of homology between both groups was 13.0%, sharing 34 sequences (Figure 6B). 
As illustrated in Figure 6D and 6F, comparable patterns were demonstrated for the two major 
whey proteins. 112 peptides were observed in the in vivo β-lactoglobulin jejunal digests, 27 of 
them matched with a total of 46 peptides found in vitro (Figure 6D). From α-lactalbumim, 25 
sequences were recognized in vivo and 14 in the in vitro digests, sharing 5 of them (Figure 6F). 
Therefore, the percentage of identical sequences between in vitro samples and in vivo jejunal 
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effluents showed a certain similarity for most abundant milk proteins, ranging from 14.7% (α-
lactalbumin) to 23% (β-casein). 
 
 
Figure 6: Venn diagrams with the number of identical and different peptides found in human jejunal 
digests and in vitro simulated gastrointestinal digestion of casein (A) and whey protein (B) and specified for 
β-casein (C), αs1-casein (E), β-lactoglobulin (D) and α-lactalbumin (F). 
 
Validation of in vitro methods with results obtained from in vivo studies has been 
urgently stated. The static in vitro protocol of Minekus et al. (2014) was built by consensus of 
different research groups, considering the physiologically in vivo data published in the literature. 
It is presented in a robust and simply mode and it has recently shown consistency in inter-
laboratory trials (Egger et al., 2016). However, these authors indicated the limitations of static in 
vitro models as simplified methods of the intricate in vivo digestion process. Several parameters 
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such as chewing, gastric emptying, continuous changes in pH, secretion flow rates and 
feedback systems that regulate the progress of digestion, among others, have been described 
as limiting factors for these protocols (Guerra et al., 2012). In the present work, an in vitro/in 
vivo comparison at peptide level was attempted. Although some differences were found, the in 
vitro protocol resembles the in vivo intestinal digestion regarding protein degradation and 
peptide release. Finally, it was found shown that the correlation found for the in vivo/in vitro 
comparison was similar to the inter-individual variability, i.e. the correlation coefficients found 
between in vitro digests and the jejunal effluents were within the range found for the different 
volunteers of the study. Therefore, these results illustrate that the proposed in vitro digestion 
protocol constitutes a good approximation of the physiological gastrointestinal digestion of milk 
proteins. 
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187 Discusión 
El tracto digestivo es considerado como el órgano endocrino más extenso del 
organismo. Se encuentra en contacto continuo y directo con una gran cantidad de 
compuestos derivados de la digestión de los alimentos. Esto ha llevado a que en los 
últimos años haya crecido el interés científico por el efecto de los péptidos bioactivos 
en el tracto digestivo, bien por su actividad moduladora sobre las células y los 
receptores de este sistema del organismo (Shimizu y Hachimura, 2011), como por la 
influencia directa ejercida por los procesos digestivos sobre la funcionalidad biológica 
de dichos péptidos (Sánchez-Rivera y col., 2014a). Los trabajos experimentales 
incluidos en esta Tesis Doctoral revelan nuevos datos acerca de la digestión y las 
propiedades beneficiosas relacionadas con la salud digestiva del péptido lunasina, de 
proteínas lácteas y de péptidos derivados. En concreto, se ha demostrado el papel 
protector que tiene el inhibidor de proteasas IBB1 sobre la digestión in vitro del péptido 
lunasina simulando las condiciones fisiológicas y se han identificado los péptidos 
liberados tras la acción de las enzimas gástricas y pancreáticas sobre ambos 
polipéptidos. En base a estos resultados, se ha evaluado el transporte intestinal in vitro 
del péptido lunasina y de cuatro fragmentos liberados durante su digestión que 
comprenden la secuencia completa del péptido. Además, se demuestra el potencial 
efecto de los digeridos gastrointestinales de la lunasina y de algunos de los péptidos 
contenidos en dichos digeridos sobre la viabilidad de células tumorales del tracto 
gastrointestinal. Posteriormente, se profundizó en los mecanismos protectores 
relacionados con la actividad quimiopreventiva del péptido lunasina. Para ello, se ha 
evaluado el efecto antiproliferativo de este péptido en células nativas y células madre 
de cáncer colorrectal, así como su capacidad de protección frente al estrés oxidativo 
inducido químicamente en células hepáticas. Por otro lado, se ha evaluado el 
mecanismo modulador de péptidos lácteos sobre la expresión relativa de genes que 
codifican para mucinas en células caliciformes intestinales, identificándose en este 
estudio nuevas secuencias con actividad opioide. Además, se determinó el efecto in 
vivo sobre el mucus intestinal de un hidrolizado de proteínas lácteas que contiene 
 
188 Discusión 
dichos péptidos. Este efecto estaba mediado por la estimulación de la expresión 
génica y de la secreción fecal y luminal de mucinas intestinales. Por último, se ha 
llevado a cabo un estudio comparativo de la digestión gastrointestinal de proteínas 
lácteas entre un protocolo in vitro recientemente consensuado a nivel internacional y 
muestras obtenidas del contenido intestinal del yeyuno de individuos humanos tras la 
ingestión de caseínas y proteínas de suero. 
3.1. Digestión, biodisponibilidad y mecanismos quimiopreventivos del péptido 
lunasina en modelos celulares 
 La digestión gastrointestinal de las proteínas alimentarias supone tanto una 
barrera física y enzimática como el origen de múltiples modificaciones en la estructura 
y secuencia de los péptidos derivados. Estos procesos pueden provocar la liberación 
de nuevos fragmentos con mayor, menor o nula actividad comparada con la de sus 
precursores. Dada esta importancia, en los últimos años, se ha incrementado 
notablemente el número de trabajos que consideran aspectos propios de la digestión y 
la biodisponibilidad de los péptidos bioactivos a la hora de establecer una relación 
causa-efecto con la salud y su potencial aplicación como ingredientes funcionales 
(Miner-Williams y col., 2014; Nongonierma y FitzGerald, 2016). 
 Algunos estudios basados en ensayos inmunológicos habían sugerido que el 
péptido lunasina resistía la acción proteolítica de las enzimas digestivas debido a la 
actividad de los inhibidores de proteasas presentes de forma natural en las proteínas 
vegetales, como el BBI y el KTI (Jeong y col., 2007a; b; Park y col., 2007; Hernández-
Ledesma y col., 2009a). Por ello, se planteó, por primera vez, el estudio mediante 
cromatografía de líquidos de alta eficacia acoplada a espectrometría de masas en 
tándem (HPLC-MS/MS) de la digestión in vitro del péptido lunasina simulando las 
condiciones fisiológicas en ausencia y presencia de la principal isoforma del BBI, el 
IBB1, reconocida por su actividad inhibitoria de tripsina y quimiotripsina. Se comprobó 
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la funcionalidad del isoinhibidor IBB1 mediante el uso de su forma activa y 
químicamente inactivada (Clemente y col., 2010). Se observó que dicha inactivación 
reducía su actividad inhibitoria de las enzimas tripsina y quimiotripsina en más de un 
95%, lo que permitía determinar la influencia del estado del IBB1 (activo versus 
inactivo) sobre la potencial protección frente a la digestión de la lunasina. Además, el 
análisis por HPLC-MS/MS corroboró que un 2% del IBB1 total permaneció todavía 
activo en la preparación químicamente inactivada. En comparación con los trabajos 
anteriores, este estudio permitía avanzar en la investigación del péptido lunasina 
mediante su cuantificación a nivel gástrico e intestinal y la identificación de los 
péptidos liberados durante el proceso digestivo. 
 Se confirmó, por un lado, el efecto protector que ejerce el IBB1 sobre la 
degradación que sufre el péptido lunasina durante el proceso digestivo. En ausencia 
del IBB1, la pepsina hidrolizó la lunasina, permaneciendo un 2,6% del péptido inicial 
intacto. Sin embargo, en presencia del IBB1 activo en ratios lunasina:IBB1 1:1 y 1:2 
(peso:peso), el porcentaje de lunasina intacto tras la acción de la enzima gástrica fue 
significativamente mayor, del 34,3 y 35,1%, respectivamente, demostrando que está 
protección no dependía del ratio empleado. Estos resultados indicaban que la 
protección ejercida frente a la digestión gástrica estaba mediada por factores 
independientes al mecanismo enzimático. De acuerdo con este planteamiento, Hajela 
y col. (1999) habían descrito previamente la mínima actividad inhibitoria que presenta 
el BBI frente a la pepsina. Esta hipótesis se reforzó cuando la digestión se llevó a cabo 
en presencia del IBB1 en un estado inactivo (lunasina:IBB1, 1:2), obteniéndose 
resultados estadísticamente similares (28,4%). Por ello, se sugirió que la simple 
presencia del isoinhibidor y su mayor tamaño con respecto a la lunasina, 
independientemente de su actividad, podría ser responsable del efecto preventivo 
frente al ataque de la enzima gástrica. Por el contrario, a nivel intestinal, el IBB1 
ejerció un efecto protector dosis-dependiente mediado por su actividad inhibitoria de 
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tripsina y quimiotripsina. En ausencia del IBB1, la lunasina se degradó prácticamente 
en su totalidad (0,1%), pero su resistencia intestinal aumentó significativamente con la 
presencia de IBB1 a ambos ratios 1:1 y 1:2, permaneciendo intacta un 1,8 y 5,3% del 
péptido inicial, respectivamente. Sin embargo, el isoinhibidor en un mismo ratio de 
lunasina:IBB1 (1:2) pero inactivado químicamente tuvo un efecto significativamente 
menor. En este caso, el porcentaje de lunasina intacta al final del proceso digestivo fue 
del 1,5%, similar al observado en presencia del IBB1 a una relación 1:1. 
Paralelamente, se confirmó la extraordinaria resistencia que presenta el isoinhibidor a 
su paso por el tracto gastrointestinal (Clemente y col., 2011). Esta resistencia se debe 
a la particular estabilidad de su estructura mantenida por una red compacta de siete 
puentes disulfuro (Clemente y Domoney, 2006; Trivedi y col., 2009). En nuestro 
estudio, la inactivación química del IBB1 inducida mediante reducción-alquilación, 
además de reducir en un 95% su actividad inhibitoria de proteasas intestinales, 
aumentó notablemente su sensibilidad a las enzimas digestivas, liberándose un total 
de 19 y 24 fragmentos durante su digestión a nivel gástrico e intestinal, 
respectivamente. En el caso del análisis del péptido lunasina, el mayor número de 
fragmentos derivados se identificó en el digerido obtenido a partir de lunasina en 
ausencia del IBB1 (20 y 18 del total de 22 y 33 secuencias liberadas a nivel gástrico e 
intestinal, respectivamente). Además, en el caso de esta simulación, se formaron 5 
fragmentos durante la fase gástrica y 15 durante la intestinal, que no fueron 
identificadas en los digeridos obtenidos a partir de mezclas de lunasina con el IBB1. 
Esto indicó el papel protector que ejercía el isoinhibidor, no sólo en la digestión de la 
lunasina, sino también y, predominantemente, en la región central entre los 
aminoácidos 11 y 28, donde se originaron la mayoría de estas nuevas secuencias. Sin 
embargo, en presencia del IBB1 activo a ambos ratios lunasina:IBB1, el perfil peptídico 
de las digestiones gástricas y gastrointestinales fue bastante similar. El número de 
fragmentos liberados en estos digeridos varió ligeramente, entre 13 y 16, originándose 
 
191 Discusión 
a partir de cuatro regiones concretas, 1-10, 11-18, 19-28 y 29-43, que mostraron una 
destacada estabilidad durante toda la simulación digestiva. 
 En base a estos resultados, se propuso evaluar la biodisponibilidad del péptido 
lunasina en el modelo de células Caco-2 en monocapa mediante HPLC-MS/MS. 
Además, se planteó el mismo estudio con cuatro fragmentos identificados que habían 
demostrado una marcada resistencia a las enzimas gastrointestinales y que integran la 
secuencia completa del péptido lunasina: 1SKWQHQQDSC10, 11RKQLQGVN18, 
19LTPCEKHIME28 y 29KIQGRGDDDDDDDDD43. En primer lugar, en el estudio del 
compartimento apical, se observó que el péptido lunasina y los fragmentos 
11RKQLQGVN18 y 19LTPCEKHIME28 se hidrolizaban en contacto con las enzimas del 
epitelio intestinal en un 42,8, 20,3 y 21,3%, respectivamente, mientras que los 
fragmentos 1SKWQHQQDSC10 y 29KIQGRGDDDDDDDDD43 permanecieron 
prácticamente intactos. Resulta interesante destacar como en el ensayo con lunasina, 
se comprobó que la acción de las enzimas epiteliales fue predominantemente dirigida 
hacia la región central de su secuencia, como sucede con las proteasas pepsina, 
tripsina y quimiotripsina en ausencia del IBB1. En el caso de los otro cuatro péptidos 
analizados, la mayoría de los fragmentos liberados se formaron a consecuencia de 
cortes desde el extremo N-terminal, sugiriéndose la acción de la enzima dipeptidil 
peptidasa-IV, de acuerdo con los resultados publicados en varios estudios similares 
(Howell y col., 1992; Quirós y col., 2008; Ding y col., 2015). En el estudio del 
compartimento basolateral, se comprobó la biodisponibilidad de la lunasina y del 
péptido derivado 11RKQLQGVN18, con coeficientes de transporte, expresados como 
permeabilidad aparente, de 3,3 x 10-7 y 2,5 x 10-7 cm/s, respectivamente. Estos valores 
son similares a los descritos para otros péptidos bioactivos como los fragmentos 
90RYLGY94 y 143AYFYPEL149 de la αs1-CN (Contreras y col., 2012), y el péptido 
recombinante VLPVP (Lei y col., 2008). Ninguno de los otros fragmentos evaluados, 
1SKWQHQQDSC10, 19LTPCEKHIME28 y 29KIQGRGDDDDDDDDD43 de la lunasina, ni 
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el resto de secuencias formadas en el compartimento apical fue capaz de atravesar la 
monocapa de células Caco-2. Por ello, se sugirió que la secuencia 11RKQLQGVN18 
podría ser potencialmente responsable de la absorción intestinal mostrada para el 
péptido lunasina. En este sentido, también merece la pena indicar que el IBB1 ejerció 
un papel determinante en la protección de esta región frente a la acción de las 
proteasas intestinales sobre los enlaces 11R-K12, 12K-Q13, 13Q-L14, 14L-Q15, 15Q-G16 y 
16G-V17 (Publicación I). Este hecho sería fisiológicamente muy relevante si se confirma 
mediante más estudios la hipótesis planteada sobre el papel que cumple esta región 
en la biodisponibilidad de la lunasina. Además, se demostró que tanto el péptido 
lunasina como el fragmento 11RKQLQGVN18 eran absorbidos a través de la barrera 
intestinal mediante un mecanismo de difusión paracelular. Esta vía es una ruta 
favorable para la absorción de moléculas solubles y evita la acción de las peptidasas 
intracelulares (Salamat-Miller y Johnston, 2005). De manera similar, también se ha 
identificado esta vía en el transporte intestinal de varios péptidos (Segura-Campos y 
col., 2011). 
 La FDA recomendó el consumo de 25 g de proteínas de soja al día para reducir 
el riesgo de desarrollar enfermedades cardiovasculares (FDA, 1999). Según el trabajo 
de de Mejia y col. (2010), estos 25 g supondrían una ingesta total diaria de lunasina de 
0,94 g. Bajo las condiciones experimentales de nuestros estudios, en presencia de 
IBB1 activo (lunasina:IBB1 1:2), 49,82 mg de lunasina (5,3% de la inicial ingerida) 
llegarían a nivel intestinal tras el proceso gastrointestinal. Un porcentaje del 42,8% 
sería hidrolizado por las peptidasas del borde del epitelio intestinal, dando lugar a 
28,50 mg en el lumen intestinal, que podrían actuar a nivel local sobre las células y los 
receptores digestivos. De esta cantidad, un 0,88% sería biodisponible con una 
permeabilidad aparente de 3,3 x 10-7 cm/s. Por lo tanto, 0,25 mg de lunasina totales 
podrían pasar al torrente sanguíneo en forma intacta para ejercer efectos sistémicos. 
En este sentido, Dia y col. (2009) determinaron la presencia de 0,21 mg de lunasina en 
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el plasma de individuos adultos a los 60 min de la ingesta de 50 g de una dieta basada 
en proteínas de soja. A pesar de las diferencias experimentales entre este estudio in 
vivo y la evaluación llevada a cabo en nuestros trabajos, los resultados obtenidos se 
acercaron razonablemente. 
 El péptido lunasina había sido ampliamente estudiado por sus propiedades 
quimiopreventivas demostradas en ensayos in vitro, cultivos celulares y modelos 
animales (Hernández-Ledesma y Hsieh, 2015). Inicialmente, se decidió evaluar el 
efecto de los digeridos gastrointestinales de las mezclas de lunasina, con o sin IBB1, 
frente al crecimiento de dos líneas de células de adenocarcinoma colorrectal, HT-29 y 
Caco-2. En ausencia del IBB1, los digeridos de lunasina redujeron la viabilidad de las 
células HT-29 con un valor de IC50 de 0,29 mg/mL. Este efecto sería atribuible a los 
fragmentos derivados de la digestión de la lunasina, ya que la presencia de este 
péptido en el digerido fue residual (0,1%). Por el contrario, este digerido no mostró 
efecto en células Caco-2. La presencia del IBB1 en las digestiones aumentó los 
efectos observados. Este hecho podría deberse a la propia actividad quimiopreventiva 
previamente descrita para el IBB1 (Clemente y col., 2010), así como a la mayor 
presencia de lunasina y de péptidos derivados protegidos de la acción de las enzimas 
digestivas en presencia del isoinhibidor. Los valores IC50 para los distintos digeridos 
fueron menores en las células HT-29 (0,16-0,23 mg/mL) que en las Caco-2, 
observándose además se observó un claro efecto dosis-dependiente. 
Partiendo de estos resultados, se planteó evaluar el efecto individual del 
péptido lunasina y de algunos fragmentos derivados identificados en sus digeridos 
gástricos y gastrointestinales, 1SKWQHQQDSC10, 11RKQLQGVN18, 
17VNLTPCEKHIME28, 19LTPCEKHIME28, 29KIQGRGDDDDDDD41, 
29KIQGRGDDDDDDDDD43 y 34GDDDDDDDDD43, sobre la viabilidad de la línea celular 
de adenocarcinoma gástrico AGS y de las dos líneas de adenocarcinoma colorrectal 
usadas previamente (HT-29 y Caco-2). De acuerdo con los resultados encontrados en 
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el trabajo anterior, las células HT-29 resultaron ser las más susceptibles a la acción del 
péptido lunasina, que mostró efectos dosis- y tiempo-dependientes con una máxima 
actividad inhibitoria tras 72 h de tratamiento con la concentración de 200 µM (inhibición 
de la viabilidad celular en un 23,8% con respecto al control). Sin embargo, esta 
actividad fue notablemente menor a la descrita en estas células para la lunasina 
aislada a partir de harinas de soja a una concentración de 100 µM (62,8%) (Dia y de 
Mejia, 2010). Por ello, se decidió evaluar la pureza del péptido lunasina sintético 
(usado en nuestros trabajos). Mediante purificación por HPLC, se determinó que el 
péptido sintético presentaba tan solo un 10% de impurezas. Por lo que se sugirió que 
las diferencias estructurales entre el péptido sintético y el aislado desde la fuente 
proteica natural podrían ser, principalmente, las responsables de la menor actividad 
demostrada en el presente estudio. De una forma similar, los siete fragmentos 
derivados de la lunasina mostraron un mayor efecto en la línea celular HT-29, en 
comparación con los experimentos en células AGS y Caco-2. Esta situación fue 
particularmente destacable para el fragmento 1SKWQHQQDSC10 que inhibió la 
viabilidad de las células HT-29 en un porcentaje máximo del 25,8% (200 µM, 72 h). En 
este sentido, Chang y col. (2014) recientemente encontraron que el fragmento 
1SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQG32 tenía un efecto inmunomodulante 
equiparable a la secuencia completa de la lunasina mediante la activación de células 
“natural killer”; mientras que Hernández-Ledesma y col. (2011) vieron que la región N-
terminal, 1SKWQHQQDSCRKQLQGVNLTPC22, era menos activa que la C-terminal, 
23EKHIMEKIQGRGDDDDDDDDD43, y el péptido lunasina completo en la inhibición del 
crecimiento de células de cáncer de mama MDA-MB-231, con valores de IC50 de 
323,0, 138,0 y 181,0 µM respectivamente. Por lo tanto, nuestro trabajo ha sido el 
primer estudio que ha propuesto una actividad quimiopreventiva para la región N-
terminal, concretamente para el fragmento 1SKWQHQQDSC10 de la lunasina. Sin 
embargo, con los resultados del presente estudio no se pudo justificar la actividad 
observada para los digeridos de lunasina:IBB1 (Publicación I), por lo que el efecto 
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inhibitorio de otros componentes del digerido, del IBB1, o un efecto sinérgico entre los 
péptidos identificados podría haber contribuido a los efectos previamente 
demostrados. 
El siguiente paso consistió en profundizar en el conocimiento de los 
mecanismos implicados en la actividad quimiopreventiva del péptido lunasina. La 
reciente teoría de las células madre cancerosas sugiere que muchos tipos de cáncer, 
entre ellos, predominantemente el cáncer colorrectal, se inician y mantienen por una 
pequeña población de células tumorogénicas capaces de auto-renovarse y 
diferenciarse en múltiples tipos celulares de forma continuada, desarrollando nuevos 
tumores a partir de los originales (Anderson y col., 2011). Además, estas células 
pueden ser responsables de las capacidades de recidiva, metástasis y resistencia a 
los tratamientos anticancerígenos que se presentan frecuentemente en esta 
enfermedad (Clevers, 2011). Esta situación ha dado lugar a la búsqueda de nuevos 
agentes farmacológicos, nutricionales y fitoquímicos con capacidad preventiva frente a 
esta subpoblación tumorogénica (Kim y col., 2012; Oh y col., 2016). Partiendo de este 
planteamiento, se evaluó el efecto citotóxico del péptido lunasina en la línea celular de 
carcinoma colorrectal HCT-116, cultivada bajo distintas condiciones que permitieron 
ensayar la actividad tanto en células nativas (parentales) como en células madre 
(esferas) tumorales (Publicación III). La lunasina fue capaz de inhibir la viabilidad de 
las células nativas tumorales a las 72 h de tratamiento con un valor de IC50 de 107,5 
µM, mientras que su capacidad preventiva frente a la formación de esferas tumorales 
tras 10 días se dio a un valor de IC50 de 161,0 µM. Así, las células madre tumorales 
HCT-116 mostraron una menor sensibilidad a la lunasina, al igual que se había 
descrito en células de adenocarcinoma colorrectal SW620 para el ácido graso 
docosahexaenoico (Yang y col., 2013). Sin embargo, McConnell y col. (2015) 
encontraron que el efecto inhibitorio de la lunasina en células de cáncer de pulmón no 
microcítico aumentó notablemente cuando las células se cultivaron en un ambiente de 
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crecimiento no-adherente (propio de las células madre tumorales), en comparación 
con las condiciones adherentes. En esta misma línea, estos resultados también han 
sido recientemente demostrados en ensayos con células madre y nativas de 
melanoma de piel (Shidal y col., 2016). De estas observaciones y de nuestros trabajos, 
se puede confirmar que el efecto antiproliferativo del péptido lunasina depende de las 
condiciones de cultivo y de la línea tumoral celular evaluada. 
Algunos de los mecanismos implicados en la supervivencia y proliferación de 
las células tumorales se relacionan con su elevado umbral de apoptosis y su 
replicación incontrolada durante el progreso del ciclo celular (Hanahan y Weinberg, 
2011). Mediante el ensayo de anexina V-yoduro de propidio por citometría de flujo, se 
observó que la lunasina ejercía un efecto inductor de la apoptosis de hasta 1,8 y 2,0 
veces, con respecto al control, a la máxima dosis empleada (80 µM) en las células 
nativas y madre HCT-116, respectivamente. Mediante Western-Blot se comprobó que 
este efecto desencadenante del proceso apoptótico estaba mediado por la activación 
de la vía de señalización caspasa-3, la cual se acompañaba de una disminución de la 
señal proteica PARP, relacionada con la viabilidad celular y la reparación del ADN. En 
este sentido, Dia y de Mejia (2010; 2011a) habían demostrado que el péptido lunasina 
participaba en la activación de la vía apoptótica mitocondrial de las células de cáncer 
colorrectal HT-29 y KM12L4, mediante un aumento de las señales Bax, citocromo c, 
caspasa-3, -2 y -9 y el cluster nuclear y una disminución de la señal Bcl-2. 
Paralelamente, en nuestro trabajo, ambas poblaciones tumorales nativas y madre se 
tiñeron con yoduro de propidio para determinar por citometría de flujo la cantidad de 
ADN presente y evaluar la fase del ciclo celular en la que se encontraban. Los 
resultados mostraron un moderado incremento concentración-dependiente en el 
porcentaje de células tratadas que se encontraban en la fase G1. Así, la dosis de 80 
µM aumentó significativamente este porcentaje tanto en las células nativas (control: 
66,5% versus lunasina: 72,0%) como células madre tumorales (control: 69,4% versus 
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lunasina: 74,0%). Este hecho demostraba la capacidad preventiva del péptido al 
bloquear la progresión del ciclo celular en dicha fase. Además, en el caso de las 
células nativas HCT-116, se observó un incremento de la población celular en fase 
sub-G0/G1, lo que sugiere degradación del ADN potencialmente debida a la muerte 
celular inducida por el efecto pro-apóptotico anteriormente descrito. Asociado con este 
efecto regulatorio sobre el ciclo celular, se demostró que el péptido lunasina era capaz 
de inducir levemente la expresión proteica del inhibidor de la quinasa dependiente de 
ciclina 1a, p21, que regula el avance en el ciclo celular de la fase G1 hacia la fase S, 
como también había sido descrito previamente en las células HT-29 y KM12L4 (Dia y 
de Mejia 2010; 2011a). En conjunto, estos resultados permitieron avanzar en el 
conocimiento de los mecanismos antiproliferativos ejercidos por el péptido lunasina 
frente al cáncer colorrectal al inhibir, tanto la proliferación de las células cancerígenas 
nativas como la expansión de la subpoblación de células madre tumorales. 
El estrés oxidativo ha sido descrito como agente causal implicado en el inicio y 
la progresión de los procesos tumorales, mediante inducción de las mutaciones del 
ADN, inestabilidad genómica, daño a las moléculas celulares y aumento de la 
proliferación celular (Reuter y col., 2010; Sosa y col., 2013). Además, el exceso en los 
niveles de ROS ha sido vinculado con la patogénesis de múltiples enfermedades 
crónicas y degenerativas, como la inflamación, las enfermedades cardiovasculares y 
neurodegenerativas, la diabetes y el envejecimiento (Ramos, 2008; Wadley y col., 
2013). En concreto, el hígado es un órgano diana del daño inducido por ROS, donde 
estas especies reactivas participan en patologías como la hepatitis vírica y alcohólica, 
la esteatosis no alcohólica, la fibrosis hepática o el hepatocarcinoma (Cichoz-Lach y 
Michalak, 2014). En varios estudios in vivo se había aislado el péptido lunasina en una 
forma intacta y bioactiva a partir del hígado de ratas alimentadas con dietas 
enriquecidas en dicho péptido (Jeong et al., 2007a; 2007c; 2009; 2010). Por ello, se 
propuso evaluar el efecto de la lunasina sobre los mecanismos celulares hepáticos de 
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defensa antioxidante (Publicación IV). En virtud de dichas consideraciones, se 
seleccionó la línea celular HepG2, como modelo aceptado en estudios bioquímicos, 
farmacológicos y nutricionales que evalúan la funcionalidad de las células del hígado 
en cultivo (Goya y col., 2009). El t-BOOH se utilizó como agente químico inductor del 
estrés oxidativo en esta línea celular (Alía y col., 2005). Se ha descrito que para 
determinar la actividad antioxidante celular de un compuesto es necesario evaluar sus 
efectos sobre la viabilidad celular, los niveles intracelulares de ROS, la respuesta de 
los mecanismos de defensa enzimáticos y no enzimáticos, y los marcadores de daño 
oxidativo celular (Valko y col., 2006). En los resultados del efecto directo del péptido 
lunasina (0,5 – 10 µM, 20 h) sobre las células HepG2 no estresadas, se encontró que 
la lunasina no afectaba a la viabilidad celular, además de disminuir la producción basal 
de ROS (máximo efecto a 5 µM: 63,6% con respecto al control), y aumentar el 
contenido en GSH (máximo efecto a 10 µM: 125,6% con respecto al control). Estos 
efectos situarían a la célula en un estado más favorable a la hora de afrontar una 
situación de estrés oxidativo (Goya y col., 2009). Se observó que el agente químico t-
BOOH (400 µM, 3 h) inducía muerte celular en un 67,5%, mediante un aumento de las 
ROS (190,0% con respecto al control) y un descenso del GSH citosólico (42,2% con 
respecto al control). Sin embargo, el pretratamiento con el péptido lunasina durante 20 
h fue capaz de proteger a las células frente al t-BOOH, recuperando por completo su 
viabilidad y mejorando parcialmente la generación de ROS (5 µM: 122,0%) y el 
contenido de GSH (0,5 µM: 66,5%), pero sin mostrar una tendencia dosis-dependiente. 
El GSH es el principal mecanismo intracelular de defensa no enzimático, estando 
presente en el hígado en altas concentraciones como agente detoxificante de la 
producción en exceso de ROS y mitigador de la peroxidación celular (Mari y col., 
2009). Las enzimas GPx, en su relación con el GSH, y CAT, independiente de este 
mecanismo, son fundamentales para controlar el equilibrio redox celular. En este 
trabajo se demostró como el péptido lunasina disminuía la actividad de ambas 
enzimas CAT (máximo efecto a 5 µM: 102,1%) y, de una forma dosis-dependiente en 
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el caso de la GPx (máximo efecto a 10 µM: 127,9%), con respecto al marcado 
aumento inducido durante el daño oxidativo con t-BOOH (CAT: 256,8% y GPx: 
235,3%). La oxidación de los grupos sulfuro de las proteínas y la consiguiente 
formación de grupos carbonilos, biomarcadores de daño oxidativo, puede conllevar la 
pérdida de la funcionalidad de enzimas, receptores y múltiples proteínas implicadas en 
la señalización celular (Wang y col., 2016). El agente químico t-BOOH provocó una 
elevación notable en la formación de grupos carbonilo en las células HepG2 (290,3% 
con respecto al control). Sin embargo, el péptido lunasina consiguió disminuirlos al 
nivel basal. Además, el estrés oxidativo también es capaz de inducir daño celular 
alterando vías de señalización sensibles al estado redox (Singh y Czaja, 2008) y al 
contenido intracelular de GSH (Franco y Cidlowski, 2012), como las desencadenantes 
de la apoptosis. Utilizando la caspasa-3 como biomarcador, se observó como el 
péptido lunasina (1 – 10 µM) evitaba la activación de la caspasa-3 inducida por el t-
BOOH (185,7% con respecto al control). Por lo tanto, en este trabajo se identificó, por 
primera vez para el péptido lunasina, un notable efecto potenciador de los 
mecanismos de defensa antioxidantes de las células HepG2 que podría contribuir a la 
actividad quimiopreventiva previamente demostrada. 
Las peptidasas presentes en el cultivo celular podrían degradar la lunasina, 
liberándose formas inactivas o bien generándose nuevas secuencias con mayor 
actividad a la descrita para el péptido precursor. Por lo tanto, resultó interesante 
evaluar, mediante HPLC-MS/MS, la estabilidad del péptido lunasina en las líneas 
celulares empleadas (Publicación II y IV). El análisis de los sobrenadantes de las 
células de cáncer gástrico (AGS) y colorrectal (HT-29 y Caco-2), reveló una 
degradación moderada del péptido lunasina durante las 72 h de tratamiento en 
contacto con las células AGS (27,0%) y HT-29 (32,0%). Este descenso en el 
porcentaje de lunasina se vio acompañado de la formación de varios fragmentos 
derivados de su extremo C-terminal: 23EKHIMEKIQGRGDDDDDDDDD43, 
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25HIMEKIQGRGDDDDDDDDD43, 29KIQGRGDDDDDDDDD43 y 32GRGDDDDDDDDD43. 
Por el contrario, en el caso de las células Caco-2, la señal del péptido lunasina se 
mantuvo al mismo nivel durante las 72 h, por lo que la pérdida del efecto inhibitorio 
observado a este tiempo de tratamiento no se pudo atribuir ni a la degradación de la 
lunasina ni a la formación de fragmentos derivados con menor actividad. En el caso de 
las células hepáticas HepG2 tratadas con dicho péptido, se observó una marcada 
diferencia con respecto al trabajo anterior, ya que el contenido en lunasina descendió 
completamente con el tiempo de incubación quedando menos de un 1,0% de lunasina 
intacta a las 20 h. Además se identificaron varios fragmentos derivados: 
25HIMEKIQGRGDDDDDDDDD43, 26IMEKIQGRGDDDDDDDDD43, 
29KIQGRGDDDDDDDDD43, 30IQGRGDDDDDDDDD43 y 32GRGDDDDDDDDD43. 
Merece la pena mencionar que los fragmentos identificados en ambos trabajos 
provienen de la misma región C-terminal de la lunasina, por lo que se podría sugerir 
que las líneas celulares AGS, HT-29 y HepG2 comparten mecanismos enzimáticos 
frente a la incubación con dicho péptido, aunque las células hepáticas indujeron un 
descenso en su contenido mucho mayor. Además, estos fragmentos pertenecen al 
dominio C-terminal descrito, hasta el momento, como la región activa de la lunasina 
(Hernández-Ledesma y col., 2009c) y contienen el motivo 33RGD35 relacionado con la 
interacción del péptido con los receptores e integrinas celulares (Galvez y col., 2001; 
Dia y de Mejia, 2011a). En este sentido, la reducción del contenido en lunasina en el 
sobrenadante del medio celular podría también deberse a la internalización celular del 
péptido, cómo ha sido descrito en varios trabajos (Galvez y col., 2001; Dia y de Mejia, 
2011a; Galvez y col., 2011; Cam y col., 2013).  
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3.2. Efectos de péptidos lácteos sobre la mucosa intestinal. Estudio peptidómico 
de digeridos humanos en comparación con digeridos in vitro 
 El epitelio gastrointestinal se encuentra protegido por una capa de mucus, cuya 
producción puede estar modulada por diferentes componentes alimentarios (Macha y 
col., 2015). Entre ellos, el péptido β-CM-7, derivado de la β-CN, había demostrado 
influencia en la producción de mucinas mediada por los receptores opioides del 
subtipo µ en yeyuno aislado de rata (Claustre y col., 2002; Trompette y col., 2003) y en 
células caliciformes intestinales humanas y de rata (Zoghbi y col., 2006). 
Recientemente, Martínez-Maqueda y col. (2013a) demostraron que los péptidos 
derivados de la αs1-CN 
143AYFYPEL149 e 144YFYPEL149 inducían un aumento en la 
secreción y expresión génica de la mucina 5AC en células HT29-MTX. Debido a que 
estas dos secuencias presentaban una estructura favorable para interaccionar con los 
receptores opioides localizados en el tracto digestivo (Meisel, 1997), se decidió evaluar 
la actividad opioide de estos péptidos, y de los fragmentos derivados 144YFYPE148, 
144YFYP147 e 144YFY146 (Publicación V). En los primeros ensayos con íleon aislado de 
cobaya, usando una curva dosis-acumulativa, se observó efecto opioide para los 
péptidos 144YFYPEL149 e 144YFYPE148 a la dosis de 5,5 × 10-7 M. Sin embargo, el efecto 
tendía a disminuir durante el tiempo del ensayo, lo que planteó la hipótesis de que los 
péptidos pudieran estar degradándose por las peptidasas propias de la preparación, 
como se había descrito previamente para péptidos opioides endógenos (McKnight y 
col., 1983). Este hecho se confirmó mediante HPLC-MS/MS y al repetir los ensayos en 
presencia de inhibidores de proteasas (Aoki y col., 1984). En estas condiciones, se 
describió, por primera vez, una moderada actividad opioide dosis-dependiente para 
144YFYPE148 (máximo efecto a 5,0 × 10-6 M: 31,6% de inhibición) seguida de 
144YFYPEL149 (26,2%), 144YFY146 (25,5%) y 143AYFYPEL149 (22,2%). Estos efectos en el 
tejido de íleon de cobaya fueron revertidos por el antagonista opioide naloxona, pero 
disminuyeron notablemente en la preparación de deferente de ratón, lo que sugería 
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selectividad de los péptidos por el subtipo µ-opioide, tal como se había descrito para 
las β-CMs (Teschemacher, 2003). Para explicar la falta de actividad del péptido 
144YFYP147, en este trabajo se llevó a cabo, por primera vez, una modelización de la 
interacción molecular entre un péptido opioide alimentario (144YFYPEL149, activo, 
versus 144YFYP147, inactivo)  y el receptor µ-opioide. Las simulaciones con ambos 
péptidos mostraron una variación marcada de energía en las posiciones del receptor 
145-150, 195-200, 240-250 y la región C-terminal. Sin embargo, la flexibilidad de la 
región 195-200, íntimamente relacionada con la actividad del receptor (Waldhoer y 
col., 2004), se vio comprometida en el caso del péptido 144YFYP147. Además, las 
interacciones entre los residuos de los péptidos y los del receptor opioide se 
distribuyeron de forma diferente en ambos casos, tanto por el tipo de unión establecida 
como por la intensidad de las mismas. El residuo prolina N-terminal del péptido 
144YFYP147 fue determinante en la interacción con el receptor, lo que no se observó en 
la simulación con 144YFYPEL149,  resultando en un claro cambio en la disposición y 
orientación de ambos péptidos con respecto al lugar de unión activo del receptor 
opioide.  
Paralelamente, se planteó determinar, mediante reacción en cadena de la 
polimerasa cuantitativa con transcriptasa inversa (qRT-PCR), la expresión relativa de 
MUC5AC en células HT29-MTX bajo la acción de estos péptidos lácteos. 
Considerando los efectos opioides descritos, cabría esperar que además de 
143AYFYPEL149 e 144YFYPEL149 (Martínez-Maqueda y col., 2013a), la secuencia 
144YFYPE148 pudiera mostrar un efecto estimulatorio sobre la expresión de mucinas. 
Aunque se observó un incremento por encima del nivel basal de las células control, 
este aumento no fue significativo, como ocurrió en el caso de los péptidos 144YFYP147 e 
144YFY146. Por ello, se estableció que el péptido 144YFYPEL149 constituye el fragmento 
mínimo con actividad estimulante sobre la expresión génica de MUC5AC. Nuestros 
resultados muestran una aparente falta de correspondencia entre la actividad opioide 
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en íleon de cobaya y la sobreexpresión de MUC5AC en células HT29-MTX. En este 
sentido, algunos estudios con otros péptidos alimentarios han conseguido caracterizar 
bien esta relación (Zoghbi y col., 2006; Martínez-Maqueda y col., 2013b). Sin embargo, 
en otros trabajos se han obtenido resultados contradictorios entre la interacción 
opioide y la producción de mucinas (Martínez-Maqueda y col., 2012; Plaisancié y col., 
2013; 2015). Por todo ello, se sugiere que el efecto de las proteínas alimentarias y sus 
péptidos derivados sobre la capa mucosa puede estar mediado por más de un 
mecanismo, además del descrito a nivel de los receptores opioides.  
Partiendo de estos resultados, y del estudio de Martínez-Maqueda y col. 
(2013a) en el que se demostró el efecto estimulatorio de los péptidos 143AYFYPEL149 e 
144YFYPEL149, y de un hidrolizado de caseínas con pepsina que los contiene, sobre el 
fortalecimiento de la mucosa intestinal, se planteó evaluar in vivo el efecto de este 
hidrolizado lácteo (Publicación VI). Para ello, el hidrolizado se incorporó a la dieta de 
ratas Zucker durante 8 semanas (0,43 g de hidrolizado/kg/día) y se estudió la 
expresión génica correspondiente a las tres principales mucinas del intestino de rata 
(Muc2, Muc3 y Muc4) y la secreción de contenido mucoso en el lumen digestivo y en 
las heces. Mediante qRT-PCR, se observó que las ratas que habían consumido el 
hidrolizado de caseínas presentaban un aumento significativo en la expresión relativa 
de los genes que codifican para la mucina secretada Muc2 y la mucina de membrana 
Muc3 en el íleon (1,31 y 1,20 veces la expresión basal, respectivamente) y el colon 
(1,51 y 1,47, respectivamente). Plaisancié y col. (2013) demostraron que la 
administración intragástrica en ratas del péptido β-CN f(94-123) (0,01-100 µM) 
incrementaba los niveles de ARNm de los genes Muc2 en el yeyuno (1,39 – 1,52) y 
Muc4 en el duodeno (1,56), yeyuno (1,60 – 1,61) e íleon (1,57), con respecto al 
control, aunque no se describió una actividad dosis-dependiente. A diferencia de 
nuestros resultados, en este trabajo no se encontraron efectos a nivel de la mucosa 
del colon, que cobran especial importancia debido al papel protector que ejerce 
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principalmente la mucina Muc2 en este tejido. Se ha descrito que ratones 
genéticamente deficientes en la mucina Muc2 pueden desarrollar de forma espontánea 
colitis (Van der Sluis y col., 2006) y cáncer colorrectal (Velcich y col., 2002). Por ello, el 
hidrolizado de caseínas utilizado en nuestro estudio podría demostrar un efecto 
particularmente beneficioso a nivel de la mucosa colónica mediante el incremento en 
la expresión de genes correspondientes a las principales mucinas intestinales. Por otro 
lado, este hidrolizado también demostró efectos regulatorios en la secreción de 
mucinas. En comparación con las ratas control, el contenido mucoso fecal a las 2 y 8 
semanas de tratamiento se incrementó en un 129 y 147%, respectivamente. Estos 
resultados son similares a los descritos por Sprong y col. (2010) para proteínas de 
suero lácteo en un modelo animal de colitis inducida. Sin embargo, aunque la cantidad 
de mucinas en el contenido luminal de las ratas alimentadas con el hidrolizado de 
caseínas también fue mayor al de las ratas control (124%), las diferencias encontradas 
no fueron estadísticamente significativas.  
El potencial papel regulatorio que pueden ejercer los componentes alimentarios 
en contacto continuo con la barrera mucosa gastrointestinal había sido propuesto en la 
bibliografía (Moughan y col., 2007; Bischoff y col., 2014). El hidrolizado de caseínas 
empleado en el presente trabajo había mostrado previamente un efecto estimulante, 
con respecto a las células HT29-MTX control, de la secreción de mucinas (210%) y de 
la expresión génica de MUC5AC (1,80) (Martínez-Maqueda y col. 2013a). Estos 
efectos se atribuyeron, principalmente, a los péptidos 143AYFYPEL149 e 144YFYPEL149, 
secuencias que han demostrado actividad opioide en esta memoria (Publicación V). 
Mediante HPLC-MS/MS se cuantificó la presencia del péptido 143AYFYPEL149 en el 
hidrolizado de caseínas (4,1 mg de péptido/g de hidrolizado). Considerando el 
volumen del contenido gastrointestinal de la rata, esta determinación sería 
fisiológicamente compatible con el rango de concentraciones (0,05-0,50 mM) que 
mostró actividad en las células HT29-MTX (Martínez-Maqueda y col. 2013a). Además, 
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tal como describieron estos autores, otros componentes y péptidos del hidrolizado 
podrían contribuir en los efectos descritos. 
 Una gran parte de los trabajos experimentales incluidos en esta Tesis Doctoral 
han contribuido al conocimiento existente acerca de la influencia directa ejercida por el 
proceso digestivo sobre la actividad biológica de las proteínas alimentarias y los 
péptidos derivados (Picariello y col., 2013b; Sánchez-Rivera y col., 2014a). Impulsados 
por este objetivo, se ha publicado en la bibliografía una amplia variedad de 
metodologías para reproducir in vitro las condiciones fisiológicas de la digestión 
gastrointestinal (Guerra y col., 2012). En el ámbito de la Acción COST FA 1005 
INFOGEST, Minekus y col. (2014) propusieron un protocolo consensuado a nivel 
internacional entre distintos grupos de investigación acerca de las condiciones 
estándar a aplicar en estos ensayos de simulación in vitro de la digestión 
gastrointestinal. Por ello, se planteó un estudio comparativo de los resultados 
obtenidos tras la digestión de caseínas y proteínas de suero lácteo mediante dicho 
protocolo y la digestión in vivo a nivel del yeyuno de individuos sanos (Publicación VII). 
Este estudio ha permitido avanzar hacia la validación de las metodologías in vitro con 
datos obtenidos in vivo, lo cual constituye una prioridad reconocida a nivel 
internacional. 
 La degradación que sufrieron las proteínas lácteas durante el proceso digestivo 
se evaluó mediante electroforesis en gel de poliacrilamida (SDS-PAGE). Tal como se 
había encontrado en otras simulaciones in vitro (Dupont y col., 2010; Picariello y col., 
2010; Kopf-Bolanz y col., 2012; Ménard y col., 2014), las caseínas se degradaron 
rápidamente durante la fase gástrica, no detectándose a partir de los 30 minutos con 
este protocolo, mientras que las proteínas de suero β-Lg y α-La resistieron la actividad 
de la pepsina, pero se hidrolizaron completamente tras 60 minutos de fase intestinal. 
En el caso de las muestras obtenidas in vivo, no se detectó la presencia de caseínas 
intactas a nivel del yeyuno, pero sí de β-Lg en algunos individuos, con intensidad 
 
206 Discusión 
variable, 1 y 2 h tras la ingesta de las proteínas de suero. Estos resultados están de 
acuerdo con lo descrito por Mahé y col. (1996), donde se describe que tras la ingesta 
de las proteínas lácteas, mientras las caseínas se degradan completamente, las 
proteínas de suero resisten parcialmente llegando en una forma intacta al yeyuno 
humano. 
 El perfil peptídico de los digeridos obtenidos in vitro/in vivo se analizó mediante 
HPLC-MS/MS, y se elaboraron unos mapas térmicos para facilitar la comparación a 
nivel cualitativo. En general, se observó que la diversidad del peptidoma in vivo era 
mayor a la encontrada in vitro, probablemente debido a la mayor complejidad de las 
condiciones propias de la digestión y a la variabilidad entre los distintos individuos. Por 
otro lado, los resultados encontrados fueron distintos según la proteína láctea 
analizada. Los perfiles peptídicos in vivo e intestinales in vitro de la β-CN fueron 
comparables en todos los tiempos evaluados, predominantemente en las regiones N- y 
C-terminales. Sin embargo, los péptidos procedentes de la región central de la 
proteína, y de una manera más marcada en el caso de la αs1-CN, se identificaron en 
mayor medida en las muestras de la digestión in vivo. Los péptidos derivados de la 
digestión in vitro de la β-Lg se detectaron únicamente en la fase intestinal, de acuerdo 
a lo observado por SDS-PAGE. En este caso, la mayoría de los péptidos encontrados 
pertenecían a la región central, en especial entre los aminoácidos 42-68 y 107-135, 
mientras que en la digestión in vivo se identificó una mayor variabilidad de fragmentos 
que cubrieron la secuencia de la proteína prácticamente en su totalidad. Sin embargo, 
los perfiles peptídicos in vitro/in vivo de la α-La fueron bastante parecidos, 
coincidiendo en las regiones 40-52, 63-68 y 80-90. Merece la pena destacar que en 
este trabajo, al igual que describieron Boutrou y col. (2013), los péptidos obtenidos in 
vivo tras la ingesta de caseínas tendieron a mantener su presencia en el yeyuno 
durante las 4 h del estudio, mientras que el número de los péptidos derivados de 
proteínas de suero disminuyó notablemente después de las 3 h.  
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 Además, la frecuencia de aparición de cada aminoácido de las proteínas 
mayoritarias β-CN y β-Lg se usó para correlacionar los resultados encontrados en los 
digeridos in vitro e in vivo. Al comparar los digeridos intestinales in vitro y los digeridos 
in vivo, los coeficientes de correlación de Spearman variaron entre 0,39 y 0,67 en el 
caso de la β-CN, y entre 0,55 y 0,71 para la β-Lg. Resulta interesante destacar que 
estos coeficientes son del mismo orden a los encontrados entre los distintos individuos 
del estudio: 0,51-0,77 (β-CN) y 0,28-0,77 (β-Lg). Por lo tanto, la comparación llevada a 
cabo entre los resultados in vitro e in vivo podría ser equiparable a la propia variación 
inter-individual.  
Ciertas regiones proteicas, como aquellas ricas en aminoácidos hidrofóbicos y 
residuos de prolina, habían demostrado una especial resistencia al ataque de las 
enzimas digestivas (Hausch y col., 2002). Por ejemplo, el péptido opioide β-CM-7 (β-
CN 60YPFPGPI66) así como varios fragmentos que contenían las secuencias de la β-
CN 74IPPLT78, 83VVPP86, 134HLPLP138, 150PLPP153, 157FPP159, 172PVP174 y 204PFPI207, se 
detectaron tanto en los digeridos in vitro como en los digeridos obtenidos en el yeyuno 
humano. Asimismo, en ambos digeridos, se identificó el péptido derivado de la αs1-CN 
143AYFYPEL149, precursor de secuencias con efecto opioide y estimulante de la 
expresión génica de mucinas intestinales (Publicación V). Este péptido también había 
sido identificado en el estómago de humanos que consumieron leche (Chabance y 
col., 1998). Asimismo, los CPPs han sido descritos como regiones con particular 
resistencia al proceso digestivo (Vegarud y col., 2000; García-Nebot y col., 2010). En 
el presente estudio se llevó a cabo un procedimiento de precipitación selectiva sobre 
los digeridos in vivo de caseínas para favorecer la identificación de regiones 
fosforiladas. Así, se detectó en el yeyuno humano la presencia de varios fragmentos 
fosforilados como aquellos pertenecientes a la región 1-24 de la β-CN, y 42-52, 64-68 
y 110-119 de la αs1-CN. Resulta interesante mencionar que algunas secuencias como 
αs1-CN f(43-52)2P, identificada durante las 4 h de la digestión in vivo en varios 
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individuos, han sido recientemente detectadas en el plasma de humanos tras la 
ingesta de queso (Caira y col., 2016), lo que reforzaría la importancia de su presencia 
en el tracto digestivo.  
 Con el fin de comparar más en profundidad los resultados in vivo/in vitro se 
cuantificó el número de péptidos comunes entre los distintos digeridos. En el caso de 
las caseínas, se identificaron un total de 465 péptidos después de la ingesta in vivo (β-
CN: 176, αs1-CN: 131, κ-CN: 84 y αs2-CN: 74) y 338 tras la simulación in vitro (β-CN: 
97, αs1-CN: 78, κ-CN: 97 y αs2-CN: 66). De todos ellos, 101 secuencias (14,4%) fueron 
idénticas entre ambas digestiones. El mayor porcentaje de péptidos comunes se 
encontró en la proteína β-CN (23,0% del total de los péptidos identificados). Una 
situación similar se encontró para las proteínas de suero con 34 secuencias comunes 
(13,0%) entre las 179 y 117 encontradas in vivo e in vitro, respectivamente.  
La metodología empleada en este trabajo se había presentado como una 
herramienta simple y eficaz para simular in vitro la digestión gastrointestinal (Minekus y 
col., 2014), y su reproducibilidad ha sido demostrada recientemente mediante ensayos 
inter-laboratorio (Egger y col., 2016). Con el presente estudio comparativo se ha 
conseguido avanzar hacia su correlación y validación con resultados obtenidos in vivo. 
Aunque todavía presenta las limitaciones propias de los métodos estáticos de 
simulación gastrointestinal en comparación al conjunto de complejos procesos 
involucrados en el fenómeno de la digestión, los resultados del presente trabajo 
muestran una buena aproximación del método in vitro hacia la digestión fisiológica de 
las proteínas lácteas. 
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CONCLUSIONS 
 
1. Bowman-Birk isoinhibitor 1 exerts a protective effect on lunasin degradation under 
conditions that simulate gastrointestinal digestion. The regions 1SKWQHQQDSC10, 
11RKQLQGVN18, 19LTPCEKHIME28 and 29KIQGRGDDDDDDDDD43 from lunasin 
are particularly resistant to the action of digestive enzymes. 
  
2. It has been demonstrated the absorption of peptide lunasin and the derived 
fragment 11RKQLQGVN18 through Caco-2 cell monolayers, being the paracellular 
pathway the main mechanism involved in the transport of these peptides. 
 
3. Lunasin and some derived fragments identified in its gastric and gastrointestinal 
digests have preventive effects against the growth of gastric cancer AGS and 
colorectal cancer HT-29 and Caco-2 cells. The fragment 1SKWQHQQDSC10 is the 
main responsible for the proved inhibitory activity on cellular viability, especially in 
HT-29 cells. 
 
4. Lunasin exerts a chemopreventive effect in colorectal cancer HCT-116 cells, both, 
the bulk tumor population and the derived cancer stem cells. This effect is mediated 
by inhibiting cell proliferation, inducing apoptosis and arresting cell cycle at G1 
phase. 
 
5. In liver HepG2 cells, peptide lunasin plays a protective role against chemical-
induced oxidative stress. This capacity is modulated through stimulation of 
antioxidant defense cellular systems, and reduction of apoptosis and oxidative 
damage to proteins. 
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6. Milk αs1-casein peptides 
144YFYPEL149 and 144YFYPE148 and, to a lower extent, 
144YFY146 and 143AYFYPEL149 show opioid activity in guinea pig ileum preparations. 
By molecular dynamics simulations, it is demonstrated that the C-terminal proline 
residue from peptide 144YFYP147 affects to its interaction with the μ-opioid receptor 
active binding site, decreasing activity. 
 
7. The peptic casein hydrolyzate that contains the previously identified opioid peptides 
promotes the rat intestinal mucus barrier. This hydrolyzate stimulates gene 
expression of ileal and colonic mucins, Muc2 and Muc3, and induces the secretion 
of fecal mucus material. 
 
8. Protein degradation and peptidome of human jejunal digests from casein and whey 
protein are comparable to those found after in vitro simulated gastrointestinal 
digestion following a harmonized protocol. Spearman correlation coefficients 
between in vivo and in vitro digests are within the range found for the different 
volunteers of the study, suggesting that the in vitro method constitutes a good 
approximation of the physiological digestion of milk proteins. 
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CONCLUSIONES 
 
1. El isoinhibidor-1 de Bowman Birk ejerce un efecto protector frente a la degradación 
del péptido lunasina en condiciones que simulan la digestión gastrointestinal. Las 
regiones de la lunasina 1SKWQHQQDSC10, 11RKQLQGVN18, 19LTPCEKHIME28 y 
29KIQGRGDDDDDDDDD43 son especialmente resistentes a la acción de las 
enzimas digestivas. 
 
2. Se ha demostrado la absorción del péptido lunasina y el fragmento derivado 
11RKQLQGVN18 en un modelo de células Caco-2 en monocapa, siendo la vía 
paracelular el principal mecanismo de transporte para estos péptidos.  
 
3. El péptido lunasina y algunos fragmentos derivados identificados en sus digeridos 
gástricos y gastrointestinales ejercen efectos preventivos frente al crecimiento de 
células de cáncer gástrico AGS y colorrectal HT-29 y Caco-2. La región 
1SKWQHQQDSC10 es la principal responsable de la actividad inhibitoria sobre la 
viabilidad celular, especialmente en células HT-29.  
 
4. El péptido lunasina ejerce un efecto quimiopreventivo en células de cáncer 
colorrectal HCT-116, tanto en la población nativa como en la correspondiente a 
células madre tumorales. Este efecto está mediado por una acción antiproliferativa, 
inductora de la apoptosis y bloqueante del ciclo celular en la fase G1. 
 
5. En células hepáticas HepG2, el péptido lunasina protege frente al estrés oxidativo 
inducido químicamente. Esta protección está modulada por la estimulación de los 
sistemas celulares de defensa antioxidante, y la disminución de la apoptosis 
celular y del daño oxidativo a proteínas. 
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6. Los péptidos lácteos derivados de la αs1-caseína 
144YFYPEL149 e 144YFYPE148 y, en 
menor medida, 144YFY146 y 143AYFYPEL149 presentan actividad opioide en íleon 
aislado de cobaya. Mediante modelización dinámica, se demuestra que la 
presencia de prolina en el extremo carboxi-terminal del péptido 144YFYP147 afecta 
negativamente a su interacción con el centro activo del receptor μ-opioide, 
disminuyendo su actividad. 
 
7. El hidrolizado de caseínas con pepsina que contiene los péptidos opioides 
previamente identificados fortalece la capa mucosa del intestino en un modelo de 
rata. Este hidrolizado estimula la expresión génica de las mucinas Muc2 y Muc3 en 
íleon y colon, y produce un aumento del contenido mucoso fecal. 
 
8. La degradación proteica y el peptidoma de los digeridos de caseínas y proteínas 
de suero obtenidos en yeyuno humano son comparables a los encontrados tras 
aplicar un protocolo de digestión gastrointestinal in vitro consensuado a nivel 
internacional. Los coeficientes de correlación de Spearman obtenidos tras la 
comparación de la digestión in vitro e in vivo son del mismo orden a los 
encontrados entre los distintos individuos del estudio, demostrando que la 
metodología in vitro es una buena aproximación a la digestión fisiológica de 
proteínas lácteas. 
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During food digestion, proteins are hydrolysed into a large variety of peptides. Some of these peptides are
structurally similar to sequences acting in the organism as endogenous signals, or hormones. Therefore,
homologous food peptides can interact with the same receptors or enzymes in the organism, and in this
form, exert an agonistic or antagonistic activity. The evidence of the potential of these dietary peptides to
modulate numerous physiological conditions has been mainly achieved using in vitro assays; however, it
is accepted that health evidence has to be based on in vivo trials (animals or humans) since the activity of
these molecules depends on the ability of these peptides to reach the target tissue in an active form,
which in turn depends on their structure. This article reviews the literature on the physiological effects of
milk-derived bioactive peptides with special emphasis in the evidence achieved in animal and human
trials.
 2013 Elsevier Ltd. All rights reserved.Contents
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the enzyme from the protein mixture reaction and, furthermoreIt is recognised that diet is one of the environmental factors that
inﬂuences our health and the development of certain diseases.
Among the different food components, protein constitutes a major
nutrient with daily ingests between 95 and 120 g of protein, which
is hydrolysed into a large variety of peptides during gastrointestinal
digestion. Some of these peptides share structural characteristics
with endogenous peptides that act in the organism as hormones,
neurotransmitters, or regulatory peptides. These exogenous food-
derived peptides can interact with the same receptors in the or-
ganism and exert an agonistic or antagonistic activity. There are
many examples of food-derived peptides structurally similar to
endogenous peptides; one of the most representative examples is
opioid peptides, which have been demonstrated to behave as
opioid receptors ligands (Teschemacher, 2003). This group of food-
derived bioactive peptides was the ﬁrst described in 1979
(Henschen, Lottspeich, Brantl, & Teschemacher, 1979) and since
then, and especially during the last two decades, much effort has
been dedicated to the identiﬁcation of peptides with different
physiological effects. However, the level of evidence built for these
food peptides is diverse. For instance, for antihypertensive pep-
tides, activity has been demonstrated in animal models and clinical
trials, but for other peptides, bioactivity has been just proven in cell
cultures or in vitro assays. In addition, there are many examples of
lack of correlation between in vitro and in vivo results, mainly due to
further degradation of peptides during gastrointestinal digestion,
or the impossibility to reach the target organ in a sufﬁcient amount
to exert the physiological effect.
On the other hand, absorption of food-derived peptides is not a
requirement to exert a biological function in the organism. The gut
is considered to be the largest endocrine organ in the body with a
large range of endogenous peptides secreted and receptors
expressed. The gastrointestinal tract is in contact with food digests
and therefore, with an important quantity (and variety) of food-
derived peptides. For this reason, the effects of peptides on
different intestinal functions and health are attracting an increasing
interest (Moughan, Fuller, Han, Kies, & Miner-Williams, 2007;
Shimizu & Hachimura, 2011). It cannot be disregarded that given
the low bioavailability described for some bioactive peptides,
certain observed physiological effects might be mediated through
interaction with receptors located at the gut.
The aim of this paper is to review the literature on the physio-
logical effects of milk-derived bioactive peptides with special
emphasis in the evidence achieved in animal and human trials. A
short section deals with the advances on hydrolysis technologies.
Finally, a section with future trends, and challenges on dairy pep-
tides research is included.2. Technology: dairy protein hydrolysates
During the last two decades, there has been a growing interest
in the use of dairy hydrolysates containing bioactive peptides as
agents for maintaining general health and preventing chronic hu-
man diseases. As a result, several technologies, mainly based on the
enzymatic hydrolysis, have been developed for the production of
these bioactive hydrolysates (Hernández-Ledesma, Recio, Ramos, &
Amigo, 2002; Korhonen & Pihlanto, 2006; McDonagh & Fitzgerald,
1998; Phelan, Aherne, Fitzgerald, & O’Brien, 2009). This strategy is
the main choice, but some disadvantages in the method have been
reported, such as the need for using chemical or thermal processes,
to stop the proteolysis reaction that could affect the ﬁnal attributes
of the hydrolysed proteins (Kosseva, Panesar, Kaur, & Kennedy,
2009). Immobilisation of enzyme molecules over differentmaking possible its reuse (Madadlou, Sheehan, Emam-Djomeh, &
Mousavi, 2011; Marqués et al., 2011; Rocha, Gonçalves, & Texeira,
2011). In the food industry, the use of enzymatic membrane re-
actors represents an interesting technology that allows protein
hydrolysis and the subsequent separation of peptides generated by
microﬁltration or chromatography techniques, such as size exclu-
sion or ion-exchange chromatography (Welderufael, Gibson, &
Jauregui, 2012). Some studies have applied these methodologies
for the recovery of caseinophosphopeptides (CPPs), antimicrobial,
and angiotensin-converting enzyme (ACE)-inhibitory peptides
from bovine casein (CN) hydrolysates (Recio & Visser, 1999a; Wu
et al., 2013; Zhao, Xu, Yang, & Katiyo, 2013).
Moreover, alternatively to traditional methods, subcritical water
hydrolysis strategies have been proposed for dairy hydrolysates
productionwithout the need for acids, bases or enzymes. The study
of Espinoza, Morawicki, and Hager (2012) demonstrated success-
fully subcritical water hydrolysis of a whey protein isolate (WPI)
and evaluated how treatment conditions (temperature and reac-
tion time) affected the degree of hydrolysis, and the production,
composition and concentration of peptides and free amino acids
released. In addition, high hydrostatic pressure causes substantial
modiﬁcations to milk proteins, and ultimately inﬂuences their
functional properties. The potential utilities of high pressure
treatments in dairy technologies have been reviewed (Chawla,
Patil, & Singh, 2011; Da Cruz et al., 2010; López-Fandiño, 2006).
As an example, some studies employing high pressure conditions
have yielded protein hydrolysates with enhanced antioxidant and
anti-inﬂammatory effects in intestinal epithelial cells exposed to
hydrogen peroxide (Piccolomini, Iskandar, Lands, & Kubow, 2012).
3. Health beneﬁts
3.1. Effects on the cardiovascular system
Cardiovascular diseases have become a worldwide health
problem that goes beyond socio-economic barriers and equally
affects men andwomen. Diet plays a key role in the development of
the most signiﬁcant risk factors of these diseases, such as hyper-
tension, obesity, diabetes, low-grade systemic inﬂammation, and
atherosclerosis. In recent years, bioactivemilk peptides have gained
interest because of their notable antihypertensive, antioxidant,
anti-inﬂammatory and hypocholesterolaemic effects. In this sec-
tion, the most current scientiﬁc information from cell culture, an-
imal experiments and clinical studies on the role of milk proteins-
derived peptides on cardiovascular diseases is summarised and
discussed.
3.1.1. Antihypertensive peptides
Elevated blood pressure is one of the major independent risk
factors for cardiovascular disease (Erdmann, Cheung, & Schröder,
2008). ACE (EC 3.4.15.1) is one of the main regulators of blood
pressure; thus, inhibition of this enzyme is considered as one of the
strategies for the treatment of hypertension. In recent years, anti-
hypertensive effects of some peptides derived from milk proteins
have been evaluated by in vitro and in vivo studies, becoming the
best known class of bioactive peptides. One of the greatest chal-
lenges in developing milk peptides as antihypertensive food in-
gredients has been proving their in vivo efﬁcacy. It mainly depends
on the capacity of peptides, after being orally ingested, to reach the
target organs in an intact and active form. In the last years, studies
demonstrating the bioavailability of potential antihypertensive
peptides have been carried out. Most of these studies aimed to
evaluating the resistance of bioactive sequences to gastrointestinal
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(Contreras, Sancho, Recio, & Mills, 2012; Picariello et al., 2013;
Quirós, Dávalos, Lasunción, Ramos, & Recio, 2008).
The dairy peptides have been evaluated using spontaneously
hypertensive rats (SHR), and the peptide sequences, doses and
maximum decrease of systolic blood pressure (SBP) have beenTable 1
Antihypertensive activity in spontaneously hypertensive rats of peptide derived milk pro
Procedure Enzyme/microorganism Protein fragment Peptide seq
Hydrolysis Trypsin aS1-CN f(23e34)
aS1-CN f(194e199)
b-CN f(177e183)
CMP f(106e112)
FFVAPFPGV
TTMPLW
AVPYPQR
MAIPPKK
Pepsin aS1-CN f(90e94)
aS1-CN f(143e149)
aS2-CN f(89e95)
aS2-CN f(203e208)
Lfcin f(20e25)
Lfcin f(22e23)
RYLGY
AYFYPEL
YQKFPQY
PYVRYL
RRWQWR
WQ
Gastric and pancreatic
enzymes
a-La f(50e53) YGLF
Pepsin, chymotrypsin and
trypsin
k-CN f(22e24)
k-CN f(61e66)
k-CN f(76e86)
k-CN f(98e105)
IAK
YAKPVA
WQVLPNAV
HPHPHLSF
Proteinase K b-CN f(59e61)
b-CN f(59e64)
b-CN f(80e90)
b-Lg f(78e80)
BSA f(221e222)
VYP
VYPFPG
TPVVVPPFL
IPA
FP
Proteinase of Lb. helveticus
CP790
aS1-CN f(104e109)
aS2-CN f(189e192)
aS2-CN f(190e197)
aS2-CN f(198e202)
b-CN f(140e143)
b-CN f(169e174)
b-CN f(169e175)
YKVPQL
AMPKPW
MKPWIQPK
TKVIP
LQSW
KVLPVP
KVLPVPQ
Thermolysin b-Lg f(58e61)
b-Lg f(103e105)
LQKW
LLF
AS1.398 neutral protease k-CN f(15e18)
k-CN f(25e30)
DERF
RYPSYG
Flavourzyme þ
S. thermophilus and Lb.
bulgaricus
k-CN f(58e61) YPYY
Prozyme 6 and mixture
of lactic acid bacteria
aS1-CN f(162e164)
b-Lg f(17e19)
GVW
GTW
Fermentation Lb. helveticus CPN4 aS1-CN f(146e147) YP
Lb. helveticus and S. cerevisiae b-CN f(74e76)
b-CN f(84e86)
IPP
VPP
E. faecalis b-CN f(58e76)
b-CN f(133e138)
b-CN f(133e139)
b-CN f(134e138)
b-CN f(197e206)
b-CN f(201e209)
LVYPFPGPI
PQNIPP
LHLPLP
LHLPLPL
HLPLP
VLGPVRGP
VRGPFPIIV
Caprine keﬁr b-CN f(58e68) LVYPFTGPI
Manchego cheese aS1-CN f(102e109) KKYNVPQL
Gouda cheese aS1-CN f(1e9)
b-CN f(60e68)
RPKHPIKHQ
YPFPGPIPN
Enzyme-modiﬁed cheese
Lc. lactis NRRL B-50571
Lc. lactis NRRL B-50572
b-CN f(102e104)
k-CN f(98e110)
b-CN f(69e77)
k-CN f(35e40)
b-CN f(194e209)
k-CN f(35e40)
MAP
HPHPHLSFM
SLPQNIPPL
YPSYGL
VLGPVRGP
YPSYGL
a Adapted from Martínez-Maqueda et al. (2012b); SBP, systolic blood pressure.
b Effect observed after administration of casein hydrolysate.summarised in some reviews (Fitzgerald, Murray, & Walsh, 2004;
Hernández-Ledesma, Contreras, & Recio, 2011; Martínez-
Maqueda, Miralles, Recio, & Hernández-Ledesma, 2012b).
As shown in Table 1, two strategies have been used to release
antihypertensive milk peptides: milk protein hydrolysis and
fermentation. Hydrolysates of whole milk protein, caseinates andteins by enzymatic hydrolysis and fermentation.a
uence Dose
(mg kg1)
Decrease in
SBP (mm Hg)
Reference
FGK 100.0
100.0
100.0
10.0
34.0
13.6
10.0
28.0
Karaki et al. (1990)
Miguel, Manso, López-Fandiño,
Alonso, and Salaices (2007)
5.0
5.0
5.0
3.0
10.0
10.0
25.0
20.0
15.0
23.4
16.7
11.4
Contreras et al. (2009)
Recio et al. (2006)
Ruiz-Giménez et al. (2010)
0.1 23.4 Nurminen et al. (2000)
PAK
4.0
6.0
7.0
10.0
20.7
23.1
18.4
15.7
Miguel, Gómez-Ruiz, Recio,
and Aleixandre (2010)
QP
8.0
8.0
8.0
8.0
8.0
21.0
22.0
8.0
31.0
27.0
Abubakar et al. (1998)
2.0
2.0
2.0
2.0
2.0
2.0
2.0
13.0
5.0
3.0
9.0
2.0
32.2
31.5
Maeno et al. (1996)
10.0
10.0
18.1
29.0
Hernández-Ledesma et al. (2007)
300.0b
e
n.d.b
e
Jiang et al. (2010)
3.4 15.9 Tsai et al. (2008)
3.3 22.0 Chen et al. (2007)
2.0 32.1 Maeno et al. (1996)
0.3
0.6
28.3
32.1
Nakamura, Yamamoto, Sakai,
Okubo et al. (1995);
Nakamura, Yamamoto, Sakai,
and Takano (1995)
PNSL-
FP
6.0
3.0
10.0
7.0
10.0
10.0
14.9
25.3
7.7
23.5
16.2
16.1
Miguel et al. (2006);
Quirós et al. (2007)
PN 10.0 28.0 Miguel et al. (2010)
10.0 11.5 Miguel et al. (2010);
Gómez-Ruiz, Ramos,
and Recio (2002)
6.1
7.5
9.3
7.0
Saito, Nakamura, Kitazawa,
Kawai, and Itoh (2000)
AIPP
FP
3.0
35.0
50.0
e
17.0
17.7
16.7
e
Tonouchi, Suzuki, Uchida,
and Oda (2008)
Rodríguez-Figueroa et al. (2012, 2013)
Rodríguez-Figueroa et al. (2012, 2013)
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combination, have shown antihypertensive activity in SHR. As an
example, the tryptic CN hydrolysate containing the peptide corre-
sponding to aS1-CN f(23e34) has been patented and commercial-
ised as antihypertensive agent under the name of peptide C12.
More recently, in a pepsin casein hydrolysate, two peptides derived
from aS1-CN, with sequences RYLGY and AYFYPEL, have demon-
strated potent SBP reducing effects in SHR (Contreras, Carrón,
Montero, Ramos, & Recio, 2009). The action of pepsin is also
required to release the antihypertensive fragments RRWQWR and
WQ from peptide lactoferricin (LFcin) (Ruiz-Giménez et al., 2010).
Combination of gastric and pancreatic enzymes has been reported
to be a successful strategy to produce potent antihypertensive
peptides from milk proteins (Gómez-Ruiz, Ramos, & Recio, 2007;
Nurminen et al., 2000). Similarly, the use of food-grade enzymes
derived from microorganisms have become usual for the release of
peptides with demonstrated SBP reducing effects in SHR (Abubakar,
Saito, Kitazawa, Kawai, & Itoh, 1998; Chen, Tsai, & Pan, 2007;
Hernández-Ledesma, Miguel, Amigo, Aleixandre, & Recio, 2007;
Jiang, Tian, Brodkorb, & Huo, 2010; Maeno, Yamamoto, & Takano,
1996; Tsai, Chen, Pan, Gong, & Chung, 2008) (Table 1).
Another strategy to produce antihypertensive peptides is the
use of the proteolytic system of lactic acid bacteria proteins during
the elaboration of fermented milks and cheeses. The most repre-
sentative example is the production of the b-CN-derived peptides,
IPP and VPP, in sour milk fermented by Lactobacillus helveticus and
Saccharomyces cerevisiae (Calpis) with potent decreasing effects
on the SBP of SHR (Nakamura et al., 1995; Nakamura, Yamamoto,
Sakai, & Takano, 1995). Other peptides derived from b-CN
released after milk fermentation with Enterococcus faecalis, with
sequences LHLPLP and HLPLP, have also shown antihypertensive
effect in this rat model (Miguel, Recio, Ramos, Delgado, &
Aleixandre, 2006; Quirós et al., 2007). In recent studies, fer-
mented milks with Lactococcus lactis NRRLB-50571 and NRRLB-
50572 have presented important SBP, diastolic blood pressure
(DBP), and heart rate-lowering effects in SHR (Rodríguez-Figueroa,
González-Córdova, Torres-Llanez, Garcia, & Vallejo-Cordoba, 2012;
Rodríguez-Figueroa, González-Córdova, Astiazaran-Garcia, Her-
nández-Mendoza, & Vallejo-Cordoba, 2013).
Most of the human intervention studies have focused on the
tripeptides IPP and VPP. Two meta-analyses performed with the
published data of 17 and 12 clinical trials have been reported by
Pripp (2008) and Xu, Qin, Wang, Li, and Chang (2008), respectively.
These meta-analyses have reported an average decrease in SBP of
5.1 and 4.8 mm of Hg, respectively. A recent meta-analysis carried
out with 28 clinical trials has reported a mean reduction of SBP of
1.66 mm of Hg (Qin et al., 2013). However, other clinical trials have
reached controversial results. In fact, Engberink et al. (2008) and
Usinger, Jensen, Flambard, Linnneberg, and Ibsen (2010) did not
ﬁnd an effect on human blood pressure in Dutch and Danish sub-
jects when they daily consumed fermented milks containing pep-
tides IPP and VPP. Recently, the meta-analysis of Cicero, Gerocarni,
Laghi, and Borghi (2011), which included 18 trials, has reported that
IPP and VPP reduce SBP in Asian subjects while this effect was
lower in Caucasian individuals. Moreover, Cicero, Aubin, Azais-
Braesco, and Borghi (2013) have found that these peptides can
signiﬁcantly decrease SBP in European subjects, as previously
shown in Japanese subjects, although the effects were more note-
worthy in middle-age adults. These ﬁndings suggest that genetics
and/or dietary patterns might exert an important inﬂuence on the
antihypertensive effects of peptides IPP and VPP, with further
studies being needed to conﬁrm this hypothesis. Moreover, the
European Food Safety Authority (EFSA) Panel on Dietetic Products,
Nutrition and Allergies (NDA) (ESFA, 2009) has concluded that the
evidence presented to date on the antihypertensive effects ofpeptides VPP and IPP is insufﬁcient to establish a cause/effect
relationship between the consumption of these peptides and the
maintenance of normal blood pressure and, therefore, further
studies are required.
Other milk protein-derived hydrolysates and peptides have
been tested in clinical trials. The consumption of a whey protein
hydrolysate for 6 weeks resulted in a reduction of SBP and DBP of
hypertensive subjects, although peptides responsible for the
observed effects have not been identiﬁed yet (Pins & Keenan,
2006). More recently, it was reported that peptides RYLGY and
AYFYPEL could also reduce blood pressure in hypertensive
humans (Recio et al., 2011). A yoghurt enriched with these
peptides was administrated to 71 hypertensive subjects (divided
in placebo and active substances groups), and 50 normotensive
volunteers that only received active substance. After 6 weeks of
consumption, the hypertensive patients showed a notable
reduction in their SBP, while no signiﬁcant changes in blood
pressure were detected in both the placebo and the normoten-
sive groups.
3.1.2. Anti-inﬂammatory and antioxidant properties of peptides
Chronic inﬂammation is involved in many age-related diseases,
such as atherosclerosis, vascular diseases, arthritis, cancer, diabetes,
osteoporosis, dementia, obesity, and metabolic syndrome (Yu &
Chung, 2006). Different cytokines play a pivotal role as mediators
in the production of biomarkers implied in the progression of
inﬂammation and the endothelial dysfunction. The down-
regulation of these cytokines by food components, including pep-
tides, may retard or alleviate inﬂammation, thus exerting beneﬁcial
effects against cardiovascular diseases (Tompa et al., 2010). To date,
only the commercial peptide NOP-47, derived from whey, has
demonstrated in a clinical study to enhance the vascular function
by modulating glucose levels and biomarkers of inﬂammation and
oxidative stress in healthy individuals (Ballard et al., 2009).
In vitro, a preliminary study using lipopolysaccharide (LPS)-
stimulated murine peritoneal macrophages suggests the potential
role of a yak CN hydrolysate with alcalase to prevent inﬂammation-
related disorders because of its ability to reduce the secretion of
pro-inﬂammatory cytokines, and the production of nitric oxide
(NO). Also, this hydrolysate has demonstrated to exert radical
scavenging activity that might contribute to its beneﬁcial proper-
ties (Mao, Cheng, Wang, & Wu, 2011).
Obesity is accompanied by low-grade chronic inﬂammation in
different tissues such as adipose tissue, liver, pancreas, muscle and
brain (Troncon Rosa, Zulet, Marchini, & Martínez, 2012). The in-
ﬂammatory response associated to obesity provokes the activation
of cytokines and transcriptional factors, and the penetration of
macrophages in the adipose tissue, resulting in an unresolved
response associated with insulin resistance, endothelial dysfunc-
tion and subsequent cardiovascular disorders (Chung et al., 2009).
Dietary interventions targeted at reducing adipose tissue inﬂam-
mation can be a valuable alternative for improving the general
metabolic proﬁle (Siriwardhana et al., 2013). However, Pal and Ellis
(2010, 2011) did not observe signiﬁcant reductions in inﬂammatory
biomarkers of overweight and obese subjects after neither acute
nor chronic supplementation with sodium caseinate or WPI
compared with the controls. These results are in agreement with
those reported by Lee, Skurk, Hennig, and Hauner (2007) that did
not show any signiﬁcant difference after administration of skim-
med milk to mild hypertensive subjects. These authors suggested
that potential bioactive peptides could be hydrolysed by intestinal
or plasma peptidases, losing their anti-inﬂammatory activity. The
lack of concluding ﬁndings makes difﬁcult guaranteeing the anti-
inﬂammatory activity of peptides derived from CN or whey pro-
teins, and more studies are needed to conﬁrm it.
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evolution of cardiovascular diseases. Natural antioxidants provide
additional beneﬁts to the endogenous defence strategies in the
battle against oxidative stress (Erdmann et al., 2008). Food-derived
peptides have shown to be potent antioxidants without important
side effects (Sarmadi & Ismail, 2010), with milk proteins being one
of the most frequently studied sources. To date, many antioxidant
peptides derived from both CN and whey proteins have been
characterised by in vitro chemical assays (Pihlanto, 2006; Power,
Jakeman, & Fitzgerald, 2013). These assays are restricted because
of their limited similarity to physiological conditions, and further
studies are needed to conﬁrm the demonstrated effects. In the last
few years, cell cultures have being used to assess the potential
health effects of antioxidant milk-derived hydrolysates and/or
peptides. These models are useful because they allow evaluation of
additional factors such as peptide bioavailability and metabolism
besides biological activity. However, to our knowledge, no cell
culture experiments demonstrating the antioxidant activity on the
cardiovascular system have been conducted.
The results of animal experiments and human trials suggest that
fermented milk products may exert antioxidant effects associated
to cardiovascular beneﬁts. Zommara, Tougo, Sakanao, and
Imaizumi (1998) found that fermented milk produces an anti-
peroxidative action on rats fed a vitamin-E deﬁcient diet. More-
over, the consumption of fermented goat milk by healthy in-
dividuals improved the total plasma antioxidant activity, lowered
the levels of oxidised low density lipoprotein, isoprostanes and the
glutathione redox ratio, and prolonged the resistance of the lipo-
protein fraction to oxidation, resulting in the improvement of the
anti-atherogenicity (Kullisaar et al., 2003). Although the com-
pounds responsible for these effects have not been identiﬁed yet,
peptides released during milk fermentation might have a key
function. Consequently, further studies elucidating the role of
antioxidant peptides in the protective activity of fermented milks
on the cardiovascular system are needed.
3.1.3. Hypocholesterolaemic peptides
Diet plays a key role in plasma lipids proﬁle, and consequently it
is used as a strategy to prevent or decrease the incidence of car-
diovascular diseases (Erdmann et al., 2008). It was observed that
whey protein displayed a hypocholesterolaemic effect in rats after
the ingestion of cholesterol free or cholesterol-enriched diets
compared to CN or soybean proteins enriched diets (Nagaoka,
Kanamaru, & Kuzuya, 1991; Nagaoka, Kanamaru, Kuzuya, Kojima,
and Kuwata, 1992). This effect was conﬁrmed when a tryptic hy-
drolysate of b-lactoglobulin (b-Lg) was administered to rats fed a
diet rich in cholesterol. A notable reduction in the cholesterol level
as well as an increase of the high density lipoproteinsecholesterol
content, and of the excretion of fecal steroid was observed
(Nagaoka et al., 2001).
A peptide called lactostatin, IIAEK, corresponding to fragment
f(71e75) of b-Lg, obtained from its tryptic hydrolysate, showed
hypocholesterolaemic activity in rats, being this effect higher than
that showed by b-sitosterol (Nagaoka et al., 2001). Another b-Lg
derived peptide, b-lactotensin (HIRL), obtained by hydrolysis with
chymotrypsin, decreased total cholesterol and low density lipo-
proteins plus very low density lipoproteinsecholesterol content in
mice fed a cholesterol-enriched diet (Yamauchi, Ohinata, &
Yoshikawa, 2003). The exact mechanisms involved in the hypo-
cholesterolaemic activity of these peptides have not been eluci-
dated yet, but the preliminary results suggested that the amino acid
composition may play a key inﬂuence (Erdmann et al., 2008).
However, more studies are clearly needed to conﬁrm the results,
especially in humans determining the exact mechanism of this
action.3.2. Effects on intestinal health
The intestine is an organ responsible for nutrient absorption,
barrier functions, signal recognition, and the production of
endogenous active molecules. Many physiological actions are
known to be regulated by hormones or cytokines, but substances
contained in the diet are also thought to play a role asmodulators of
intestinal functions. Peptides derived from milk proteins are a
group of substances with potential effects at gastrointestinal level
through different mechanisms of action. They have been shown to
exert protective actions on intestinal mucus, modulatory effects of
mineral absorption, and anti-inﬂammatory, antidiabetic, and sati-
ating activities.
3.2.1. Protective effect on the gut mucosa
The protective properties of the gastrointestinal mucus gel are
attributed to its principal component, mucins, high molecular
weight glycoproteins secreted by goblet cells. Disruption of the
structure of this mucus has important physiological implications
(Corﬁeld et al., 2000; Linden, Sutton, Karlsson, Korolik, &
McGuckin, 2008), and strong evidence was reported when spon-
taneous colitis and colon cancer were developed in mice geneti-
cally deﬁcient in the mucin gene Muc2 (Van der Sluis et al., 2006;
Velcich et al., 2002).
Although intestinal epithelial cells functions are usually
controlled by endogenous agents, it is worth mentioning that these
cells come into continuous contact with high concentrations of
food components and substances along the gut luminal surface;
hence, they might be also regulated by external factors, such as
nutrients (Gibson & Muir, 2005; Moughan et al., 2007). Interest-
ingly, some dietary compounds have proven capacity to positively
inﬂuence the protective properties of the mucus gel layer
(Montagne, Piel, & Lalles, 2004). Dairy proteins, hydrolysates, and
peptides have been demonstrated to modify the dynamics of
mucus mainly via inﬂuencing the mucin secretion and expression,
and the number of goblet cells. The published studies showing
evidence of these bioactivities in ex-vivo, in vitro and/or in vivo
assays are summarised in Table 2.
In the ﬁrst studies carried out using an ex-vivo preparation of rat
jejunum, CN and a-lactalbumin (a-La) hydrolysates evoked an in-
crease in the mucin secretion, while native CN did not produce any
effect (Claustre et al., 2002; Trompette et al., 2003). The peptide b-
casomorphin 7, derived from b-CN, showed a strong rise in the
mucin glycoprotein secretion. Since the observed effects were
abolished by pre-treatment with opioid antagonist naloxone, it has
been suggested that the activity might be mediated by interaction
with opioid receptors. Additionally, Zoghbi et al. (2006) demon-
strated that b-casomorphin 7 signiﬁcantly enhanced the mucin
secretion and stimulated the expression of mucin Muc2 and Muc3
genes in rat intestinal cells DHE, and MUC5AC gene in human in-
testinal cells HT29-MTX. Recently, a whey protein hydrolysate rich
in b-Lg-derived peptides was found to induce mucin secretion and
MUC5AC gene expression in HT29-MTX cells (Martínez-Maqueda,
Miralles, Ramos, & Recio, 2013b). Among the peptides contained
in this hydrolysate, sequence b-lactorphin was identiﬁed as the
major responsible for the observed effects. Cells exposed to b-lac-
torphin increased their mucin synthesis, whereas no signiﬁcant
differences were observed in the MUC5AC expression analysis
(Martínez-Maqueda et al., 2013b). The stimulatory effect of a CN
hydrolysate has been also assessed in HT29-MTX cells byMartínez-
Maqueda, Miralles, Cruz-Huerta, and Recio (2013a). The hydroly-
sate and two aS1-CN-peptides contained in it, promoted the mucin
output via inducing mucin-like glycoprotein secretion andMUC5AC
over-expression. Similarly, Plaisancié et al. (2013) have evaluated
the impact of a total peptide pool from commercial yoghurt in
Table 2
Dairy proteins, hydrolysates and peptides carrying biological activities related to gastrointestinal mucosal protection.
Ex-vivo/in vitro/in
vivo assays
Protein fragment/
hydrolysatea
Peptide
sequence
Doseb Mechanisms of action/effects % of controlsc Reference
Preparation of isolated
vasculary perfused
rat jejunum
CN hydrolysate e 0.5d Induction of jejunal mucin secretion 417 Claustre et al. (2002)
a-La hydrolysate e 5.0d Induction of jejunal mucin secretion 335 Claustre et al. (2002)
b-CN f(60e63) YPFP 0.001 Induction of jejunal mucin secretion N.R. Trompette et al. (2003)
b-CN f(60e63) YPFP-NH2 0.001 Induction of jejunal mucin secretion 445 Trompette et al. (2003)
b-CN f(60e66) YPFPGPI 0.120 Induction of jejunal mucin secretion 563 Claustre et al. (2002)
b-CN f(60e66) YPFPGPI 0.120 Induction of jejunal mucin secretion 555 Trompette et al. (2003)
Rat intestinal
mucin-producing
cells (DHE)
b-CN f(60e66) YPFPGPI 0.100 Induction of mucinlike glycoprotein secretion
Mucin genes Muc2 and Muc3 overexpression
227
225/208
Zoghbi et al. (2006)
Human intestinal
mucin-producing
cells (HT29-MTX)
CN hydrolysate e 0.1d Induction of mucinlike glycoprotein secretion
Mucin gene MUC5AC overexpression
210
180
Martínez-Maqueda et al. (2013a)
WPC hydrolysate e 0.1d
1.0d
Induction of mucinlike glycoprotein secretion
Mucin gene MUC5AC overexpression
152
153
Martínez-Maqueda et al. (2013b)
aS1-CN f(143e149) AYFYPEL 0.050
0.100
Induction of mucinlike glycoprotein secretion
Mucin gene MUC5AC overexpression
162
174
Martínez-Maqueda et al. (2013a)
aS1-CN f(144e149) YFYPEL 0.050
0.500
Induction of mucinlike glycoprotein secretion
Mucin gene MUC5AC overexpression
166
179
Martínez-Maqueda et al. (2013a)
b-CN f(51e55) YPFVE 0.100 Induction of mucinlike glycoprotein secretion 234 Martínez-Maqueda et al. (2012a)
b-CN f(60e66) YPFPGPI 0.100 Induction of mucinlike glycoprotein secretion
Mucin gene MUC5AC overexpression
163
176
Zoghbi et al. (2006)
b-CN f(94e123) GVSKVKEAM
APKHKEMPF
PKYPVEPFTESQ
0.10e Induction of mucinlike glycoprotein secretion
Mucin genes MUC2 and MUC4 overexpression
N.R.
N.R.
Plaisancié et al. (2013)
a-La f(50e53) YGLF-NH2 0.10
0.50
Induction of mucinlike glycoprotein secretion
Mucin gene MUC5AC overexpression
201
160
Martínez-Maqueda et al. (2013a)
b-Lg f(102e105) YLLF 0.50 Induction of mucinlike glycoprotein secretion 174 Martínez-Maqueda et al. (2013b)
b-Lg f(102e105) YLLF-NH2 0.10
0.50
Induction of mucinlike glycoprotein secretion
Mucin gene MUC5AC overexpression
453
222
Martínez-Maqueda et al., 2012a
Martínez-Maqueda et al., 2013b
Rat gastric epitelial
cells (RGM1)
a-La protein e 3.0f Stimulate mucin synthesis, mucin secretion
and prostaglandin E2 synthesis
123/119/140 Ushida, Shimokawa,
Toida, Matsui, and Takase (2007)
Supplementation
in the diet of rats
CN hydrolysate e 114g Average daily gain, average daily food intake,
gain:feed ratio and ileal endogenous
nitrogen ﬂow enhanced
Upregulation of mucin genes Muc3 in the
small intestine and Muc4 in the colon
410/149/270
277/325
Han et al. (2008)
Cheese whey
protein
e 160g Protection against DSS-induced colitis:
decrease in mucosal and luminal markers
of colitis, and faecal mucin excretion and
faecal microbiota enhanced
N.R. Sprong et al. (2010)
Intragastric
gavage in rats
WPI e 0.75g Protection against ethanol-induced
ulcerative lesions: reduction of
ulcerative lesion index and plasma gastrin,
and stimulation of gastric mucus production
74/38
168
Castro, Carvalho, Tinti,
Possenti, and Sgarbieri (2010)
a-La protein e 0.30g Increase the thickness of the mucus gel
layer in corpus and antrum gastric mucosa
163/164 Ushida et al. (2007)
a-La hydrolysate e 0.20g Protection against indomethacin-
induced ulcerative
lesions: induction of gastric mucus
production and prostaglandin
E2 biosynthesis
134/536 Mezzaroba et al. (2006)
b-CN f(94e123) GVSKVKEAMA
PKHKEMPFPK
YPVEPFTESQ
0.01e
0.10e
0.100
Upregulation of duodenal and
ileal Muc4 mRNA expression
Increase in the duodenal goblet
cells recount
Upregulation of jejunal Muc2
mRNA expression
Increase in the jejunal and ileal
goblet cells recounts
Upregulation of jejunal Muc4
mRNA expression
156/157
133
152
143/134
161
Plaisancié et al. (2013)
a WPC, whey protein concentrate.
b Dose given in mM except where otherwise indicated.
c Maximum effect within the different treatment conditions assessed; N.R., non-reported.
d Dose is weight/volume.
e Dose is mM.
f Dose is mg mL1.
g Dose is g kg1.
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the mRNA levels of MUC2 and MUC4 genes. The b-CN fragment
f(94e123) was suggested to be responsible for the reported bio-
activities after evaluating its effects in intestinal cells and in rats.
Oral administration of this peptide to rats yielded an increase in the
goblet cells counts, modiﬁed Muc2 and Muc4 mRNA expression,
and ultimately improved gut mucosa protection by enhancing
crypts containing Paneth cells and increasing the number of rat
defensin 5 and lysozyme (LZ) mRNA transcripts in the rat small
intestine (Plaisancié et al., 2013).
Other in vivo studies have also pointed to the regulation of the
protective mucus layer by dairy proteins and their degradation
products. A diet containing a CN hydrolysate as the exclusive source
of nitrogen was given to rats in which enhancements in the ileal
endogenous nitrogen ﬂow and in the expression of Muc3 in the
small intestine, and Muc4 in the colon were observed (Han,
Deglaire, Sengupta, & Moughan, 2008). In the study of Sprong,
Schonewille, and van der Meer (2010), the protective effect of
cheese whey proteinwas examined in the dextran sulphate sodium
(DSS)-induced model of rat colitis. After seven days of DSS con-
sumption, rats fed the cheese whey protein diet showed lower
levels for both mucosal and luminal markers of colitis. Although
faecal mucin excretion was higher, expression ofMuc2 in the colon
was not statistically different from controls. Incorporation of cheese
whey protein to the diet also resulted in an increase of the counts of
protective microbiota species. Interestingly, one group of rats fed a
diet consisting in CNwith threonine/cysteine supplementationwas
included in the study, and the observed protection against DSS-
induced colitis was similar to the rats fed the cheese whey pro-
tein diet (Sprong et al., 2010). It was therefore suggested that re-
ported beneﬁcial effects of cheese whey protein might be due to its
high threonine and cysteine content. In this context, availability of
speciﬁc amino acids like threonine, cysteine, proline and serine has
been shown to be important to increase the number of Muc2-
containing goblet cells, up-regulate the mucin synthesis, and
restore the bowel microbiota, thus helping colonic defences and
mucosal healing in DSS-treated rats (Faure et al., 2006).
3.2.2. Modulatory peptides of mineral absorption
Mineral deﬁciencies are the most important nutritional prob-
lems worldwide, with the iron deﬁciency being the most common.
This disorder happens when the mineral ingestion from diet does
not meet a daily need of minerals. In this context, the mineral
fortiﬁcation is one of the best and most common strategies to
prevent this deﬁciency (Zimmermann & Hurrell, 2007). It has been
proposed that the phosphorylated regions released from CN during
digestion, CPPs, could increase mineral solubility at intestinal pH,
modulating its bioavailability (Meisel & Fitzgerald, 2003). Several
authors have demonstrated the release of CPPs in rats and minipigs
after the ingestion of CN (Kasai, Iwasaki, Tanaka, & Kiriyama, 1995;
Meisel & Frister, 1988, 1989; Naito & Suzuki, 1972, 1974; Sato,
Noguchi, & Naito, 1986; Sato, Shindo, Gunshin, Noguchi, & Naito,
1991). In humans, the liberation of CPPs has been reported after
consumption of milk, yogurt, and CN (Boutrou et al., 2013;
Chabance et al., 1998; Meisel et al., 2003). Also, CPPs have been
demonstrated to resist further degradation by digestive enzymes
and enteric bacteria in both rats and humans (Brommage, Juillerat,
& Jost, 1991; Hirayama, Toyota, Hidaka, & Naito, 1992; Kasai et al.,
1995; Meisel et al., 2003). Regarding the in vivo studies with CPP
preparations, several authors have reported an increase of the
soluble calcium concentration in the intestine of rats due to CPPs
released from CN contained in the diet, which should improve the
absorption of this mineral (Kitts, Yuan, Nagasawa, & Moriyama,
1992; Lee, Noguchi, & Naito, 1979, 1980, 1983; Sato, Noguchi, &
Naito, 1983; Sato et al., 1986). However, the results of studies onthe inﬂuence of CPPs upon calcium absorption in humans and
animal models are controversial.
The addition of a pool of CPPs to aqueous solutions and infant
foods containing phytate increased calcium absorption in rat pups
after gastric intubation, being able to overcome the negative effect
of phytate on its absorption (Hansen, Sandström, & Lönnerdal,
1996). In agreement with this result, in rats fed an isolated soy
protein-based diet supplemented with CPPs and calcium, an in-
crease of calcium absorption was reported, although the effect was
not dose dependent (Saito, Lee, & Kimura, 1998). In contrast, diet
supplementation with CPPs and calcium did not improve calcium
absorption in growing pigs fed a soy-based diet (Pointillart &
Guéguen, 1989), in rats fed a whey protein-based diet (Brommage
et al., 1991; Kopra, Scholz-Ahrens, & Barth, 1992; Scholz-Ahrens,
Kopra, & Barth, 1990), or in rats fed an experimental diet contain-
ing mainly egg albumin, corn starch, and glucose (Bennett et al.,
2000; Tsuchita, Goto, Yonehara, & Kuwata, 1995). In ovariectom-
ised rats, used as a postmenopausal bone loss model, calcium ab-
sorption was enhanced in the ﬁrst three days when CPPs derived
from b-CN and calcium (at higher doses) were supplemented
(Tsuchita, Sekiguchi, Kuwata, Igarashi, & Ezawa, 1993). No effects of
CPPs upon calcium absorption was observed in rats after adminis-
tration by gastric intubation of non-fortiﬁed milk while an increase
was observed when administered milk was fortiﬁed with calcium
(Mora-Gutierrez, Farrell, Attaie, McWhinney, & Wang, 2007;
Tsuchita, Suzuki, & Kuwata, 2001). Using a ligated duodenal loop
technique, CPPs increased calcium absorption in rachitic and
normal chicks (Mykkänen & Wasserman, 1980), and rats (Kitts
et al., 1992; Sato et al., 1986). These results are in disagreement
with the observations of Yuan and Kitts (1991) in the same model,
who did not observe any difference on calcium absorption after
addition of CPPs to CN or soybean enriched diets. The controversial
results obtained in the abovementioned studies could be caused by
several factors inﬂuencing the effect of CPPs, such as the animal
model, physiological status of the individuals, type of diet and its
calcium or vitamin D content, source and composition of CPPs, and
the length of the assay, among others.
In humans, an increase of calcium absorption has been shown
due to the addition of CPPs to rice-based cereal, although the effect
was not observed after addition to whole-grain cereal or to three
different meals with different calcium and phytate contents
(Hansen, Sandström, Jensen, & Sorensen, 1997a,b). It has been not
observed inﬂuence of CPPs upon calcium bioavailability after their
ingestionwith milk (López-Huertas et al., 2006; Narva, Kärkkäinen,
Poussa, Lamberg-Allardt, & Korpela, 2003) or with a drink of cal-
cium lactate (Teucher et al., 2006). In contrast, Heany, Saito, and
Orimo (1994) showed a positive role of CPPs in postmenopausal
women with low calcium absorption capacity, despite the fact that
this effect was not observed in women with normal absorption
capacity of this mineral.
CPPs bound to calcium salts have been also found to be useful to
remineralise the teeth of mammals, displaying anticariogenic ef-
fects when added to dentifrices, oral care products, chewing gum or
other confectionery foods (Luo & Wong, 2004). In human trials,
synthetic nanocomplexes of CPPs and calcium salts incorporated in
mouth rinses and sugar-free chewing gums have been proven to be
potential anticariogenic agents (Reynolds, Cai, Shen, & Walker,
2003).
Concerning the iron bioavailability, a positive inﬂuence of CPPs
on this parameter has been reported, reﬂected in an increase in the
haemoglobin and haematocrit levels, as well as in the iron liver
storage when iron deﬁcient rats were supplemented with iron and
hydrolysed b-CN or b-CN fragment f(1e25)4P (Aït-Oukhatar et al.,
1997, 1999). Likewise, the blood iron levels were increased in rats
after ingestion of iron bound to hydrolysed CN (Chaud et al., 2002).
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loop system, in which the iron bound to b-CN f(1e25)4P increased
the absorption of this mineral in iron deﬁcient and non-iron deﬁ-
cient rats (Aït-Oukhatar et al., 2002; Ani-Kibangou et al., 2005;
Bouhallab et al., 2002; Pérès et al., 1997; Pérès, Bouhallab, Bureau,
Neuville et al., 1999; Pérès, Bouhallab, Bureau, Maubois et al., 1999).
In addition, diverse fractions of CPPs exerted different effects on
iron absorption, being this effect higher when the iron was bound
to b-CN fractions than to aS-CN fractions (Bouhallab et al., 2002;
Kibangou et al., 2005), suggesting the inﬂuence of the structural
characteristics and conformations of CPPs on their capacity to
improve the iron bioavailability.
In humans, the effect of CPPs on iron bioavailability is contro-
versial. Whereas Hurrell, Lynch, Trinidad, Dassenko, and Cook
(1989) reported an improvement of iron absorption after the
intake of hydrolysed CN, Aït-Oukhatar et al. (2002) did not observe
any effect after the ingestion of iron bound to b-CN f(1e25). In vivo
studies with other minerals, such as zinc, have also found variable
results. Hansen et al. (1996) reported an increased zinc absorption
in rat pups after the addition of CPPs to aqueous solutions and in-
fant foods containing phytate, avoiding the negative effect of this
compound on zinc bioavailability. However, no effect was reported
from soybean protein based diet containing CPPs in rats (Matsui,
Okumura, & Yano, 2002). As observed for calcium, zinc absorption
was reported to increase when CPPs were added to rice-based
cereal. However, no effects were observed when CPPs were added
to whole-grain cereal or three different meals with different cal-
cium and phytate contents (Hansen et al., 1997a,b). These results
indicate that the effects of CPPs can be inﬂuenced by factors, such as
the food matrix, i.e., liquid or solid diet, as well as the phytate
content (Miquel & Farré, 2007).
3.2.3. Anti-inﬂammatory peptides at gastrointestinal level
Inﬂammatory bowel disease is a chronic and degenerative
condition comprising a group of disorders, being the ulcerative
colitis and Crohn’s disease the most relevant both in incidence and
prevalence. Although the aetiology of this disease remains un-
known, it has been demonstrated that genetic, immunological,
environmental, and lifestyle factors are implied (Bernstein et al.,
2009). Currently, inﬂammatory bowel disease is mainly treated
with drugs that suppress the immune system. However, the mul-
tiple adverse effects shown by these drugs havemade that their use
is limited and selective to a small number of patients. To avoid these
limitations, new and natural treatments without side effects are
being searched and developed (Sánchez deMedina et al., 2010). The
most extensively studied peptide for its activity against intestinal
inﬂammation is the bovine caseinomacropeptide (CMP). In recent
years, different animalmodels of intestinal inﬂammation have been
used to provide evidence on the anti-inﬂammatory effect of CMP at
gastrointestinal level. The activity of this peptide in mice with co-
litis and ileitis induced by 2,4,6-trinitrobenzene sulphonic acid
(TNBS), a model that shares important similarities with human
Crohn’s disease has been established (Daddaoua et al., 2005;
Requena et al., 2008). Recently, the effects have been assessed in
the DSS-induced model of rat colitis (López Posadas et al., 2010).
These studies also evaluated the mechanism of action of CMP
indicating that it mainly acts on the inﬂammatory/immune
response by the activation of macrophages, favouring the differ-
entiation of regulatory T cells and limiting the activation of T helper
1 cells (Sánchez de Medina et al., 2010).
Preliminary studies have shown the anti-inﬂammatory effect of
b-CN hydrolysates by Lactobacillus delbrueckii ssp. lactis CRL581 in a
murine TNBS-induced colitis model (Espeche Turbay, deMoreno de
LeBlanc, Perdigón, Savoy de Giori, & Hebert, 2012). Thus, these re-
sults suggest that other milk peptides in addition to CMP might actas protective agents on intestinal inﬂammation, and further studies
focused on the identiﬁcation of potentially responsible sequences,
and the evaluation of their mechanism of action should be
designed.
3.2.4. Peptides against type 2 diabetes
Ingestion of a meal provokes the secretion, at gastrointestinal
level, of incretins hormones, such as glucagon-like peptide-1 (GLP-
1), and glucose-dependent insulinotropic polypeptide (GIP). These
hormones are involved in the modulation of gut motility, secretion
of gastric and pancreatic enzymes, nutrient absorption, and stim-
ulation of the insulin secretion from the pancreas that allows the
disposal of the absorbed glucose (Drucker & Nauck, 2006). Type 2
diabetes, representing 90e95% of the diagnosed cases of diabetes,
is characterised by multiple pathophysiologic defects including
progressive dysfunction of pancreatic cells, insulin resistance, and
increased production of hepatic glucose (Bharatam, Patel, Adane,
Mittal, & Sundriyal, 2007). It has been demonstrated that contin-
uous intravenous administration of GLP-1 normalises blood glucose
levels in diabetic patients (Nauck et al., 1993). However, the rapid
degradation of this hormone by the enzyme dipeptidyl-peptidase
IV (DPP-IV) makes this strategy for the type 2 diabetes treatment
unfeasible. Currently, incretin-based therapies include a combina-
tion of GLP-1 analogues resistant to DPP-IV action, and orally
bioavailable DPP-IV inhibitors (Fadini & Avogaro, 2011).
Diet supplementation with whey protein has been demon-
strated, by preclinical and clinical studies, to potentiate insulin
release and ameliorate postprandial glucose control in both healthy
and type 2 diabetic subjects (Sousa et al., 2012). Initially, it was
suggested that these effects were due to its rapid digestion and the
consequent fast increase of the levels of different amino acids in
plasma (Luhovyy, Akhavan, & Anderson, 2007). However, the intake
of free amino acid mixtures did not produce the same effects
(Nilsson, Holst, & Bjorck, 2007). Recently, it has been hypothesised
that peptides released from whey proteins during their transit
through gastrointestinal tract might be responsible for the post-
meal glycaemic response produced after whey intake (Akhavan,
Luhovyy, Brown, Cho, & Anderson, 2010). Even the acute inges-
tion of a whey protein hydrolysate by rats resulted in a higher
transient leucine response with a sequential increase in insulin
(Toedebusch et al., 2012). A recent study has demonstrated the
dose-dependent insulinotropic effect of whey protein hydrolysates
in a cell-based co-culture approach using pancreatic BRIN-BD11
beta cells and Caco-2 cells monolayers (Gaudel et al., 2013). These
authors conﬁrmed these effects in obese (ob/ob) mice, observing,
after the oral administration of those hydrolysates, an improve-
ment of blood glucose clearance, reduction of hyperinsulinemia,
and restoration of the pancreatic islet capacity to secrete insulin in
response to glucose.
In addition, a signiﬁcant reduction of DPP-IV activity was
observed in the proximal small bowel of rodents fed whey proteins
(Gunnarsson et al., 2006), suggesting that peptides released from
these proteins might exert DPP-IV inhibitory effects at intestinal
level. Recent studies have demonstrated the in vitro DPP-IV inhib-
itory activity of hydrolysates derived from whey proteins, and
peptides contained in these hydrolysates, and potentially respon-
sible for the observed effects have been identiﬁed (Nongonierma &
Fitzgerald, 2013). Among these peptides, sequences IPA (b-lactosin)
and IPAVF, derived from b-Lg are amongst themost effective DPP-IV
inhibitory peptides described to date (Silveira, Martínez-Maqueda,
Recio, & Hernández-Ledesma, 2013; Tulipano, Sibilia, Caroli, &
Cocchi, 2011). A b-Lg-derived peptide, with the sequence
VAGTWY, presented hypoglycemic effects in the oral glucose
tolerance test in mice (Uchida, Ohshiba, & Mogami, 2011). This
in vivo effect has been also demonstrated for the peptide LPQNIPPL,
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Kabuki, Seto, Serizawa, & Nakajima, 2012). In fact, a recent in sil-
ico study has shown that both CN and whey proteins serve as
precursors of DPP-IV inhibitory peptides because of the high
number of fragments contained within them that match DPP-IV
inhibitory sequences described in the literature (Lacroix & Li-
Chan, 2012).
3.2.5. Effect on satiety
It is recognised that protein is the most satiating macronutrient
of food (Fromentin et al., 2012). Although it is not clear if the source
of protein can inﬂuence this satiating effect, the consumption of
dairy foods and calcium has been recommended in several diets
aiming the regulation of the body weight. Several clinical studies
have proposed a certain satiating effect for dairy products. For
instance, in a 6-month trial with an energy-restricted diet, the
group receiving milk supplementation showed a decreased desire
to eat and hunger versus the placebo group, although no differ-
ences in the level of ghrelin or leptin were found (Gilbert et al.,
2011). In a recent study with 49 overweight and obese adults, the
high-dairy group had similar weight loss than the low-dairy group,
but high-dairy group showed slightly higher peptide YY concen-
trations in plasma and enhanced sensation of satisfaction (Jones
et al., 2013).
The mechanisms of action of different protein types on satiety
are still under investigation, but it has been proposed that it could
be related to a slowdown of the gastric emptying, an increase in
brain amino acids, or the presence of speciﬁc peptides or amino
acids. In this respect, it has been highlighted that in animal or
human trials, diet has to be well equilibrated in its essential amino
acid content in order to prevent depression in food intake due to
conditioned food aversion (Fromentin et al., 2012). In particular, it
has been proposed that whey proteins contribute to short term
appetite suppression, with this effect being higher than that ob-
tained with CN, soy protein and egg albumin (Anderson, Tecimer,
Shah, & Zafar, 2004). This effect can be attributed to the high con-
tent in branched-chain amino acids (mainly, L-leucine), the pres-
ence of certain peptides, such as CMP, or it can be mediated by the
release of satiety hormones (cholecystokinin, GLP-1, GIP, peptide
YY or ghrelin). A review that summarises the evidence built in
animal and human trials on the effect of whey protein consumption
on satiety and intake regulatory mechanisms has been previously
published (Luhovy et al., 2007). Later reports have compared the
effect of whey protein and a whey protein hydrolysate, when
consumed before a meal, on glucose and insulin levels and pre- and
post-meal satiety. Interestingly, it was found that the whey protein,
but not the whey protein hydrolysate, reduced post-meal blood
glucose and insulin concentrations in a dose-dependent manner,
and diminished food intake (Akhavan et al., 2010). Therefore, it
seems relevant the form inwhich the protein is ingested, or in other
words, the peptides that reach the gut during gastrointestinal
digestion of whey proteins. Peptide composition and characteri-
sation of hydrolysates is deﬁnitive in this kind of studies to extract
cause-effect conclusions. Other studies have conﬁrmed that whey
proteins enhance satiety in humans in a short time period of time
compared with carbohydrates but the effect could not be attributed
to CMP since same effect was achieved with a WPI without CMP
(Lam, Moughan, Awati, & Morton, 2009). Similarly, in a double-
blind acute study with 20 overweight/obese males, no differences
were found on plasma cholecystokinin levels or subjective satiety
after ingestion of CMP with different glycosylation levels (Keogh
et al., 2010). However, a positive effect was shown in a study
with individuals with phenylketonuria where the consumption of
CMP at breakfast was compared with an amino acid-based formula.
Lower postprandial ghrelin levels after breakfast containing CMPassociated with a greater feeling of fullness were found (MacLeod,
Clayton, van Calcar, & Ney, 2010). Consequently, more work is
needed to conﬁrm the effect or certain whey components on
satiety, and to elucidate the mechanism of action implicated in the
activity of the whey protein fraction. Finally, it has been pointed out
that the difference in satiety by various proteins can be also inﬂu-
enced by the physical properties of food in the gut, and factors, such
as, viscosity, or clotting of proteins in the gut play an important role.
For instance, in a comparative study with whey protein drinks and
alginate-based drinks with different viscosities and protein con-
tents, it was found that subjects reported reduced hunger with
protein drinks with higher viscosity independently of the protein
content, suggesting that viscosity can exert a higher effect than
protein concentration (Solah et al., 2010).
Concerning the CN fraction of milk, it is known that peripheral
opioid and cholecystokinin receptors are activated by ingestion of
CN, and blocking receptors with antagonists reduces their effect on
food intake (Froetschel, Azain, Edwards, Barb, & Amos, 2001;
Pupovac & Anderson, 2002). Therefore, the presence of peptides
able to interact with these receptors will determine the activity of
CN hydrolysates. Because the composition of the CN hydrolysates
varies with the hydrolysis process, peptidomic characterisation of
the products is essential.
In a comparative study of CN and whey on gastrointestinal
hormone secretion and appetite, it was found a greater subjective
satiety after the whey load. Whey also produced a higher increase
in postprandial plasma amino acid concentration, and higher levels
of cholecystokinin, GLP-1 and GIP than CN. These results emphasise
the importance of the type of protein, and conﬁrm that post-
absorptive increases in plasma amino acids and gastrointestinal
hormones are involved in the appetite response (Hall, Millward,
Long, & Morgan, 2003).3.3. Effects on body defences
Apart from their nutritional value, milk proteins are able to exert
physiological activities aiming to protect the newborn mammal.
Furthermore, throughout the course of digestion of milk, bioactive
peptides are released from consumed proteins. These peptides may
possess not only immunomodulatory, but also antimicrobial and
antiproliferative properties that help improving the defence system
of the neonate.3.3.1. Antimicrobial peptides
The antimicrobial activities of milk protein-derived peptides are
very diverse, ranging from those with a prebiotic effect, peptides
with the ability to prevent the attachment or invasion of pathogen
microorganisms, to peptides killing or inhibiting the growth of
microorganisms. This section will refer to this latter group of pep-
tides with special emphasis on those peptides with antibacterial
activity. The antiviral activity of dairy proteins, modiﬁcations
thereof, and derived peptides has been reviewed by different au-
thors (Berlutti et al., 2011; Pan et al., 2006).
Milk-derived antimicrobial peptides are characterised by a
highly positively charged sequence and certain amphiphilic char-
acter. It has been proposed that the net positive charge will aid
binding to negatively charged bacterial membranes and the
amphiphilic character will help membrane disruption. Some pep-
tides, like LFcin and lactoferrampin, contain also a hydrophobic
region with a tryptophan residue, which is involved in membrane
insertion (Schiffer, Chang, & Stevens, 1992). However, recent re-
ports have also described the activity of anionic peptides-enriched
extracts from Cheddar cheese against Listeria monocytogenes
(Demers-Mathieu et al., 2013a). The origin and activity of some of
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are summarised in Table 3.
The antimicrobial peptides that have received most attention in
the last two decades are derived from lactoferrin (LF). Hydrolysis of
bovine LF with pepsin generates several protein fragments with
antibacterial activity. Among them, fragment f(17e41/42), known
as LFcin (Bellamy et al., 1992), is one of themost potentwith a broad
spectrum against Gram-positive and Gram-negative bacteria; but
also other active fragments from the N-lobe of the protein, i.e.,
f(267e285), f(267e288), and f(277e288), are released by the action
of this enzyme (Recio & Visser, 1999b). A peptide from this region of
the protein, f(268e288), called lactoferrampin, was later chemically
synthesised, and it has demonstrated activity against Bacillus sub-
tilis, Escherichia coli and Pseudomonas aeruginosa (Van der KraanTable 3
Fragments, origin, antibacterial, and other biological activities of the most relevant antib
Fragmentb Isolation Antibacterial act
aS1-CN f(1e23) Bovine CN digested with chymosin Gram-positive b
and yeast
aS1-CN f(99e109) Bovine sodium caseinate
digested with pepsin
Several Gram-po
Gram-negative b
aS1-CN f(21e29)
aS1-CN f(30e38)
Bovine sodium caseinate
fermented with Lactobacillus
acidophilus DPC6026
Several Gram-po
Gram-negative b
aS2-CN f(164e169)
aS2-CN f(183e207)
Bovine aS2-CN digested with pepsin Several Gram-po
Gram-negative b
OaS2-CN f(165e170)
OaS2-CN f(165e181)
OaS2-CN f(184e208)
OaS2-CN f(203e208)
Ovine aS2-CN digested with pepsin Several Gram-po
Gram-negative b
Hk-CN f(43e97) Human milk digested with pepsin Several Gram-po
Gram-negative b
k-CN f(106e169) Bovine CN digested with chymosin S. mutans
P. gingivalis
E. coli
k-CN f(18e24)
k-CN f(30e32)
k-CN f(139e146)
Bovine k-CN digested with pepsin Several Gram-po
Gram-negative b
Hb-CN f(184e210) Human b-CN digested with
a proteinase of Lactobacillus
helveticus PR4
Several Gram-po
Gram-negative b
LF f(17-41/42) Bovine LF digested with
pepsin or chymosin
Several Gram-po
Gram-negative b
fungi, parasites
HLF f(1e47) Human LF digested with pepsin Several Gram-po
Gram-negative b
LF f(1e48)
LF f(1e47)
LF f(277e288)
LF f(267e285)
LF f(267e288)
Bovine LF digested with pepsin Micrococcus ﬂav
CLF f(14e42) Caprine LF digested with pepsin Micrococcus ﬂav
Escherichia coli
a-La f(1e5)
a-La f(17e31)S-S(109e114)
a-La f(61e68)S-S(75e80)
Bovine a-La digested
with chymotrypsin
Several Gram-po
b-Lg f(15e20)
b-Lg f(25e40)
b-Lg f(78e83)
b-Lg f(92e100)
Bovine b-Lg digested with trypsin Several Gram-po
LZ f(98e112) Hen egg white LZ digested
with clostripain
Several Gram-po
Gram-negative b
LZ f(98e108)
LZ f(15e21)
Hen egg white LZ digested with
pepsin and trypsin
Gram-positive a
bacteria
LZ (46e61) Hen egg white LZ digested with
papain and trypsin
Gram-positive a
bacteria
a Fragments are bovine unless otherwise indicated; peptides obtained by chemical sy
b Upper case superscripts deﬁne the origin of the precursor protein if not bovine: O, o
c N.R., Non-reported.et al., 2004). Recently, it has been shown that chimerisation of
LFcin and lactoferrampin increases activity against various micro-
organisms, such as Candida albicans, and Burkholderia pseudomallei
(Bolscher, Nazmi, van Marle, van ’t Hof, & Veerman, 2012; Puknun
et al., 2013).
Digestion of the major bovine whey proteins, b-Lg and a-La,
with trypsin and chymotrypsin, respectively, releases peptides with
moderate activity against Gram-positive bacteria (Pellegrini,
Dettling, Thomas, & Hunziker, 2001; Pellegrini, Thomas, Bramaz,
Hunziker, & Von Fellenberg, 1999). Recently, Demers-Mathieu
et al. (2013b) obtained an antibacterial fraction rich in anionic
peptides of about 8 amino acids long by nanoﬁltration of a tryptic
hydrolysate of a WPI. The same research group has recently
demonstrated the antibacterial activity of a peptic hydrolysate of aacterial peptides.a
ivity Other activitiesc References
acteria, fungi Immunomodulatory Lahov and Regelson (1996)
sitive and
acteria
N.R. McCann et al. (2006)
sitive and
acteria
N.R. Hayes, Ross, Fitzgerald, Hill, and
Stanton (2006)
sitive and
acteria
Growth promoter Recio and Visser (1999b)
Smith, Wilkinson, and Liu (1997)
sitive and
acteria
Antihypertensive
Antioxidant
López-Expósito, Gómez-Ruiz, Amigo,
and Recio (2006), Recio et al. (2006)
sitive and
acteria, yeasts
N.R. Liepke, Zucht, Frossmann, and
Stöndker (2001)
Biﬁdogenic
Immunomodulatory
Malkoski et al. (2001)
Prouxl, Gauthier, and Roy (1992)
Brody (2000)
sitive and
acteria
N.R. López-Expósito, Minervini, Amigo,
and Recio (2006)
sitive and
acteria
N.R. Minervini et al. (2003)
sitive and
acteria, viruses,
Antitumoral
Antiinﬂamatory
Bellamy et al. (1992)
Hoek, Milne, Grieve, Dionoysius,
and Smith (1997)
Iigo et al. (1999)
Levay and Viljoen (1995)
sitive and
acteria
N.R. Bellamy et al. (1992)
us N.R. Recio and Visser (1999b)
us N.R. Recio and Visser (2000)
sitive bacteria N.R. Pellegrini et al. (1999)
sitive bacteria N.R. Pellegrini et al. (2001)
sitive and
acteria
N.R. Pellegrini et al. (1997)
Ibrahim, Thomas, and
Pellegrini (2001)
nd Gram-negative N.R. Mine, Ma, and Lauriau (2004)
nd Gram-negative N.R. Memarpoor-Yazdi, Assodeh, and
Chamani (2012)
nthesis are not included. Adapted from López-Expósito and Recio (2008).
vine; H, human; C, caprine origin.
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a-La (Theolier, Hammami, Labelle, Fliss, & Jean, 2013).
Although CN has been traditionally considered important from
the nutritional point of view, it is also source of antibacterial pep-
tides. Most relevant peptides from the CN fraction correspond to
the N-terminal region of aS1-CN, several fragments from the C-
terminal domain of aS2-CN and some peptides from k-CN (Table 3).
All of them are active against Gram-positive and -negative bacteria,
andmost of them have a net positive charge. More details about the
formation and the in vitro activity of these sequences have been
reviewed by López-Expósito & Recio (2008).
Because evidence of the activity of these antibacterial fragments
should be based on in vivo studies, several animal assays and few
clinical trials with some of these sequences or hydrolysates have
been conducted. Most of the in vivo studies have used the entire
protein LF, but the observed activity can be attributed to the protein
or some of the generated peptides during digestion, such as LFcin-
containing fragments (Kuwata, Yip, Tomita, & Hutchens, 1998;
Kuwata, Yip, Yamauchi et al., 1998). In vivo studies with bovine LF
orally administered to mice have demonstrated protective effects
against infections or septic shock, although it is not clear whether
these effects can be attributed to the antibacterial activity of the
protein or to immunity modulation (reviewed by Legrand, 2012;
Van Hooijdonk, Kussendrager, & Steijns, 2000). It has been
demonstrated that orally administered LF or its hydrolysate can
play a role on gastrointestinal health and intestinal ﬂora of new-
borns (animals or humans). For instance, a recent clinical trial with
472 infants in neonatal care showed that LF reduced fungal late-
onset sepsis, especially in low weight infants (Manzoni et al.,
2012). Several clinical studies on the role of LF in children and
neonates have been recently reviewed (Embleton, Berrington,
McGuire, Stewart, & Cummings, 2013; Ochoa, Pezo, Cruz, Chea-
Woo, & Cleary, 2012). Other studies with LF or hydrolysates
thereof have shown their in vivo protective effect in urinary tract
infection (Håversen et al., 2000), and hepatic colonisation of L.
monocytogenes in mice (Lee et al., 2005).
The in vivo antibacterial activity of a aS1-CN derived antibacterial
fragment, isracidin, against L. monocytogenes, Streptococcus pyo-
genes, and Staphylococcus aureus, has been demonstrated in mice.
Protection of other mammals (rabbits, guinea pigs and sheeps)
against this latter microorganism has been also conﬁrmed. Later on,
a tryptic CN hydrolysate that exerts antimicrobial activity through
stimulation of the bacterial autolytic system was assayed in
newborn calves affected with colibacillosis. The hydrolysate acted
as antimicrobial but also as immunostimulant and growth pro-
moter (Biziulevicius, Zukaité, Normantienè, Biziulevicienè, &
Arestov, 2003).
3.3.2. Immunomodulatory peptides
Milk contains several components, essential during neonatal
development, that exhibit an important protective role against
infection by modulating the immune system of the newborn.
Among these components, it is found that CN, its fractions, whey
proteins, LF, and their different hydrolysates show modulatory ef-
fects on the immune system in both in vitro and in vivo studies
(Gauthier, Pouliot, & Saint-Sauveur, 2006; Gill, Doull, Rutherfurd, &
Cross, 2000). However, most of these studies have been conducted
by in vitro assays, focussing on the speciﬁc immune system, which
requires an antigen-speciﬁc response (Cross & Gill, 2000).
It has been reported that whey protein and its peptide fractions,
obtained from hydrolysis with trypsin and chymotrypsin, modu-
lated the immune system when they were administered to mice
(Saint-Sauveur, Gauthier, Boutin, Montoni, & Fliss, 2009). These
authors showed an increase in serum immunoglobulin (Ig) A levels
in non-infected and E. coli O157:H7 infected mice. In relation towhey proteins, it has been shown that a-La enhanced humoural
immune response in mice, with this effect being higher than that
shown for CN, soy or wheat diet (Bounous & Kongshavn, 1985;
Bounous, Létourneau & Kongshavn, 1983; Bounous, Shenouda,
Kongshavn, & Osmond, 1985). These results were conﬁrmed
when mice were fed a-La hydrolysate (Bounous, 1981; Bounous &
Kongshavn, 1982).
LF is considered one of themain host defences against infections,
displaying different biological activities including immunomodu-
lation (González-Chávez, Erévalo-Gallegos, & Rascón-Cruz, 2009;
Tomita, Wakabayashi, Yamauchi, Teraguchi, & Hayasawa, 2002;
Wakabayashi, Yamauchi, & Takase, 2006). Thus, the ingestion of LF
accelerated the improvement of immune system in immunocom-
promisedmice (Artym, Zimecki, Paprocka, & Kruzel, 2003; Takahura
et al., 2004). In this sense, it was observed a higher IgA level in the
bile and intestine of mice orally immunised with cholera toxin and
fed apepsin LFhydrolysate (Miyauchi, Kaino, Shinoda, Fukuwatari, &
Hayasawa,1997), indicating that this hydrolysate improvedmucosal
immunity. It has to be pointed out that IgA production is the main
humoural immune response given by gut-associated lymphoid tis-
sue, which prevents the entry of potentially harmful antigens that
could enter through the oral route. Wang et al. (2000) showed that
the administration of LF and its pepsin hydrolysate increased the
mucosal immune response in mice, and this increase was higher in
tumour bearing mice, suggesting an anti-metastasis and anti-
carcinogenesis activity mediated by interleukine (IL)-18 produc-
tion. In piglets, the ingestion of a LFcin-lactoferrampin mixture
increased serum IgA, IgG and IgM levels, thus improving the im-
mune function and gut health (Tang et al., 2009).
Several studies have shown that peptides released from milk
fermented with L. helveticus R389 are able to improve the mucosal
immune system in non-infected (LeBlanc, Matar, Valdéz, LeBlanc, &
Perdigón, 2002; Vinderola, Matar, Palacios, & Perdigón, 2007;
Vinderola, Matar, & Perdigón, 2007) or E. coli O157:H7 infected
mice (LeBlanc, Fliss, & Matar, 2004), as well as to decrease the
development of induced ﬁbrosarcoma inmice (LeBlanc et al., 2002).
On the other hand, a tryptic CN hydrolysate has also shown an
immunostimulatory activity in newborn calf partly due to the ca-
pacity of this hydrolysate to stimulate the autolytic microbial sys-
tem (Biziulevicius et al., 2003). Likewise, an immunomodulatory
activity of CPPs was shown in mice fed ovalbumin-based diet
supplemented with these peptides that was mediated by an in-
crease of IgA levels in serum, intestine, and faeces towards b-Lg
injected peritoneally or bacterial LPS of Salmonella typhimurium
orally administered (Otani, Kihara, & Park, 2000; Otani, Nakano, &
Kawahara, 2003). These authors attributed these effects to an in-
crease in IL-5 and IL-6 levels (Otani et al., 2003). A previous study
reported increased IgA level in human faeces after the ingestion of
cake supplemented with CPPs (Kitamura & Otani, 2002), with this
effect being higher in people that ingested dairy products with low
frequency.
Despite all these studies where an immunomodulant activity of
different hydrolysates obtained from milk proteins was observed,
the peptides responsible for this activity remain unidentiﬁed. Thus,
further studies intended to identify these sequences, elucidate their
mechanism of action, and discover new bioactive sequences are
needed.
3.3.3. Antiproliferative peptides
Currently, cancer is the second leading cause of mortality
worldwide. It is well known that 90e95% of cancer cases are
attributed to environment and lifestyle factors, including tobacco
and alcohol consumption, diet, sun exposure, pollutants, infections,
stress, obesity, and physical inactivity (Anand et al., 2008). Among
these factors, dietary patterns and food components are closely
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35% of cancer deaths (Manson, 2003). However, in vitro and in vivo
studies have revealed that a large number of food compounds could
lower cancer risk and even sensitise tumour cells to anti-cancer
therapies (De Kok, van Breda, & Manson, 2008).
In the last few years, food protein-derived peptides have
become a group of nutraceuticals with demonstrated activity pre-
venting the different stages of cancer, including initiation, promo-
tion, and progression (De Mejia & Dia, 2010). Among the milk
derived peptides, LFcin B is the most extensively studied. As shown
in Table 4, LFcin has demonstrated, by cell culture experiments, a
potent activity against different types of cancer cell lines, including
breast, colon, ﬁbrosarcoma, leukaemia, oral, and ovarian cancer
cells, without harming normal lymphocytes, ﬁbroblasts, endothe-
lial, or epithelial cells (Furlong, Mader, & Hoskin, 2010). The selec-
tivity of action of this peptide seems to be due to its strongly
cationic character that allows it to interact with negatively charged
structures on cancer cells, resulting in the destabilisation of cancer
cell membranes (Hoskin & Ramamoorthy, 2008). However, the net
neutral charge of healthy non-transformed cells keeps them
spared. In addition to this mechanism of action related to its
cationic nature, LFcin has been shown in vitro to act inducing
apoptosis, arresting cell cycle, modulating gene expression, and
preventing the angiogenesis (De Mejia & Dia, 2010).
In vivo evidence has revealed that subcutaneous administration
of LFcin B resulted in a signiﬁcant inhibition of tumour growth andTable 4
Effects of peptide lactoferricin against cancer demonstrated by cell culture experiments
Type of cancer Cell line/animal model Effects/me
Breast cancer MCF-7, T-47D, MDA-MB-435 cells Cytotoxic
Colon carcinoma C26 cells
Caco2 cells
Ultraviolet-irradiated Caco2 cells
Colo-35 and HT-29 cells
Cytotoxic
Reduction
S phase b
Reduction
Cytotoxic
Fibrosarcoma Meth A cells Cytotoxic
membran
Leukaemia THP-1 human monocytic leukaemic cells
Jurkat T leukaemia cells
Induction
productio
species (R
dependen
Induction
ROS, activ
sequentia
Reduction
Lymphoma Subcutaneous inoculation
of A20 cell lymphomas in syngeneic mice
Spontaneous metastasis models
(L5178Y-ML25) in syngeneic mice
Raji and Ramos Burkitt’s B-lymphoma cells
Deﬁcient mice bearing B-lymphoma xenografts
Tumour n
tumors/in
immunity
Inhibition
Induction
chromatin
nuclear di
Extension
Melanoma B16F10 cells
Spontaneous metastasis models
(B16-BL6 cells) in syngeneic mice
Cytotoxic
Inhibition
Neuroblastoma Human MYCN-ampliﬁed and non-MYCN
ampliﬁed neuroblastoma cell lines
Neuroblastoma xenografts in nude rats
Cytotoxic
cytoplasm
of caspase
Reduction
neuroblas
Oral cancer Oral squamous cell carcinoma cell line SAS Induction
and poly-
of extrace
N-termina
Ovarian cancer Skov3 and Caov3 Cytotoxicliver and lung metastases of lymphoma and melanoma cells in
spontaneous and experimental metastasis mice models (Yoo,
Watanabe, Koike et al., 1997; Yoo, Watanabe, Watanabe et al.,
1997). Moreover, these authors demonstrated the capacity of this
peptide to reduce the number of tumour-induced blood vessels
inhibiting tumour angiogenesis. Subcutaneous treatment of Meth A
ﬁbrosarcoma mice xenografts with LFcin B signiﬁcantly inhibited
tumour growth (Eliassen et al., 2002). Same effect was observed
after treating established neuroblastoma xenografts with repeated
injections of this peptide (Eliassen et al., 2006).
The ability of CPPs to bind calcium has been demonstrated to be
responsible for the protective effect of these peptides from toxicity
caused by calcium overload in differentiated intestinal cells, pre-
venting their apoptosis (Perego et al., 2013). In addition, CPPs act
against intestinal tumour HT-29 and AZ-97 cells inhibiting their
proliferation and inducing programmed cell death through acti-
vation of voltage-activated calcium channels, which mediate the
calcium ﬂood according to the depolarisation state of the cell
(Perego, Cosentino, Fiorilli, Tettamanti, & Ferraretto, 2012).
Opioid CN-derived peptides, b-casomorphin 7 and b-casomor-
phin 5, have also shown antiproliferative and cell cycle arresting
activity on breast cancer cells (Hatzglou, Bakogeorgou, Hatzoglou,
Martin, & Castanas, 1996; Maneckjee, Biswas, & Vonderhaar,
1990). It has been suggested that these effects are mediated by
interaction with opioid receptors. Similarly, the interaction with
speciﬁc opioid and somatostatin receptors present in the intestinaland animals models.
chanisms of action Reference
activity/induction of apoptosis Mader, Salsman, Conrad, and
Hoskin (2005)
activity
of cell proliferation/cell cycle arrest at
y down regulation of cyclin E1
of DNA damage
activity/induction of apoptosis
Eliassen et al. (2002)
Freiburghaus, Janicke,
Lindmark-Månsson,
Oredsson, and Paulsson (2009)
Freiburghaus, Lindmark-Månsson,
Oredsson, and Paulsson (2012)
Mader et al. (2005)
activity/tumour cell
e disruption
Eliassen et al. (2002)
of apoptosis mediated by
n of intracellular reactive oxygen
OS) and activation of Ca2þ/Mg2þ-
t endonucleases
of apoptosis mediated by production of
ation of caspases-3 and -9, and
l permeabilisation of the cell membrane
of DNA methyltransferases expression
Yoo, Watanabe, Koike et al. (1997)
Mader et al. (2005, 2007)
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effects on colon cancer cells demonstrated for these b-casomor-
phins and other milk-derived opioid peptides (Pepe, Tenore,
Mastrocinque, Stusio, & Campiglia, 2013).
3.4. Effects on the nervous system
3.4.1. Relaxing peptides
The popular sedative and calming properties of milk can be
attributed to various compounds including proteins and peptides
released during digestion. In fact, a-casozepine (YLGYLEQLLR), a
peptide derived from tryptic hydrolysis of aS1-CN, with
benzodiazepine-like activity has shown anticonvulsant and anxi-
olytic activities in rats (Miclo et al., 2001). However, the mechanism
of action of the tryptic hydrolysate differs from that of diazepam.
While diazepam induced a disinhibition state in rats, the tryptic
hydrolysate did not display such a side effect (Violle et al., 2006)
despite its afﬁnity for gamma-aminobutyric acid (GABA) type A
receptors. Speciﬁc linking of bovine aS1-CN tryptic hydrolysate-
derived peptides on GABA receptor is involved in anxiolysis, but
not on that implied in memory-impairing effects (Messaoudi,
Lalonde, Schroeder, & Desor, 2009). A fragment, corresponding to
sequence aS1-CN f(91e97) could be the responsible for the in vivo
activity of a-casozepine (Cakir-Kiefer et al., 2011). Oral intake of an
encapsulated aS1-CN tryptic hydrolysate, containing this peptide,
before a stressing situation, decreases the blood pressure increase
induced by the stress. Moreover, the plasma cortisol concentration
decreased in the treated subjects compared with those who have
taken a placebo (Messaoudi, Lefranc-Millot, Desor, Demagny, &
Bourdon, 2005). In another study, the oral intake of the encapsu-
lated hydrolysate by female volunteers signiﬁcantly reduced their
digestive, cardiovascular, intellectual, emotional and social stress-
related symptoms (Kim et al, 2007).
Moreover, it has been reported an anti-stress effect of LF in the
neonatal maternal separation model (Takeuchi et al., 2003), and in
an elevated plus-maze test combined with an electric foot-shock in
adult rats (Kamemori, Takeuchi, Hayashida, & Harada, 2004).
3.4.2. Antinociceptive peptides
Pain receptors or nociceptors are nerve endings found in the
tissues of various organs and systems, characterised by dis-
tinguishing securely and efﬁciently a harmless event from another.
It has been reported that milk proteins such as LF reduces noci-
ceptive activity mediated by m-opioid receptor in several models of
pain in rats (Hayashida, Takeuchi, Shimizu, Ando, & Harada, 2003a).
Moreover, these authors have demonstrated that the analgesia
induced by spinal administration of morphine was greatly poten-
tiated by coadministration of LF (Hayashida, Takeuchi, Shimizu,
Ando, & Harada, 2003b), and that LF may block the development
of tolerance to morphine in mice, possibly via the selective acti-
vation of NO synthase (Tsuchiya et al., 2006). Raju, Kumar,
Arutselvan, Thejomoorthy, and Puvanakrishan (2005) have found
that PEEP1261, a tetrapeptide corresponding to f(39e42) of human
LF possesses antinoceptive activity with optimal effect at
40 mg kg1 body weight in both tail-ﬂick model and acetic acid
induced writhing in rats. Furthermore, it was observed that this
peptide exhibited also antipyretic activity.
4. Future prospects
Beyond their well-known nutritional value, milk proteins may
exhibit a plethora of biological activities that inﬂuence the growth,
development and function of speciﬁc organs, metabolic responses
to absorbed nutrients, and defence systems, among others. Many of
these activities could be exerted by peptides released from parentprotein during gastrointestinal digestion or food processing. The
research area of bioactive peptides is only at its beginning andmore
sequences along with additional physiological effects will be
discovered in the future. Most of the properties of milk bioactive
peptides have been demonstrated by in vitro assays and/or animal
model systems. However, data obtained from these studies are
insufﬁcient to demonstrate efﬁcacy of those peptides in humans.
Evaluation of the peptide doses and treatment durations, and
elucidation of the molecular mechanisms of actions are still
required for many bioactive peptides. So far, evidence for such ef-
fect exists only for a few proteins and peptides, and once the
beneﬁcial effect has been demonstrated in acute human interven-
tion studies the results cannot be always translated to longitudinal
effects. To generate evidence of these beneﬁcial effects, further
long-term human trials using sufﬁcient number of subjects,
controlled doses and formulations are needed. It has been proposed
that discrepancies found in some clinical trials could be due to
human diversity and phenotypic differences between individuals.
In this context, future clinical trials of food bioactives could beneﬁt
from data on genotype, metabolomic proﬁles and proteomics or
transcriptomics data of the volunteers. In these studies, there is also
a need to identify and validate biomarkers that conclusively be
related to a certain health beneﬁt. It is expected that new bio-
markers will be developed using novel approaches including
functional genomics, food metabolomics, microbiomics and epi-
genetics, and by exploring markers in human studies based on
foods and diets, and not just their individual ingredients.
Bioavailability of food peptides is also crucial in these studies, since
it is dependent of numerous factors such as the food matrix, food
composition but also it may vary between individuals. Finally, it has
to be taken into account that the pharmacological approach is not
always applicable to food bioactives where the physiological effects
are smaller. Scientiﬁc progress in the ﬁeld must be targeted at a
better understanding of how these food-derived peptides interact
with the human body and can prevent the initiation, development
or progression of risk factors for diet-related chronic diseases.Acknowledgements
This work has received ﬁnancial support from projects
AGL2011-24643, Consolider Ingenio 2010 FUN-C-Food CSD2007-
00063, PIE 201270E076, FEDER-INNTERCONECTA-GALICIA (ENVEL-
LEFUN), and FP7-SME-2012-315349 (FOFIND). The authors are
participant in the FA1005COST Action INFOGEST on food digestion.
B. H. -L. and S. F. -T. acknowledge CSIC and the Ministry of Economy
and Competitiveness for their Ramón y Cajal contract and FPI
fellowship, respectively. The authors thank B. Miralles for text
revision.References
Abubakar, A., Saito, T., Kitazawa, H., Kawai, Y., & Itoh, T. (1998). Structural analysis of
new antihypertensive peptides derived from cheese whey protein by proteinase
K digestion. Journal of Dairy Science, 81, 3131e3138.
Aït-Oukhatar, N., Bouhallab, S., Arhan, P., Maubois, J. L., Drosdowsky, M., & Bouglé, D.
(1999). Iron tissue storage and hemoglobin levels of deﬁcient rats repleted with
iron bound to the caseinophophopeptides 1-25 of b-casein. Journal of Agricul-
tural and Food Chemistry, 47, 2786e2790.
Aït-Oukhatar, N., Bouhallab, S., Bureau, F., Arhan, P., Maubois, J. L.,
Drosdowsky, M. A., et al. (1997). Bioavailability of caseinophosphopeptide
bound iron in the young rat. Nutritional Biochemistry, 8, 190e194.
Aït-Oukhatar, N., Pèrés, J. M., Bouhallab, S., Neuville, D., Bureau, F., Bouvard, G., et al.
(2002). Bioavailability of caseinophopshopeptide-bound iron. Journal of Labo-
ratory and Clinical Medicine, 140, 290e294.
Akhavan, T., Luhovyy, B. L., Brown, P. H., Cho, C. E., & Anderson, G. H. (2010). Effect of
premeal consumption of whey protein and its hydrolysate on food intake and
postmeal glycemia and insulin responses in young adults. American Journal of
Clinical Nutrition, 91, 966e975.
B. Hernández-Ledesma et al. / International Dairy Journal 38 (2014) 82e100 95Anand, P., Kunnumakara, A. B., Sundaram, C., Harikumar, K. B., Tharakan, S. T.,
Lai, O. S., et al. (2008). Cancer is a preventable disease that requires major
lifestyle changes. Pharmaceutical Research, 25, 2097e2116.
Anderson, G. H., Tecimer, S. N., Shah, D., & Zafar, T. A. (2004). Protein source,
quantity, and time of consumption determine the effect of proteins on short-
term food intake in young men. Journal of Nutrition, 134, 3011e3015.
Ani-Kibangou, B., Bouhallab, S., Mollé, D., Henry, G., Bureau, F., Neuville, D., et al.
(2005). Improved absorption of caseinophosphopeptide-bound iron: role of
alkaline phosphatase. Journal of Nutritional Biochemistry, 16, 398e401.
Artym, J., Zimecki, M., Paprocka, M., & Kruzel, M. L. (2003). Orally administered
lactoferrin restores humoral immune response in immunocompromised mice.
Immunology Letters, 89, 9e15.
Ballard, K. D., Bruno, R. S., Seip, R. L., Quann, E. E., Volk, B. M., Freidenreich, D. J., et al.
(2009). Acute ingestion of a novel whey-derived peptide improves vascular
endothelial responses in healthy individuals: a randomized, placebo controlled
trial. Nutrition Journal, 8. Article No 34.
Bellamy, W., Takase, M., Yamauchi, K., Wakabayashi, H., Kawase, K., & Tomita, M.
(1992). Identiﬁcation of the bactericidal domain of lactoferrin. Biochimica et
Biophysica Acta, 1121, 130e136.
Bennett, T., Desmond, A., Harrington, M., McDonagh, D., FitzGerald, R., Flynn, A.,
et al. (2000). The effect of high intakes of casein and casein phosphopeptide on
calcium absorption in the rat. British Journal of Nutrition, 83, 673e680.
Berge, B., Eliassen, L. T., Camilio, K. A., Bartnes, K., Sveinbjørnsson, B., & Rekdal, Ø.
(2010). Therapeutic vaccination against a murine lymphoma by intratumoral
injection of a cationic anticancer peptide. Cancer Immunology and Immuno-
therapy, 59, 1285e1294.
Berlutti, F., Pantanella, F., Natalizi, T., Frioni, A., Paesano, R., Polimeni, A., et al. (2011).
Antiviral properties of lactoferrin. A natural immunity molecule. Molecules, 16,
6992e7018.
Bernstein, C. N., Fried, M., Krabshuis, J. H., Cohen, H., Eliakim, R., Fedail, S., et al.
(2009). World gastroenterology organisation practice guidelines for the
diagnosis and management of IBD in 2010. Inﬂammatory Bowel Disease, 16,
112e124.
Bharatam, P. V., Patel, D. S., Adane, L., Mittal, A., & Sundriyal, S. (2007). Modeling and
informatics in designing anti-diabetic agents. Current Pharmaceutical Design, 13,
3518e3530.
Biziulevicius, G. A., Zukaité, V., Normantienc, T., Biziulevicienè, G., & Arestov, I. G.
(2003). Non-speciﬁc immunity-enhancing effects of tryptic casein hydrolysate
versus Fermosorb for treatment/prophylaxis of newborn calf colibacillosis.
FEMS Immunology and Medical Microbiology, 39, 155e161.
Bolscher, J., Nazmi, K., van Marle, J., van ’t Hof, W., & Veerman, E. (2012). Chime-
rization of lactoferricin and lactoferrampin peptides strongly potentiates the
killing activity against Candida albicans. Biochemistry and Cell Biology, 90, 378e
388.
Bouhallab, S., Cinga, V., Aït-Oukhatar, N., Bureau, F., Neuville, D., Arhan, P., et al.
(2002). Inﬂuence of various phosphopeptides of caseins on iron absorption.
Journal of Agricultural and Food Chemistry, 50, 7127e7130.
Bounous, G. (1981). Inﬂuence of dietary lactalbumin hydrolysate on the immune
system of mice and resistance to Salmonellosis. Journal of Infectious Diseases,
144, 281.
Bounous, G., & Kongshavn, P. A. L. (1982). Inﬂuence of dietary protein on the im-
mune system of mice. Journal of Nutrition, 112, 1747e1755.
Bounous, G., & Kongshavn, P. A. L. (1985). Differential effect of dietary protein type
on B-cell and T-cell immune response in mice. Journal of Nutrition, 115, 1403e
1408.
Bounous, G., Létourneau, L., & Kongshavn, P. L. A. (1983). Inﬂuence of dietary protein
type on the immune system of mice. Journal of Nutrition, 113, 1415e1421.
Bounous, G., Shenouda, N., Kongshavn, P. A. L., & Osmond, D. (1985). Mechanism of
altered B-cell response induced by changes in dietary protein type in mice.
Journal of Nutrition, 115, 1409e1417.
Boutrou, R., Gaudichon, C., Dupont, D., Jardin, J., Airinei, G., Marsset-Baglieri, A.,
et al. (2013). Sequential release of milk protein-derived bioactive peptides in
the jejunum in healthy human. American Journal of Clinical Nutrition, 97, 1314e
1323.
Brody, E. P. (2000). Biological activities of bovine glycomacropeptide. British Journal
of Nutrition, 84, S39eS46.
Brommage, R., Juillerat,M. A., & Jost, R. (1991). Inﬂuence of caseinphosphopeptides and
lactulose on intestinal calcium absorption in adult female rats. Lait, 71, 173e180.
Cakir-Kiefer, C., Le Roux, Y., Balandras, F., Trabalon, M., Dary, A., Laurent, F. M., et al.
(2011). In vitro digestibility of a-casozepine, a benzodiazepine-like peptide
from bovine casein, and biological activity of its main proteolytic fragment.
Journal of Agricultural and Food Chemistry, 59, 4464e4472.
Castro, G. A., Carvalho, J. E., Tinti, S. V., Possenti, A., & Sgarbieri, V. C. (2010). Anti-
ulcerogenic effect of a whey protein isolate and collagen hydrolysates against
ethanol ulcerative lesions on oral administration to rats. Journal of Medicinal
Food, 13, 83e90.
Chabance, B., Marteau, P., Rambaud, J. C., Migliore-Samour, D., Boynard, M.,
Perrotin, P., et al. (1998). Casein peptide release and passage to the blood in
humans during digestion of milk or yogurt. Biochimie, 80, 155e156.
Chaud, M. V., Izumi, C., Nahaal, Z., Shuhama, T., Pires Bianchi, M. L., & De Freitas, O.
(2002). Iron derivates from casein hydrolysates as a potential source in the
treatment of iron deﬁciency. Journal of Agricultural and Food Chemistry, 50,
871e877.
Chawla, R., Patil, G. R., & Singh, A. K. (2011). High hydrostatic pressure technology in
dairy processing: a review. Journal of Food Science and Technology, 48, 260e268.Chen, G. W., Tsai, J. S., & Pan, B. S. (2007). Puriﬁcation of angiotensin I-converting
enzyme inhibitory peptides and antihypertensive effect of milk produced by
protease-facilitated lactic fermentation. International Dairy Journal, 17, 641e647.
Chung, H. Y., Cesari, M., Anton, S., Marzetti, E., Giovannini, S., Seo, A. Y., et al. (2009).
Molecular inﬂammation: underpinnings of aging and age-related diseases.
Ageing Research Reviews, 8, 18e30.
Cicero, A. F. G., Aubin, F., Azais-Braesco, V., & Borghi, C. (2013). Do the lacto-
tripeptides isoleucine-proline-proline and valine-proline-proline reduce sys-
tolic blood pressure in European subjects? A meta-analysis of randomized
controlled trials? American Journal of Hypertension, 25, 425e436.
Cicero, A. F. G., Gerocarni, B., Laghi, L., & Borghi, C. (2011). Blood pressure lowering
effect of lactotripeptides assumed as functional foods: a meta-analysis of cur-
rent available clinical trials. Journal of Human Hypertension, 25, 425e436.
Claustre, J., Toumi, F., Trompette, A., Jourdan, G., Guignard, H., Chayvialle, J. A., et al.
(2002). Effects of peptides derived from dietary proteins on mucus secretion in
rat jejunum. American Journal of Physiology e Gastrointestinal and Liver Physi-
ology, 283, G521eG528.
Contreras, M. M., Carrón, R., Montero, M. J., Ramos, M., & Recio, I. (2009). Novel
casein-derived peptides with antihypertensive activity. International Dairy
Journal, 19, 566e573.
Contreras, M. M., Sancho, M. A., Recio, I., & Mills, C. (2012). Absorption of casein
antihypertensive peptides through an in vitro model of intestinal epithelium.
Food Digestion, 3, 16e24.
Corﬁeld, A. P., Myerscough, N., Longman, R., Sylvester, P., Arul, S., & Pignatelli, M.
(2000). Mucins and mucosal protection in the gastrointestinal tract: new
prospects for mucins in the pathology of gastrointestinal disease. Gut, 47,
589e594.
Cross, M. L., & Gill, H. S. (2000). Immunomodulatory properties of milk. British
Journal of Nutrition, 84, S81eS89.
Da Cruz, A. G., de Assis Fonseca Faria, J., Isay Saad, S. M., Andre Bolini, H. M.,
Sant’Ana, A. S., et al. (2010). High pressure processing and pulsed electric ﬁelds:
potential use in probiotic dairy foods processing. Trends in Food Science and
Technology, 21, 483e493.
Daddaoua, A., Puerta, V., Zarzuelo, A., Suárez, M. D., Sánchez de Medina, F., &
Martínez-Augustin, O. (2005). Bovine glycomacropeptide is anti-inﬂammatory
in rats with hapten induced colitis. Journal of Nutrition, 135, 1164e1170.
De Kok, T. M., van Breda, S. G., & Manson, M. M. (2008). Mechanisms of combined
action of different chemopreventive dietary compounds. European Journal
Nutrition, 47, 51e59.
De Mejia, E. G., & Dia, V. P. (2010). The role of nutraceutical proteins and peptides in
apoptosis, angiogenesis, and metastasis of cancer cells. Cancer Metastasis Re-
view, 29, 511e528.
Demers-Mathieu, V., Gauthier, S. F., Britten, M., Fliss, I., Robitaille, G., & Jean, J.
(2013a). Inhibition of Listeria monocytogenes growth in Cheddar cheese by an
anionic peptides-enriched extract from whey proteins. International Dairy
Journal, 32, 6e12.
Demers-Mathieu, V., Gauthier, S. F., Britten, M., Fliss, I., Roobitaille, G., & Jean, J.
(2013b). Antibacterial activity of peptides extracted from tryptic hydrolyzate of
whey protein by nanoﬁltration. International Dairy Journal, 28, 94e101.
Drucker, D. J., & Nauck, M. A. (2006). The incretin system: glucagon-like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet, 368, 1696e1705.
EFSA. (2009). EFSA Panel on Dietetic Products Nutrition and Allergies (NDA). Sci-
entiﬁc opinion on the substantion of health claims related to isoleucine-
proline-proline (IPP) and valine-proline-proline (VPP) and maintenance of
normal blood pressure (ID 615, 661, 1831, 1832, 2891), and maintenance of the
elastic properties of the arteries (ID 1832,) pursuant to Article 13(1) of regu-
lation (EC) No 1924/2006 on request from the European Commission. EFSA
Journal, 7, 1259e1277.
Eliassen, L. T., Berge, G., Leknessund, A., Wilkman, M., Lindin, I., Løkke, C., et al.
(2006). The antimicrobial peptide, Lactoferricin B, is cytotoxic to neuroblastoma
cells in vitro and inhibits xenograft growth in vivo. International Journal of
Cancer, 119, 493e500.
Eliassen, L. T., Berge, G., Sveinbjørnsson, B., Svendsen, J. S., Vorland, L. H., &
Rekdal, Ø. (2002). Evidence for a direct antitumor mechanism of action of
bovine lactoferricin. Anticancer Research, 22, 2703e2710.
Embleton, N. D., Berrington, J. E., McGuire, W., Stewart, C. J., & Cummings, S. P.
(2013). Lactoferrin: antimicrobial activity and therapeutic potential. Seminars in
Fetal and Neonatal Medicine, 18, 143e149.
Engberink, M. F., Schouten, E. G., Kok, F. J., Van Mierlo, L. A. J., Brouwer, I. A., &
Geleijnse, J. M. (2008). Lactotripeptides show no effect on human blood pres-
sure: results from a double-blind randomized controlled trial. Hypertension, 51,
399e405.
Erdmann, K., Cheung, B. W. Y., & Schröder, H. (2008). The possible roles of food-
derived bioactive peptides in reducing the risk of cardiovascular disease. Jour-
nal of Nutritional Biochemistry, 19, 643e654.
Espeche Turbay, M. B., de Moreno de LeBlanc, A., Perdigón, G., Savoy de Giori, G., &
Hebert, E. M. (2012). b-casein hydrolysate generated by the cell envelope-
associated proteinase of Lactobacillus delbrueckii ssp. lactis CRL 581 protects
against trinitrobenzene sulfonic acid-induced colitis in mice. Journal of Dairy
Science, 95, 1108e1118.
Espinoza, A. D., Morawicki, R. O., & Hager, T. (2012). Hydrolysis of whey protein
isolate using subcritical water. Journal of Food Science, 71, C20eC26.
Fadini, G. P., & Avogaro, A. (2011). Cardiovascular effects of DPP-4 inhibition: beyond
GLP-1. Vascular Pharmacology, 55, 10e16.
B. Hernández-Ledesma et al. / International Dairy Journal 38 (2014) 82e10096Faure, M., Mettraux, C., Moennoz, D., Godin, J. P., Vuichoud, J., Rochat, F., et al.
(2006). Speciﬁc amino acids increase mucin synthesis and microbiota in
dextran sulfate sodium-treated rats. Journal of Nutrition, 136, 1558e1564.
Fitzgerald, R. J., Murray, B. A., & Walsh, D. J. (2004). Hypotensive peptides from milk
proteins. Journal of Nutrition, 134, S980eS988.
Freiburghaus, C., Janicke, B., Lindmark-Månsson, H., Oredsson, S. M., &
Paulsson, M. A. (2009). Lactoferricin treatment decreases the rate of cell pro-
liferation of a human colon cancer cell line. Journal of Dairy Science, 92, 2477e
2484.
Freiburghaus, C., Lindmark-Månsson, H., Oredsson, S. M., & Paulsson, M. A. (2012).
Reduction of ultraviolet light-induced DNA damage in human colon cancer cells
treated with a lactoferrin-derived peptide. Journal of Dairy Science, 95, 5552e
5560.
Froetschel, M. A., Azain, M. J., Edwards, G. L., Barb, C. R., & Amos, H. E. (2001).
Opioid and cholecystokinin antagonists alleviate gastric inhibition of food
intake by premeal loads of casein in meal-fed rats. Journal of Nutrition, 131,
3270e3276.
Fromentin, G., Darcel, N., Chaumontet, C., Marsset-Baglieri, A., Nadkarni, N., &
Tomé, D. (2012). Peripheral and central mechanisms involved in the control of
food intake by dietary amino acids and proteins. Nutrition Research Reviews, 25,
29e39.
Furlong, S. J., Mader, J. S., & Hoskin, D. W. (2010). Bovine lactoferricin induces
caspase-independent apoptosis in human B-lymphoma cells and extends the
survival of immune-deﬁcient mice bearing B-lymphoma xenografts. Experi-
mental and Molecular Pathology, 88, 371e375.
Gaudel, C., Nongonierma, A. B., Maher, S., Flynn, S., Krause, M., Murray, B., et al.
(2013). A whey protein hydrolysate promotes insulinotropic activity in a clonal
pancreatic beta-cell line and enhances glycemic function in ob/ob mice. Journal
of Nutrition, 143, 1109e1114.
Gauthier, S. F., Pouliot, Y., & Saint-Sauveur, D. (2006). Immunomodulatory peptides
obtained by the enzymatic hydrolysis of whey proteins. International Dairy
Journal, 16, 1315e1323.
Gibson, P. R., & Muir, J. G. (2005). Reinforcing the mucus: a new therapeutic
approach for ulcerative colitis? Gut, 54, 900e903.
Gilbert, J. A., Joanisse, D. R., Chaput, J. P., Miegueu, P., Cianﬂone, K., Almeras, N., et al.
(2011). Milk supplementation facilitates appetite control in obese women
during weight loss: a randomised, single-blind, placebo-controlled trial. British
Journal of Nutrition, 105, 133e143.
Gill, H. S., Doull, F., Rutherfurd, K. J., & Cross, M. L. (2000). Immunoregulatory
peptides in bovine milk. British Journal of Nutrition, 84, S111eS117.
Gómez-Ruiz, J. A., Ramos, M., & Recio, I. (2002). Angiotensin-converting enzyme-
inhibitory peptides in Manchego cheeses manufactured with different starter
cultures. International Dairy Journal, 12, 697e706.
Gómez-Ruiz, J. A., Ramos, M., & Recio, I. (2007). Identiﬁcation of novel angiotensin
converting enzyme-inhibitory peptides from ovine milk proteins by CE-MS and
chromatographic techniques. Electrophoresis, 28, 4202e4211.
González-Chávez, S. A., Erévalo-Gallegos, S., & Rascón-Cruz, Q. (2009). Lactoferrin:
structure, function and applications. International Journal of Antimicrobial
Agents, 33, 301e1e301e8.
Gunnarsson, P. T., Winzell, M. S., Deacon, C. F., Larsen, M. O., Jelic, K., Carr, R. D., et al.
(2006). Glucose-induced incretin hormone release and inactivation are differ-
ently modulated by oral fat and protein in mice. Endocrinology, 147, 3173e3180.
Hall, W. L., Millward, D. J., Long, S. J., & Morgan, L. M. (2003). Casein and whey exert
different effects on plasma amino acid proﬁles, gastrointestinal hormone
secretion and appetite. British Journal of Nutrition, 89, 239e248.
Han, K. S., Deglaire, A., Sengupta, R., & Moughan, P. (2008). Hydrolyzed casein in-
ﬂuences mucin gene expression in the rat. Journal of Agricultural and Food
Chemistry, 56, 5572e5576.
Hansen, M., Sandström, B., & Lönnerdal, B. (1996). The effect of casein phospho-
peptides on zinc and calcium absorption from high phytate infant diets
assessed in rat pups and Caco-2 cells. Pediatric Research, 40, 547e552.
Hansen, M., Sandström, B., Jensen, M., & Sorensen, S. S. (1997a). Casein phospho-
peptides improve zinc and calcium absorption from rice-based but not from
whole-grain infant cereal. Journal of Pediatric Gastroenterology and Nutrition, 24,
56e62.
Hansen, M., Sandström, B., Jensen, M., & Sorensen, S. S. (1997b). Effect of casein
phosphopeptides on zinc and calcium absorption from bread meals. Journal of
Trace Elements in Medicine and Biology, 11, 143e149.
Hatzoglou, A., Bakogeorgou, E., Hatzoglou, C., Martin, P. M., & Castanas, E. (1996).
Antiproliferative and receptor binding properties of a- and b-casomorphins in
the T47D human breast cancer cell line. European Journal of Pharmacology, 310,
217e223.
Håversen, L. A., Engberg, I., Baltzer, L., Dolphin, G., Hanson, L.Å., & Mattsby-Baltzer, I.
(2000). Human lactoferrin and peptides derived from a surface-exposed helical
region reduce experimental Escherichia coli urinary infection in mice. Infection
and Immunity, 68, 5816e5823.
Hayashida, K., Takeuchi, T., Shimizu, H., Ando, K., & Harada, E. (2003a). Novel
function of bovine milk derived lactoferrin on antinociception mediated by m-
opioid receptor in the rat spinal cord. Brain Research, 965, 239e245.
Hayashida, K., Takeuchi, T., Shimizu, H., Ando, K., & Harada, E. (2003b). Lactoferrin
enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord.
American Journal of Physiology, 285, R306eR312.
Hayes, M., Ross, R. P., Fitzgerald, G. F., Hill, C., & Stanton, C. (2006). Casein-derived
antimicrobial peptides generated by Lactobacillus acidophilus DPC6026. Applied
and Environmental Microbiology, 72, 2260e2264.Heany, R. P., Saito, Y., & Orimo, H. (1994). Effect of caseinophosphopeptide on
absorbability of co-ingested calcium in normal postmenopausal women. Journal
of Bone and Mineral Metabolism, 12, 77e81.
Henschen, A., Lottspeich, F., Brantl, V., & Teschemacher, H. (1979). Beta-casomor-
phins e exorphins derived from casein peptone. Hoppe-Seylers Zeitschrift fur
Physiologische Chemie, 360, 1157e1158.
Hernández-Ledesma, B., Contreras, M. M., & Recio, I. (2011). Antihypertensive
peptides: production, bioavailability and incorporation into foods. Advances in
Colloid and Interface Science, 165, 23e35.
Hernández-Ledesma, B., Miguel, M., Amigo, L., Aleixandre, M. A., & Recio, I. (2007).
Effect of simulated gastrointestinal digestion of the antihypertensive properties
of b-lactoglobulin-derived peptides. Journal of Dairy Research, 74, 336e339.
Hernández-Ledesma, B., Recio, I., Ramos, M., & Amigo, L. (2002). Preparation of
ovine and caprine b-lactoglobulin hydrolysates with ACE-inhibitory activity.
Identiﬁcation of active peptides from caprine b-lactoglobulin hydrolysed with
thermolysin. International Dairy Journal, 12, 805e812.
Hirayama, M., Toyota, K., Hidaka, H., & Naito, H. (1992). Phosphopeptides in rat
intestinal digests after ingesting casein phosphopeptides. Bioscience, Biotech-
nology and Biochemistry, 56, 1128e1129.
Hoek, K., Milne, J. M., Grieve, P. A., Dionoysius, D. A., & Smith, R. (1997). Antibacterial
activity of bovine lactoferrin-derived peptides. Antimicrobial Agents and
Chemotherapy, 41, 54e59.
Hoskin, D. W., & Ramamoorthy, A. (2008). Studies on anticancer activities of anti-
microbial peptides. Biochimica et Biophysica Acta, 1778, 357e385.
Hurrell, R. F., Lynch, S. R., Trinidad, T. P., Dassenko, S. A., & Cook, J. D. (1989). Iron
absorption in humans as inﬂuenced by bovine milk proteins. American Journal
of Clinical Nutrition, 49, 546e552.
Ibrahim, H. R., Thomas, U., & Pellegrini, A. (2001). A helix-loop-helix peptide at the
upper lip of the active site cleft of lysozyme confers potent antimicrobial ac-
tivity with membrane permeabilization action. Journal of Biological Chemistry,
276, 43767e43774.
Iigo, M., Kuhara, T., Ushida, Y., Sekine, K., Moore, M. A., & Tsuda, H. (1999). Inhibitory
effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice.
Clinical and Experimental Metastasis, 17, 35e40.
Jiang, Z., Tian, B., Brodkorb, A., & Huo, G. (2010). Production, analysis and in vivo
evaluation of novel angiotensin-I-converting enzyme inhibitory peptides from
bovine casein. Food Chemistry, 123, 779e786.
Jones, K. W., Eller, L. K., Parnell, J. A., Doyle-Baker, P. K., Edwards, A. L., & Reimer, R. A.
(2013). Effect of a dairy- and calcium-rich diet on weight loss and appetite
during energy restriction in overweight and obese adults: a randomized trial.
European Journal of Clinical Nutrition, 67, 371e376.
Kamemori, N., Takeuchi, T., Hayashida, K., & Harada, E. (2004). Suppressive effects of
milk-derived lactoferrin on the psychological stress in adult rats. Brain Research,
1029, 34e40.
Karaki, H., Doi, K., Sugano, S., Uchiwa, H., Sugai, R., Murakami, U., et al. (1990).
Antihypertensive effect of tryptic hydrolysate of milk casein in spontaneously
hypertensive rats. Comparative Biochemistry and Physiology. Part C. Pharma-
cology, Toxicology, and Endocrinology, 96, 367e371.
Kasai, T., Iwasaki, R., Tanaka, M., & Kiriyama, S. (1995). Caseinphosphopeptides
(CPP) in feces and contents in digestive tract of rats fed casein and CPP prep-
arations. Bioscience, Biotechnology and Biochemistry, 59, 26e30.
Keogh, J. B., Woonton, B. W., Taylor, C. M., Janakievski, F., Desilva, K., & Clifton, P. M.
(2010). Effect of glycomacropeptide fractions on cholecystokinin and food
intake. British Journal of Nutrition, 104, 286e290.
Kibangou, I. B., Bouhallab, S., Henry, G., Bureau, F., Allouche, S., Blais, A., et al. (2005).
Milk proteins and iron absorption: contrasting effects of different casein-
ophosphopeptides. Pediatric Research, 58, 731e734.
Kim, J. H., Desor, D., Kim, Y. T., Yoon, W. J., Kim, K. S., Jun, J. S., et al. (2007). Efﬁcacy of
aS1-casein hydrolysate on stress-related symptoms in women. European Journal
Clinical Nutrition, 61, 536e541.
Kitamura, H., & Otani, H. (2002). Fecal IgA levels in healthy persons who
ingested cakes with or without bovine casein phosphopeptides. Milchwis-
senschaft, 57, 11e12.
Kitts, D. D., Yuan, Y. V., Nagasawa, T., & Moriyama, Y. (1992). Effect of casein, casein
phosphopeptides and calcium intake on ileal 45Ca disappearance and temporal
systolic blood pressure in spontaneously hypertensive rats. British Journal of
Nutrition, 68, 765e781.
Kopra, N., Scholz-Ahrens, K., & Barth, C. A. (1992). Effect of casein phosphopeptides
on utilization of calcium in vitamin D-replete and vitamin D-deﬁcient rats.
Milchwissenschaft, 47, 488e493.
Korhonen, H., & Pihlanto, A. (2006). Bioactive peptides: production and function-
ality. International Dairy Journal, 16, 945e960.
Kosseva, M. R., Panesar, P. S., Kaur, G., & Kennedy, J. F. (2009). Use of immobilised
biocatalysts in the processing of cheese whey. International Journal of Biological
Macromolecules, 45, 437e447.
Kullisaar, T., Songisepp, E., Mikelsaar, M., Zilmer, K., Vihalemm, T., & Zilmer, M.
(2003). Antioxidative probiotic fermented goats’ milk decreases oxidative
stress-mediated atherogenicity in human subjects. British Journal of Nutrition,
90, 449e456.
Kuwata, H., Yip, T. T., Tomita, M., & Hutchens, T. W. (1998). Direct evidence of the
generation in human stomach of an antimicrobial peptide domain (lactoferri-
cin) from ingested lactoferrin. Biochimica et Biophysica Acta, 1429, 129e141.
Kuwata, H., Yip, T. T., Yamauchi, K., Teraguchi, S., Hayasawa, H., Tomita, M., et al.
(1998). The survival of ingested lactoferrin in the gastrointestinal tract of adult
mice. Biochemistry Journal, 334, 321e323.
B. Hernández-Ledesma et al. / International Dairy Journal 38 (2014) 82e100 97Lacroix, I. M. E., & Li-Chan, E. C. Y. (2012). Evaluation of the potential of dietary
proteins as precursors of dipeptidyl peptidase (DPP)-IV inhibitors by an in silico
approach. Journal of Functional Foods, 4, 403e422.
Lahov, E., & Regelson, W. (1996). Antibacterial and inmunostimulating casein-
derived substances from milk: casecidin, isracidin peptides. Federal Chemistry
Toxicology, 34, 131e145.
Lam, S. M. S. C. C., Moughan, P. J., Awati, A., & Morton, H. R. (2009). The inﬂuence of
whey protein and glycomacropeptide on satiety in adult humans. Physiology
and Behavior, 96, 162e168.
LeBlanc, J. G., Matar, C., Valdéz, J. C., LeBlanc, J., & Perdigón, G. (2002). Immuno-
modulating effects of peptidic fractions issued from milk fermented with
Lactobacillus helveticus. Journal of Dairy Science, 85, 2733e2742.
LeBlanc, J., Fliss, I., & Matar, C. (2004). Induction of a humoral immune response
following an Escherichia coli O157:H7 infection with an immunomodulatory
peptidic fraction derived from Lactobaciluus helveticus-fermented milk. Clinical
and Diagnostic Laboratory Immunology, 11, 1171e1181.
Lee, H. Y., Park, J. H., Seok, S. H., Baek, M. W., Kim, D. J., Lee, B. H., et al. (2005).
Potencial antimicrobial effects of human lactoferrin against oral infection with
Listeria monocytogenes in mice. Journal of Medical Microbiology, 54, 1049e1054.
Lee, Y. M., Skurk, T., Hennig, M., & Hauner, H. (2007). Effect of a milk drink sup-
plemented with whey peptides on blood pressure in patients with mild hy-
pertension. European Journal of Nutrition, 46, 21e27.
Lee, Y. S., Noguchi, T., & Naito, H. (1979). An enhanced intestinal absorption of
calcium in the rat directly attributed to dietary casein. Agricultural and Biological
Chemistry, 43, 2009e2011.
Lee, Y. S., Noguchi, T., & Naito, H. (1980). Phosphopeptides and soluble calcium in
the intestine of rats given a casein diet. British Journal of Nutrition, 43, 457e467.
Lee, Y. S., Noguchi, T., & Naito, H. (1983). Intestinal absorption of calcium in rats
given rats containing casein or amino acid mixture: the role of casein phos-
phopeptides. British Journal of Nutrition, 49, 67e76.
Legrand, D. (2012). Lactoferrin, a key molecule in immune and inﬂammatory pro-
cesses. Biochemistry and Cell Biology, 90, 252e268.
Levay, P. F., & Viljoen, M. (1995). Lactoferrin, a general review. Haematologica, 80,
252e267.
Liepke, C., Zucht, H. D., Forssmann, W. G., & Ständker, L. (2001). Puriﬁcation of
novel peptide antibiotics from human milk. Journal of Chromatography B, 752,
369e377.
Linden, S. K., Sutton, P., Karlsson, N. G., Korolik, V., & McGuckin, M. A. (2008).
Mucins in the mucosal barrier to infection. Mucosal Immunology, 1, 183e197.
López-Expósito, I., & Recio, I. (2008). Protective effect of milk peptides: antibacterial
and antitumor properties. Advances in Experimental Medicine and Biology, 606,
271e293.
López-Expósito, I., Gómez-Ruiz, J. A., Amigo, L., & Recio, I. (2006). Identiﬁcation of
antibacterial peptides from ovine aS2-casein. International Dairy Journal, 16,
1072e1080.
López-Expósito, I., Minervini, F., Amigo, L., & Recio, I. (2006). Identiﬁcation of
antibacterial peptides from bovine k-casein. Journal of Food Protection, 69,
2992e2997.
López-Fandiño, R. (2006). High pressure-induced changes in milk proteins and
possible applications in dairy technology. International Dairy Journal, 16, 1119e
1131.
López-Huertas, E., Teucher, B., Boza, J. J., Martínez-Férez, A., Majsak-Newman, G.,
Baró, L., et al. (2006). Absorption of calcium from milks enriched with fructo-
oligosacharides, caseinophosphopeptides, tricalcium phosphate, and milk
solids. American Journal of Clinical Nutrition, 83, 310e316.
López-Posadas, R., Requena, P., González, R., Suárez, M. D., Zarzuelo, A., Sánchez de
Medina, F., et al. (2010). Bovine glycomacropeptide has intestinal antiin-
ﬂammatory effects in rats with dextran sulfate-induced colitis. Journal of
Nutrition, 140, 2014e2019.
Luhovyy, B. L., Akhavan, T., & Anderson, G. H. (2007). Whey proteins in the regu-
lation of food intake and satiety. Journal of the American College of Nutrition, 26,
S704eS712.
Luo, S. J., & Wong, L. L. (2004). Oral care confections and method of using. US Patent,
6733818.
MacLeod, E. L., Clayton, M. K., van Calcar, S. C., & Ney, D. M. (2010). Breakfast with
glycomacropeptide compared with amino acids suppresses plasma ghrelin
levels in individuals with phenylketonuria. Molecular Genetics and Metabolism,
100, 303e308.
Madadlou, A., Sheehan, D., Emam-Djomeh, Z., & Mousavi, M. E. (2011). Ultrasound-
assisted generation of ACE-inhibitory peptides from casein hydrolyzed with
nanoencapsulated protease. Journal of the Science of Food and Agriculture, 91,
2112e2116.
Mader, J. S., Richardson, A., Salsman, J., Top, D., de Antueno, R., Duncan, R., et al.
(2007). Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by
sequential permeabilization of the cell membrane and targeting of mitochon-
dria. Experimental Cell Research, 313, 2634e2650.
Mader, J. S., Salsman, J., Conrad, D. M., & Hoskin, D. W. (2005). Bovine lactoferricin
selectively induces apoptosis in human leukemia and carcinoma cell lines.
Molecular Cancer Therapeutics, 4, 612e624.
Maeno, M., Yamamoto, N., & Takano, T. (1996). Identiﬁcation of an antihypertensive
peptide from casein hydrolysate produced by a proteinase from Lactobacillus
helveticus CP790. Journal of Dairy Science, 79, 1316e1321.
Malkoski, M., Dashper, S. G., O’Brien-Simpson, N. M., Talbo, G. H., Macris, M.,
Cross, K. J., et al. (2001). Kappacin, a novel antimicrobial peptide from bovine
milk. Antimicrobial Agents and Chemotherapy, 45, 2309e2315.Maneckjee, R., Biswas, R., & Vonderhaar, B. K. (1990). Binding of opioides to human
MCF-7 breast-cancer cells and their effects on growth. Cancer Research, 50,
2234e2238.
Manson, M. (2003). Cancer prevention e the potential for diet to modulate mo-
lecular signaling. Trends in Molecular Medicine, 9, 11e18.
Manzoni, P., Stolﬁ, I., Messner, H., Cattani, S., Laforgia, N., Romeo, M. G., et al. (2012).
Bovine lactoferrin prevents invasive fungal infections in very low birth weight
infants: a randomized controlled trial. Pediatrics, 129, 116e123.
Mao, X.-Y., Cheng, X., Wang, X., & Wu, S.-J. (2011). Free-radical-scavenging and anti-
inﬂammatory effect of yak milk casein before and after enzymatic hydrolysis.
Food Chemistry, 126, 484e490.
Marqués, D., Pessela, B. C., Betancor, L., Monti, R., Carrascosa, A. V., Rocha-Martín, J.,
et al. (2011). Protein hydrolysis by immobilized and stabilized trypsin.
Biotechnology Progress, 27, 677e683.
Martínez-Maqueda, D., Miralles, B., Cruz-Huerta, E., & Recio, I. (2013a). Casein hy-
drolysate and derived peptides stimulate mucin secretion and gene expression
in human intestinal cells. International Dairy Journal, 32, 13e19.
Martínez-Maqueda, D., Miralles, B., de Pascual-Teresa, S., Reverón, I., Muñoz, R., &
Recio, I. (2012a). Food-derived peptides stimulate mucin secretion and gene
expression in intestinal cells. Journal of Agricultural and Food Chemistry, 60,
8600e8605.
Martínez-Maqueda, D., Miralles, B., Ramos, M., & Recio, I. (2013b). Effect of b-lacto-
globulin hydrolysate and b-lactorphin on intestinal mucin secretion and gene
expression in human goblet cells. Food Research International, 54, 1287e1291.
Martínez-Maqueda, D., Miralles, B., Recio, I., & Hernández-Ledesma, B. (2012b).
Antihypertencive peptides from food proteins: a review. Food and Function, 3,
350e361.
Matsui, T., Okumura, H., & Yano, H. (2002). Absorption of zinc from dietary casein
phosphopeptide complex with zinc in rats given a soybean protein-based diet.
Journal of Nutritional Science and Vitaminology, 48, 247e250.
McCann, K. B., Shiell, B. J., Michalski, W. P., Lee, A., Wan, J., Roginski, H., et al. (2006).
Isolation and characterisation of a novel antibacterial peptide from bovine as1-
casein. International Dairy Journal, 16, 316e323.
McDonagh, D., & Fitzgerald, R. J. (1998). Production of caseinophosphopeptides
(CPPs) from sodium caseinate using a range of commercial protease prepara-
tions. International Dairy Journal, 8, 39e45.
Meisel, H., & Fitzgerald, R. J. (2003). Biofunctional peptides from milk proteins:
mineral binding and cytomodulatory effects. Current Pharmaceutical Design, 9,
1289e1295.
Meisel, H., & Frister, H. (1988). Chemical characterization of a casein-
ophosphopeptide isolated from in vivo digests of a casein diet. Biological
Chemistry Hoppe-Seyler, 369, 1275e1279.
Meisel, H., & Frister, H. (1989). Chemical characterization of bioactive peptides from
in vivo digests of casein. Journal of Dairy Research, 56, 343e349.
Meisel, H., Bernard, H., Fairweather-Tait, S., Fitzgerald, R. J., Hartmann, R., Lane, C. N.,
et al. (2003). Detection of caseinophosphopeptides in the distal ileostomy ﬂuid
of human subjets. British Journal of Nutrition, 89, 351e358.
Memarpoor-Yazdi, M., Asoodeh, A., & Chamani, J. (2012). A novel antioxidant and
antimicrobial peptide from egg white lysozyme hydrolysates. Journal of Func-
tional Foods, 4, 278e286.
Messaoudi, M., Lalonde, R., Schroeder, H., & Desor, D. (2009). Anxiolytic-like effects
and safety proﬁle of a tryptic hydrolysate from bovine as1-casein in rats.
Fundamental and Clinical Pharmacology, 23, 323e330.
Messaoudi, M., Lefranc-Millot, C., Desor, D., Demagny, B., & Bourdon, L. (2005). Ef-
fects of a tryptic hydrolysate from bovine milk aS1-casein on hemodynamic
responses in healthy human volunteers facing successive mental and physical
situations. European Journal of Nutrition, 44, 128e132.
Mezzaroba, L. F. H., Carvalho, J. E., Ponezi, A. N., Antônio, M. A., Monteiro, K. M.,
Possenti, A., et al. (2006). Antiulcerative properties of bovine a-lactalbumin.
International Dairy Journal, 16, 1005e1012.
Miclo, L., Perrin, E., Driou, A., Papadopoulos, V., Boujrad, N., Vanderesse, R., et al.
(2001). Characterization of a-casozepine, a tryptic peptide from bovine aS1-
casein with benzo diazepine-like activity. FASEB Journal, 15, 1780e1782.
Miguel, M., Gómez-Ruiz, J. A., Recio, I., & Aleixandre, A. (2010). Changes in arterial
blood pressure after single oral administration of milk-casein derived peptides
in spontaneously hypertensive rats. Molecular Nutrition and Food Research, 54,
1422e1427.
Miguel, M., Manso, M. A., López-Fandiño, R., Alonso, M. J., & Salaices, M. (2007).
Vascular effects and antihypertensive properties of kappa-casein macropeptide.
International Dairy Journal, 17, 1473e1477.
Miguel, M., Recio, I., Ramos, M., Delgado, M. A., & Aleixandre, A. (2006). Antihy-
pertensive effect of peptides obtained from Enterococcus faecalis-fermented
milk in rats. Journal of Dairy Science, 89, 3352e3359.
Mine, Y., Ma, F. P., & Lauriau, S. (2004). Antimicrobial peptides released by enzy-
matic hydrolysis of hen egg white lysozyme. Journal of Agricultural and Food
Chemistry, 52, 1088e1094.
Minervini, F., Algaron, F., Rizzello, C. G., Fox, P. F., Monnet, V., & Gobetti, M. (2003).
Angiotensin I-converting-enzyme-inhibitory and antibacterial peptides from
Lactobacillus helveticus PR4 proteinase-hydrolyzed caseins of milk from six
species. Applied and Environmental Microbiology, 69, 5297e5305.
Miquel, E., & Farré, R. (2007). Effects and future trends of casein phosphopeptides
on zinc bioavailability. Trends in Food Science and Technology, 18, 139e143.
Miyauchi, H., Kaino, A., Shinoda, I., Fukuwatari, Y., & Hayasawa, H. (1997). Immu-
nomodulatory effect of bovine lactoferrin pepsin hydrolysate on murine sple-
nocytes and Peyer’s patch cells. Journal of Dairy Science, 80, 2330e2339.
B. Hernández-Ledesma et al. / International Dairy Journal 38 (2014) 82e10098Montagne, L., Piel, C., & Lalles, J. P. (2004). Effect of diet on mucin kinetics
and composition: nutrition and health implications. Nutrition Reviews, 62,
105e114.
Mora-Gutierrez, A., Farrell, H. M., Attaie, R., McWhinney, V. J., & Wang, C. (2007).
Inﬂuence of bovine and caprine casein phosphopeptides differing in as1-casein
content in determining the absorption of calcium from bovine and caprine
calcium-fortiﬁed milks in rats. Journal of Dairy Research, 75, 356e366.
Moughan, P. J., Fuller, M. F., Han, K. S., Kies, A. K., & Miner-Williams, W. (2007). Food-
derived bioactive peptides inﬂuence gut function. International Journal of Sport
Nutrition and Exercise Metabolism, 17, S5eS22.
Mykkänen, H. M., & Wasserman, R. H. (1980). Enhanced absorption of calcium by
casein phosphopeptides in rachitic and normal chicks. Journal of Nutrition, 110,
2141e2148.
Nagaoka, S., Futamura, Y., Miwa, K., Awano, T., Yamauchi, K., Kanamaru, Y., et al.
(2001). Identiﬁcation of novel hypocholesterolemic peptides derived from
bovine milk b-lactoglobulin. Biochemical and Biophysical Research Communica-
tions, 281, 11e17.
Nagaoka, S., Kanamaru, Y., & Kuzuya, Y. (1991). Effects of whey protein and casein
on the plasma and liver lipids in rats. Agricultural and Biological Chemistry, 55,
813e818.
Nagaoka, S., Kanamaru, Y., Kuzuya, Y., Kojima, T., & Kuwata, T. (1992). Comparative
studies on the serum cholesterol lowering action of the whey protein and soy-
bean protein in rats. Bioscience, Biotechnology and Biochemistry, 56, 1484e1485.
Naito, H., & Suzuki, H. (1972). In vivo formation of phosphopeptide with calcium-
binding property in the small intestinal tract of the rat fed on casein. Agricul-
tural and Biological Chemistry, 36, 409e415.
Naito, H., & Suzuki, H. (1974). Further evidence for the formation in vivo of phos-
phopeptide in the intestinal lumen from dietary b-casein. Agricultural and
Biological Chemistry, 38, 1543e1545.
Nakamura, Y., Yamamoto, N., Sakai, K., Okubo, A., Yamazaki, S., & Takano, T. (1995).
Puriﬁcation and characterization of antiotensin-I-converting enzyme inhibitors
from sour milk. Journal of Dairy Science, 78, 777e783.
Nakamura, Y., Yamamoto, N., Sakai, K., & Takano, T. (1995). Antihypertensive effect
of sour milk and peptides isolated from it that are inhibitors of angiotensing I-
converting enzyme. Journal of Dairy Science, 78, 1253e1257.
Narva, M., Kärkkäinen, M., Poussa, T., Lamberg-Allardt, C., & Korpela, R. (2003).
Caseinphosphopeptides in milk and fermented milk do not affect calcium
metabolism acutely in postmenopausal women. Journal of the American College
Nutrition, 22, 88e93.
Nauck, M. A., Kleine, N., Ørskov, C., Holst, J. J., Willms, B., & Creutzfeldt, C. (1993).
Normalization of fasting hyperglycemia by exogenous-1 (7e36 amide) in type 2
GLP diabetic patients. Diabetologia, 36, 741e744.
Nilsson, M., Holst, J. J., & Bjorck, I. M. (2007). Metabolic effects of amino acid
mixtures and whey protein in healthy subjects: studies using glucose equiva-
lent drinks. American Journal of Clinical Nutrition, 85, 996e1004.
Nongonierma, A. B., & Fitzgerald, R. J. (2013). Dipeptidyl peptidase IV inhibitory and
antioxidative properties of milk protein-derived dipeptides and hydrolysates.
Peptides, 39, 157e163.
Nurminen, M. L., Sipola, M., Kaarto, H., Pihlanto-Leppälä, A., Piilola, K., Korpela, R.,
et al. (2000). Alpha-lactorphin lowers blood pressure measured by radiote-
lemetry in normotensive and spontaneously hypertensive rats. Life Science, 66,
1535e1543.
Ochoa, T. J., Pezo, A., Cruz, K., Chea-Woo, E., & Cleary, T. G. (2012). Clinical studies of
lactoferrin in children. Biochemistry and Cell Biology-Biochimie et Biologie Cel-
lulaire, 90, 457e467.
Otani, H., Kihara, Y., & Park, M. (2000). The immunoenhancing property of a dietary
casein phosphopeptide preparation inn mice. Food and Agricultural Immunology,
12, 165e173.
Otani, H., Nakano, K., & Kawahara, T. (2003). Stimulatory effect of a dietary casein
phosphopeptide preparation on the mucosal IgA response of mice to orally
ingested lipopolysaccharide from Salmonella typhimurium. Bioscience, Biotech-
nology and Biochemistry, 67, 729e735.
Pal, S., & Ellis, V. (2010). The chronic effects of whey proteins on blood pressure,
vascular function, and inﬂammatory markers in overweight individuals. Obesity
(Silver Spring), 18, 1354e1359.
Pal, S., & Ellis, V. (2011). Acute effects of whey protein isolate on blood pressure,
vascular function and inﬂammatory markers in overweight postmenopausal
women. British Journal of Nutrition, 105, 1512e1519.
Pan, Y., Lee, A., Wan, J., Coventry, M. J., Michalski, W. P., Shiell, B., et al. (2006).
Antiviral properties of milk proteins and peptides. International Dairy Journal,
16, 1252e1261.
Pellegrini, A., Dettling, C., Thomas, U., & Hunziker, P. (2001). Isolation and charac-
terization of four bactericidal domains in the bovine b-lactoglobulin. Biochimica
et Biophysica Acta, 1526, 131e140.
Pellegrini, A., Thomas, U., Bramaz, N., Hunziker, P., & Von Fellenberg, R. (1999).
Isolation and identiﬁcation of three bactericidal domains in the bovine a-lact-
albumin molecule. Biochimica et Biophysica Acta, 1426, 439e448.
Pellegrini, A., Thomas, U., Bramaz, N., Klauser, S., Humziker, P., & von Fellenberg, R.
(1997). Identiﬁcation and isolation of a bactericidal domain in chicken egg
white lysozyme. Journal of Applied Microbiology, 82, 372e378.
Pepe, G., Tenore, G. C., Mastrocinque, R., Stusio, P., & Campiglia, P. (2013). Potential
anticarcinogenic peptides from bovine milk. Journal of Amino Acids, 2013,
939804.
Perego, S., Cosentino, S., Fiorilli, A., Tettamanti, G., & Ferraretto, A. (2012). Casein
phosphopeptides modulate proliferation and apoptosis in HT-29 cell linethrough their interaction with voltage-operated L-type calcium channels.
Journal of Nutritional Biochemistry, 23, 808e816.
Perego, S., Zabeo, A., Marasco, E., Giussani, P., Fiorilli, A., Tettamanti, G., et al. (2013).
Casein phosphopeptides modulate calcium uptake and apoptosis in Caco2 cells
through their interaction with the TRPV6 calcium channel. Journal of Functional
Foods, 5, 847e857.
Pérès, J. M., Bouhallab, S., Bureau, F., Maubois, J. L., Arhan, P., & Bouglé, D. (1997).
Absorption digestive du fer lié au caséinophosphopeptide 1-25 de la b-caséine.
Lait, 77, 433e440.
Pérès, J. M., Bouhallab, S., Bureau, F., Maubois, J. L., Arhan, P., & Bouglé, D. (1999).
Reduction of iron/zinc interactions using metal bound to the casein-
ophospeptide 1-25 of b-casein. Nutrition Research, 19, 1655e1663.
Pérès, J. M., Bouhallab, S., Bureau, F., Neuville, D., Maubois, J. L., Devroede, G., et al.
(1999). Mechanisms of absorption of caseinophosphopeptide bound iron.
Journal of Nutritional Biochemistry, 10, 215e222.
Phelan, M., Aherne, A., Fitzgerald, R. J., & O’Brien, N. M. (2009). Casein-derived
bioactive peptides: biological effects, industrial uses, safety aspects and regu-
latory status. International Dairy Journal, 19, 643e654.
Picariello, G., Iacomino, G., Mamone, G., Ferranti, P., Fierro, O., Gianfrani, C., et al.
(2013). Transport across Caco-2 monolayers of peptides arising from in vitro
digestion of bovine milk proteins. Food Chemistry, 139, 203e212.
Piccolomini, A. F., Iskandar, M. M., Lands, L. C., & Kubow, S. (2012). High hydrostatic
pressure pre-treatment of whey proteins enhances whey protein hydrolysate
inhibition of oxidative stress and IL-8 secretion in intestinal epithelial cells.
Food and Nutrition Research, 56. Article No 17549.
Pihlanto, A. (2006). Antioxidative peptides derived from milk proteins. International
Dairy Journal, 16, 1306e1314.
Pins, J. J., & Keenan, M. D. (2006). Effects of whey peptides on cardiovascular disease
risk factors. Journal of Clinical Hypertension, 8, 775e782.
Plaisancié, P., Claustre, J., Estienne, M., Henry, G., Boutrou, R., Paquet, A., et al.
(2013). A novel bioactive peptide from yoghurts modulates expression of
the gel-forming MUC2 mucin as well as population of globet cells and
Paneth cells along the small intestine. Journal of Nutritional Biochemistry,
24, 213e221.
Pointillart, A., & Guéguen, L. (1989). Absence d’effect de l’incorporation d’un
phosphopeptide du lait sur l’utlisation du calcium et du phosphore chez le
jeune porc. Reproduction, Nutrition, Development, 29, 477e486.
Power, O., Jakeman, P., & Fitzgerald, R. J. (2013). Antioxidative peptides: enzymatic
production, in vitro and in vivo antioxidant activity and potential applications
of milk-derived antioxidative peptides. Amino Acids, 44, 797e820.
Pripp, A. H. (2008). Effect of peptides derived from food proteins on blood
pressure: a meta-analysis of randomized controlled trials. Food and Nutrition
Research, 52, 1e9.
Prouxl, M., Gauthier, S. F., & Roy, D. (1992). Effect of casein hydrolysates on the
growth of Biﬁdobacteria. Lait, 72, 393e404.
Puknun, A., Bolscher, J. G. M., Nazmi, K., Veerman, E. C. I., Tungpradabkul, S.,
Wongratanacheewin, S., et al. (2013). A heterodimer comprised of two bovine
lactoferrin antimicrobial peptides exhibits powerful bactericidal activity against
Burkholderia pseudomallei. World Journal of Microbiology and Biotechnology, 29,
1217e1224.
Pupovac, J., & Anderson, G. H. (2002). Dietary peptides induce satiety via
cholecystokinin-A and peripheral opioid receptors in rats. Journal of Nutrition,
132, 2775e2780.
Qin, L.-Q., Xu, J.-Y., Dong, J.-Y., Zhao, Y., van Bladeren, P., & Zhang, W. (2013). Lac-
totripeptides intake and blood pressure management: a meta-analysis of ran-
domized controlled clinical trials. Nutrition, Metabolism & Cardiovascular
Diseases, 23, 395e402.
Quiros, A., Davalos, A., Lasuncion, M. A., Ramos, M., & Recio, I. (2008). Bioavailability
of the antihypertensive peptide LHLPLP: transepithelial ﬂux of HLPLP. Interna-
tional Dairy Journal, 18, 279e286.
Quirós, A., Ramos, M., Muguerza, B., Delgado, M. A., Miguel, M., Aleixandre, A., et al.
(2007). Identiﬁcation of novel antihypertensive peptides in milk fermented
with Enterococcus faecalis. International Dairy Journal, 17, 33e41.
Raju, K. V. S. N., Kumar, D. A., Arutselvan, N., Thejomoorthy, P., & Puvanakrishan, R.
(2005). Antinociceptive and antipyretie effects of derivatized tetrapeptide from
lactoferrinin rats. Peptides, 26, 615e619.
Recio, I., & Visser, S. (1999a). Two ion-exchange chromatographic methods for the
isolation of antibacterial peptides from lactoferrin. In situ enzymatic hydrolysis
on an ion-exchange membrane. Journal of Chromatography A, 831, 191e201.
Recio, I., & Visser, S. (1999b). Identiﬁcation of two distinct antibacterial domains
within the sequence of bovine aS2-casein. Biochimica et Biophysica Acta, 1428,
314e326.
Recio, I., & Visser, S. (2000). Antibacterial bing characteristics of bovine, ovine,
caprine lactoferrins: a comparative study. International Dairy Journal, 10,
597e605.
Recio, I., Contreras, M. M., Gomez-Sala, B., Vázquez, C., Fernández-Escribano, H., &
del Campo, R. (2011). Effect of a casein hydrolysate containing novel peptides in
hypertensive subjects. Annals of Nutrition and Metabolism, 58, 16e17.
Recio, I., Quirós, A., Hernández-Ledesma, B., Gómez-Ruiz, J. A., Miguel, M., Amigo, L.,
et al. (2006). Bioactive peptides in enzymatic hydrolysates milk caseins and
method of obtaining same. International WO Patent, 131586.
Requena, P., Daddaoua, A., Martínez-Plata, E., González, M., Zarzuelo, A.,
Suarez, M. D., et al. (2008). Bovine glycomacropeptide ameliorates experimental
rat ileitis by mechanisms involving downregulation of interleukin 17. British
Journal of Pharmacology, 154, 825e832.
B. Hernández-Ledesma et al. / International Dairy Journal 38 (2014) 82e100 99Reynolds, E. C., Cai, F., Shen, P., & Walker, G. D. (2003). Retention in plaque and
remineralization of enamel lesions by various forms of calcium in a mouthrinse
or sugar-free chewing gum. Journal of Dental Research, 82, 206e211.
Rocha, C., Gonçalves, M. P., & Teixeira, J. A. (2011). Immobilization of trypsin on
spent grains for whey protein hydrolysis. Process Biochemistry, 46, 505e511.
Rodríguez-Figueroa, J. C., González-Córdova, A. F., Astiazaran-García, H., & Vallejo-
Cordoba, B. (2013). Hypotensive and heart rate-lowering effects in rats
receiving milk fermented by speciﬁc Lactococcus lactis strains. British Journal of
Nutrition, 109, 827e833.
Rodríguez-Figueroa, J. C., González-Córdova, A. F., Torres-Llanez, M. J., García, H. S.,
& Vallejo-Cordoba, B. (2012). Novel angiotensin I-converting enzyme inhibitory
peptides produced in fermented milk by speciﬁc wild Lactococcus lactis strains.
Journal of Dairy Science, 95, 5536e5543.
Ruiz-Giménez, P., Ibáñez, A., Salom, J. B., Marcos, J. F., López-Díez, J. J., Vallés, S., et al.
(2010). Antihypertensive properties of lactoferricin B-derived peptides. Journal
of Agricultural and Food Chemistry, 58, 6721e6727.
Saint-Sauveur, D., Gauthier, S. F., Boutin, Y., Montoni, A., & Fliss, I. (2009). Effect of
feeding whey peptide fractions on the immune response in the healthy and
Escherichia coli infected mice. International Dairy Journal, 19, 537e544.
Saito, T., Nakamura, T., Kitazawa, H., Kawai, Y., & Itoh, T. (2000). Isolation and
structural analysis of antihypertensive peptides that exist naturally in Gouda
cheese. Journal of Dairy Science, 83, 1434e1440.
Saito, Y., Lee, Y. S., & Kimura, S. (1998). Minimum effective dose of casein phos-
phopeptides (CPP) for enhancement of calcium absorption in growing rats.
International Journal for Vitamin and Nutrition Research, 68, 335e340.
Sakai, T., Banno, Y., Kato, Y., Nozawa, Y., & Kawaguchi, M. (2005). Pepsin-digested
bovine lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral
cancer cells. Journal of Pharmacological Science, 98, 41e48.
Sánchez de Medina, F., Daddaoua, A., Requena, P., Capitán-Cañadas, F., Zarzuelo, A.,
Suárez, M. D., et al. (2010). New insights into the immunological effects of food
bioactive peptides in animal models of intestinal inﬂammation. Proceedings of
the Nutrition Society, 69, 454e462.
Sarmadi, B. H., & Ismail, A. (2010). Antioxidative peptides from food proteins: a
review. Peptides, 31, 1949e1956.
Sato, R., Noguchi, T., & Naito, H. (1983). The necessity for the phosphate protion of
casein molecules to enhance Ca absorption from the small intestine. Agricultural
and Biological Chemistry, 47, 2415e2417.
Sato, R., Noguchi, T., & Naito, H. (1986). Casein phosphopeptide (CPP) enhances
calcium absorption from the ligated segment of rat small intestine. Journal of
Nutritional Science and Vitaminology, 32, 67e76.
Sato, R., Shindo, M., Gunshin, H., Noguchi, T., & Naito, H. (1991). Characterization
of phosphopeptide derived from bovine b-casein e an inhibitor to intra-
intestinal precipitation of calcium-phosphate. Biochimica et Biophysica Acta,
1077, 413e415.
Schiffer, M., Chang, C. H., & Stevens, F. J. (1992). The functions of tryptophan resi-
dues in membrane proteins. Protein Engineering, 5, 213e214.
Scholz-Ahrens, K. E., Kopra, N., & Barth, C. A. (1990). Effect of casein phosphopep-
tides on utilization of calcium in minipigs and vitamin-D-deﬁcient rats. Zeits-
chrift für Ernährunswissenschaft, 29, 295e298.
Shimizu, M., & Hachimura, S. (2011). Gut as target for functional food. Trends in Food
Science and Technology, 22, 646e650.
Silveira, S. T., Martínez-Maqueda, D., Recio, I., & Hernández-Ledesma, B. (2013).
Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of
a whey protein concentrate rich in b-lactoglobulin. Food Chemistry, 141, 1072e
1077.
Siriwardhana, N., Kalupahanab, N. S., Cekanovac, M., LeMieuxa, M., Greerd, B.,
& Moustaid-Moussa, N. (2013). Modulation of adipose tissue inﬂammation
by bioactive food compounds. Journal of Nutritional Biochemistry, 24, 613e
623.
Smith, J. A., Wilkinson, M. C., & Liu, Q. M. (1997). Casein fragments having growth
promoting activity. International patent WO 1997016460 A1.
Solah, V. A., Kerr, D. A., Adikara, C. D., Meng, X. Q., Binns, C. W., Zhu, K., et al. (2010).
Differences in satiety effects of alginate- and whey protein-based foods.
Appetite, 54, 485e491.
Sousa, G. T. D., Lira, F. S., Rosa, J. C., de Oliveira, E. P., Oyama, L. M., et al. (2012).
Dietary whey protein lessens several risk factors for metabolic diseases: a re-
view. Lipids in Health and Disease, 11, 67e75.
Sprong, R. C., Schonewille, A. J., & van der Meer, R. (2010). Dietary cheese whey
protein protects rats against mild dextran sulfate sodium-induced colitis: role
of mucin and microbiota. Journal of Dairy Science, 93, 1364e1371.
Takahura, N., Wakabayashi, H., Ishibashi, H., Yamauchi, K., Teraguchi, S., Tamura, Y.,
et al. (2004). Effect of orally administered bovine lactoferrin on the immune
response in the oral candidiasis murine model. Journal of Medical Microbiology,
54, 495e500.
Takeuchi, T., Hayashida, K., Inagaki, H., Kuwahara, M., Tsubone, H., & Harada, E.
(2003). Opioid mediated suppressive effect of milk-derived lactoferrin on
distress induced by maternal separation in the rat pups. Brain Research, 979,
216e224.
Tang, Z., Yin, Y., Zhang, Y., Huang, R., Sun, Z., Li, T., et al. (2009). Effects of dietary
supplementation with an expressed fusion peptide bovine lactoferricin-
lactoferrampin on performance, immune function and intestinal mucosal
morphology in piglets weaned at age 21 d. British Journal of Nutrition, 101,
998e1005.
Teschemacher, H. (2003). Opioid receptor ligands derived from food proteins.
Current Pharmaceutical Design, 9, 1331e1344.Teucher, B., Majsak-Newman, G., Dainty, J. R., McDonagh, D., Fitzgerald, R. J., &
Fairweather-Tait, S. J. (2006). Calcium absorption is not increased by casein-
ophosphopeptides. American Journal of Clinical Nutrition, 84, 162e166.
Theolier, J., Hammami, R., Labelle, P., Fliss, I., & Jean, J. (2013). Isolation and iden-
tiﬁcation of antimicrobial peptides derived by peptic cleavage of whey protein
isolate. Journal of Functional Foods, 5, 706e714.
Toedebusch, R. G., Childs, T. E., Hamilton, S. R., Crowley, J. R., Booth, F. W., &
Roberts, M. D. (2012). Postprandial leucine and insulin responses and toxico-
logical effects of a novel whey protein hydrolysate-based supplement in rats.
Journal of the International Society of Sports Nutrition, 9, 24e33.
Tomita, M., Wakabayashi, H., Yamauchi, K., Teraguchi, S., & Hayasawa, H. (2002).
Bovine lactoferrin and lactoferricin derived from milk: production and appli-
cations. Biochemistry and Cell Biology, 80, 109e112.
Tompa, G., Laine, A., Pihlanto, A., Korhonen, H., Rogelj, I., & Marnilab, P. (2010).
Chemiluminescence of non-differentiated THP-1 promonocytes: developing an
assay for screening anti-inﬂammatory milk proteins and peptides. The Journal of
Biological and Chemical Luminiscence, 26, 251e258.
Tonouchi, H., Suzuki, M., Uchida, M., & Oda, M. (2008). Antihypertensive effect of an
angiotensin converting enzyme inhibitory peptide from enzyme modiﬁed
cheese. Journal of Dairy Research, 75, 284e290.
Trompette, A., Claustre, J., Caillon, F., Jourdan, G., Chayvialle, J. A., & Plaisancié, P.
(2003). Milk bioactive peptides and b-casomorphins induce mucus release in
rat jejunum. Journal of Nutrition, 133, 3499e3503.
Troncon Rosa, F., Zulet, M. A., Marchini, J. S., & Martínez, J. A. (2012). Bioactive
compounds with effects on inﬂammation markers in humans. International
Journal of Food Sciences and Nutrition, 63, 749e765.
Tsai, J. S., Chen, T. J., Pan, B. S., Gong, S. D., & Chung, M. Y. (2008). Antihypertensive
effect of bioactive peptides produced by protease-facilitated lactic acid
fermentation of milk. Food Chemistry, 106, 552e558.
Tsuchita, H., Goto, T., Yonehara, Y., & Kuwata, T. (1995). Calcium and phosphorus
availability from casein phosphopeptides in male growing rats. Nutrition
Research, 15, 1657e1667.
Tsuchita, H., Sekiguchi, I., Kuwata, T., Igarashi, C., & Ezawa, I. (1993). The effect of
casein phosphopeptides on calcium utilization in young ovariectomized rats.
Zeitschrift für Ernährunswissenschaft, 32, 121e130.
Tsuchita, H., Suzuki, T., & Kuwata, T. (2001). The effect of casein phosphopeptides on
calcium absorption from calcium-fortiﬁed milk in growing rats. British Journal
of Nutrition, 85, 5e10.
Tsuchiya, T., Takeuchi, T., Hayashida, K., Shimizu, H., Ando, K., & Harada, E. (2006).
Milk-derived lactoferrin may block tolerance to morphine analgesia. Brain
Research, 1068, 102e108.
Tulipano, G., Sibilia, V., Caroli, A. M., & Cocchi, D. (2011). Whey proteins as source
of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides, 32,
835e838.
Uchida, M., Ohshiba, Y., & Mogami, O. (2011). Novel dipeptidyl peptidase-4-
inhibiting peptide derived from b-lactoglobulin. Journal of Pharmacological
Sciences, 117, 63e66.
Uenishi, H., Kabuki, T., Seto, Y., Serizawa, A., & Nakajima, H. (2012). Isolation and
identiﬁcation of casein-derived dipeptidyl-peptidase 4 (DPP-IV)-inhibitory
peptide LPQNIPPL from gouda-type cheese and its effect on plasma glucose in
rats. International Dairy Journal, 22, 24e30.
Ushida, Y., Shimokawa, Y., Toida, T., Matsui, H., & Takase, M. (2007). Bovine a-
lactalbumin stimulates mucus metabolism in gastric mucosa. Journal of Dairy
Science, 90, 541e546.
Usinger, L., Jensen, L. T., Flambard, B., Linnneberg, A., & Ibsen, H. (2010). The anti-
hypertensive effect of fermented milk in individuals with prehypertension or
borderline hypertension. Journal of Human Hypertension, 24, 678e683.
Van der Kraan, M. I. A., Groenink, J., Nazmi, K., Veerman, E. C. I., Bolscher, J. G. M., &
Nieuw Amerongen, A. V. (2004). Lactoferrampin: a novel antimicrobial peptide
in the N1-domain of bovine lactoferrin. Peptides, 25, 177e183.
Van der Sluis, M., De Koning, B. A., De Bruijn, A. C., Velcich, A., Meijerink, J. P., Van
Goudoever, J. B., et al. (2006). Muc2-deﬁcient mice spontaneously develop
colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology,
131, 117e129.
Van Hooijdonk, A. C. M., Kussendrager, K. D., & Steijns, J. M. (2000). In vivo anti-
microbial and antiviral activity of components in bovine milk and colostrums
involved in non-speciﬁc defence. British Journal of Nutrition, 84, 127e134.
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., et al. (2002).
Colorectal cancer in mice genetically deﬁcient in the mucin Muc2. Science, 295,
1726e1729.
Vinderola, G., Matar, C., Palacios, J., & Perdigón, G. (2007). Mucosal immunomo-
dulation by the non-bacterial fraction of milk fermented by Lactobacillus hel-
veticus R389. International Journal of Food Microbiology, 115, 180e186.
Vinderola, G., Matar, C., & Perdigón, G. (2007). Milk fermentation products of
L. helveticus R389 active calineurin as a signal to promote gut mucosal immu-
nity. BMC Immunology, 8, 19e28.
Violle, N., Messaoudi, M., Lefranc-Millot, C., Desor, D., Nejdi, A., Demagny, B., et al.
(2006). Ethological comparison of the effects of a bovine aS1-casein tryptic
hydrolysate and diazepam on the behaviour of rats in two models of anxiety.
Pharmacology, Biochemistry and Behaviour, 84, 517e523.
Wakabayashi, H., Yamauchi, K., & Takase, M. (2006). Lactoferrin research, technol-
ogy and applications. International Dairy Journal, 16, 1241e1251.
Wang, W.-P., Iigo, M., Sato, J., Sekine, K., Adachi, I., et al. (2000). Activation of in-
testinal mucosal immunity in tumor-bearing mice by lactoferrin. Japanese
Journal of Cancer Research, 91, 1022e1027.
B. Hernández-Ledesma et al. / International Dairy Journal 38 (2014) 82e100100Welderufael, F. T., Gibson, T., & Jauregi, P. (2012). Production of angiotensin-I-
converting enzyme inhibitory peptides from b-lactoglobulin and casein-
derived peptides: an integrative approach. Biotechnology Progress, 28, 746e755.
Wu, S., Qi, W., Li, T., Lu, D., Su, R., & He, Z. (2013). Simultaneous production of multi-
functional peptides by pancreatic hydrolysis of bovine casein in an enzymatic
membrane reactor via combinational chromatography. Food Chemistry, 141,
2944e2951.
Xu, J. Y., Qin, L. Q., Wang, P. Y., Li, W., & Chang, C. (2008). Effect of milk tripeptides on
blood pressure: a meta-analysis of randomized controlled trials. Nutrition, 24,
933e940.
Yamauchi, R., Ohinata, K., & Yoshikawa, M. (2003). b-Lactotensin and neurotensin
rapidly reduce serum cholesterol via NT2 receptor. Peptides, 24, 1955e1961.
Yoo, Y. C., Watanabe, R., Koike, Y., Mitobe, M., Shimazaki, K.-I., et al. (1997).
Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk
protein-derived peptide: involvement of reactive oxygen species. Biochemical
and Biophysical Research Communications, 237, 624e628.
Yoo, Y. C.,Watanabe, S.,Watanabe, R., Hata, K., Shimazaki, K., & Azuma, I. (1997). Bovine
lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit
tumor metastasis in mice. Japanese Journal of Cancer Research, 88, 184e190.
Yu, B. P., & Chung, H. Y. (2006). The inﬂammatory process in aging. Reviews in
Clinical Gerontology, 16, 179e187.Yuan, Y. V., & Kitts, D. D. (1991). Conﬁrmation of calcium absorption and femoral
utilization in spontaneously hypertensive rats fed casein phosphopeptide
supplemented diets. Nutrition Research, 11, 1257e1272.
Zhang, T.-N., & Liu, N. (2010). Effect of bovine lactoferricin on DNA methyl-
transferase 1 levels in Jurkat T-leukemia cells. Journal of Dairy Science, 93,
3925e3930.
Zhao, W., Xu, G., Yang, R., & Katiyo, W. (2013). Preparation of casein phosphopep-
tides using a novel continuous process of combining an enzymatic membrane
reactor with anion-exchange chromatography. Journal of Food Engineering, 117,
105e112.
Zimmermann, M. B., & Hurrell, R. F. (2007). Nutritional iron deﬁciency. Lancet, 370,
511e520.
Zoghbi, S., Trompette, A., Claustre, J., El Homsi, M., Garzón, J., Jourdan, G., et al.
(2006). b-Casomorphin-7 regulates the secretion and expression of gastroin-
testinal mucins through a m-opioid pathway. American Journal of Physiology e
Gastrointestinal and Liver Physiology, 290, G1105eG1113.
Zommara, M., Tougo, H., Sakanao, M., & Imaizumi, K. (1998). Prevention of perox-
idative stress in rats fed on a low vitamin E containing diet by supplementing
with a fermented bovine milk whey preparation: effect of lactic acid and b-
lactoglobulin on the antiperoxidative action. Bioscience, Biotechnology and
Biochemistry, 62, 710e717.
 
Review Article
Milk Proteins, Peptides, and Oligosaccharides: Effects against
the 21st Century Disorders
Chia-Chien Hsieh,1 Blanca Hernández-Ledesma,2 Samuel Fernández-Tomé,2
Valerie Weinborn,3,4 Daniela Barile,3,4 and Juliana María Leite Nobrega de Moura Bell3,4
1Department of Human Development and Family Studies (Nutritional Science & Education), National Taiwan Normal University,
No.162, Section 1, Heping East Road, Taipei 106, Taiwan
2Instituto de Investigacio´n en Ciencias de la Alimentacio´n (CIAL, CSIC-UAM, CEI UAM+CSIC), Nicola´s Cabrera 9,
28049 Madrid, Spain
3Food Science Department, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA
4Foods for Health Institute, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA
Correspondence should be addressed to Blanca Herna´ndez-Ledesma; b.hernandez@csic.es
Received 21 October 2014; Accepted 21 December 2014
Academic Editor: Jinsong Ren
Copyright © 2015 Chia-Chien Hsieh et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Milk is the most complete food for mammals, as it supplies all the energy and nutrients needed for the proper growth and
development of the neonate. Milk is a source of many bioactive components, which not only help meeting the nutritional require-
ments of the consumers, but also play a relevant role in preventing various disorders. Milk-derived proteins and peptides have the
potential to act as coadjuvants in conventional therapies, addressing cardiovascular diseases, metabolic disorders, intestinal health,
and chemopreventive properties. In addition to being a source of proteins and peptides, milk contains complex oligosaccharides
that possess important functions related to the newborn’s development and health. Some of the health benefits attributed to milk
oligosaccharides include prebiotic probifidogenic effects, antiadherence of pathogenic bacteria, and immunomodulation. This
review focuses on recent findings demonstrating the biological activities of milk peptides, proteins, and oligosaccharides towards
the prevention of diseases of the 21st century. Processing challenges hindering large-scale production and commercialization of
those bioactive compounds have been also addressed.
1. Introduction: Role of Milk in Human Health
Milk, as the first food for mammals, supplies all the energy
and nutrients needed for the proper growth and development
of the neonate. For all mammalians, the consumption of
milk ends at the weaning period with the exception of
humans that continue consuming milk throughout their
life. Milk and derived dairy products are considered an
important constituent of a balanced diet. Moreover, it is a
source of many bioactive components, such as high-quality
proteins, lipids, carbohydrates, lactose, vitamins, minerals,
enzymes, hormones, immunoglobulins, and growth factors,
among others. These components not only help meeting
human nutritional requirements, but also play a relevant
role in preventing various disorders such as hypertension
and cardiovascular diseases [1], obesity [2], osteoporosis [3],
dental caries [4], poor gastrointestinal health [5], colorectal
cancer [6], ageing [7], and others [8].
Milk proteins supply nitrogen and amino acids to young
mammals and possess multiple physiological properties in
the intact form. Moreover, studies carried out in the past
decades have demonstrated the role of these proteins as
a source of biologically active peptides. Bioactive peptides
are inactive within the sequence of the parent protein but,
once released by in vitro processing conditions or by in vivo
gastrointestinal digestion, are capable of acting as regulatory
compounds exerting a positive impact on body functions and
ultimately promoting health benefits to the consumer [9].
Human milk is undoubtedly the most complete source of
nourishment for the newborn. Breastfed infants have been
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Table 1: Commercial milk products containing peptides with proven antihypertensive activity.
Commercial name Obtention process Protein source Active sequence(s) Publicationnumber [reference]
Peptide C12 Hydrolysis with trypsin 𝛼s1-Casein FFVAPFPEVFGK JP62270533 [31]
Biozate Hydrolysis with trypsin Whey proteins Whey peptides US6998259 [157]
Lowpept Hydrolysis with pepsin 𝛼s1-Casein RYLGY, AYFYPEL
WO2005012355
[158]
Calpis Fermentation 𝛽-Casein VPP, IPP US5449661A[37, 38]
Evolus Fermentation 𝛽-Casein VPP, IPP US6972282 [159]
shown to be less susceptible to diseases (i.e., diarrhea and
respiratory diseases) than those that were not breastfed. This
protective effect, which was previously attributed to human
milk antibodies, is today strongly correlatedwith the presence
of complex oligosaccharides (OS), the third most abundant
component of human milk [10]. Human milk is composed
of OS in concentrations varying according to different stages
of lactation: 20–23 g/L in colostrum and 12–14 g/L in mature
milk [11], being even more abundant than proteins (12 g/L)
[12]. Human milk oligosaccharides (HMO) are complex
sugars having 3 to 20 monosaccharide units [13] that are not
digestible by human enzymes [14]. These compounds have
important functions related to the newborn’s development
and health at local and systemic levels, including prebiotic
probifidogenic effects and antiadherence of pathogenic bac-
teria [15], brain development [16], and immunomodulatory
properties [17], among others.
In the last fifty years, chronic disorders have become the
leading cause of morbidity and mortality in industrialized
countries, with increasing incidence also observed in devel-
oping countries. Chronic disorders include cardiovascular
and neurological diseases, stroke, cancers, immune disor-
der and chronic respiratory disease, obesity, diabetes, and
metabolic syndrome [18]. In Europe, 87% of all deaths occur
due to chronic diseases and the number of people affected
is expected to rise considerably over the next few decades.
The majority of chronic diseases are caused by risk factors
which are mostly preventable. Diet and lifestyle are two
environmental factors that strongly affect these diseases; thus
modifications of these habits are becoming a new strategy for
disease prevention/treatment.
The aim of this paper is to review the recent literature on
the physiological effects of proteins, peptides, and oligosac-
charides with special emphasis on animal and human trials.
Other aspects such as the limited availability of in vivo studies
demonstrating the biological activities of OS frombovine and
caprine milk and the current challenges associated with the
recovery and commercial production of these compounds
have also been addressed.
2. Impact of Milk Proteins and Peptides on
the 21st Century Diseases
2.1. Milk-Derived Peptides against Cardiovascular Diseases.
Cardiovascular diseases (CVD) have become the leading
cause of morbidity and mortality worldwide, representing
an important medical and public health issue [19]. Although
earlier studies associated the consumption of wholemilk with
higher incidence of CVD, it has been demonstrated that milk
contains a plethora of bioactive substances which may con-
tribute to the prevention of most of the risk factors of CVD
[20]. Recently, bioactive milk peptides have gained interest
because of their notable antihypertensive, antioxidant, anti-
inflammatory, and hypocholesterolaemic effects. In this sec-
tion, the most current scientific information regarding in
vitro and in vivo studies on the role of milk proteins-derived
peptides on CVD is summarized and discussed.
2.1.1. Milk Peptides with Antihypertensive Activity. Epidemi-
ological studies suggest that the dietary intake of milk and
dairy foods is related to decreased risk of hypertension [21].
In addition to their high mineral content (e.g., calcium,
potassium, and magnesium) that can lower blood pressure
[22], other milk components, such as proteins and their
hydrolyzed products, have been also linked to the antihy-
pertensive effect of milk and dairy products. Angiotensin-
converting enzyme (ACE) is a multifunctional enzyme that
acts as one of the main regulators of blood pressure.
Thus, ACE inhibition is currently considered as one of the
best strategies for hypertension treatment. Most biologically
active peptides generated from milk proteins have demon-
strated ACE inhibitory activity. In the last two decades,
antihypertensive effects of some of these peptides have been
evaluated in spontaneously hypertensive rats (SHR) and
hypertensive humans, and the peptide sequences, doses, and
maximum decreases of systolic blood pressure (SBP) have
been summarized in several reviews [23–25].The hydrolyzate
obtained by the action of pepsin on casein, containing the
𝛼s1-casein-derived peptides RYLGY and AYFYPEL, has been
patented and commercialized under the name of Lowpept
by its antihypertensive properties demonstrated in both
SHR [26] and hypertensive humans [27] (Table 1). Pepsin
has been also used to hydrolyze whey protein lactoferrin,
with the release of peptides containing ACE activity and
ACE-dependent vasoconstriction inhibitory properties [28].
Antihypertensive effects in SHR after short-term and long-
term treatments have been also observed for those peptides
[29, 30]. Trypsin is another gastrointestinal enzyme used to
release the antihypertensive peptide 𝛼s1-casein peptide f(23–
34) from casein during the manufacture of the commercial
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ingredient peptide C12 [31, 32] (Table 1). In addition to the use
of gastric and pancreatic enzymes, alone or in combination,
to produce antihypertensive peptides, the use of food-grade
enzymes derived frommicroorganisms has become common
for the release of peptides with demonstrated SBP lowering
effects in SHR [33–36].
Milk fermentation is another strategy to produce anti-
hypertensive peptides by the proteolytic action of lactic acid
bacteria on milk proteins. The most representative peptides
are those derived from 𝛽-casein and identified in sour
milk fermented by Lactobacillus helveticus and Saccharomyces
cerevisiae (Calpis, Table 1). These tripeptides, with sequences
VPP and IPP, have demonstrated an ability to exert potent
decreasing effects on the SBP of SHR [37, 38]. A number
of clinical trials have been conducted to confirm their anti-
hypertensive properties in humans although controversial
results have been found. Three meta-analyses performed
with the published data of 17 [39], 12 [40], and 28 [41]
clinical trials have reported an average decrease in SBP of
5.1, 4.8mm, and 1.7mm of Hg, respectively. However, no
effects were found in Dutch and Danish subjects consuming
fermented milk containing peptides VPP and IPP [42, 43]. A
recent meta-analysis including 18 trials has reported higher
antihypertensive effects for these two tripeptides in Asian
than in Caucasian people [44]. Those findings suggest that
genetics and/or dietary patterns might exert an important
influence on the antihypertensive effects of peptides IPP
and VPP. Similarly, the age has been described as another
major influencing factor [45]. With the evidence presented
to date, the European Food Safety Authority (EFSA) Panel
on Dietetic Products, Nutrition and Allergies (NDA) [46]
concluded that there are no sufficient data to establish a
cause/effect relationship between the consumption of pep-
tides VPP and IPP and the control of hypertension, and
further studies are thus required. Other peptides derived
from 𝛽-casein during milk fermentation with Enterococcus
faecalis, in which sequences are LHLPLP and HLPLP, have
also shown antihypertensive effects in SHR [47]. In recent
studies, fermentedmilkwith Lactococcus lactisNRRLB-50571
and NRRLB-50572 has presented important SBP, diastolic
blood pressure (DBP), and heart rate-lowering effects in SHR
[48, 49] although the peptides responsible for the activity
have not been identified.
Accumulating evidence built in animal and clinical stud-
ies is currently available on the antihypertensive activity of
milk-derived peptides. However, much work is still needed.
Identification of the active form reaching the target organs
and elucidation of its bioavailability after oral ingestion and
its complete mechanism of action are two of the main aspects
required to be deeply investigated in the future to support
health claims.
2.1.2. Antioxidant and Anti-Inflammatory Milk-Derived Pep-
tides. Oxidative stress is one of the main responsible factors
for the initiation or evolution of CVD. The search of natural
antioxidants providing additional benefits to the endogenous
antioxidant defense system is gaining interest [50]. Among
food-derived peptides with antioxidant properties without
harm side effects, those derived from milk proteins are most
frequently studied. The majority of the studies carried out
to characterize antioxidant peptides derived from casein and
whey proteins have only used in vitro chemical assays [51, 52].
However, their limited similarity to physiological conditions
makes the in vitro assays very restrictive, and reported effects
need to be confirmed by animal models and/or human
trials. Nevertheless, to date, just few in vivo trials have been
carried out to demonstrate the antioxidant effects of milk-
derived peptides related to benefits on cardiovascular health.
Zommara et al. [53] reported the antiperoxidative action of
fermented milk on rats fed a vitamin-E deficient diet. The
consumption of fermented milk by healthy subjects has been
also demonstrated to lower the levels of oxidized low-density
lipoprotein, isoprostanes, and the glutathione redox ratio.
Improvements of total plasma antioxidant activity and of
the resistance of the lipoprotein fraction to oxidation have
resulted in enhanced antiatherogenicity [54].The compounds
responsible for the observed effects have not been identified
yet, although milk peptides liberated during fermentation
process might have a crucial role. Thus, further studies
focused on evaluating the potential of milk-derived peptides
as antioxidant at cardiovascular level should be of great
relevance.
Chronic inflammation is another responsible factor for
the development of CVD. The downregulation of cytokines
involved in the inflammation-associated endothelial dys-
function by food components, including peptides, may delay
or alleviate inflammation, thus exerting favorable effects
against CVD [55]. A recent study using lipopolysaccharide-
(LPS-) stimulated mouse macrophages has reported the
ability of a yak casein hydrolyzate to reduce the secretion
of proinflammatory cytokines and the production of nitric
oxide and to scavenge free radicals, suggesting a potential role
as preventive agent against inflammation related disorders
[56]. To date, only one human trial has been conducted
to demonstrate the anti-inflammatory properties of milk
peptides. This study reported an improvement in the vas-
cular function through modulation of the glucose levels
and inflammation and oxidative stress biomarkers after the
consumption of the commercial whey derived peptide NOP-
47 by healthy individuals [57]. This finding opens a new
door towards searching of new milk-derived peptides with
antioxidant and anti-inflammatory activity.
2.1.3. Hypocholesterolaemic Milk Peptides. Blood lipids are
represented in various forms including total cholesterol,
triglycerides, lipoproteins (high-density lipoproteins orHDL,
low-density lipoproteins or LDL, and very-low-density
lipoproteins or VLDL), and free fatty acids. An inappropriate
ratio of these lipids is one of the most important risk factors
for developing CVD. Therefore, CVD therapy/prevention
strategies focus on reaching an optimal lipid balance in
order to achieve a positive cardiovascular health. Those
therapies aim at increasing the physiological levels of desir-
able lipids (e.g., HDL cholesterol) while reducing the others
associated with atherogenic functions (e.g., LDL choles-
terol, triglycerides). Milk proteins, mainly whey proteins
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and derived hydrolyzates or peptides, have been reported
to exert hypocholesterolaemic effects in different animal
models. The ingestion of whey protein was correlated with
a significant reduction of total cholesterol levels in rats fed
with cholesterol-free and cholesterol-enriched diets [58, 59].
Nagaoka et al. [60] have reported similar effects for a 𝛽-
lactoglobulin tryptic hydrolyzate administered to rats fed
with a diet rich in cholesterol. The hydrolyzate reduced total
cholesterol and increased HDL cholesterol and fecal steroid
excretion.The fragment f(71–75) of this whey protein, known
as lactostatin, with sequence IIAEK, has been reported as
the main factor responsible for the observed effects [60].
𝛽-Lactotensin, another 𝛽-lactoglobulin peptide, released by
chymotrypsin hydrolysis, decreased total cholesterol, LDL,
and VLDL cholesterol content in mice fed with a cholesterol-
enriched diet [61]. Although themechanismof action of those
peptides has not been completely elucidated, preliminary
results suggest a key role played by the amino acid compo-
sition [50]. Further studies are clearly needed to corroborate
those results. The exact mode of this hypocholesterolaemic
action needs to be determined in clinical trials.
2.2. Milk-Derived Hydrolyzates and Peptides on Intestinal
Health. The gastrointestinal tract (GIT) serves as a special-
ized interface between the body and the external environ-
ment. The GIT is strategically covered by a monolayer of
specially designed epithelial cells continually exposed to a
high concentration of food components and substances along
the gut luminal surface. Hence, the modulator effect of the
diet on GIT functions has been accepted as essential for
maintaining and improving the general health of the host
[62]. Interestingly, more than 70% of the current “food for
specified health uses products” (FOSHU) are related to GIT
functions [63].
Dairy proteins, hydrolyzates, and peptides have been
demonstrated to transform the dynamics of mucus mainly
via influencing the mucin secretion and expression and the
number of goblet cells. In ex vivo preparations of rat jejunum,
casein hydrolyzates increased mucin secretion [64, 65]. The
𝛽-casein derived peptide 𝛽-casomorphin 7 produced the
same effects which have been suggested to be mediated by
interaction with opioid receptors. Also, this peptide has been
reported to stimulate the expression of mucin Muc2 and
Muc3 genes in rat intestinal DHE cells and MUC5AC gene
in human intestinal HT29-MTX cells [66]. Another 𝛽-casein
fragment, f(94–123), identified in commercial yoghurt, also
had the ability to increase the mucin output and the mRNA
levels of MUC2 and MUC4 genes in HT29-MTX cells [67].
Casein and whey proteins hydrolyzates have been reported
to be a source of peptides with capacity to induce mucin
secretion andMUC5AC gene expression in HT29-MTX cells
[68]. Among these peptides, the 𝛼s1-casein fragments f(143–
149) and f(144–149) and the 𝛽-lactoglobulin fragment f(102–
105) known as 𝛽-lactorphin were suggested as the major
peptides responsible for the observed effects.
A few in vivo studies have also pointed out the regulation
of the protective mucus layer by dairy proteins and products
thereof. Rats fed with a diet based on casein hydrolyzates, as
the exclusive source of nitrogen, were found to enhance their
endogenous nitrogen flow and expression of mucin genes
Muc3 andMuc4 in the small intestine and colon, respectively
[69]. Plaisancie´ et al. [67] reported the capacity of the 𝛽-
casein fragment f(94–123), once orally ingested by rats, to
upregulate the Muc2, Muc4, rat defensing 5 and lysozyme
mRNA transcripts expression, the goblet cells recounts, and
the number of crypts containing Paneth cells in the rat small
intestine. In the dextran sulphate sodium- (DSS-) induced
model of rat colitis, the studies of Sprong et al. [70] and Faure
et al. [71] demonstrated the gut-protective effects exerted by
a cheese whey protein diet and a diet supplemented with
Thr, Ser, Cys, and Pro residues, respectively. Moreover, this
protection has been reported for a whey protein isolate and𝛼-
lactalbumin hydrolyzate against chemical-induced ulcerative
gastric lesions [72, 73].
Enhancement of the mucosal immune response is also
a dietary modulating strategy of the defense systems pro-
tecting the GIT. Animal models have proved the improve-
ment of the mucosal immunity by promotion of gut-related
immunoglobulin (Ig) levels after ingestion of lactoferrin or
its derived peptides, lactoferricin and lactoferrampin [74, 75].
Likewise, immunomodulatory effects have been reported for
a trypsin casein hydrolyzate in newborn calves [76] and
casein phosphopeptides (CPPs) and peptides released from
Lactobacillus helveticusR389-fermentedmilk inmice [77, 78].
Furthermore, Kitamura and Otani [79] demonstrated that
ingestion by healthy humans of CPPs-enriched cakes induced
an increase in the faecal IgA content, suggesting a positive
effect on mucosal immunity.
Oxidative and inflammatory imbalances are both
involved in the etiology of several human chronic gut-related
disorders such as ulcerative colitis and Crohn’s disease. The
search of natural preventive treatments against these imbal-
ances is being prompted [80, 81]. Whey protein has been
suggested to exert beneficial effects through enhancement
of antioxidant enzymes and downregulation of both oxi-
dative markers and proinflammatory cytokines [82]. These
protective findings were found in animal [83, 84] and humans
trials [85, 86]. The whey-derived peptide caseinomacro-
peptide has been proven to have protective properties in the
2,4,6-trinitrobenzene sulphonic acid (TNBS) and DSS-
induced model of rat ileitis and colitis, through immunomo-
dulation of the regulatory T helper cells activation and inter-
leukin secretions [87, 88]. Turbay et al. [89] demonstrated, in
the TNBS-induced murine colitis model, the anti-inflam-
matory effects exerted by 𝛽-casein hydrolyzates generated
by the cell envelope-associated proteinase of Lactobacillus
delbrueckii ssp. lactis CRL 581. However, peptides released
and responsible for the observed bioactivity have not been
identified yet.
2.3. Milk Proteins and Peptides against Metabolic Disorders.
Diabetes mellitus is considered one of the most common
metabolic disorders and one of the major health problems
worldwide. It affects almost 6% of the world’s population,
with type 2 diabetes representing approximately 90–95% of
the diagnosed cases [90]. Diet and lifestyle interventions
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are the preferred treatment strategies for this metabolic
disorder, with pharmacotherapy being prescribed only if
supervised lifestyle intervention fails [91]. Epidemiological
evidence supports that consumption of milk and dairy foods
is associated with a lower incidence of type 2 diabetes. These
beneficial effects on metabolic and inflammation factors
linked to diabetes and insulin resistance have been also
demonstrated by cell and animal models, being multiple
milk components, such as calcium, medium-chain fatty
acids, linoleic conjugated acid, lactose, citrate, proteins, and
peptides characterized as the main responsible factors for
the observed effects acting through different mechanisms of
action [92].
During the ingestion of a meal, the presence of nutri-
ents at gastrointestinal level stimulates the secretion of two
incretins hormones, the glucagon-like peptide-1 (GLP-1)
and the glucose-dependent insulinotropic polypeptide (GIP).
Both hormones are implicated in the stimulation of the
insulin secretion from the pancreatic 𝛽-cells, secretion of
gastric and pancreatic enzymes, and modulation of gut
motility and nutrient absorption, allowing the clearance of
the absorbed glucose [93]. Type 2 diabetes is characterized by
different disorders including progressive dysfunction of pan-
creatic cells, insulin resistance, and augmented production of
hepatic glucose [94]. Continuous intravenous administration
of GLP-1 has been demonstrated to normalize blood glucose
levels in diabetic subjects [95]. However, the rapid degrada-
tion of this hormone by the enzyme dipeptidyl peptidase-IV
(DPP-IV) and its consequent inactivation makes this type 2
diabetes treatment strategy impracticable. Currently, specific
DPP-IV inhibitors are thus incorporated to GLP-1 analogues
in new oral therapies against this metabolic disease [96].
Diet supplementation with whey protein is currently
under preclinical and clinical trials as a promising alternative
in the prevention and/or treatment of type 2 diabetes and
related diseases [97, 98]. Several mechanisms of action have
been suggested for whey protein, including the stimulation of
insulin release, improvement of glucose tolerance in diabetic
patients, reduction of body weight, and modulation of gut
hormones such as cholecystokinin, leptin, and GLP-1 [99]. In
the last years, the role of peptides released during the transit
of whey proteins through the GIT on the observed effects
has been hypothesized [100]. Cell culture and animal models
have been used to confirm this hypothesis. A dose-dependent
insulinotropic activity of whey protein hydrolyzates has been
observed in a cell-based coculture using pancreatic BRIN-
BD11 cells and Caco-2 cells monolayers [101]. These authors
also observed that the oral administration of the hydrolyzates
to obese mice evoked an improvement of blood glucose
clearance, reduction of hyperinsulinemia, and restoration
of the pancreatic capacity to secrete insulin in response to
glucose. The main mechanism of action suggested for these
hydrolyzates is the DPP-IV inhibitory activity exerted by
the peptides contained in them [102]. Among the bioac-
tive peptides described to date, sequences derived from 𝛽-
lactoglobulin IPA and IPAVF are the most potent as DPP-
IV inhibitors [103, 104]. Another 𝛽-lactoglobulin fragment
with sequenceVAGTWYhas been also demonstrated to exert
hypoglycemic effects in the oral glucose tolerance test inmice
[105]. Likewise, both in vitro DPP-IV inhibitory and in vivo
hypoglycemic effects have been reported for peptides released
from caseins [106]. Recent in silico studies have shown that
both caseins and whey proteins might serve as precursors
of DPP-IV inhibitory peptides because of the high number
of fragments contained within them that match DPP-IV
inhibitory sequences [107, 108].Thus, this research area holds
a great potential, and currently a number of investigations are
focused on the identification of new milk proteins-derived
peptide with capacity to prevent diabetes and associated
metabolic syndromes.
2.4. Chemopreventive Role of Milk Proteins and Peptides.
Cancer is the second leading cause of mortality worldwide,
and its incidence will continue rising in the next few years in
spite of the important advances achieved in the development
of cancer therapies. It has been estimated that, by 2020,
approximately 15 million new cancer cases will be diagnosed,
and 12 million cancer patients will die [109]. It is well known
that 35% of cancer deaths are attributed to diet and its
food components [110]. However, cell culture and animal
and human trials results have shown that an important
number of food constituents can lower cancer risk and even
sensitize tumor cells against anticancer therapies [111]. In
the last few years, food proteins and derived peptides have
become one of the food components with themost promising
preventive properties against cancer initiation, promotion,
and progression stages [112].
Among the milk proteins, lactoferrin and its derived
peptide lactoferricin are the most studied. For both com-
pounds, their antioxidant, immunomodulatory, and anti-
inflammatory activities are closely linked to their protective
effects against cancer (Table 2). Lactoferrin acts by inducing
apoptosis, inhibiting angiogenesis, and modulating carcino-
gen metabolizing enzymes, in addition to its antioxidant and
immunomodulatory properties [113]. Moreover, lactoferricin
has shown potent anticancer properties in different cell lines,
including breast, colon, fibrosarcoma, leukemia, and oral and
ovarian cancer cells, without harming normal lymphocytes,
fibroblasts, or endothelial or epithelial cells [114]. Also, animal
models have confirmed the beneficial properties of this
milk-derived peptide. The possible mechanism of bovine
lactoferricin in anticarcinogenesis has been shown to be
related to its ability to induce apoptosis. It is its strongly
cationic nature that allows this peptide to target negatively
charged cancer cells with the outer membrane [115]. The
suppressed ability in angiogenesis of bovine lactoferricin
was in vitro and in vivo demonstrated to contribute to its
chemopreventive properties [116]. A significant inhibition of
tumor growth and of liver and lung metastasis was reported
after subcutaneous administration of bovine lactoferricin in
both spontaneous and experimental metastasis mice mod-
els [117]. Similar results were observed after subcutaneous
treatment and repeated injections of this peptide on Meth A
fibrosarcoma xenograftsmice and established neuroblastoma
xenografts, respectively [118, 119].
𝛼-Lactalbumin is a whey protein with anticancer proper-
ties which has been reported when it forms a complex with
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oleic acid known as “human alpha-lactalbumin made lethal
to tumor cells, HAMLET” or “bovine alpha-lactalbumin
made lethal to tumor cells, BAMLET.” It has been recognized
that both protein and fatty acid are required to show cytotoxic
activity against cancer cells [115]. Treatment of cancer cells
with HAMLET provokes morphological changes typical of
apoptotic cells through caspase activation and causes mito-
chondrial permeability transition resulting in mitochondrial
swelling, loss of mitochondrial membrane potential, and
cytochrome c release [120].These authors also found that this
complex induced autophagic cell death and changes in the
proteasome structure and function. Similar effects resulting
from chromatin condensation and cell shrinkage have been
observed after treatment of cancer cells with the complex
BAMLET. The efficacy of both complexes has been shown to
be influenced by the type of cancer cell line [120]. In the last
years, the therapeutic effects against bladder cancer have been
studied in animal models as preliminary step for BAMLET
use in human trials. It has been demonstrated that intravesical
administration of HAMLET delays tumor progression in a
murine bladder cancer model although no preventive effects
on tumor formation were observed [121].
Intact caseins have not been characterized as chemopre-
ventive proteins but they have been suggested as an important
source of peptides with anticancer properties. CPPs are
able to bind calcium, to inhibit cell proliferation, and to
induce apoptosis of intestinal tumor HT-29 and AZ-97 cells
through activation of voltage-activated calcium channels,
whichmediate the calcium flood according to the depolariza-
tion state of the cell [122]. However, in differentiated epithelial
intestinal cells, a protective effect from programmed cell
death is observed after treatment with these peptides [123].
𝛽-Casomorphin 7 and 𝛽-casomorphin 5, two casein-derived
sequences with opioid properties, have shown antiprolifer-
ative and cell cycle arresting activities on breast and colon
cancer cells [115, 124, 125]. It has been suggested that these
effects are mediated by interaction with specific opioid and
somatostatin receptors although further studies confirming
this mode of action are needed.
3. Impact of Milk Oligosaccharides on
Human Health
Despite the important role of HMO in infant health, the
limited supply of human milk has hindered its use in com-
mercial infant formula [126] and in large-scale clinical trials.
Presumably, the health benefits provided by HMO to infants
could be extended to humans of all ages if alternative sources
of these complex OS are identified [127]. In that view, the
need of finding other sources of human-likeOS has prompted
the identification, characterization, and quantification of
unknown OS present in many other types of milk and their
respective industrial streams [128, 129].
3.1. Alternative Sources of Oligosaccharides: Major Sources
of Nonhuman Milk Oligosaccharides and Their Industrial
Effluents. Increasing interest on plant- and lactose-derived
OS has been observed in the past decade as an alternative
source for complex HMO. Some of these OS include galacto-
OS (GOS), fructo-OS (FOS), and lactulose, among others
[130]. These indigestible OS are considered prebiotics due
to their ability to confer health benefits to the host through
the selective growth and activity of commensal bacteria
[131]. One such example is inulin, an oligofructan with D-
fructofuranosyl 𝛽(1-2) links that cannot be broken down by
human digestive enzymes, thus exerting several intestinal
physiological effects that contribute to the host health. GOS,
commonly produced by transgalactosylation of lactose by
𝛽-galactosidases, are another example of a current available
source of OS for use by the infant formula industry.
Despite the fact that some health promoting effects, such
as improved bifidogenic activity, have been attributed to some
of those OS [131], little similarity has been observed between
commercially available GOS and HMO, except that they are
both built on a lactose core [127]. GOS and FOS are composed
of a simple linear core, being devoid of structures having
high biological activity such as fucose, sialic acid, and N-
acetyl glucosamine. Because GOS and FOS do not possess
the intrinsic structural complexity observed in HMO, it is
expected that domestic farm animals and their processing
streams, such as whey permeate from cheese manufacturing,
can be a source of OS more similar to the ones present in
human milk [132].
World milk production is almost entirely derived from
cattle (83%), buffaloes (13%), goats (2%), sheep (1%), and
camels (0.3%) (http://www.fao.org/agriculture/dairy-gate-
way/milk-production/dairy-animals/en/#.VA95gvldXXs).
Considering that cow milk accounts for 83% of the world
milk production, the enormous interest of the scientific
community to identify, quantify, and characterize the OS
present in cattle milk and their industrial byproducts is
not surprising. A comprehensive review by Urashima et
al. [132] shows that approximately 25 bovine milk OS
(BMO) structures had been characterized before 2011.
The development of advanced analytic techniques, such
as several mass spectrometric methods and hydrophilic
interaction liquid chromatography-high performance liquid
chromatography, has enabled significant improvement in the
identification of new BMO; as many as 40 BMO have been
characterized [133, 134].
The low concentration of BMO makes it challenging to
identify and characterize these compounds when compared
with HMO. The OS concentration can reach values as high
as 0.7–1.0 g/L in bovine colostrum or can be detected as
just trace amounts in bovine milk [135], being much lower
than the OS concentration in human milk. Caprine milk is
another type of milk, which contains complex OS similar
to HMO. The discovery of the presence of fucosylated and
sialylated OS that are considered as prebiotics and which
have the ability to reduce pathogen adherence to the intestine
wall has opened up translational opportunities to human
health [136]. Approximately 37 caprine milk OS (COS) have
been identified, of which nearly half of them have had their
structural complexity elucidated. Similar to bovinemilk, COS
are present in very small concentrations when comparedwith
HMO. However, they have been found in concentrations of
0.25–0.3 g/L, which is 4-5 times higher than BMO [137].
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From those two alternative sources of HMO-like OS
(BMO and COS), industrial streams arising from cheese
manufacturing and production of whey protein concen-
trates (WPC) and isolates (WPI) have been considered as
a more realistic source of OS for future commercialization
[129, 138]. Considering the enormous worldwide production
of whey (180–190 × 106 tonnes/year; http://www.adpi.org/
Portals/0/PDF/09Conference/TAGEAFFERTSHOLT.pdf)
and the fact that the major industrial application of whey
to produce WPC and WPI generates a new byproduct
containing the target OS, the development of economically
feasible processes to recover these compounds represents a
key step in enabling the large-scale production of OS.
3.2. Biological Activities of Oligosaccharides. While a wide
range of biological functions has been attributed to HMO,
less information is available regarding the biological activities
of BMO and COS. The limited availability of large quantities
of OS with high degree of purity can be inferred by the
limited number of in vivo studieswith those compounds, with
the majority of milk OS biological activities being described
by in vitro studies. Recent reports of some of the biological
activities of HMO, BMO, and COS are reported in Table 3.
3.2.1. Prebiotic Activity. One of the main features of HMO
is that they can only be consumed by very specific bacteria
strains that possess the appropriate set of enzymes to cleave
their complex structure. This prebiotic effect is associated
with improved health outcomes. A prebiotic is “a selectively
fermented ingredient that allows specific changes, both in
the composition and/or in the activity in the gastrointestinal
microflora, conferring benefits upon host well-being and
health” [139]. Because HMO are only partially digested in
the small intestine, they can reach the colon intact where
they selectively stimulate the development of bifidogenic
flora. A recent study has demonstrated the bifidogenic effect
of major fucosylated and sialylated HMO when fed as a
sole source of carbon to 25 major isolates of the human
intestinal microbiota [140]. Most of the Bifidobacteria spp.
and Bacteroides spp. were able to consume those OS and to
produce short chain fatty acids, while common pathogenic
bacteria were not able to grow on those OS. In vitro biological
activities of HMO have been supported by in vivo studies.
One of the newest publications in this topic demonstrated the
ability of 2-fucosyllactose and 3-fucosyllactose to selectively
increase some intestinal bacteria populations like Barnesiella,
the major bacterial genus in mice [141], being this effect
correlated with reduced level of colitis.
Prebiotic activities of COS, recovered from caprine whey,
have been evaluated by in vitro studies [142]. The purified
COS fraction favored the development of Bifidobacterium
spp. and produced short chain fatty acids such as lactic and
propionic acids but presented no inhibition of Staphylococcus
aureus and Escherichia coli grown in human faeces.
3.2.2. Antipathogenic Activity. A second feature of OS is the
ability to reduce pathogen biding to the intestinal mucosa.
The intestinal mucosa is heavily glycosylated and covered
with complex glycans including glycoproteins, glycolipids,
andmucins, among others [143, 144]. Bacteria and viruses are
able to recognize certain types of fucosylated and sialylated
OS and adhere to them [130], therefore acting as anti-infective
agents.Milk OS are also fucosylated and sialylated so bacteria
and viruses, in presence of OS, will attach less to intestinal
cells. The ability of pathogens to bind to specific OS seems
to be intrinsically correlated with their structure. Neutral
OS containing HexNAc block adhesion of pathogens that
cause diarrhea (Vibrio cholerae) and pneumonia (Strepto-
coccus pneumoniae) [15, 145], while neutral fucosylated OS
have been shown to inhibit adhesion of other pathogens
(i.e., Campylobacter jejuni and diarrheagenic E. coli) that
cause gastrointestinal disorders [146]. Acidic OS containing
sialic acid are able to block adhesion of Helicobacter pylori,
which causes peptic ulcers and other gastric diseases [147],
Staphylococcus aureus, and Clostridium botulinum [148].
Recent in vitro studies have demonstrated that BMO also
possess antibacterial properties as observed for HMO. BMO
from colostrum permeate proved to be effective in protect-
ing HEp-2 cells from enteropathogenic E. coli, Cronobacter
sakazakii, and Salmonella enterica serovar typhimurium [149].
It has also been demonstrated that BMO can inhibit the
pili-mediated adhesion of Neisseria meningitidis in vitro
[150]. Several studies have demonstrated the inhibition of
the attachment of enteric pathogens such as E. coli and
Campylobacter jejuni and noroviruses with HMO [151]. This
effect has also been demonstrated by in vivo studies in which
isolated HMO were fed to suckling mice before and after
infection with enteropathogenic E. coli. Mice that received
HMO significantly reduced colonization of this species com-
pared with untreated controls [152].
3.2.3. Anti-Inflammatory Activity. OS have been also con-
sidered as anti-inflammatory agents due to their prebiotic
activities and their ability to act as receptors of microorgan-
isms. In vivo studies have demonstrated that COS possess
anti-inflammatory properties towards the development of
experimental colitis in rats. Pretreatment of the rats with
isolated COS reduced the typical signs of induced colitis,
including less anorexia, better body weight gain, and less
macroscopic intestinal lesions, among others [153]. Similar
results were observed by Lara-Villoslada et al. [154], where
COS were shown to play an important role in intestinal
protection and repair after a damage caused by DSS in rats.
4. Future Prospects
Milk has long been recognized as a source of macro- and
micronutrients. Recent identification of many important bio-
logically active substances on milk and its derivatives has
attracted much attention from the scientific community. Not
only are many of these bioactive compounds associated with
growth, but they also confer many health benefits that might
support disease prevention. Milk proteins and peptides are
usually well tolerated and demonstrate oral bioavailability. In
this view, they have the potential to act as health promoting
ingredients and to participate in auxiliary therapies to boost
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Table 3: Biological activities of human, bovine, and goat oligosaccharides.
Microorganisms/animals Molecule used Dose Duration/details Outcome measured Reference
Bifidobacterium spp.,
Bacteroides spp.,
Clostridium spp.,
Lactobacillus spp.,
Enterococcus spp.,
Streptococcus spp.,
Staphylococcus spp.,
Enterobacter spp., and
Escherichia coli
HMO (2󸀠-FL, 3󸀠-FL,
LDFT, 3󸀠-SL and
6󸀠-SL)
0.5–2 g/L 48 hrs OS incubation
SCFA quantification,
bacterial growth, and
OS consumption
[140]
Mice HMO (2
󸀠-FL and
3󸀠-FL)
500mM, starting with
5mL, increasing by
2.5mL every 3 d
reaching a daily
amount of 25mL on
day 20
From day 1 to day 20
after birth
Bacterial amount,
colitis signs [141]
Bacteria from human feces Pooled GOS During incubation Bacterial amount [142]
Mice Pooled HMO 15mg/day
One day before and
after infection with
EPEC
Intestinal
colonization of EPEC [152]
HEp-2 cells Pooled BMO fromcolostrum
20mg/L of total
carbohydrate in
culture
During incubation Adherence inhibition [149]
Bovine thyroglobulin and
human salivary agglutinin
glycoproteins
Pooled HMO and
BMO 40 g/L During incubation
Neisseria meningitidis
Pili attachment [150]
Rats Pooled GOS 500mg/(kg∗d)
2 days before and 6
days after induced
colitis
Colonic damage [153]
HMO: human milk oligosaccharides; FL: fucosyllactose; LDFT: lacto-difucosyl-tetraose; SL: sialyllactose; GOS: galacto-oligosaccharides; BMO: bovine milk
oligosaccharides.
overall success in chronic diseases. However, this research
area is only at its beginning and more peptides with physi-
ological effects are to be discovered in the future. Confirming
the health benefits of these bioactive compounds requires
the design of clinical trials based on metabolomic genomics,
proteomics, transcriptomics, and epigenetic data, in order
to explore new biomarkers related to the observed health
benefits.
While larger data for in vivo biological activities of milk
and peptides is observed, the same is not observed for OS. To
date, few studies have demonstrated the safety and efficacy
of OS supplementation [155, 156]. The reduced number of
biological activities evaluated for BMO and COS reveals the
challenges associated with the production of OS in adequate
quantities and purity needed for clinical trials. The develop-
ment of new synthetic pathways to produce highly purified
OS and of large-scale processes to recover those OS from
their respective industrial streams will likely improve the
elucidation of their biological activities and determine their
safety and efficacy in clinical trials with humans. Moreover,
the development of more environmentally friendly processes
that are also economically feasible not only will enable the
production of a new generation of prebiotics but will address
environmental issues associated with the disposal of OS-
containing waste streams and poor economic viability of our
food industry.
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Italian legumes: effect of sourdough 
fermentation on lunasin-like polypeptides
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Abstract 
Background: There is an increasing interest toward the use of legumes in food industry, mainly due to the qual‑
ity of their protein fraction. Many legumes are cultivated and consumed around the world, but few data is available 
regarding the chemical or technological characteristics, and especially on their suitability to be fermented. Never‑
theless, sourdough fermentation with selected lactic acid bacteria has been recognized as the most efficient tool to 
improve some nutritional and functional properties. This study investigated the presence of lunasin‑like polypeptides 
in nineteen traditional Italian legumes, exploiting the potential of the fermentation with selected lactic acid bacteria 
to increase the native concentration. An integrated approach based on chemical, immunological and ex vivo (human 
adenocarcinoma Caco‑2 cell cultures) analyses was used to show the physiological potential of the lunasin‑like 
polypeptides.
Results: Italian legume varieties, belonging to Phaseulus vulgaris, Cicer arietinum, Lathyrus sativus, Lens culinaris and 
Pisum sativum species, were milled and flours were chemically characterized and subjected to sourdough fermenta‑
tion with selected Lactobacillus plantarum C48 and Lactobacillus brevis AM7, expressing different peptidase activities. 
Extracts from legume doughs (unfermented) and sourdoughs were subjected to western blot analysis, using an anti‑
lunasin primary antibody. Despite the absence of lunasin, different immunoreactive polypeptide bands were found. 
The number and the intensity of lunasin‑like polypeptides increased during sourdough fermentation, as the conse‑
quence of the proteolysis of the native proteins carried out by the selected lactic acid bacteria. A marked inhibitory 
effect on the proliferation of human adenocarcinoma Caco‑2 cells was observed using extracts from legume sour‑
doughs. In particular, sourdoughs from Fagiolo di Lamon, Cece dell’Alta Valle di Misa, and Pisello riccio di Sannicola 
flours were the most active, showing a decrease of Caco‑2 cells viability up to 70 %. The over‑expression of Caco‑2 
filaggrin and involucrin genes was also induced. Nine lunasin‑like polypeptides, having similarity to lunasin, were 
identified.
Conclusions: The features of the sourdough fermented legume flours suggested the use for the manufacture of 
novel functional foods and/or pharmaceuticals preparations.
Keywords: Legumes, Sourdough, Lactic acid bacteria, Lunasin
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Background
According to the Food and Agricultural Organization 
(FAO) pulses are dry seeds of annual legume plants, 
belonging to the Fabaceae (also known as Leguminosae) 
family. FAO classifies the large number of legume species 
and varieties employed as food or feed into eleven main 
groups (dry beans, dry broad beans, dry peas, chick-
peas, dry cowpeas, pigeon peas, lentils, bambara beans, 
vetches and lupins) and minor pulses [1]. Nutritionally, 
pulses are an important source of proteins, which, in 
spite of being deficient in sulfur-containing amino acids 
and tryptophan, possess higher amounts of lysine, argi-
nine, glutamic, and aspartic acid compared to cereal 
grains [2]. Beyond the nutritional benefits, consumption 
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of pulses is recently associated with protective or thera-
peutic effects on chronic health conditions, such as car-
diovascular diseases, diabetes, cancer, overweight, and 
obesity [2]. Owing to the low cost and easy adaptation 
to grow under poor conditions, pulses are used as staple 
foods in several low-income countries, serving as main 
source of both protein and calories [2, 3]. Otherwise, in 
high-income countries of America and Europe, pulses 
consumption is low and efforts are done to promote their 
healthy intake.
Several health organizations recommend pulse con-
sumption as a part of a healthy diet and initiatives are 
addressed to increase the cultivation, intake, and food 
processing uses [2, 4]. The protein content of pulses 
ranges from 20 to 40 % of dry weight. Within this inter-
val, the most abundant are the seed storage proteins. 
The remaining part are minor or housekeeping proteins, 
which include enzymes, protease, amylase inhibitors, lec-
tins, lipoxygenases, defense proteins, and others [3, 5]. 
Legume seeds also contain proteins, which are consid-
ered as anti-nutritional compounds due to the effect on 
the quality of the diet. Nevertheless, the harmful effects 
of such compounds is easily inactivated after cooking 
or processes like fermentation, germination and dehull-
ing [6]. Once inactivated, lectins or protease inhibitors 
may present potential health benefits. Protease inhibitors 
are potential anti-inflammatory and anticancer agents, 
whereas lectins have demonstrated to play a key role in 
preventing certain cancers and activating innate defense 
mechanisms. Besides, lectins are also proposed as thera-
peutic agents to prevent or control obesity [5].
Many of the physiological and functional properties 
of proteins are attributed to biologically active peptides 
which are often encrypted in the native sequence [7, 8]. 
Biogenic or bioactive peptides are released from their 
precursor proteins either by enzymes during gastroin-
testinal digestion or through proteolysis (e.g., microbial 
fermentation), which occurs during food processing [8]. 
In particular, legume hydrolysates and bioactive peptides 
had in vitro activities towards cancer and cardiovascular 
diseases or their physiological manifestations like oxi-
dative damage, inflammation, hypertension, and high 
cholesterol [2]. Lunasin is a 43-amino acid peptide with 
anticancer, anti-inflammatory, antioxidant and choles-
terol lowering activities [9]. It is purified from soybean 
and commercialized as an ingredient or dietary supple-
ment. In the quest for readily available natural sources 
of lunasin, the identification and purification of lunasin 
from different vegetable sources deserve a marked inter-
est [10, 11]. Moreover, the potential of sourdough fer-
mentation for increasing the concentration of lunasin 
in food matrices was recently investigated [12]. Sour-
dough is the natural starter traditionally used for making 
leavened baked goods, harboring a rich lactic acid bacte-
ria and yeast microbiota. A large number of studies [13] 
showed that the fermentative and proteolytic activities of 
sourdough lactic acid bacteria not only determined opti-
mal sensory, technology and nutritional characteristics, 
but also increased the functional value of leavened baked 
goods. Compared to unfermented soybean, amaranth, 
barley and wheat flours, the concentration of lunasin and 
related fragments increased up to four times during fer-
mentation with lactic acid bacteria, which were selected 
based on proteolytic activities [12].
This study reported the presence of lunasin-like poly-
peptides in nineteen traditional Italian legumes, and 
exploited the potential of the fermentation with selected 
lactic acid bacteria to increase the native concentration. 
An integrated approach based on chemical, immuno-
logical and ex vivo (human adenocarcinoma Caco-2 cell 
cultures) analyses was used to show the physiological 
potential of the lunasin-like polypeptides.
Results
Chemical and microbiological characteristics of the flours
All the traditional Italian legumes used in this study 
have specific certifications (names, abbreviations, geo-
graphical origin and certification are listed in Table  1). 
Legume grains were milled to obtain the correspond-
ing flours. The proximate composition of the flours is 
reported in Table  2. Moisture ranged from 7.2 ±  0.4 to 
11.1 ± 0.7 %. The protein concentration of all the flours 
was higher than 15 % of dry matter (d.m.). In particular, 
grass pea flours (CS and CC) showed the highest values 
(>24.0 %). The lipid concentration varied from 1.4 ± 0.2 
to 3.5  ±  0.1  % of d.m., with the exception of chickpea 
flours (CM and CV), showing a significantly (P  <  0.05) 
higher concentration. All flours had an amount of car-
bohydrates higher than 60 % of d.m. The highest concen-
tration was found for FCo and LA flours, produced by 
milling Fagiolo di Controne kidney beans and Lenticchia 
di Altamura lentils, respectively. Legume flours had con-
centrations of total dietary fiber higher than 17 % of d.m. 
PS and CC flours had the highest values (35.5 ± 2.9 and 
32.1 ± 2.0 %, respectively), whereas the lentils group con-
tained the lowest value of total dietary fiber. Ash ranged 
from 2.1 ± 0.2 to 4.6 ± 0.3 %, being the lowest values for 
lentil flours.
Total mesophilic aerobic bacteria ranged from 
1.61  ±  0.32 to 4.31  ±  0.11 log cfu/g (Table  3). Entero-
bacteria were below 2.0 log cfu/g in all the samples. 
The number of presumptive lactic acid bacteria var-
ied from 1.0 ± 0.08 to 2.54 ± 0.12 log cfu/g. Except for 
grass pea flour CC (4.23  ±  0.22 log cfu/g), yeasts were 
1.11 ± 0.05–2.77 ± 0.20 log cfu/g. Yeasts were not found 
in 10 g of LP, FV, FSa, and FBb flours. Molds were found 
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at 2.0 ± 0.21–3.51 ± 0.13 log cfu/g in most of the flours 
and were absent in 10 g of LS, FCo, CC, and PS flours.
Lactic acid bacteria fermentation
After incubation for 24  h at 30  °C, control doughs (D), 
without bacterial inoculum, showed values of pH that 
ranged from 5.8 ± 0.2 to 6.5 ± 0.3, corresponding to val-
ues of TTA of 3.8 ± 0.2 to 8.5 ± 0.5 ml 0.1 M NaOH/10 g 
of dough (Table 4). When L. plantarum C48 and L. bre-
vis AM7 were used as starters for sourdough (S) fer-
mentation, the cell density of presumptive lactic acid 
bacteria was 9.8–10.2 log cfu/g. All S had values of pH 
significantly (P < 0.05) lower (3.9 ± 0.1–4.5 ± 0.3) than 
the corresponding D. TTA ranged from 20.2  ±  1.3 to 
27.2 ± 1.5 ml NaOH/10 g of dough.
The concentration of total free amino acids (FAA) 
of D and S is reported in Table  4. Before incubation, 
doughs had concentrations of total FAA varying from 
2429 ± 20 (D made with LU flour) to 4547 ± 18 mg/kg 
(D made with FBw flour). In several cases, the concen-
tration of total free amino acids (FAA) of S was signifi-
cantly (P < 0.05) higher than that of the corresponding D. 
The average increase was ca. 28  % for kidney bean and 
pea S. Almost the same average increases (23–26 %) were 
found for grass pea, chickpea, and lentil S. Compared to 
D, slight increases of total FAA were shown by FSa, CM, 
CC, LS, and PS sourdoughs.
Western blot
The water/salt soluble extracts (WSE) of D and S were 
analyzed by SDS PAGE, and the proteins were elec-
troblotted and detected after incubation with luna-
sin polyclonal primary antibody (Fig. 1). A polyclonal 
primary antibody was already used for identification 
and quantification of lunasin and its use proposed for 
optimized methods of detection [14]. Lunasin peptide 
was not found in any of the samples analyzed. Nev-
ertheless, different immunoreactive bands, having 
molecular masses higher than lunasin, were found. 
Among D, grass pea and chickpea doughs did not 
shown any immunoreactive bands, while pea and all 
the lentil doughs (with the exception of LV) showed 
very weak signals, mainly distributed below 15  kDa. 
A large variability was found among the doughs made 
with bean flours. Very weak bands were found for Fl, 
FCo, FCu, and Fst, while a large protein band (molec-
ular mass of ca. 17  kDa) was found for LV, FV, FSa, 
FBw, and FBb.
Table 1 List and abbreviations of the Italian legumes
Product certifications and origin are also reported
a IGP (Indicazione Geografica Protetta, Protected Geographical Indication) and DOP (Denominazione d’Origine Protetta, Designation of Protected Origin) are 
regulated by Reg. (CE) N. 510/2006 (20.03.2006); PAT (Prodotti Agroalimentari Tradizionali, Traditional Food Products) are included in the list of the Italian Ministry of 
Agriculture, Food and Forestry (D.M. 07/06/2012); SFP (Slow Food Presidia) are listed at http://www.slowfoodfoundation.org
Legume Name Abbreviation Product certificationa Origin
Kidney bean (Phaseolus vulgaris) Fagiolo di Lamon FL IGP Veneto
Fagiolo di Controne FCo DOP Campania
Fagiolo di Cuneo FCu PAT Piedmont
Fagiolo Stregoni FSt PAT Piedmont
Fagiolo Vellutina FV PAT Sicily
Fagiolo di Saluggia FSa PAT Piedmont
Fagiolo Badda di Polizzi (white) FBw SFP Sicily
Fagiolo Badda di Polizzi (black) FBb SFP Sicily
Chickpea (Cicer arietinum) Cece di Merella CM PAT Piedmont
Cece dell’Alta Valle del Misa CV SFP Marche
Grass pea (Lathyrus sativus) Cicerchia di Serra de Conti CS SFP Marche
Cicerchia di Campodimele CC PAT Lazio
Lentil (Lens culinaris) Lenticchia di Castelluccio di Norcia LN IGP Umbria
Lenticchia di Ustica LU SFP Sicily
Lenticchia di Santo Stefano di Sessanio LS SFP Abruzzo
Lenticchia rossa di Pantelleria LP PAT Sicily
Lenticchia di Altamura LA PAT Apulia
Lenticchia di Villalba LV PAT Sicily
Pea (Pisum sativum) Pisello riccio di Sannicola PS PAT Apulia
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Lactic acid bacteria fermentation induced a large modi-
fication of the profiles of immunoreactive protein of 
all the legume flours. A band of ca. 30  kDa, which was 
absent in the corresponding D, was found for LN, LU, LS, 
LP, and LA sourdoughs. The intensity of the 17 kDa band 
of fermented LV increased compared to D. The same sig-
nal became evident in all bean sourdoughs, especially for 
FL. Two protein bands were detected at ca. 30 kDa in FV, 
FSa, FBw and FBb. The same was found for CS and PS. 
Moreover, FV, FSa, FBw and FBb showed reactive bands 
also having molecular masses of 14–17 kDa.
Effect on proliferation of Caco‑2 cells
Aiming at determining the cytotoxicity effect of the 
freeze-dried WSE from D and S towards human colon 
adenocarcinoma cells (Caco-2), five samples (FL, CV, 
CC, LN, and PS) with different immunoreactive protein 
profiles, were chosen as representatives of the legume 
species considered in this study, and were subjected 
to further characterization. On the basis of the results 
obtained from the western blot analysis, WSE were par-
tially purified by ultra-filtration, collecting the fractions 
containing the molecules with molecular mass lower 
than 30 kDa. In particular, the MTT assay was performed 
after treatment of Caco-2 cells with 0.1, 1, and 10 mg/ml 
of proteins for 24, 48, or 72 h.
Overall, all the WSE from D and S allowed a significant 
(P < 0.05) decrease of the cell proliferation compared to 
control (Fig.  2). Compared to the results obtained after 
24  h-treatment, the inhibitory effect increased after 
prolonging the incubation to 48  h, and in many cases, 
to 72  h. Exceptions were the treatments with 10  mg/
ml of proteins, which did not cause a further significant 
decrease of proliferation. The cytotoxic effect of WSE 
from S was in all the cases higher than the corresponding 
D. Besides the effect of the treatment duration, cytotoxic-
ity increased proportionally to the concentration of pro-
teins tested.
After 24 h of treatment (Fig. 2a), a weak anti-prolifer-
ative effect was found for WSE from D and S at 0.1 mg/
ml of proteins. The strongest effect corresponded to LN: 
(72.25 ± 2.12 and 69.54 ± 1.88 % of vitality for D and S, 
respectively. When WSE from S were used at concentra-
tion of 1 mg/ml, the vitality of Caco-2 cells decreased by 
Table 2 Proximate composition of the Italian legume flours
The data are the means of three independent experiments ± standard deviations (n = 3)
d.m. dry matter
a–e Values in the same column with different superscript letters differ significantly (P < 0.05)
Moisture  
(%)
Proteins  
(% of d.m.)
Lipids  
(% of d.m.)
Carbohydrates  
(% of d.m.)
Dietary fiber  
(% of d.m.)
Ash (% of d.m.)
FL Fagiolo di Lamon 7.2 ± 0.4e 20.2 ± 1.5b 3.4 ± 0.2b 65.0 ± 3.5c 21.2 ± 1.5d 4.0 ± 0.4b
FCo Fagiolo di Controne 7.2 ± 0.5e 17.3 ± 1.5d 2.7 ± 0.3c 69.2 ± 5.0a 26.0 ± 1.3b 3.5 ± 0.2c
FCu Fagiolo di Cuneo 8.0 ± 0.8d 20.5 ± 2.0b 2.0 ± 0.4d 65.2 ± 3.0c 24.3 ± 2.3c 3.5 ± 0.3b
FSt Fagiolo Stregoni 10.2 ± 0.7b 17.2 ± 1.5e 2.3 ± 0.2c 67.3 ± 2.5b 22.6 ± 2.2c 3.3 ± 0.2c
FV Fagiolo Vellutina 11.1 ± 0.7a 18.6 ± 1.4d 2.5 ± 0.3c 64.5 ± 5.0c 26.5 ± 1.9b 3.8 ± 0.1b
FSa Fagiolo di Saluggia 10.9 ± 0.8a 18.4 ± 0.6d 2.6 ± 0.4c 65.8 ± 4.0c 22.7 ± 1.7c 3.0 ± 0.1c
FBw Fagiolo Badda di Polizzi 
(white)
7.3 ± 0.2e 21.0 ± 1.4b 2.6 ± 0.3c 65.4 ± 3.6c 19.6 ± 2.3d 3.6 ± 0.2b
FBb Fagiolo Badda di Polizzi 
(black)
8.5 ± 0.5d 19.0 ± 1.8c 3.5 ± 0.1b 65.2 ± 3.4c 19.4 ± 0.9d 3.6 ± 0.2b
CM Cece di Merella 8.8 ± 0.5d 15.7 ± 1.0e 6.2 ± 0.4a 66.5 ± 3.6b 27.5 ± 1.1b 3.5 ± 0.3c
CV Cece Alta Valle di Misa 8.9 ± 0.3d 20.0 ± 0.8c 6.3 ± 0.1a 61.2 ± 3.5e 26.8 ± 2.3b 4.0 ± 0.2b
CS Cicerchia di Serra de Conti 9.2 ± 0.5c 24.3 ± 1.5a 1.4 ± 0.2e 60.8 ± 3.5e 25.1 ± 1.2c 3.7 ± 0.4b
CC Cicerchia di Campodimele 9.3 ± 0.6c 24.1 ± 2.0a 2.2 ± 0.4d 61.5 ± 3.1e 32.1 ± 2.0a 3.8 ± 0.2b
LN Lenticchia di Castelluccio di 
Norcia
8.2 ± 0.7d 23.5 ± 1.2a 3.0 ± 0.5b 62.8 ± 2.5d 18.2 ± 1.9e 2.6 ± 0.1d
LU Lenticchia di Ustica 8.8 ± 0.4d 23.0 ± 1.0a 3.4 ± 0.2b 62.6 ± 3.7d 17.6 ± 2.1e 2.3 ± 0.2e
LS Lenticchia di Santo Stefano 
di Sessanio
8.7 ± 0.8d 22.0 ± 1.3b 3.2 ± 0.2b 64.1 ± 3.0d 25.2 ± 1.9c 3.0 ± 0.3d
LP Lenticchia rossa di Pantelleria 8.0 ± 0.5d 21.2 ± 1.5b 2.7 ± 0.1c 65.9 ± 2.9c 20.5 ± 1.1d 2.2 ± 0.1e
LA Lenticchia di Altamura 7.4 ± 0.2e 18.7 ± 0.9d 2.4 ± 0.2d 69.1 ± 2.2a 22.8 ± 1.8c 2.5 ± 0.2d
LV Lenticchia di Villalba 8.6 ± 0.5d 20.8 ± 1.5b 2.1 ± 0.2d 65.9 ± 3.0b 17.5 ± 0.4e 2.1 ± 0.2e
PS Pisello riccio di Sannicola 9.2 ± 0.7c 19.6 ± 1.0c 2.2 ± 0.2d 65.3 ± 2.0c 35.5 ± 2.9a 4.6 ± 0.3a
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ca. 10 %. In particular, WSE from CC sourdough caused 
the highest decrease of vitality (58.47 ±  2.08 %). At the 
highest concentration assayed, the most remarkable 
cytotoxicity was found for CC, LN, and PS sourdoughs 
(30.49 ± 1.13, 36.97 ± 1.01, and 35.13 ± 0.95 %, respec-
tively). The same trend was found after 48  h of treat-
ment (Fig.  2b), although lower values of vitality were 
observed. The lowest proliferation was found for CC 
sourdough, when treatments were done with 1  mg/ml 
(39.59 ±  1.05  %), and for CC, LN, and PS sourdoughs, 
when 10 mg/ml of proteins (30.67 ± 0.87, 29.32 ± 1.11, 
and 37.75 ± 1.23 %, respectively) were used.
After 72 h of treatment (Fig. 2c), the vitality of Caco-2 
cells was lower than that found after 24 or 48 h for treat-
ments performed with 0.1 and 1 mg/ml of proteins, while 
the use of 10  mg/ml of proteins was less effective than 
48 h-treatments, with the only exception of FL sourdough.
Transcriptional regulation of filaggrin (FLG) and involucrin 
(IVL)
Human colon adenocarcinoma cells (Caco-2) were treated 
with the partially purified and freeze dried WSE from leg-
ume D and S aiming at investigating filaggrin (FLG) and 
involucrin (IVL) gene expressions through RT-PCR. Treat-
ments were lasting 4, 8, and 24  h, After 4  h of exposure 
(Fig. 3A), a significant (P < 0.05 %) over-expression of FLG 
was found only for fermented PS. All the other WSE, both 
from D and S, did not cause significant (P < 0.05) variations 
compared to LPS (positive control). After 8 h of exposure, 
a significant (P < 0.05) up-regulation of the FLG gene was 
also found for FL dough and FL, CV, and PS sourdoughs 
(Fig. 3B). The same trend was found for treatment lasting 
24 h (Fig. 3C) with FL, CV, CC, and PS sourdoughs.
Regarding IVL gene, none of the extracts, except for PS 
sourdough, induced an expression after 4 h of treatment 
higher than that of LPS after 4 h of treatment (Fig. 4A). 
After 8  h of treatment, WSE extracted from S caused 
significant (P  <  0.05) increases of the expression com-
pared to the corresponding D, especially FL, CV, and PS 
(Fig. 4B). A longer treatment with the WSE (24 h) did not 
favour a further increase of the gene expression. Only 
PS sourdough caused the same expression of IVL gene 
under all the conditions assayed (Fig. 4C).
Identification of lunasin‑like polypeptides
Based on the results from the MTT assay on Caco-2 
cell, the immunoreactive protein bands of FL, CV, and 
PS sourdoughs were recovered from Tris-Tricine gels, 
and subjected to tryptic digestion, and HPLC coupled to 
nanoESI-MS/MS analysis.
Table 3 Microbiological analyses of the Italian legume flours
Total mesophilic aerobic bacteria were estimated on Plate Count Agar (PCA), lactic acid bacteria on agar MRS; yeasts and molds on Yeast extract Peptone Dextrose 
Agar (YPD-y and YPD-m, respectively); and total enterobacteria on Violet Red Bile Glucose Agar (VRBGA). Details are reported in “Methods” section
The data are the means of three independent experiments ± standard deviations (n = 3)
a–e Values in the same column with different superscript letters differ significantly (P < 0.05)
Legume Total mesophilic  
aerobic bacteria
Lactic acid  
bacteria
Yeasts Molds Total entero‑
bacteria
FL 3.52 ± 0.12b 1.93 ± 0.12b 2.77 ± 0.20c 3.51 ± 0.13ª 0.82 ± 0.11b
FCo 3.60 ± 0.20b 2.49 ± 0.22ª 1.84 ± 0.20d nf 0.53 ± 0.09c
FCu 3.23 ± 0.22b 2.54 ± 0.12ª 1.11 ± 0.05e 3.33 ± 0.21ª 0.82 ± 0.11b
FSt 4.21 ± 0.18ª 2.25 ± 0.23ª 2.14 ± 0.21c 3.31 ± 0.22ª 0.91 ± 0.07b
FV 2.92 ± 0.13c 1.14 ± 0.24c nf 2.81 ± 0.15b 0.51 ± 0.09c
FSa 2.55 ± 0.25c 1.16 ± 0.11c nf 2.47 ± 0.15c 0.62 ± 0.13c
FBw 3.34 ± 0.19b 1.47 ± 0.15c 1.30 ± 0.21e 3.23 ± 0.16a 0.73 ± 0.09b
FBb 1.61 ± 0.32d 1.00 ± 0.16c nf 2.45 ± 0.15c 0.82 ± 0.09b
CM 2.84 ± 0.22c 1.31 ± 0.18c 1.69 ± 0.23d 2.47 ± 0.22c 0.91 ± 0.14b
CV 2.47 ± 0.14c 1.47 ± 0.21c 1.95 ± 0.09c 2.30 ± 0.24c 0.9 ± 0.09b
CS 2.25 ± 0.15c 1.69 ± 0.23b nf 2.00 ± 0.21c 0.8 ± 0.10b
CC 2.32 ± 0.23c 1.84 ± 0.22b 4.23 ± 0.22a nf 0.53 ± 0.05c
LN 2.69 ± 0.21c 1.77 ± 0.24b 1.47 ± 0.13e 2.04 ± 0.23c 1.32 ± 0.10a
LU 2.36 ± 0.24c 1.84 ± 0.25b 2.08 ± 0.15c 2.30 ± 0.20c 0.64 ± 0.11c
LS 2.95 ± 0.09c 1.47 ± 0.24c 2.11 ± 0.15c nf 0.75 ± 0.13b
LP 4.31 ± 0.11a 1.30 ± 0.25c nf 3.23 ± 0.20a 0.52 ± 0.22c
LA 3.69 ± 0.16b 1.30 ± 0.08c 3.50 ± 0.15b 2.11 ± 0.20c 0.72 ± 0.14b
LV 2.61 ± 0.17c 1.00 ± 0.08c 2.47 ± 0.12c 2.23 ± 0.15c 0.82 ± 0.12b
PS 2.47 ± 0.23c 1.30 ± 0.10c 1.30 ± 0.21e nf 0.92 ± 0.13b
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Ten different proteins were identified through the 
Mascot research on the NCBI database (Table  5). It can 
be hypothesized that lunasin-like polypeptides were 
released from native legume proteins via proteolysis dur-
ing sourdough fermentation. This should explain the lack 
of correspondence between the molecular masses of the 
proteins identified and the polypeptide bands revealed 
by western blot analyses. The immunodetected polypep-
tide bands from FL sourdough corresponded to the fol-
lowing matches: Subtilisin inhibitor 1 (P16064), Legumin 
A2 (P15838) and Phaseolin (P02853). The protein bands 
from CV sourdough matched with: leucoagglutinating 
phytohemagglutinin (P05087), phatogenesis related pro-
tein (CAA56142) and seed linoleate 9S-lipoxygenase-3 
(P09918). The proteins from PS sourdough were identified 
as: Provicilin (P02855), seed linoleate 9S-lipoxygenase-2 
(P14856), seed biotin-containing protein SBP65 (Q41060) 
and Albumin-1 C (P62928). All the database matches cor-
responded to proteins previously identified from legumes. 
For five proteins, the exact correspondence between the 
species analyzed and the database matches was not found, 
especially for CV. Probably, this was due to the limited 
number of legume protein sequences previously identified 
and included in the NCBI database.
The protein sequences were compared to soy lunasin 
sequence (deposited at the National Center for Biotech-
nology Information, NCBI database with the accession 
number AAP62458) using BLAST. Except for Provici-
lin identified that was identified in PS sourdough, all 
the sequences might be aligned with different lunasin 
epitopes (Fig. 5). The longest alignments were found for 
Legumin A2, corresponding to fragments (f ) 24–38 and 
33–41 of the soy lunasin sequence, and Phaseolin (f13–
28) from FL sourdough; pathogenesis related protein 
and seed-linoleate 9S lipoxygenate-3 (f9–32 and f1–18, 
respectively) from CV, and seed-linoleate 9S lipoxygen-
ate-2 and seed biotin-containing protein SBP65 (f1–22 
and f11–36, respectively) from PS. The alignments 
showed identities from 26 to 67 % (pathogenesis related 
protein and subtilisin inhibitor1/leucoagglutinating phy-
toemagglutinin, respectively) and positives from 35 to 
93 % (Albumin-1C and Legumin A2, respectively).
Peptidase activities
The peptidase activities of the two lactic acid bacte-
ria strains used as starters were assayed using relatively 
specific synthetic substrates. Significant (P  <  0.05) dif-
ferences were found between strains. Compared to that 
Table 4 Biochemical characteristics of doughs
Control doughs (D), without bacterial inoculation, and sourdoughs (S), started with selected lactic acid bacteria, made with the Italian legume flours were incubated 
at 30 °C for 24 h
The data are the means of three independent experiments ± standard deviations (n = 3)
a–f Values in the same column with different superscript letters differ significantly (P < 0.05)
Legume pH TTA (ml of 0.1 M NAOH) Free amino acids (mg/kg)
D S D S D S
FL 6.5 ± 0.2a 4.4 ± 0.1a 5.7 ± 0.5c 26.6 ± 1.3a 4272 ± 10ª 5900 ± 18b
FCo 6.2 ± 0.1b 4.2 ± 0.2c 6.3 ± 0.2b 23.0 ± 0.9c 3348 ± 14c 5414 ± 17c
FCu 6.5 ± 0.3a 4.4 ± 0.2a 5.5 ± 0.3c 26.8 ± 2.1a 4018 ± 9ª 5605 ± 15b
FSt 6.4 ± 0.5a 4.5 ± 0.3a 3.1 ± 0.4e 22.7 ± 0.9d 3025 ± 11c 3982 ± 16e
FV 6.5 ± 0.2a 4.2 ± 0.2c 4.7 ± 0.3d 23.5 ± 1.8c 3991 ± 13b 5904 ± 12b
FSa 6.2 ± 0.2b 4.3 ± 0.1b 5.2 ± 0.4c 20.2 ± 1.3e 3512 ± 12b 3634 ± 18e
FBw 6.4 ± 0.3a 4.2 ± 0.1c 6.1 ± 0.6b 25.5 ± 1.8b 4547 ± 18ª 6620 ± 12ª
FBb 6.2 ± 0.6b 4.4 ± 0.2a 7.1 ± 0.5a 25.4 ± 1.5b 3901 ± 15b 6269 ± 14ª
CM 6.0 ± 0.1c 3.9 ± 0.1e 3.8 ± 0.2e 22.5 ± 1.0d 2550 ± 9d 2573 ± 16f
CV 6.2 ± 0.3b 4.1 ± 0.4d 5.1 ± 0.5c 22.3 ± 0.7d 2961 ± 13c 4524 ± 20d
CS 6.3 ± 0.2b 4.2 ± 0.1c 6.2 ± 0.3b 23.2 ± 1.2c 2652 ± 11d 4183 ± 17d
CC 6.0 ± 0.5c 4.2 ± 0.1c 7.4 ± 0.3a 27.2 ± 1.5a 2611 ± 13d 2730 ± 15f
LN 6.3 ± 0.5b 4.2 ± 0.2c 4.6 ± 0.4d 23.1 ± 1.4c 2825 ± 18d 3634 ± 18e
LU 6.0 ± 0.3c 4.0 ± 0.1d 4.2 ± 0.6d 22.2 ± 1.5d 2429 ± 20d 3274 ± 16e
LS 5.8 ± 0.2d 4.0 ± 0.1d 8.5 ± 0.2a 22.8 ± 2.0d 4324 ± 11ª 4743 ± 21d
LP 6.3 ± 0.4b 4.1 ± 0.4d 4.1 ± 0.2d 23.1 ± 1.5c 2631 ± 9d 3173 ± 11e
LA 6.3 ± 0.2b 4.1 ± 0.2d 3.9 ± 0.3e 22.5 ± 0.9d 3207 ± 13c 5104 ± 17c
LV 6.0 ± 0.2c 4.1 ± 0.3d 5.3 ± 0.2c 22.2 ± 1.1d 3196 ± 15c 5173 ± 22c
PS 6.3 ± 0.5b 4.4 ± 0.5a 4.3 ± 0.4d 20.4 ± 1.5e 3629 ± 16b 3686 ± 19e
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(See figure on next page.) 
Fig. 2 Effect of lunasin‑like polypeptides on the Caco‑2 cells proliferation. Box-plot showing aggregate data for human colon adenocarcinoma 
(Caco‑2) cells proliferation after treatments of 24 (panel a), 48 (panel b), and 72 h (panel c) with water/salt soluble extracts obtained from control 
doughs (D), without bacterial inoculum, and sourdoughs (S), started with selected lactic acid bacteria, made with Italian legume flours. Protein 
concentration of 0.1, 1.0, and 10 mg/ml were assayed. Data were expressed as the mean percentage of viable cells compared to the control culture, 
grown in basal media without the addition of the WSE. The centre line of the box represents the median (open square), the top and bottom of the box 
represent the 75th and 25th percentile of the data, respectively. The top and bottom of the bars represent the 5th and 95th percentile of the data, 
respectively. Outliers (open circle) and extremes (aterisk) are represented
of L. plantarum C48 (5.87  ±  0.02 and 3.52  ±  0.02 U), 
PepN activity on Leu-p-NA and endopeptidase activ-
ity (PepO) of L. brevis AM7 were higher (6.83  ±  0.08 
U and 4.31 ± 0.03). Also PepA activity was higher in L. 
brevis AM7 (14.02 ± 0.04 U). That of L. plantarum C48 
resulted 35 % lower. This latter strain showed higher trip-
eptidase (PepT) activity (9.12 ± 0.02 vs. 5.61 ± 0.05 U). 
No significant differences (P > 0.05) were found between 
the two strains for PepT (7.20 ± 0.04 and 7.12 ± 0.05 U) 
and PepX (0.95 ± 0.03 and 1.01 ± 0.02 U) activities.
Discussion
Despite the beneficial effects on the human diet, the 
worldwide consumption of legumes is declining [15] and 
below the recommended dose [16]. One potential way to 
increase the consumption of legumes could be the redis-
covery of traditional and local varieties, and, especially, 
the use of legumes into novel and healthy foods, also 
exploiting the potential of non-conventional processing 
[17]. The complementation between cereal and legume 
flours into new formulas may deserve an interest either 
to increase the levels of biogenic compounds or to fulfill 
nutritional deficiencies of cereal-based diets [18].
Traditional Italian legumes, all with product certifica-
tions and belonging to Phaseulus vulgaris, Cicer arieti-
num, Lathyrus sativus, Lens culinaris and Pisum sativum 
species, were used in this study. Seeds were milled, and 
flours were subjected to sourdough fermentation, using 
Fig. 1 Western blot analysis. Water/salt soluble extracts obtained from control doughs (D), without bacterial inoculum, and sourdoughs (S), started 
with selected lactic acid bacteria, made with Italian legume flours, were used. A lunasin polyclonal primary antibody was used. Before electroblot‑
ting, the electrophoretic separation was obtained by Tris‑Tricine SDS‑PAGE. Image was performed using the VersaDoc Imaging System (Bio‑Rad). 
Synthetic lunasin (L) was included in the analysis. The correspondence of the legume flour abbreviations is reported in Table 1
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the selected Lactobacillus plantarum C48 and Lactoba-
cillus brevis AM7.
Compared to cereals, all legume flours showed elevated 
amount of protein (mainly grass pea and several lentil 
flours), FAA (>2 g/kg), dietary fibers, and ash. In particular, 
grass pea varieties had the highest concentration of pro-
teins, while pea, chickpea, and grass pea flours contained 
the highest levels of dietary fibre. The microbiota of leg-
ume flours was poorly represented by lactic acid bacteria 
and yeasts. All the data agreed with previous findings [19].
Recently, the potential of sourdough fermentation was 
exploited to enhance the nutritional and functional fea-
tures of legume flours [19]. Apart from the legume species 
and variety, sourdough fermentation with selected start-
ers is a suitable biotechnology option either to increase 
the nutritional and functional value or to decrease the 
levels of anti-nutritional factors [19]. Selected sourdough 
lactic acid bacteria were able to decrease the concentra-
tion of raffinose up to ca. 64  % and a similar trend was 
found for the concentration of condensed tannins [19]. 
The sourdough fermentation also increased the concen-
tration of GABA, and promoted antioxidant and phytase 
activities compared to the raw flours [19].
According to protocols used for cereal sourdough fer-
mentation [20], legume flours were started with Lactoba-
cillus brevis AM7 and Lactobacillus plantarum C48 [21]. 
As previously shown [19], the conditions of incubation 
(24 h at 30 °C) allowed the optimal growth and metabo-
lism of selected lactic acid bacteria [19, 22]. As expected, 
fermentation caused a marked decrease of the values of 
pH as well as an increase of TTA and of the concentra-
tion of peptides and FAA, especially when kidney bean 
flours were used.
Based on their proteolytic activity towards vegetable 
proteins [20], the use of sourdough lactic acid bacteria 
for synthesizing bioactive peptides deserves a marked 
interest [23]. Bioactive peptides derived from food pro-
teins may possess physiological properties beyond the 
role in nutrition. These properties are influenced by the 
protein source, enzyme and processing conditions used 
[24]. Most of the research related to bioactive peptides 
and cancer was focused on lunasin [25] and, recently, on 
pulse hydrolysates [2].
To the best of our knowledge, no literature data dealt 
with the presence of lunasin or lunasin-like polypeptides 
from native protein sequences of Italian pulses, and with 
the effect of sourdough fermentation on bioactivity and 
bioavailability.
Proteinase activity and a large portfolio of peptidases 
are the pre-requisites to liberate bioactive peptides from 
native oligopeptides [7, 26]. Although with some differ-
ences, the two starters used showed different peptidase 
activities.
Western blot analyses showed that the sequence of 
lunasin sequence was absent in all the legume flours, 
and, therefore, in the corresponding sourdoughs. Nev-
ertheless, immunoreactive polypeptides with molecu-
lar masses lower than 30 kDa were detectable in all the 
samples. In some cases, immunoreactive polypeptides 
appeared as multiple bands in western blot, probably 
due to the presence of multiple fragments differing for 
few aminoacid residues [12]. Regarding unfermented 
doughs, proteins with high intensity signals were found 
for all the bean, followed by lentil varieties. After lactic 
acid bacteria fermentation, the number and the intensity 
of the proteins reacting with the anti-lunasin antibody 
increased for all the legume flours. This was probably due 
to an acid activation of endogenous proteinases, respon-
sible for primary proteolysis, and peptidase activities by 
lactic acid bacteria, which completed the hydrolysis (sec-
ondary proteolysis). All the reactive protein bands had 
molecular masses higher than that of lunasin. Although 
some differences were found among varieties, one repre-
sentative was chosen for each legume species to assay the 
effect on Caco-2 cells proliferation. Caco-2 cells derived 
from a colonic tumor and have a cancerous phenotype, 
and can be cultivated to become confluent. In this case, 
they differentiate into enterocyte-like cells [27].
(See figure on next page.) 
Fig. 4 Expression of the involucrin (IVL) gene in Caco‑2 cells. The expression of the IVL gene in human colon adenocarcinoma cells (Caco‑2) was 
determined using RT‑PCR. Caco‑2 cells were treated at 37 °C for 4 (A), 8 (B) and 24 h (C) with basal medium containing 1.0 mg/ml of the freeze‑
dried water/salt soluble extracts obtained from control doughs (D), without bacterial inoculum, and sourdoughs (S), started with selected lactic 
acid bacteria, made with FL, CV, CC, LN, and PS legume flours. Data are the mean ± SD of three separate experiments, performed in triplicate. a–c 
Columns with different superscript letters differ significantly (P < 0.05)
(See figure on previous page.) 
Fig. 3 Expression of the filaggrin (FLG) gene in Caco‑2 cells. The expression of the FLG gene in human colon adenocarcinoma cells (Caco‑2) was 
determined using RT‑PCR. Caco‑2 cells were treated at 37 °C for 4 (A), 8 (B) and 24 h (C) with basal medium containing 1.0 mg/ml of the freeze‑
dried water/salt soluble extracts obtained from control doughs (D), without bacterial inoculum, and sourdoughs (S), started with selected lactic 
acid bacteria, made with FL, CV, CC, LN, and PS legume flours. Data are the mean ± SD of three separate experiments, performed in triplicate. a–c 
Columns with different superscript letters differ significantly (P < 0.05)
Page 11 of 20Rizzello et al. Microb Cell Fact  (2015) 14:168 
Page 12 of 20Rizzello et al. Microb Cell Fact  (2015) 14:168 
Ta
bl
e 
5 
Lu
na
si
n-
lik
e 
po
ly
pe
pt
id
es
 s
eq
ue
nc
es
W
SE
Pr
ot
ei
n
Se
qu
en
ce
a
N
CB
I a
cc
es
si
on
 
nu
m
be
r
Th
eo
re
tic
al
  
m
as
s 
(k
D
a)
Se
qu
en
ce
 
co
ve
ra
ge
M
as
co
t 
sc
or
e
FL
‑S
Su
bt
ili
si
n 
in
hi
bi
to
r 1
 (V
ig
na
 a
ng
ul
ar
is)
Q
EQ
G
TN
PS
Q
EQ
N
VP
LP
RN
YK
Q
A
LE
TN
TP
TK
TS
W
PE
LV
G
VT
A
EQ
A
ET
KI
 
KE
EM
VD
VQ
IQ
VS
PH
D
SF
VT
A
D
YN
PK
RV
RL
YV
D
ES
N
KV
TR
TP
SI
G
P1
60
64
10
.3
8
82
11
4
Le
gu
m
in
 A
2 
(P
isu
m
 sa
tiv
um
)
M
AT
KL
LA
LS
LS
FC
FL
LL
G
G
C
FA
LR
EQ
PE
Q
N
EC
Q
LE
RL
N
A
LE
PD
 
N
RI
ES
EG
G
LI
ET
W
N
PN
N
KQ
FR
C
A
G
VA
LS
RA
TL
Q
H
N
A
LR
RP
Y 
YS
N
A
PQ
EI
FI
Q
Q
G
N
G
YF
G
M
VF
PG
C
PE
TF
EE
PQ
ES
EQ
G
EG
R 
RY
RD
RH
Q
KV
N
RF
RE
G
D
IIA
VP
TG
IV
FW
M
YN
D
Q
D
TP
VI
AV
SL
TD
IR
SS
N
 
N
Q
LD
Q
M
PR
RF
YL
A
G
N
H
EQ
EF
LR
YQ
H
Q
Q
G
G
KQ
EQ
EN
EG
N
N
IF
 
SG
FK
RD
FL
ED
A
FN
VN
RH
IV
D
RL
Q
G
RN
ED
EE
KG
A
IV
KV
KG
G
LS
IIS
P 
PE
KQ
A
RH
Q
RG
SR
Q
EE
D
ED
ED
EE
RQ
PR
H
Q
RG
SR
Q
EE
EE
D
ED
EE
R 
Q
PR
H
Q
RR
RG
EE
EE
ED
KK
ER
RG
SQ
KG
KS
RR
Q
G
D
N
G
LE
ET
VC
TA
KL
RL
 
N
IG
PS
SS
PD
IY
N
PE
A
G
RI
KT
VT
SL
D
LP
VL
RW
LK
LS
A
EH
G
SL
H
KN
A
M
FV
 
PH
YN
LN
A
N
SI
IY
A
LK
G
RA
RL
Q
VV
N
C
N
G
N
TV
FD
G
EL
EA
G
RA
LT
VP
Q
N
 
YA
VA
A
KS
LS
D
RF
SY
VA
FK
TN
D
RA
G
IA
RL
A
G
TS
SV
IN
N
LP
LD
VV
A
AT
FN
 
LQ
RN
EA
RQ
LK
SN
N
PF
KF
LV
PA
RQ
SE
N
RA
SA
P1
58
38
59
.6
3
62
41
0
Ph
as
eo
lin
 (P
ha
se
ol
us
 v
ul
ga
ris
)
M
M
RA
RV
PL
LL
LG
IL
FL
A
SL
SA
SF
AT
SL
RE
EE
ES
Q
D
N
PF
YF
N
SD
N
 
SW
N
TL
FK
N
Q
YG
H
IR
VL
Q
RF
D
Q
Q
SK
RL
Q
N
LE
D
YR
LV
EF
RS
KP
ET
LL
L 
PQ
Q
A
D
A
EL
LL
VV
RS
G
SA
IL
VL
VK
PD
D
RR
EY
FF
LT
SD
N
PI
FS
D
H
Q
KI
PA
G
I 
FY
LV
N
PD
PK
ED
LR
IIQ
LA
M
PV
N
N
PQ
IH
EF
FL
SS
TE
A
Q
Q
SY
LQ
EF
SK
H
 
IL
EA
SF
N
SK
FE
EI
N
RV
LF
EE
EG
Q
Q
EG
VI
VN
ID
SE
Q
IK
EL
SK
H
A
KS
SS
RK
 
SL
SK
Q
D
N
TI
G
N
EF
G
N
LT
ER
TD
N
SL
N
VL
IS
SI
EM
EE
G
A
LF
V 
PH
YY
SK
A
IV
IL
VV
N
EG
EA
H
VE
LV
G
PK
G
N
KE
TL
EY
ES
YR
A
EL
SK
D
 
D
VF
VI
PA
AY
PV
A
IK
AT
SN
VN
FT
G
FG
IN
A
N
N
N
N
RN
LL
A
G
KT
D
N
VI
SS
I 
G
RA
LD
G
KD
VL
G
LT
FS
G
SG
D
EV
M
KL
IN
KQ
SG
SY
FV
D
A
H
H
H
Q
Q
EQ
Q
 
KG
RK
G
A
FV
Y
P0
28
53
47
.5
40
75
51
5
C
V‑
S
Le
uc
oa
gg
lu
tin
at
in
g 
ph
yt
oh
em
ag
gl
ut
in
in
 (P
ha
se
ol
us
 
vu
lg
ar
is)
M
A
SS
KF
FT
VL
FL
VL
LT
H
A
N
SS
N
D
IY
FN
FQ
RF
N
ET
N
LI
LQ
RD
A
SV
SS
S 
G
Q
LR
LT
N
LN
G
N
G
EP
RV
G
SL
G
RA
FY
SA
PI
Q
IW
D
N
TT
G
TV
A
SF
AT
SF
T 
FN
IQ
VP
N
N
A
G
PA
D
G
LA
FA
LV
PV
G
SQ
PK
D
KG
G
FL
G
LF
D
G
SN
SN
FH
T 
VA
VE
FD
TL
YN
KD
W
D
PT
ER
H
IG
ID
VN
SI
RS
IK
TT
RW
D
FV
N
G
EN
A
EV
 
LI
TY
D
SS
TN
LL
VA
SL
VY
PS
Q
KT
SF
IV
SD
TV
D
LK
SV
LP
EW
VS
VG
FS
AT
T 
G
IN
KG
N
VE
TN
D
VL
SW
SF
A
SK
LS
D
G
TT
SE
G
LN
LA
N
LV
LN
KI
L
P0
50
87
29
.5
4
61
50
6
Pa
th
og
en
es
is
 re
la
te
d 
pr
ot
ei
n 
(C
ic
er
 a
rie
tin
um
)
M
G
VF
TF
EQ
ET
A
ST
VP
PA
KL
YK
A
M
VK
D
A
D
VI
IP
KA
VD
A
IK
TV
ET
VE
G
N
G
G
 
PG
TI
KK
LT
FV
EG
G
Q
TL
YV
LH
KI
EA
ID
EA
N
LG
YN
YS
IV
G
G
A
G
LS
ET
VE
RY
 
H
FE
A
KL
C
EG
PN
G
G
SI
G
KV
SV
KY
Q
TK
G
D
A
KP
N
EK
EV
Q
EG
KA
KG
D
A
 
LF
KA
IE
G
YV
LA
N
PN
YN
C
A
A
56
14
2
16
.9
3
83
40
8
Page 13 of 20Rizzello et al. Microb Cell Fact  (2015) 14:168 
Ta
bl
e 
5 
co
nt
in
ue
d
W
SE
Pr
ot
ei
n
Se
qu
en
ce
a
N
CB
I a
cc
es
si
on
 
nu
m
be
r
Th
eo
re
tic
al
  
m
as
s 
(k
D
a)
Se
qu
en
ce
 
co
ve
ra
ge
M
as
co
t 
sc
or
e
Se
ed
 li
no
le
at
e 
9S
‑li
po
xy
ge
na
se
‑3
 (P
isu
m
 sa
tiv
um
)
M
FS
G
VT
G
IL
N
RG
H
KI
KG
TV
VL
M
RK
N
VL
D
IN
SL
TT
VG
G
VI
G
Q
G
FD
IL
G
 
ST
VD
N
LT
A
FL
G
RS
VS
LQ
LI
SA
TK
PD
AT
G
KG
KL
G
KA
TF
LE
G
IIS
SL
PT
L 
G
A
G
Q
SA
FK
IH
FE
W
D
D
D
M
G
IP
G
A
FY
IK
N
FM
Q
TE
FF
LV
SL
TL
D
D
IP
N
 
H
G
SI
YF
VC
N
SW
IY
N
A
KH
H
KI
D
RI
FF
A
N
Q
TY
LP
SE
TP
A
PL
VH
YR
EE
EL
N
N
 
LR
G
D
G
TG
ER
KE
W
ER
IY
D
YD
VY
N
D
LG
N
PD
SG
EN
H
A
RP
VL
G
G
SE
 
TY
PY
PR
RG
RT
G
RK
PT
RK
D
PN
SE
SR
SD
YV
YL
PR
D
EA
FG
H
LK
SS
D
FL
 
TY
G
LK
AV
SQ
N
VV
PA
LE
SV
FF
D
LN
FT
PN
EF
D
SF
D
EV
H
G
LY
EG
G
IK
LP
T 
N
IL
SQ
IS
PL
PV
LK
EI
FR
TD
G
EN
TL
KY
PP
PK
VI
Q
VS
RS
G
W
M
TD
EE
FA
RE
M
 
LA
G
VN
PN
VI
CC
LQ
EF
PP
RS
KL
D
SQ
IY
G
D
H
TS
KI
SK
EH
LE
PN
LE
G
LT
 
VE
EA
IQ
N
KK
LF
LL
D
H
H
D
SI
M
PY
LR
RI
N
ST
ST
KA
YA
TR
TI
LF
LN
N
N
Q
N
 
LK
PL
A
IE
LS
LP
H
PQ
G
D
EH
G
AV
SY
VY
Q
PA
LE
G
VE
SS
IW
LL
A
KA
YV
IV
N
D
 
SC
YH
Q
LV
SH
W
LN
TH
AV
VE
PF
VI
AT
N
RH
LS
C
LH
PI
YK
LL
YP
H
YR
D
T 
M
N
IN
SL
A
RL
SL
VN
D
G
G
IIE
KT
FL
W
G
RY
SM
EM
SS
KV
YK
N
W
VF
TE
Q
A
L 
PA
D
LI
KR
G
M
A
IE
D
PS
SP
CG
VK
LV
VE
D
YP
YA
VD
G
LE
IW
A
IIK
TW
VQ
D
Y 
VS
LY
YT
SD
EK
LR
Q
D
SE
LQ
AW
W
KE
LV
EV
G
H
G
D
KK
N
EP
W
W
PK
M
Q
 
TR
ED
LI
EV
C
SI
VI
W
TA
SA
LH
A
AV
N
FG
Q
YS
YG
G
LI
LN
RP
TL
SR
RF
M
PE
K 
G
SA
EF
EE
LV
KS
PQ
KA
YL
KT
IT
PK
FQ
TL
ID
LS
VI
EI
LS
RH
A
SD
EL
YL
G
ER
D
 
N
PN
W
TS
D
KR
A
LE
A
FK
KF
G
N
KL
A
EI
EK
KL
TQ
RN
N
D
EK
LR
N
RH
G
PV
EM
 
PY
TL
LY
PS
SK
EG
LT
FR
G
IP
N
SI
SI
P0
99
18
97
.5
7
43
20
7
PS
‑S
Pr
ov
ic
ili
n 
(P
isu
m
 sa
tiv
um
)
D
N
A
EI
EK
IL
LE
EH
EK
ET
H
H
RR
G
LR
D
KR
Q
Q
SQ
EK
N
VI
VK
VS
KK
 
Q
IE
EL
SK
N
A
KS
SS
KK
SV
SS
RS
EP
FN
LK
SS
D
PI
YS
N
Q
YG
KF
FE
IT
PK
 
KN
PQ
LQ
D
LD
IF
VN
YV
EI
KE
G
SL
W
LP
H
YN
SR
A
IV
IV
TV
N
EG
KG
D
 
FE
LV
G
Q
RN
EN
Q
Q
G
LR
EE
D
D
EE
EE
Q
RE
EE
TK
N
Q
VQ
SY
KA
KL
TP
G
 
D
VF
VI
PA
G
H
PV
AV
RA
SS
N
LN
LL
G
FG
IN
A
EN
N
Q
RN
FL
A
G
EE
D
N
VI
S 
Q
IQ
KQ
VK
D
LT
FP
G
SA
Q
EV
D
RL
LE
N
Q
KQ
SY
FA
N
A
Q
PQ
Q
RE
TR
SQ
EI
KE
 
H
LY
SI
LG
A
F
P0
28
55
31
.5
2
53
58
9
Page 14 of 20Rizzello et al. Microb Cell Fact  (2015) 14:168 
Ta
bl
e 
5 
co
nt
in
ue
d
W
SE
Pr
ot
ei
n
Se
qu
en
ce
a
N
CB
I a
cc
es
si
on
 
nu
m
be
r
Th
eo
re
tic
al
  
m
as
s 
(k
D
a)
Se
qu
en
ce
 
co
ve
ra
ge
M
as
co
t 
sc
or
e
Se
ed
 li
no
le
at
e 
9S
‑li
po
xy
ge
na
se
‑2
 (P
isu
m
 sa
tiv
um
)
M
FP
N
VT
G
LL
N
KG
H
KI
RG
TV
VL
M
RK
N
VL
D
FN
TI
VS
IG
G
G
N
VH
G
VI
D
SG
I 
N
IIG
ST
LD
G
LT
A
FL
G
RS
VS
LQ
LI
SA
TK
SD
A
N
G
KG
KV
G
KD
TF
LE
G
V 
LA
SL
PT
LG
A
G
ES
A
FN
IH
FE
W
D
H
EM
G
IP
12
1G
A
FY
IK
N
YM
Q
VE
F 
FL
KS
LT
LE
D
VP
N
H
G
TI
RF
VC
N
SW
VY
N
SK
LY
KS
PR
IF
FA
N
KS
YL
PS
ET
 
PS
PL
VK
YR
EE
EL
Q
TL
RG
D
G
TG
ER
KL
H
ER
IY
D
YD
VY
N
D
LG
N
PD
H
G
E 
H
LA
RP
IL
G
G
SS
TH
PY
PR
RG
RT
G
RY
PT
RK
D
PN
SE
KP
AT
ET
YV
PR
D
EN
 
FG
H
LK
SS
D
FL
AY
G
IK
SV
SQ
C
VV
PA
FE
SA
FD
LN
FT
PN
EF
D
SF
Q
D
VR
N
 
LF
EG
G
IK
LP
LD
VI
ST
LS
PL
PV
VK
EI
FR
TD
G
EQ
VL
KF
TP
PH
VI
RV
SK
SA
W
 
M
TD
EE
FA
RE
M
LA
G
VN
PC
M
IR
G
LQ
EF
PP
KS
N
LD
PA
EY
G
D
H
TS
KI
SV
D
 
VL
N
LD
G
C
TI
D
EA
LA
SG
RL
FI
LD
YH
D
TF
IP
FL
RR
IN
ET
SA
KA
YA
TR
TI
LF
LK
 
EN
G
TL
KP
VA
IE
LS
LP
H
PD
G
D
KS
G
FV
SK
VI
LP
A
D
EG
VE
ST
IW
LL
A
KA
YV
 
VV
N
D
SC
YH
Q
LM
SH
W
LN
TH
AV
IE
PF
VI
AT
N
RQ
LS
VV
H
PI
N
KL
LA
PH
Y 
RD
TM
M
N
IN
A
LA
RD
SL
IN
A
N
G
LI
ER
SF
LP
SK
YA
VE
M
SS
AV
YK
YW
VF
T 
D
Q
A
LP
N
D
LI
KR
N
M
AV
KD
SS
SP
YG
LR
LL
IE
D
YP
YA
VD
G
LE
IW
TA
IK
T 
W
VQ
D
YV
SL
YY
AT
D
N
D
IK
N
D
SE
LQ
H
W
W
KE
VV
EK
G
H
G
D
LK
D
KP
W
W
P 
KL
Q
TF
D
EL
VE
VC
TI
IIW
TA
SA
LH
A
AV
N
FG
Q
YP
YG
G
LI
LN
RP
TL
SR
RL
L 
PE
EG
TA
EY
D
EM
VK
SS
Q
KA
YL
RT
IT
PK
FQ
TL
ID
LS
VI
EI
LS
RH
A
SD
EV
YL
 
G
Q
RE
N
PH
W
TS
D
SK
A
LQ
A
FQ
KF
G
N
KL
A
EI
EA
KL
TN
KN
N
D
PS
LY
H
RV
G
 
PV
Q
LP
YT
LL
H
PS
SK
EG
LT
FR
G
IP
N
SI
SI
P1
48
56
97
.0
7
36
17
8
Se
ed
 b
io
tin
‑c
on
ta
in
in
g 
pr
ot
ei
n 
SB
P6
5 
(P
isu
m
 sa
tiv
um
)
M
A
SE
Q
LS
RR
EN
IT
TE
RK
IQ
N
A
ED
SV
PQ
RT
TH
FE
LR
ET
H
EL
G
PN
 
FQ
SL
PR
N
EN
Q
AY
LD
RG
A
RA
PL
SA
N
VS
ES
YL
D
RA
RV
PL
N
A
N
IP
 
EH
RV
RE
KE
D
FG
G
VR
D
M
G
KF
Q
M
ES
KG
G
N
KS
LA
ED
RE
TL
D
TR
SR
M
 
VT
G
TP
H
IK
EA
SG
KG
Q
VV
EE
RE
RA
RE
RA
M
EE
EE
KR
LT
M
EE
IS
KY
RN
 
Q
A
Q
Q
SA
LE
A
LS
A
A
Q
EK
YE
RA
KQ
AT
N
ET
LR
N
TT
Q
A
A
Q
EK
G
EA
A
Q
A
K 
D
AT
FE
KT
Q
Q
G
YE
M
TG
D
TV
SN
SA
RT
A
SE
KA
A
Q
A
KN
TT
LG
KT
Q
Q
G
YE
 
AT
RD
TV
SN
A
A
RT
A
A
EY
AT
PA
A
EK
A
RC
VA
VQ
A
KD
VT
LE
TG
KT
A
A
EK
A
K 
C
A
A
EI
A
A
KV
AV
D
LK
EK
AT
VA
G
W
TA
SH
YA
TQ
LT
VD
G
TR
A
A
A
N
AV
E 
G
AV
G
YV
A
PK
A
SE
LA
A
KS
VE
TV
KG
LA
A
SA
G
ET
A
KE
FT
A
RK
KE
ES
W
RE
 
YE
A
KR
A
SQ
LQ
EG
EE
IL
PS
TG
G
IG
KV
LP
SG
ER
TQ
A
Q
G
TN
LQ
EK
VQ
G
K 
G
SD
IL
G
AV
TE
TV
SD
IG
SS
M
IK
PI
D
N
A
N
TK
VK
EH
G
G
TT
IT
PK
G
Q
D
A
G
 
G
VL
D
A
IG
ET
IA
EI
A
H
TT
KV
IV
VG
ED
D
EV
EK
SM
Q
KN
IG
SD
SH
SL
D
RA
KH
 
EG
YR
A
PK
N
N
VS
Q
41
06
0
59
.5
2
46
78
3
A
lb
um
in
‑1
 C
 (P
isu
m
 sa
tiv
um
)
M
A
SV
KL
A
SL
IV
LF
AT
LG
M
FL
TK
N
VG
A
IS
C
N
G
VC
SP
FD
IP
PC
G
SP
LC
RC
I 
PA
G
LV
IG
N
C
RN
PY
G
VF
LR
TN
D
EH
PN
LC
ES
D
A
D
C
RK
KG
SG
TF
CG
H
YP
 
N
PD
IE
YG
W
C
FA
SK
SE
A
ED
VF
SK
IT
PK
D
LL
KS
VS
TA
P6
29
28
13
.9
0
55
33
3
Id
en
tifi
ca
tio
n 
w
as
 c
ar
rie
d 
ou
t b
y 
na
no
-L
C–
ES
I–
M
S–
M
S.
 P
ol
yp
ep
tid
es
 w
er
e 
pu
rifi
ed
 fr
om
 w
at
er
/s
al
t-
so
lu
bl
e 
ex
tr
ac
ts
 o
bt
ai
ne
d 
fr
om
 s
ou
rd
ou
gh
s 
(-S
) m
ad
e 
w
ith
 F
ag
io
lo
 d
i L
am
on
 (F
L)
, C
ec
e 
de
ll’A
lta
 V
al
le
 d
el
 M
is
a 
(C
V
), 
an
d 
Pi
se
llo
 ri
cc
io
 d
i S
an
ni
co
la
 (P
S)
a  
Si
ng
le
-le
tt
er
 a
m
in
o 
ac
id
 c
od
e 
is
 u
se
d
Page 15 of 20Rizzello et al. Microb Cell Fact  (2015) 14:168 
Polypeptides able to regulate cell proliferation and 
survival were already liberated by enzyme hydrolysis of 
plant and animal proteins [28]. Such peptides, inhibiting 
cell growth or promoting apoptosis, could have protec-
tive effects on tumor growth at the digestive tract level 
[29, 30]. In particular, it was found that the antitumoral 
mechanism of soybean lunasin is related to the capacity 
of the peptide to bind the deacetylated histones, caus-
ing the acetylation inhibition [31, 32]. Girón-Calle et al. 
[28] assessed the cancer cell proliferation after treatment 
with chickpea hydrolysates made with pepsin/pancreatin. 
These hydrolysates inhibited the proliferation of human 
epithelial colorectal adenocarcinoma cells (Caco-2) and 
monocytics leukemia cells (THP-1) up to 48 and 78  %, 
respectively. Hydrolysates from the common bean (P. 
vulgaris) varieties Negro 8025 and Pinto Durango inhib-
ited the inflammation in lipopolysaccharide-induced 
macrophages through suppression of NF-κB pathways 
[2]. After hydrolysis with Alcalase, proteins extracted 
from both the above varieties inhibited various markers 
of inflammation (cyclooxygenase-2 expression, prosta-
glandin E2 production, inducible nitric oxide synthase 
expression, and nitric oxide production) [2]. Inflam-
mation and cancer are linked, chronic inflammation 
predisposes individuals to various types of cancer and 
inflammatory mediators and cells are involved in the 
migration, invasion, and metastasis of malignant cells 
[33]. The suppression of pro-inflammatory pathways may 
provide opportunities for both prevention and treatment 
of cancer [34].
In this study, extracts from legume doughs regu-
lated the proliferation of Caco-2 cells, including those 
obtained from control doughs, in which very weak sig-
nals of immunoreactive bands were found with the west-
ern blot analysis. It can be hypothesized that the effect 
could be related to the contribution of some legume pro-
teins or peptides able to act as anticancer compounds in 
their native form, causing cytotoxicity and apoptosis of 
tumoral cells [2, 5]. Nevertheless, a strong inhibition of 
the Caco-2 cell proliferation was found only after lactic 
acid fermentation. A marked inhibition was found when 
cells were treated for 24  h with the fermented legume 
extracts at concentrations from 1 to 10  mg/ml. Sour-
doughs from FL, CV, and PS flours were the most active, 
showing a decrease of Caco-2 cells vitality up to 70 %. A 
correlation between the anti-proliferative effect of pro-
tein hydrolysates towards Caco-2 cells and the in  vivo 
growth inhibition of tumors in the digestive tract was 
demonstrated [29, 30].
The nanoESI-MS/MS spectrometer analysis of the 
immunoreactive protein bands from water/salt-solu-
ble extracts of FL, CV and PS sourdoughs allowed the 
identification of ten legume proteins. According to the 
molecular masses of the identified proteins, it can be 
hypothesized that immunoreactive polypeptides are 
encrypted into the native sequences and released as frag-
ments during lactic acid bacteria fermentation. Nine 
of them showed similarities to soy lunasin sequence, 
probably related to their recognition by the anti-lunasin 
antibody.
Using Caco-2 cells, the capacity to induce the expres-
sion of human FLG and IVL genes by sourdough fer-
mented legumes was investigated. FLG and IVL are 
important proteins for the formation of the epidermal 
skin barrier [35, 36]. FLG aggregates keratin filaments 
and provides a cytoskeleton for the cornified envelope 
[35]. The expression of FLG was markedly induced by 
PS sourdough, and under some of the assayed condi-
tions (e.g., 8  h of treatment), also by CV and FL sour-
doughs. Compared to the unfermented dough, the level 
of IVL gene expression markedly increased when Caco-2 
cells were subjected to 24-h treatment with FL, CV, and 
PS sourdoughs. In particular, the sourdough made with 
PS was effective under all the conditions likely it was 
observed for FLG gene expression. IVL serves as a sub-
strate for the covalent attachment of ceramides to the 
cornified envelope [35, 36]. An improvement of the IVL 
activity may result in an increase of the ceramide binding 
activity, which, in turn, positively affects the barrier func-
tion [37, 38].
Fig. 5 Alignments with lunasin. Alignments of the lunasin‑like polypeptides identified from FL, CV, and PS sourdoughs with the soy lunasin 
sequence, as obtained through the BLAST alignment on‑line tool (http://blast.ncbi.nlm.nih.gov/)
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Conclusions
Nowadays, an unexpected and considerable number of 
small proteins and peptides are available as drugs [39]. 
They show high bioactivity, target specificity and wide 
spectrum of therapeutic actions, with low levels of tox-
icity, structural diversity, and absence or low levels of 
accumulation in body tissues. However, the manufactur-
ing protocols (e.g. chemical synthesis and recombinant 
transgenic approach) are very expensive, representing a 
hindrance for the use as therapeutic peptides [40]. The 
alternative option is the exploitation of the potential of 
bioactive peptides derived from food proteins. Legume 
flours were already proposed as adjuvant ingredients into 
a range of baked products and snacks for increasing the 
nutritional value [41–44], as well as sourdough fermen-
tation was shown to have a functional potential [19, 45, 
46]. Despite the need to have an in vivo confirmation, the 
presence of lunasin-like polypeptides allows to hypoth-
esize the use of sourdough fermented legumes in phar-
maceuticals preparations (e.g., capsules and powders), 
protein hydrolysates or as purified peptide mixtures to 
be incorporated as health-enhancing ingredients in novel 
functional foods (e.g., leavened baked goods).
Methods
Legumes
Nineteen Italian legume varieties, belonging to the spe-
cies Phaseulus vulgaris (Fagiolo di Lamon, Fagiolo di 
Controne, Fagiolo di Cuneo, Fagiolo Stregoni, Fagiolo 
Vellutina, Fagiolo di Saluggia, Fagiolo Badda di Polizzi—
white, and Fagiolo Badda di Polizzi—black), Cicer ari-
etinum (Cece di Merella and Cece dell’Alta Valle del 
Misa), Lathyrus sativus (Cicerchia di Serra de Conti and 
Cicerchia di Campodimele), Lens culinaris (Lenticchia 
di Castelluccio di Norcia, Lenticchia di Ustica, Lentic-
chia di Santo Stefano di Sessanio, Lenticchia rossa di 
Pantelleria, Lenticchia di Altamura and Lenticchia di 
Villalba), and Pisum sativum (Pisello riccio di Sanni-
cola), were used in this study. All legumes were chosen 
among the Italian pulses that have specific product cer-
tification (Table 1). Flours were obtained from whole leg-
ume seeds through the laboratory mill Ika-Werke M20 
(GMBH, and Co. KG, Staufen, Germany). Protein (total 
nitrogen ×5.7), ash and moisture contents were deter-
mined according to AACC approved methods 46-11A, 
08-01 and 44-15A, respectively [47]. Lipids were deter-
mined by Soxhlet method. Total carbohydrates were 
calculated as the difference, using the following formula: 
[100 −  (proteins +  lipids +  ash + moisture)]. Proteins, 
lipids, carbohydrates and ash were expressed as % of dry 
matter (d.m.). The determination of total dietary fiber 
was carried out by the enzymatic–gravimetric procedure 
approved by the Association of Official Analytical Chem-
ists [48], as described by Lee et al. [49].
Microbiological analyses of the flours
Ten grams of flour were homogenized with 90 ml of ster-
ile peptone water [1 % (wt/vol) of peptone and 0.9 % (wt/
vol) of NaCl] solution. Lactic acid bacteria were enumer-
ated using MRS (Oxoid, Basingstoke, Hampshire, UK) 
agar medium, supplemented with cycloheximide (0.1 g/l). 
Plates were incubated, under anaerobiosis (AnaeroGen 
and AnaeroJar, Oxoid), at 30 °C for 48 h. Cell density of 
yeasts and molds were estimated on Yeast Extract Pep-
tone Dextrose Agar (YPD) (Oxoid) medium (pour and 
spread plate enumeration, respectively), supplemented 
with chloramphenicol (0.15  g/l), at 30  °C for 72  h. The 
attribution (yeasts/molds) was confirmed by microscope 
observation. Total mesophilic aerobic bacteria were 
determined on Plate Count Agar (PCA, Oxoid) at 30 °C 
for 48  h, and total enterobacteria were determined on 
Violet Red Bile Glucose Agar (VRBGA, Oxoid) at 37  °C 
for 24 h.
Fermentation
Sourdough lactic acid bacteria, belonging to the Culture 
Collection of the Department of Soil, Plant, and Food 
Sciences (University of Bari, IT) and previously selected 
for some biotechnological features, were used. Lactoba-
cillus plantarum C48 showed the capacity of synthesiz-
ing relevant amount of γ-aminobutyric acid (GABA) [21], 
and Lactobacillus brevis AM7 was characterized by high 
proteolytic activities towards cereal and legume flours 
[12]. Starters were cultivated separately on MRS broth 
at 30  °C for 24  h. Cells were harvested by centrifuga-
tion (10,000×g, 10  min, 4  °C) until the late exponential 
phase of growth was reached (ca. 10 h), washed twice in 
50 mM sterile potassium phosphate buffer (pH 7.0) and 
re-suspended in tap water at the cell density of ca. 8.0 
log cfu/ml. Each legume flour was mixed with tap water, 
containing the bacterial suspension (initial cell density of 
7.0 log cfu/g of sourdough for each strain). Doughs, hav-
ing dough yield (DY, dough weight ×  100/flour weight) 
of 160 (corresponding to 62.5 and 37.5  % of flour and 
water, respectively), were mixed at 60 x g for 5 min with 
a IM 58 high-speed mixer (Mecnosud, Flumeri, Italy) and 
incubated at 30 °C for 24 h. The most common DY value 
for cereal-based sourdoughs (160) was applied [20, 22, 
46, 50]. After fermentation, legume sourdoughs (S) were 
compared to control doughs (D), without bacterial inoc-
ulum, prepared as described above (DY 160) and incu-
bated under the same conditions. S and D were stored 
at −20 °C before the chemical analyses, while microbio-
logical analysis was carried out before freezing. All the 
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doughs were obtained in triplicate and each of them was 
analyzed twice.
Characterization of fermented flours
The values of pH were determined on-line by a pHme-
ter (Model 507, Crison, Milan, Italy) with a food penetra-
tion probe. Total titratable acidity (TTA) was determined 
after homogenization of 10 g of dough with 90 ml of dis-
tilled water, and expressed as the amount (ml) of 0.1 M 
NaOH needed to reach the value of pH of 8.3.
The water/salt-soluble extract (WSE) of D and S was 
prepared according to Weiss et al. [51], and used to ana-
lyze free amino acids (FAA) by a Biochrom 30 series 
Amino Acid Analyzer (Biochrom Ltd., Cambridge Sci-
ence Park, UK) with a Na-cation-exchange column (20 by 
0.46 cm internal diameter), as described by Rizzello et al. 
[50].
Peptidase activities of the starters
General aminopeptidase type N (EC 3.4.11.11; PepN), 
specific aminopeptidase type A (EC 3.4.11.7; PepA) 
and endopeptidase (EC 3.4.23; PepO) activities were 
determined as described by Gobbetti et  al. [13], using, 
respectively, Leu-p-nitroanilides (p-NA), Glu-p-NA and 
NCBZ-Gly-Gly-Leu-p-NA (Sigma Aldrich Co.) as rela-
tively specific substrates. The assay mixture contained 
900  μl of 2.0  mM substrate in 0.05  M potassium phos-
phate buffer, pH 7.0, and 100  μl of cell suspension (9 
log cfu/ml). The mixture was incubated at 30  °C for 1 h 
and the absorbance was measured at 410  nm. The data 
obtained were compared to standard curves set up by 
using p-nitroanilide [52]. One unit (U) of activity was 
defined as the amount of enzyme required to liberate 
1 μmol/min of p-nitroanilide under the assay conditions. 
Tripeptidase (EC3.4.11.4; PepT), and X-prolyl dipeptidyl 
aminopeptidase (EC 3.4.14.5; PepX) activities were deter-
mined using Leu-Leu-Leu and Gly-Pro-Ala substrates 
(Sigma Aldrich Co.), respectively. Activities on tripep-
tides were determined by the Cd-ninhydrin method 
[52], [53]. The assay conditions were the same as those 
described for p-nitroanilide substrates. One unit (U) of 
activity was defined as the amount of enzyme required 
to liberate 1 μmol amino acid released per min under the 
assay conditions. The data obtained were compared to 
the standard curve set up by using leucine [52].
Western blot analysis
Protein concentration of samples was determined by the 
bicinchoninic acid method (Thermo Scientific, Rockford, 
IL, USA), using bovine serum albumin (BSA) as stand-
ard protein. SDS-PAGE was performed with samples 
and synthetic lunasin diluted in tricine sample buffer 
(Bio-Rad, Richmond, CA, USA), containing 2  % (v/v) 
β-mercaptoethanol, and heated at 100 °C for 5 min. Equal 
amounts of proteins (20–40 µg) were analyzed on Precast 
Criterion 16.5  % Tris-Tricine gels (Bio-Rad), and elec-
trophoretic separations were carried out at 100 V, using 
Tris-Tricine-SDS as running buffer in the Criterion cell 
(Bio-Rad). For the attribution of the molecular masses, a 
Precision Plus Protein Standards mix (BioRad) was used. 
After SDS-PAGE separation, gels were soaked in transfer 
buffer (48 mM Tris, 39 mM glycine, 20 % methanol, pH 
9.2) for 30 min. Proteins were electroblotted into nitro-
cellulose membranes by semidry transfer in a Trans-Blot 
SD (Bio-Rad) for 30 min at 18 V. Then, the membranes 
were blocked for 3 h in Tris buffered saline with 0.05 % 
(v/v) Tween 20 (TBST), containing 1  % (w/v) bovine 
serum albumin, (TBST-1 % BSA). Afterwards, the mem-
brane was washed three times with TBST, and incubated 
overnight at 4  °C with lunasin polyclonal primary anti-
body (diluted 1:2000 in TBST-0.1 % BSA). After washing 
with TBST, the membrane was incubated overnight at 
4 °C with horseradish peroxidase-conjugated mouse anti-
rabbit secondary antibody (Santa Cruz Biotechnology, 
Dallas, TX, USA; 1:3000 in TBST-0.1 % BSA). Finally, the 
membranes were washed six times with TBST, and visu-
alized by chemioluminescence using the detection agent 
Amersham TM ECL Prime (GE Healthcare, Chalfont 
St Giles, UK), according to the manufacturer´s recom-
mendations. Image acquisition (exposure time 1–4 min) 
was performed using the VersaDoc Imaging System 
(Bio-Rad).
MTT assay in Caco‑2 cells
In order to assess the effect of legume D and S on cell pro-
liferation, the viability of colon adenocarcinoma Caco-2 
cells was measured using the 3-(4,5-dimethyl-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) method [54].
Colon adenocarcinoma Caco-2 cells (ICLC HTL97023), 
provided by the National Institute for Cancer Research 
of Genoa (Italy), were cultured in RPMI medium, sup-
plemented with 10  % Fetal Bovine Serum (FBS), 1  % 
2  mM  l-glutamine, 1  % penicillin (10,000 U/ml)/strep-
tomycin (10,000  μg/ml) mixture, 0.1  % gentamicin and 
0.1  % β-mercaptoethanol, and maintained in 25  cm2 
culture flasks at 37 °C, 5 % CO2. Every 2 days, confluent 
cultures were washed with PBS 1× (without Ca2+ and 
Mg2+), split 1:3–1:6 using Trypsin/EDTA, and seeded at 
2–5 ×  104 cell/cm2, 37  °C, and 5  % CO2. For the assay, 
Caco-2 cells were harvested at 80  % confluence with 
trypsin/EDTA, seeded at the density of 5 × 104 cells/ml 
into 96-well plates, and then incubated at 37 °C, 5 % CO2 
for 24  h. Before analysis, WSE obtained from legume 
D and S were partially purified by ultra-filtration, using 
Vivaspin (GE Healthcare) centrifugal filter units (cut-off 
30 kDa), following the manufacturer’s instructions.
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Cells were exposed to partially purified and freeze 
dried WSE at the following concentrations: 0.1, 1.0, and 
10.0  mg/ml of proteins. Each WSE was tested in dupli-
cate. A control in basal medium, without addition of 
WSE, was used. Incubation was carried out for 24, 48 and 
72  h. After incubation, the medium was removed and 
replaced by 100  µl/well of MTT solution. Then, plates 
were incubated in the dark for 3 h (37 °C, 5 % CO2). MTT 
salt was dissolved in PBS (5 mg/ml) and added (1:10) to 
RPMI, containing 10 % FBS, 1 % 2 mM l-glutamine, 1 % 
penicillin (10,000 U/ml)/streptomycin (10,000  μg/ml) 
mixture, 0.1 % gentamicin and 0.1 % β-mercaptoethanol. 
Then, the medium was removed and 100 µl/well of dime-
thyl sulphoxide (DMSO) were added to dissolve the pur-
ple formazan product. Plates were shacked for 15  min 
at room temperature and the absorbance was read at a 
wavelength of 570  nm, with a Biotek microplate reader 
(BioTek Instruments Inc., Bad Friedrichshall, Germany), 
and elaborated with the ELX808 software (BioTek Instru-
ments Inc., Bad Friedrichshall, Germany). Data were 
expressed as the mean percentage of viable cells com-
pared to control culture, grown in basal media without 
addition of WSE.
Identification of the lunasin‑like polypeptides
After Western blot analysis, the immunoreactive bands, 
separated by Tris-Tricine SDS PAGE, were cut and stored 
in 20 % ethanol before identification. Protein identifica-
tion was performed by Proteome Factory (Proteome 
Factory AG, Berlin, Germany). Protein bands were in-
gel digested by trypsin (Promega, Mannheim, Germany) 
and analyzed by Nano-Liquid Cromatography-Electro-
spray Ionisation-Mass Spectrometry (nanoLC-ESI–MS/
MS). The LC–MS system consisted of an Agilent 1100 
nanoHPLC system (Agilent, Waldbronn, Germany), 
PicoTip electrospray emitter (New Objective, Woburn, 
MA, USA) and an Orbitrap XL or LTQFT Ultra mass 
spectrometer (ThermoFisher Scientific, Bremen, Ger-
many). Peptides were first trapped and desalted on the 
enrichment column (Zorbax 300SB-C18, 0.3  ×  5  mm, 
Agilent) for 5 min (solvent: 2.5 % acetonitrile/0.5 % for-
mic acid), then separated on a Zorbax 300SB-C18, 75 μm 
× 150 mm column (Agilent), using a linear gradient from 
10 to 32 % B (solvent A: 5 % acetonitrile in water, solvent 
B: acetonitrile, both with 0.1 % formic acid). Ions of inter-
est were data-dependently subjected to MS/MS, accord-
ing to the expected charge state distribution of peptide 
ions. Proteins were identified by database search against 
the plant sequences of the National Center for Biotech-
nology Information, (NCBInr, Bethesda, USA) protein 
database, using MS/MS ion search of the Mascot search 
engine (Matrix Science, London, UK). Only peptide 
matches with a score of 20 or above were accepted. The 
sequences of the protein identified were aligned using the 
BLAST on-line tools (http://blast.ncbi.nlm.nih.gov).
Transcriptional regulation of filaggrin (FLG) and involucrin 
(IVL) genes
Colon adenocarcinoma Caco-2 cells (ICLC HTL97023) 
were cultured in RPMI medium supplemented with 10 % 
FBS, 1  % 2  mM  l-glutamine, 1  % penicillin (10,000 U/
ml)/streptomycin (10,000  μg/ml) mixture, 0.1  % gen-
tamicin and 0.1 % β-mercaptoethanol and maintained in 
25 cm2 culture flasks at 37 °C, 5 % CO2. Caco-2 cells were 
incubated in 25-cm2 culture flasks at 37  °C, under 5  % 
CO2 atmosphere [55].
Subconfluent monolayers of Caco-2 cells were sub-
jected to treatment with basal medium, containing 
2.5  % FBS. The freeze-dried WSE, partially purified by 
ultra-filtration using Vivaspin (GE Healthcare) centrifu-
gal filter units (cut-off 30 kDa), were dissolved in RPMI 
medium, at the concentration of 10  mg/ml and added 
to the culture media at the final concentration of 1 mg/
ml. The control was the basal medium, containing 2.5 % 
FBS. Plates were incubated at 37  °C for 24 h, under 5 % 
CO2. Samples were taken after 4, 8, and 24  h of treat-
ment. Each experiment was carried out at least twice in 
triplicate. For quantitative real-time PCR (RT-PCR), total 
RNA was extracted from Caco-2 cells using the Ribos-
pin Minikit-GeneAll kit. cDNA was synthesized from 
2 µg RNA template in a 20-µl reaction volume, using the 
Prime Script RT reagent kit (perfect Real time) (Takara). 
Total RNA solution (10 µl) was added to the Master Mix 
and subjected to reverse transcription in a thermal cycler 
(Stratagene Mx3000P Real-time PCR System, Agilent 
Technologies Italia Spa, Milan, Italy). The conditions 
were 37 °C for 15 min, 85 °C for 5 s, holding the samples 
at 25 °C.
The cDNA was amplified and detected using the same 
instrument and the TaqMan assay (Applied Biosystems). 
The following Taqman gene expression assays were used: 
FLG Hs00863478_g1 (FLG), IVL Hs00846307_s1 (IVL), 
and GAPDH Hs99999905_m1 (human glyceraldehyde-
3-phosphate dehydrogenase, GAPDH). Human GAPDH 
was used as the housekeeping gene. PCR amplifications 
were carried out using 40 ng cDNA in a total volume of 
20  µl. The reaction mixture contained 10  μL of Premix 
Ex Taq, 0.4  μl of RoxTM reference dye II, 1  μL of 20X 
TaqMan Gene Expression assay and 4 µl of cDNA.
PCR conditions were 95 °C for 30 s (for AmpliTaq acti-
vation), followed by 40 amplification cycles (95 °C for 5 s, 
60  °C for 20  s). Analyses were carried out in triplicate. 
Based on preliminary results, the expression of FLG and 
IVL genes was also assayed by treating Caco-2 cells with 
lipopolysaccharide (LPS; Sigma Aldrich Co.) at 10 µg/ml 
in basal medium, containing 2.5  % FBS. Analyses were 
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carried out in triplicate. The average value of target gene 
was normalized using GAPDH gene and the values were 
elaborated automatically by the MXPro v.4.01 Stratagene 
software [56].
Statistical analysis
Data were subjected to one-way ANOVA; pair-compar-
ison of treatment means was achieved by Tukey’s proce-
dure at P < 0.05, using the statistical software, Statistica 
7.0 for Windows. Student’s t test was used for MTT assay 
(GraphPAD 6.0 for Windows).
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An Update on Lunasin Research, a Bioactive
Seed Peptide for Health Promotion
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ABSTRACT
Among the most prevalent and costly health conditions, chronic diseases
have become the medical challenge of the 21st century, being the management
of lifestyle habits defined as the most strategic tool for the prevention of this
public issue. Termed as nutraceuticals, several dietary compounds have
revealed desirable health-promoting benefits beyond basic nutrition. Firstly
identified in soybean and in other seeds and plants afterwards, the bioactive
peptide lunasin has proven properties that allow to point to this 43-amino
acids peptide as a potential and promising chemo-preventive candidate
against chronic diseases. The purpose of this chapter is to summarize the
current evidence on presence of lunasin in foods, bioavailability and
biological activity. The protective benefits demonstrated against cancer,
oxidative stress, inflammation and cardiovascular disorders are described,
and the physiological relevance as well as the molecular mechanisms
involved in these effects have also been discussed.
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INTRODUCTION
Chronic diseases including cardiovascular and metabolic syndrome-
associated disorders and cancer are the most common diseases leading to
death worldwide. Approximately half of the total death occurring from these
chronic disorders can be attributed to modificable risks, and thus, changes
in nutritional and lifestyle habits are considered the best preventive
strategy. A large number of compounds naturally present in the diet have
been demonstrated to exert beneficial effects on the health. Bioactive
peptides, naturally present in foods or released from the source protein by
processing conditions or in vivo gastrointestinal digestion, may act on
different body systems through their diverse biological activities. Lunasin
is one of the naturally occurring plant peptides which demonstrated
antioxidant, anti-proliferative and anti-inflammatory properties have made
it to be considered one of the most promising food-derived chemopreventive
agents. Different research institutions worldwide have conducted or are
currently conducting studies on this peptide to evaluate its bioavailability
and biological activity, and to elucidate its complete mechanism of action.
This chapter reviews the current data of the beneficial properties of lunasin
against cancer and other chronic diseases as evidenced by cell culture
experiments, animal models and clinical trials.
LUNASIN IN PLANTS AND FOOD: FROM DISCOVERY TO
CHARACTERIZATION IN COMMERCIAL PRODUCTS
Soybean lunasin is a 43-amino acids peptide corresponding to the small
subunit of the 2S albumin (Galvez and de Lumen, 1999). It is characterized
by a high content of charged amino acids (19 in total), including a continuous
sequence of nine aspartate residues at the C-terminus (sequence accession
AAB71140). Studies carried out in the last decade have purified lunasin
from different soybean species quantifying its concentration that is ranged
from 500–8130 µg lunasin/g seed or 1100–14000 µg lunasin/g extracted
protein (Table 1). The soybean genotype has been demonstrated to be the
main affecting factor on quantity of lunasin in soybean seeds, indicating
the possibility of selecting and breeding varieties of soybean with higher
content of this peptide (de Mejia et al., 2004). Other factors, such as the
stage of seed development and maturation, environmental factors, and
processing conditions have been also reported to influence on concentration
of lunasin in both soybean seeds and derived foods (Wang et al., 2008;
Hernández-Ledesma et al., 2009b; Paucar-Menacho et al., 2010a, b; Cavazos
et al., 2012).
Once the chemopreventive properties of lunasin were suggested,
researchers focused their interest on identifying this peptide in other cereals,
legumes and medicinal plants. As shown in Table 1, lunasin has been found
in different cereals such as wheat, barley, rye, oat and triticale at different
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Table 1: Lunasin´s presence in seeds, grains and plants: characterization techniques
and determination of its content
Source Isolation/ Identification Quanti- Ref.(s)
Purification ficationa
Soybean Ion exchange column Commassie Blue stai- N.R. Jeong et al.
chromatography ning and Western Blot (2003)
Immunoaffinity column MALDI peptide mass
chromatography mapping (in-gel
tryptic digest)
Proteins extraction Indirect ELISA 1100–14000b de Mejia
procedures et al. (2004)
Commassie Blue stai-
ning and Western Blot
Ion exchange column Western Blot 500–8130 Jeong et al.
chromatography (2007a)
HPLC reverse phase HPLC (Comparison
with standard
synthetic lunasin)
Ultrafiltration Indirect ELISA N.R. Dia et al.
Ion exchange column Commassie Blue stai- (2009b)
chromatography ning and Western Blot
Size exclusion column HPLC and MALDI-
chromatography TOF (comparison with
standard synthetic
lunasin)
LC/MS-MS peptide
mass mapping (in-gel
tryptic digest)
Ion exchange column Direct ELISA N.R. Seber et al.
chromatography (2012)
Reduction and Commassie Blue stai-
ultrafiltration ning and Western Blot
HPLC reverse phase ESI-MS LC-MS/MS
peptide mass mapping
(in-gel tryptic digest)
Barley Ion exchange column Commassie Blue stai- 13.6–21.5 Jeong et al.
chromatography ning and Western Blot (2002)
Immunoaffinity column MALDI peptide mass
chromatography mapping (in-gel
tryptic digest)
HPLC reverse phase Western Blot HPLC 12.7–99.0 Jeong et al.
(comparison with (2010b)
standard synthetic
lunasin)
Wheat Ion exchange column Western Blot HPLC 211.1–290.2 Jeong et al.
chromatography (comparison with (2007b)
standard synthetic
lunasin)
Table 1: (Contd...)
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LC-ESI-MS peptide
mass mapping (in-gel
tryptic digest)
HPLC reverse phase - ESI-MS/MS 10.0–233.0 Nakurte
(comparison with standard synthetic lunasin) et al. (2012)
Rye HPLC reverse phase Commassie Blue stai- 45.4 – 150.1 Jeong et al.
ning and Western Blot (2009)
HPLC (comparison
with standard
synthetic lunasin)
HPLC reverse phase - ESI-MS/MS 733.0–1510.0 Nakurte
(comparison with standard synthetic lunasin) et al. (2012)
Oat HPLC reverse phase - ESI-MS/MS 34.0–197.0 Nakurte
(comparison with standard synthetic lunasin) et al. (2013)
Triticale HPLC reverse phase - ESI-MS/MS 429.0–6458.0 Nakurte
(comparison with standard synthetic lunasin) et al. (2012)
Amar- Fractionation of seed Indirect ELISA 9.5–12.1c Silva-
anth proteins Sanchez
Two-dimensional Western Blot et al. (2007)
electrophoresis
Immuno-precipitation MALDI-TOF peptide
mass mapping (in-gel
tryptic digest)
Fractionation of seed Commassie Blue stai- N.R. Maldonado-
proteins ning and Western Blot Cervantes
et al. (2010)
Two-dimensional Cloning and charac-
electrophoresis terization of Open
Reading Frame
LC-MS peptide mass
mapping (in-gel
tryptic digest)
Solana- N.R. Western Blot 132.0–1810.0 Jeong et al.
ceae (2007c)
family
Solanum Ion exchange column Commassie Blue stai- 1810.0 Jeong et al.
nigrumL. chromatography ning and Western Blot (2007c)
HPLC reverse HPLC (comparison Jeong et al.
phase with standard (2010a)
synthetic lunasin)
a Quantification range between the different assessed varieties given in µg lunasin/g
seed, except where otherwise indicated
b µg lunasin/g extracted protein
c µg lunasin equivalent/g total extracted protein
N.R.: non-reported
Table 1: (Contd...)
Source Isolation/ Identification Quanti- Ref.(s)
Purification ficationa
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concentrations. Because of the absence of 2S albumins in cereals, Mitchell
et al. (2013) brought into question the origin of lunasin. These authors
carried out extensive searches of proteomic, transcriptome, and DNA
sequences databases for wheat and other cereals that failed to identify
sequences with similarity to those encoding the lunasin peptide in soybean.
Similar results have been recently reported by Dinelli et al. (2014) using
chemical (liquid chromatography coupled to mass spectrometry, LC-ESI/
MS) and molecular (polymerase chain reaction, PCR) analysis that pointed
out the absence of lunasin in the investigated wheat genotypes. Until now,
a definitive explanation for these results has not been found. Rizzello et al.
(2011) have suggested a possible microbial origin of lunasin. These authors
indicated that lunasin is synthesized and secreted by microorganisms, either
as a mature peptide or a precursor which is then processed by a microbial
or endogenous plant proteinase. Further studies are thus needed to
elucidate the real origin of this peptide.
LUNASIN´S BIOAVAILABILITY
Food-derived compounds are expected to exert their activities after being
taken orally, thus bioavailability is a crucial property for any preventive
agent, and studies demonstrating its ability to survive degradation by
digestive enzymes and to reach the target tissues in an intact and active
form after passing the gastrointestinal tract are crucial. In vitro
bioavailability studies simulating gastrointestinal digestion have
demonstrated that lunasin, both synthetic as well as purified from food is
markedly hydrolyzed by pepsin and pancreatin; however, lunasin in foods
has been shown to resist the action of these enzymes. Naturally present
protease inhibitors in foods, such as Bowman-Birk protease inhibitor (BBI)
and Kunitz trypsin inhibitor (KTI), have been found to be major responsible
for the lunasin’s protection against gastrointestinal enzymes (Jeong et al.,
2007a,b,c; Park et al., 2007; Hsieh et al., 2010c). Presence of BBI in soybean
products and its role protecting lunasin from in vitro digestion has been
reported (Hernández-Ledesma et al., 2009b).
In vivo bioavailability studies carried out with animals and humans
have also confirmed above in vitro findings. Hsieh et al. (2010c)
demonstrated not only that lunasin was bioavailable when orally
administered to mice and rats, being absorbed through gastrointestinal
barrier and extensively distributed reaching different tissues such as liver,
kidney, lung, mammary gland, prostate, and brain, but also that lunasin
extracted from the liver and blood of rats fed lunasin-enriched soy flour
was bioactive and able to suppress foci formation as effectively as equimolar
amount of synthetic lunasin. In this regard, several studies have found an
intact and bioactive form of this peptide in the liver and blood of rats fed
lunasin-enriched soybean (Jeong et al., 2007a), wheat (Jeong et al., 2007b),
rye (Jeong et al., 2009), and barley (Jeong et al., 2010b) diets. Interestingly,
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determination and quantification of lunasin in human plasma after
consumption of soy protein has been reported (Dia et al., 2009a). These
authors estimated an average of 4.5% absorption of lunasin from the total
lunasin ingested from 50 g of soy protein. Moreover, it has been recently
developed an optimized method for the direct isolation and quantification
of lunasin from plasma using an ion-exchange microspin column and a
validated immunoassay protocol (Dia et al., 2013).
Peptide bioavailability after oral administration is one of the main
reasons for the inconsistency between in vitro and in vivo and clinical
studies, and it must be one of the primary aspects to be studied before food
health claims and implementation of food-based therapies (Bhutia and
Maiti, 2008; Segura-Campos et al., 2011). All these results indicate that
lunasin is bioavailable after ingestion due to the protective role of naturally
occurring protease inhibitors, and are relevant in supporting future clinical
trials demonstrating the potential chemo-preventive properties of this
peptide.
CHEMOPREVENTIVE PROPERTIES OF LUNASIN
Lunasin´s Roles in Cancer Prevention
First results in the chemopreventive role of lunasin were casually found in
a project to enhance the nutritional quality of soy protein through
bioengineering (Galvez et al., 1997). Lunasin peptide was identified in a
gen (GM2S-1) coding not only for the methione-rich protein that was sought
but also for other three proteins, a signal peptide, a linker peptide, and a
43-amino acids small subunit (SKWQHQQDSCRKQLQG
VNLTPCEKHIMEKIQGRGDDDDDDDDD) termed lunasin. Transfection
and constitutive expression of the lunasin cDNA into Escherichia coli and
mammalian cells (murine hepatoma and fibroblast cells, and human breast
cancer cells) led to mitotic arrest and cell death, by lunasin’s binding to the
kinetochore of the centromere, hampering its attachment with microtubules
and subsequent cellular events involved in the mitotic replication process
(Galvez and de Lumen, 1999). Elucidation of lunasin’s sequence contributed
on suggesting these effects. It contains at its carboxyl end: (i) a poly-D
carboxyl end with 9 D-residues, with a high negatively charge, suggested
to preferentially bind to positively charged deacetylated histones and
cellular regions, such as the hypoacetylated chromatin found in telomeres
and centromeres; (ii) a RGD motif, known to allow attachment to the
extracellular matrix; and (iii) a predicted helix with structural homology
to a conserved region of chromatin-binding proteins Galvez et al., 2001; de
Lumen, 2005).
These first analyses prompted lunasin as a potential and promising
chemopreventive candidate against cancer, and since then, several studies
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Table 2: Chemopreventive effects and mechanisms of action of peptide lunasin
demonstrated by cell experiments
Type of Cell line Evidence Reference(s)
cancer
Breast MDA-MB-231 Inhibition of cell proliferation Hsieh et al.
cancer (2010a, 2011a)
Arrest cell cycle at S-phase Hernández-
Ledesma et al.
(2011)
Inhibition of H3 and H4 acetylation
Up-regulation of Rb gene expression
Down-regulation of cyclins D1, D3,
CDK4 and CDK6 and CDC25A,
caspase-8, Ets2, Myc, Erbb2, PIK3R1
and JUN signaling genes expression
Synergistic effect with aspirin and
anacardic acid
MCF-7 Up-regulation of tumor suppressor Pabona et al.
PTEN expression, protein level, and (2013)
nuclear localization
Induction of apoptosis via PTEN
Promotion of E-cadherin and -catenin
non-nuclear levels
Colon HT-29 Inhibition of cell proliferation Dia and de
cancer Mejia (2010)
Arrest cell cycle at G2/M phase
Cyclin-dependent kinase p21 increased
expression
Table 2: (Contd...)
focused on verifying this role have been carried out. Tables 2 and 3
summarize evidence on the chemo-preventive properties of this peptide
proven in different cancer cell lines and animal models, respectively.
Moreover, discussion of the cellular mechanisms involved in its
antiproliferative activity is also included below.
First studies demonstrated that lunasin, in absence of carcinogens, seems
not to affect neither cell morphology nor cell proliferation. However, when
a transformation event occurs lunasin gets into action within the cell
preventing induced-carcinogenic processes. As shown in Table 2 lunasin
has been found to suppress transformation of both chemical and viral and
ras-oncogenes-induced carcinogenesis in mammalian cells. Besides,
subsequent studies have proved that lunasin peptide also exerts several
anti-neoplastic effects in established cancer breast, colon, prostate,
leukemia, and lymphoma cells lines. Moreover, efforts demonstrating the
in vivo chemo-preventive role of this peptide have been designed in chemical
carcinogen-induced and xenograft animal models (Table 3).
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Induction of the apoptotic mitochondrial
pathway by modulating expression of
Bcl-2, Bax, nCLU, and caspase-3
Synergistic effect with cysplatin
KM12L4 Cytotoxicity to the cell line, and its Dia and de
oxaliplatin-resistant variant Mejia (2011b, c)
Arrest cell cycle at G2/M phase
Cyclin-dependent kinase p21 and p27
increased expression
Induction of the apoptotic mitochondrial
pathway by modulating expression of
Bcl-2, Bax, nCLU, cytochrome c and
caspase-2, -3 and -9
Nuclear condensation and DNA
fragmentation
Inhibition of FAK/ERK and NFB
signaling pathways
Binding to 51 integrin, and down-
regulation of its expression
Modulation on the expression of angio-
genesis and metastasis-related genes
Synergistic effect with cysplatin
HCT-116 Cytotoxicity to the cell line, and its Dia and de
oxaliplatin-resistant variant Mejia (2011b, c)
Inhibition of FAK/ERK and NFB
signaling pathways
RKO Cytotoxicity to the cell line, and its Dia and de
oxaliplatin-resistant variant Mejia (2011b, c)
Inhibition of FAK/ERK and NFB
signaling pathways
Inhibition of cell migration
Prostate RWPE-2 Up-regulation of expression of chemo- Galvez et al.
cancer preventive genes involved in tumor (2011)
suppression, apoptosis, mitotic check-
point, protein degradation, and cellular
communication pathways
Inhibition of H4K8, and induction of
H4K16 acetylation
Leukemia L1210 Inhibition of cell proliferation de Mejia et al.
(2010)
Arrest cell cycle at G2 phase, and
increased percentage of cells in sub-G1
phase
Table 2: (Contd...)
Type of Cell line Evidence Reference(s)
cancer
Table 2: (Contd...)
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Induction of apoptosis through activation
of caspase-8, -9 and -3
Lym- Human peri- Synergistic effect with IL-12 and IL-2 Chan et al.
phoma pheral blood cytokines in: restoration of IFN pro- (2014)
mononuclear; duction, up-regulation of GZMB and
Human B Raji CSF2, and down-regulation of TGFB1
and TGFB2 expression
Inhibition of H3 acetylation
Induction of NK cells-mediated anti-
tumor activity
DMBA C3H10T1/2; Inhibition of cell proliferation and foci Galvez et al.
and MCA NIH/3T3 formation (2001)
-induced Induction of tumor suppressors p21 and Hsieh et al.
cancer p15 (2010b, 2011b)
Inhibition of Rb phosphorylation and Jeong et al.
cyclin D1 expression (2010b)
Synergistic effect with aspirin and
anacardic acid
E1A C3H10T1/2; Inhibition of foci formation Galvez et al.
oncogen- NIH/3T3 Enhance p21 protein level (2001)
induced Induction of non-adherent and Lam et al.
cancer apoptotic cells (2003)
Viral ras NIH/3T3 Inhibition of colony formation Jeong et al.
oncogen- Inhibition of H3 acetylation (2002, 2003)
induced
cancer
Table 2: (Contd...)
Type of Cell line Evidence Reference(s)
cancer
Lunasin exerts its anti-neoplasic effects by modulating a number of
different cellular pathways involved in the stages of initiation, promotion
and progression of cancer. First studies highlighted the ability of lunasin
added exogenously to internalize into mammalian cells and to sit within
the nuclear compartment (Galvez et al., 2001; Lam et al., 2003). These
authors hypothesized whether RGD motif was responsible for the cellular
internalization of lunasin. Whereas Galvez et al. (2001), demonstrated that
an RGD-deletion mutant led to an inability of lunasin to be internalized,
and thus to carry its bioactivity in murine fibroblast C3H 10T1/2 cells,
Lam et al. (2003), reported that RGD-deletion mutants were slightly less
effective against neoplasic transformations compared with full length
lunasin peptide, but were able to be internalized into the nucleus of murine
fibroblast NIH/3T3 cells. This disagreement was thought to be due to
differences in the internalization mechanisms between both cell lines.
Moreover, lunasin´s ability to internalize into the cell and surround the
nucleus has been also demonstrated in cancer cell lines, such as colon
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KM12L4 cells (Dia and de Mejia, 2011b), and prostate epithelial RWPE-2
cells (Galvez et al., 2011). However, it remains unknown how lunasin exerts
this effect, thus, more studies elucidating the interactive behavior of lunasin
with and within the cell are required.
Beyond its internalization into the cell, biochemical evidence has shown
that lunasin tends to bind to deacetylated core histones and inhibits histone
acetylation. Under steady-state conditions in the cell, core H3 and H4
histones are mostly in a deacetylated (repressed) state, being the balance
between histone acetylation-deacetylation a key cellular process linked to
signal transduction pathways including those involved in cancer
development (Archer and Hodin, 1999). Lunasin either synthetic (Galvez
et al., 2001; Hernandez-Ledesma et al., 2011) or extracted from natural
soybean (Jeong et al., 2007a), barley (Jeong et al., 2002), wheat (Jeong et
al., 2007b), Solanum nigrum L. (Jeong et al., 2007c), and amaranth
Table 3: Chemopreventive effects and mechanisms of action of peptide lunasin
demonstrated by animal models
Type of cancer Animal model Evidence Reference(s)
Skin cancer DMBA-induced Reduction in tumor incidence Galvez et al.
cancer in and yield/mouse (2001)
SENCAR mice Delay in the tumor appearance
Breast cancer DMBA-induced Decrease in tumor incidence Hsieh et al.
cancer in and generation (2010b)
SENCAR mice
Xenograft Decrease in tumor incidence, Hsieh et al.
MDA-MB-231 generation, time-appearance, (2010c)
nude mice weight and volume
Inhibition of cell proliferation
Induction of cell apoptosis
Colorectal Liver metastasis Decrease in the liver meta- Dia and de
cancer mice model stasis recount, tumor burden Mejia (2011c,
and tumor weight 2013)
Increase in the cell death
recount, and reduction in the
PCNA expression
Modulation on Bcl-2/Bax
proteins
Inhibition of IKK- and p-p65
signals related to NFB
pathway
Synergistic effect with
oxaliplatin
Lymphoma Xenograft Raji Synergistic effect with IL-2 Chan et al.
mice model cytokine in reducing tumor (2014)
volume
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(Maldonado-Cervantes et al., 2010) seeds has been shown to inhibit
acetylation of core histone H3 and H4. Moreover, lunasin has been found
to inhibit the acetylation process in cells exposed to sodium butyrate, a
known histone deacetylase inhibitor, and to compete with different histone
acetyltransferases enzymes (HAT) such as PCAF, CBP/p300 and yGCN5
(Galvez et al., 2001; Jeong et al., 2002, 2003, 2007c). The affinity of this
peptide for hypoacetylated chromatin and its activity inhibiting histone
acetylation point out lunasin as a cancer-preventive food compound. These
evidence markedly imply a role in chromatin remodeling, process intimately
related to cell cycle progress and control of tumor progression signals
(Esteller and Herman, 2002; Lund and van Lohuizen, 2004), and suggest
an epigenetic nature for this chemopreventive mechanism of action
(Stefanska et al., 2012). The proposed epigenetic model indicates that
lunasin acts against cells that are being transformed or newly transformed.
Thus, when a transformation event occurs in the cell, this peptide acts as a
surrogate tumor suppressor, competing with HAT in binding to histones
(exposed as a consequence of the transformation episode), turning off the
transcription of genes encoding for the cell cycle progress, and disrupting
the dynamics of histone acetylation-deacetylation, which is perceived as
abnormal by the cell and ultimately leads to cell cycle arrest, apoptosis
and cellular death (de Lumen, 2005). The current importance of epigenetic
effects carried by food-derived compounds and their proven role in the
regulation of cellular pathways involved in aging-related diseases clearly
suggest further research in order to deeply demonstrate the lunasin’s
mechanisms of action at the genetic, epigenetic and molecular levels.
Evidence on the molecular processes underlying cancer pathogenesis
propose that cancer cells are able to display six essential alterations that
collectively lead to the development of the malignant growth. Cancer cells
are provided with their own growth signals are capable to ignore growth
inhibitor signals, present an elevated apoptotic threshold evading
programmed cell death, are potentially able to replicate without limit,
sustain angiogenesis, and can invade tissue and capillary walls supporting
the metastasis event (Hanahan and Weinberg, 2000). Food proteins and
products thereof, such as lunasin peptide, have become one group of
nutraceuticals with demonstrated effects preventing the different stages
of cancer, including initiation, promotion, and progression (de Mejia and
Dia, 2010). In this line, several studies on the lunasin´s cancer-preventive
effects have reported that this peptide is able to modulate expression of
different genes and proteins involved in former mentioned characteristics
of tumor cells by control of cell cycle, apoptosis, and signaling transduction
(Tables 2 and 3).
Disruption of the normal regulation of cell cycle progression and division
are important events in the development of cancer. This process is highly
regulated by internal checkpoints that ensure the proper transition of the
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cell to the next phase, such as the protein kinases cyclin-dependent
complexes (CDKs), catalytically competent after binding to their related
cyclin regulatory subunits (Malumbres and Barbacid, 2009). Over-
expression of cyclins and CDKs, low levels of the two families of CDK
inhibitors (Cip1/p21 and INK4), and subsequent cellular events such as
phosphorylation of the retinoblastoma protein (Rb) to E2F transcription
factors, are all hallmarks of transformed cells Qu et al., 2003; Massague,
2004). In vitro studies carried out in transfected fibroblasts, and breast
and colon cancer cells have shown lunasin´s capability to arrest cell cycle
at the S- and G2-M phases by increasing the levels of CDK inhibitors p15,
p21 and p27, and down-regulating the cyclins D1, D3, CDK4 and CDK6,
and the Rb phosphorylation (Table 2). The in vivo role of lunasin on
suppression of the cell cycle progression has been suggested by the analysis
of the proliferation molecular markers Ki-67 and proliferating cell nuclear
antigen (PCNA) in the xenograft breast MDA-MB-231 and colorectal
KM12L4 cancer liver metastasis mice models, respectively. The expression
of the human Ki-67 protein is present during all active phases of the cell
cycle while is absent in resting cells (Scholzen and Gerdes, 2000), and PCNA
is known to form a homotrimer required for DNA replication being its
expression elevated during the S-phase of the cell cycle (Wang, 2014).
Moreover, higher levels of these factors have been found in a variety of
malignant cells lines and have been markedly linked with the
aggressiveness and growth capacities of the tumor (Tan et al., 2012).
Mammary-tumor sections from intraperitoneally lunasin-treated mice have
been found to have significantly lower rate of the Ki-67 index (Hsieh et al.,
2010c). Dia and de Mejia, (2011b) showed the capability of the lunasin´s
intraperitoneally-administration to reduce the PCNA expression of liver-
tumor tissues derived from KM12L4 cells. However, these authors reported
that orally administered lunasin was able to reduce the expression of PCNA,
but lacking of statistical difference with the control group (Dia and de Mejia,
2013). The disagreement between these results might be explained by the
different route of administration and also attributed to the fact that the
remained amount of the bioavailable lunasin after digestion was not enough,
being needed more studies that determine the proper oral dose of this
peptide for cancer-preventive therapies.
Another mechanism by which lunasin has shown its anti-neoplasic effect
is through its apoptosis-inducing activity. Tumor cell populations expand
in number not only by their ability for limitlessly replicate but also by
their acquired resistance toward apoptotic signals (Hanahan and Weinberg,
2000). Cancer cells present an elevated apoptotic threshold, thus strategies
overcoming tumor resistance to either extrinsic or intrinsic apoptotic
pathways and ultimately inducing apoptosis are increasingly described as
one of the most desirable goals for chemopreventive agents (de Mejia and
Dia, 2010). In colon cancer HT-29 and KM12L4 cells lunasin has been
demonstrated to activate the apoptotic mitochondrial pathway as evidenced
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by the changes in the expression of Bcl-2:Bax ratio, pro-apoptotic nuclear
clusterin, cytochrome c, and caspase-3 activity (Table 2). Human breast
cancer MCF-7 cells treated with lunasin have been found to increase their
expression and protein levels of the tumor suppressor PTEN, and to enhance
PTEN nuclear localization resulting in the induction of PTEN-mediated
cellular apoptosis, but unlike that for genistein, p53-independent (Pabona
et al., 2013). Moreover, lunasin has been discovered to up-regulate the
caspase -8, -9, and -3 activity in leukemia L1210 cells, and to possess a
synergistic effect in combination with both aspirin and anacardic acid
increasing the percentage of cells undergoing both early and late apoptosis
in breast cancer MDA-MB-231 cells (Table 2). A few animal studies
evaluating the in vivo apoptosis-inducing effects of this peptide have been
also carried out. Histological analysis of stained tumor sections of xenograft
MDA-MB-231 mice showed that lunasin-treated animals presented tumor
destruction areas replaced by apoptotic and necrotic cells, and significantly
higher levels of TUNEL-positive apoptotic cells were further found in these
tumors (Hsieh et al., 2010c). In the colorectal cancer liver metastasis mouse
model, whereas Dia and de Mejia (2011b) reported that intraperitoneal
injection of lunasin increased the expression of the pro-apoptotic Bax
marker, non-significantly reduced the expression of the anti-apoptotic Bcl-
2 marker, and exerted a synergistic effect with oxaliplatin inducing
apoptosis by the modulation of the Bcl-2:Bax ratio. Dia and de Mejia, (2013)
found that orally-administered lunasin yielded an increase in the expression
of both pro-apoptotic Bax and anti-apoptotic Bcl-2 markers, prompting the
design of more in vivo studies that clearly and deeply evaluate the lunasin’s
role in preventing colon cancer malignancies.
The abilities of cancer cells to induce the formation of new blood vessels,
and to infiltrate into lymphatic and blood vessels, reaching bloodstream
and disseminating to other parts of the body are known as angiogenesis
and metastasis. These processes are often linked to the deregulation and
degradation of the extracellular matrix (ECM) and disorders in the integrin
family of cell adhesion receptors (Westermarck and Kahari, 1999; Parise
et al., 2000). In this line, elevated levels of 51 integrin have been associated
with enhanced invasiveness of colorectal cancer cells as well as lack of 51
function has been related with reduction of metastasis in these cells (Gong
et al., 1997; Stoeltzing et al., 2003). Moreover, peptides containing RGD-
motif have been demonstrated to alter integrin-ECM interactions by binding
to these complexes and ultimately blocking the integrin signals (Ruoslahti
and Pierschbacher, 1987). In vitro studies in colorectal cancer cell lines
have shown that lunasin is able to down-regulate the expression of 51
integrin and, interestingly, it is worthy to mention that this peptide had
the most potent cytotoxic effect in the cell line that most highly expressed
this integrin (Dia and de Mejia, 2011b). Furthermore, these authors also
reported that lunasin shows capability to modulate the expression of ECM
and adhesion genes, by down-regulating the expression of transcripts
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integrin 5, SELE, MMP10, integrin 2 and COL6A1, and up-regulating
COL12A1, mechanisms that suggest lunasin as an anti-metastatic agent
and by which this peptide might play its chemo-preventive action (Dia and
de Mejia, 2011b).
Antioxidant and Anti-inflammatory Activities
Oxygen may be partially reduced during normal metabolism to yield reactive
molecules termed reactive oxygen species (ROS). At physiological
concentrations, ROS are beneficial supporting the immune system and
acting as second messengers in a wide range of cellular processes, including
proliferation, cell cycle arrest, cell death, and signal transduction (Rosen
et al., 1995; Martindale and Holbrook, 2002; Owuor and Kong, 2002).
However, at high levels, ROS are harmful and they can oxidatively attack
nucleophilic centers in the cell causing lipid peroxidation, protein oxidation
and most importantly, genetic alterations, including DNA damage,
mutations, epigenetic changes, and genomic instability (Khan et al., 2008).
Inflammation is a complex biological response of vascular tissues against
harmful agents, such as microbial infections, damaged cells, or irritants,
however, chronic or uncontrolled inflammatory states lead to tissue damage
and disorders in cell signaling pathways. Accumulating evidence point out
repeated ROS generation, persistent inflammatory cells recruitment, and
continued proliferation of genomically unstable cells as critical triggers for
the etiology of several human degenerative diseases, including
cardiovascular and neurodegenerative disorders, and cancer (Allavena et
al., 2008; Khan et al., 2008).
In vitro, peptide lunasin has been found to exert potent antioxidant
properties through different mechanisms of action. It is able to act as a
potent scavenger of superoxide and peroxil radicals and inhibitor of linoleic
acid oxidation (Hernández-Ledesma et al., 2009a; García-Nebot et al.,
20014). Moreover, lunasin purified from Solanum nigrum L. has been found
to block the generation of hydroxyl radical by chelating iron ferrous ions,
protecting DNA from induced-oxidative damage (Jeong et al., 2010a). The
antioxidant properties of lunasin have been confirmed by cell culture. ROS
production in lipopolysaccharide (LPS)-induced RAW264.7 macrophages
was inhibited by lunasin in a dose-dependent manner (Hernández-Ledesma
et al., 2009a). Also, lunasin´s ability to improve cell viability and decrease
ROS levels has been proven in intestinal Caco-2 cells challenged by hydrogen
peroxide and tert-butylhydroperoxide (t-BOOH) (García-Nebot et al., 2014).
The protective mechanisms carried out by lunasin on several biomarkers
of redox status have been recently reported by Fernández-Tomé et al. (2014).
Pre-treatment of t-BOOH-induced liver HepG2 cells with this peptide
prevented the increased ROS generation as well as the depletion of reduced
glutathione, modulated the glutathione peroxidase and catalase activities,
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and evoked a decline in carbonyl groups and a recovery from cell death by
restraining the caspase-3 apoptotic pathway.
The anti-inflammatory properties of lunasin have been evidenced
through some in vitro studies on its effects on key mediators of the
inflammatory response. Lunasin and lunasin-like peptides purified from
defatted soybean flour have been found to inhibit pro-inflammatory
markers, such as interleukin (IL)-6, IL-1, and tumor necrosis factor (TNF)-
 by suppression of cyclooxygenase (COX)-2/prostaglandin (PG) E2, inducible
nitric oxide synthase (iNOS)/nitric oxide (NO) and nuclear factor-kappa B
(NFB) pathways, in the LPS-induced RAW 264.7 murine macrophage
cellular model (de Mejia and Dia, 2009; Dia et al., 2009b; Hernández-
Ledesma et al., 2009a). The molecular mechanisms involved on these effects
and its potential significance in the pathogenesis of inflammation-related
diseases have been recently reported (Cam and de Mejia, 2012; Cam et al.,
2013). Lunasin treatment in LPS-induced THP-1 human macrophages was
shown to inhibit the expression of NFB-dependent markers of
inflammation through down-regulation of Akt phosphorylation and NF
B subunit p65 protein expression (Cam and de Mejia, 2012). Evidence on
inflammatory cellular signaling has linked activation of V3 integrin to
the Akt pathway. In this work, lunasin was demonstrated to internalize
into macrophages and physically interact with V3 integrin, suggesting
that its biological activity could be exerted by an antagonistic effect on
V3 receptors (Cam and de Mejia, 2012). Further experiments showed
that while V3 integrin expression is enhanced in inflammatory conditions,
lunasin is able to attenuate this up-regulation in LPS-induced THP-1
macrophages, and to internalize into these cells by integrin signaling,
clathrin-coated structures and macropinosomes-mediated mechanisms
(Cam et al., 2013). Dia and de Mejia (2011a) reported the effect of lunasin
on the gene expression profile of RAW 264.7 macrophages in a normal and
LPS-challenged state. Interestingly, lunasin was found to affect the
expression of genes involved in cellular growth and proliferation, cellular
function, cell to cell signaling, cell cycle, cell death, and apoptosis.
Above-mentioned findings might contribute on lunasin’s potential chemo-
preventive activity against cancer and other oxidative and inflammatory-
related disorders.
OTHER EFFECTS OF LUNASIN
Lunasin Against Cardiovascular Diseases
Cardiovascular diseases are a significant public health problem worldwide,
ranking as the leading cause of human death in western countries. Diet
and other lifestyle habits have been remarkably demonstrated to impact
the development of the major risk factors for cardiovascular diseases, such
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as hypertension, lipid abnormalities, diabetes, obesity, inflammation and
atherosclerosis. Food-derived bioactive peptides have become one group of
nutraceuticals with proven effects in cardiovascular health (Erdmann et
al., 2008). Daily consumption of 25 g of soy protein has an approved Food
and Drug Administration (FDA) health claim for reducing the risk of
coronary heart disease (FDA, 1999). Beyond, lunasin has been reported as
one of the soy protein active nutrients responsible for reducing the risk of
cardiovascular diseases by decreasing the hepatic cholesterol biosynthesis
(Galvez, 2012). In this study, lunasin was found to down-regulate low
density lipoprotein (LDL) cholesterol content by directly inhibiting 3-
hydroxy-3-methyl-glutaryl (HMG) Co-A reductase gene expression, and
enhancing its clearance from plasma through increasing the LDL receptor
levels of HepG2 liver cells. Moreover, this effect was also tested in vivo in
LDL-receptor mutant pigs, whose LDL cholesterol levels were found to be
decreased after supplementation of their casein diets with a lunasin-
enriched soy extract (Galvez, 2012). A human trial for the evaluation of
soy-based food supplements in the management of patients with lipid
abnormalities was designed by Sison and co-workers. In this study, lower
cholesterol, LDL, triglycerides, and blood uric acid levels were shown after
60 days consumption of a lunasin-enriched food supplement. Interestingly,
these effects were even greater among the diabetic and overweight
individuals, demonstrating lunasin´s ability for the control of the lipid
imbalances associated with the cardiovascular disease.
A recent work carried out with the previously reported dietary
supplement in combination with a lunasin-enriched soy extract has shown
the lunasin’s ability to reduce free fatty acids by increasing leptin and
adiponectin levels in the plasma of LDL-receptor mutant pigs (Galvez et
al., 2013). Results of this study suggest the use of that combination as an
effective, low-cost and natural alternative to therapeutic drugs against
obesity, metabolic syndrome and associated cardiovascular diseases.
Lunasin´s Influence on the Central Nervous System
In vivo studies have shown that orally-administered lunasin is absorbed
and distributed in various target tissues, being even able to cross the blood-
brain barrier, reaching the brain (Dia et al., 2009a; Hsieh et al., 2010c).
From this point of view, the study of Dzirkale et al. (2013) has recently
assessed the central effects exerted by this peptide. Central
(intracisternally)-administered synthetic lunasin was demonstrated to
decrease the locomotor activity, amphetamine-induced hyperlocomotion,
and apomorphine-induced climbing effect of mice. Binding assays showed
that lunasin possesses a modest affinity for dopamine D1 receptors.
However, no binding effect was detected for dopamine D2 receptors. Also,
lunasin was able to inhibit the apomorphine-initiated cAMP formation in
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HEK293 cells expressing dopamine D1 receptor activation. The findings of
this study also suggested that glutamate and GABAergic systems do not
play an essential role in lunasin´s central effects (Dzirkale et al., 2013).
These authors showed for lunasin for the first time a motionless/neuroleptic/
cataleptic effect that at least in part might be provided via dopaminergic
pathways, and set up the basis for further doubtlessly needed investigations
in this novel research focus for this peptide.
FUTURE PROSPECTS
Since its discovery in 1997, lunasin has become one of the natural peptides
present in plant and derived-foods with higher potential against chronic
disorders such as cancer and cardiovascular diseases. Its notable
bioavailability and demonstrated efficacy against different types of cancer
are the two main aspects making this peptide a promising chemopreventive
agent. Animal models carried out in the last years have confirmed the
effectiveness of lunasin against skin, breast, colorectal cancer and
lymphoma, and have suggested an additional role for this peptide against
obesity, metabolic syndrome and associated cardiovascular diseases.
Nowadays, the major challenge on the use of lunasin would be the conversion
of existing results into clinical outcomes, being needed to design clinical
trials to confirm the already demonstrated properties. Moreover, genomics,
proteomics and biochemical tools should be applied to elucidate its molecular
mechanism of action. Other aspects, such as searching for lunasin in other
seeds, optimization of techniques to enrich products with this peptide and
studying lunasin’s interactions with other food constituents affecting its
activity should also be conducted.
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Abstract 
 
Soybean is source of many phytochemicals, including isoflavones, phenolic acids, 
phospholipids, oligosaccharides, protease inhibitors, lectins and bioactive peptides. Their 
demonstrated biological activities have made them to be considered excellent compounds to 
maintain a good health status preventing chronic disorders.  
Oxidative stress and inflammation play key roles in the onset and progression of many 
chronic diseases, such as intestinal inflammation, cardiovascular and neurological disorders, 
diabetes, and cancer. This chapter summarizes the antioxidative and anti-inflammatory 
properties of soy phytochemicals, emphasizing on the recent evidence and the mechanisms 
of action. 
Fermentation is not only determinant on the sensorial, technological and nutritional 
characteristics of soybean, but also might increase its functional value. Germination and 
roasting have been also recognized as economical and efficient technologies for the 
breakdown of macromolecules, increasing soybean’s digestibility, and enhancing its 
nutritional and biological value. The effects of soybean processing on its antioxidative 
properties have also included in this chapter.  
 
Keywords: soybean, oxidative stress, inflammation, disease, soy processing 
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1. Introduction: Soybean  
Soybean (Glycine max (L) Merrill family Leguminosae) is one of the most cultivated plants in 
the world. It was originated in the Orient, probably in China [1], and mostly consumed in Asian 
countries, such as China, Japan, Korea, Taiwan and Indonesia. Populations from these countries 
consume daily an average of 20 to 80 g of traditional soy foods in many forms, including soybean, soy 
milk, toasted soy protein flours, soybean sprouts, tofu, and fermented soy products, such as tempeh, 
miso, natto, soybean paste and soy sauce [2, 3]. However, the soybean consumption by people from 
Western countries is much lower, ranging from 1 to 3 g per day, and this is mostly in processed forms, 
such as soy drinks, breakfast cereals, energy bars, soy "burgers" and “dogs”, tofu sliced meat, and 
tofu ice cream, among others [4, 5].  
Soybean is rich in proteins (40-50%), lipids (20-30%) and carbohydrates (26-30%). 35% of 
soybean carbohydrates are contained in the seed and 40% in soybean meal, which are mainly 
composed of digestible sugars, starch, as well as non-digestible oligosaccharides [6]. The amount of 
protein in soybeans is larger than the protein content in other legumes (20-30%), and much larger 
than that of cereals (8-15%). Therefore, soy protein products have been presented as perfect 
substitutes for animal-based foods because they nearly offer a “complete” protein profile containing 
less fat than animal products, especially saturated fat. Only two factors limit the nutritional value of 
soybean and derived-products. By one hand, soybean is limiting in the sulphur-containing amino acids 
for humans, although this limitation can be easily overcome by including in the diet other protein 
sources rich in these amino acids, usually cereals. The second limitation of soybean is its low 
digestibility when the only treatment is heating, but further processing including soaking, sprouting, 
fermentation, grinding, and hot water extraction have been demonstrated to considerably increase 
digestibility [7]. Moreover, new soybean products such as soybean protein concentrate and isolate 
show higher digestibility than traditional soy flours [8].  
Soybean has been ranked as one of the main sources of phytochemicals. They are 
compounds present in plants that have a beneficial effect on health or play an active role in the 
diseases prevention, although they are not required for normal body metabolism [9]. Soybean 
phytochemicals include isoflavones, saponins, sterols, phytates, phenolic acids, protease inhibitors, 
lectins and bioactive peptides. The presence of these phytochemicals have made soybean being 
considered as a functional food controlling and preventing a wide variety of chronic and degenerative 
diseases such as cardiovascular disease, obesity, diabetes, and cancer [10]. This chapter 
summarizes evidence on protective effects of soybean derived compounds against chronic diseases 
associated to oxidative stress and inflammation, with particular interest on intestinal disorders. 
Chemical nature, activity and mechanisms of action of bioactive compounds will be included.  
 
2. Oxidative stress-associated diseases: concepts and mechanisms of ROS  
Oxygen is an indispensable element for the life of aerobic organisms. Most of the energy 
needed for cellular survival is stored as adenosine triphosphate molecules and provided by the 
mitochondrial respiratory chain, with the reduction of oxygen to water and the breakdown of nutrients. 
As consequence of this metabolism, several chemical entities containing partially reduced oxygen, 
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termed as reactive oxygen species (ROS), are continuously generated in cells. ROS comprise a broad 
group of highly reactive and unstable molecules, because of the presence of unpaired electrons, 
including free radicals. Moreover, ROS can be produced from endogenous sources as well as 
triggered by exogenous factors such as radiation, chemotherapy, pollutants, smoking, and xenobiotics 
including drugs, food and alcohol. At physiological levels, they play an important role as signaling 
agents in multiple cellular pathways and efficient components of the immune system. On the other 
hand, they can be harmful to the body in case of being present to excess [11].  
Cells are thus naturally provided with an extensive machinery of protective enzymatic and 
non-enzymatic antioxidants facing the potential injury from oxidizing agents. In the human cells, the 
antioxidant enzymes are mainly superoxide dismutase, glutathione peroxidase, glutathione reductase, 
and catalase; while the principal non-enzymatic antioxidant agent is the tripeptide glutamate-cysteine-
glycine, called glutathione (GSH). There is a highly-regulated cellular balance between the 
physiological and deleterious effects of ROS [12]. However, in pathological states, ROS production 
might overcome the capacity to effectively neutralize reactive intermediates leading to the oxidative 
stress state (Figure 1). In this situation, ROS interact with membrane lipids, proteins, nucleic acids, 
enzymes, and some small molecules oxidizing their structures and resulting in cellular damage [13].  
Large amount of ROS have been extensively implicated in the development of several human 
degenerative diseases, including inflammation, cardiovascular, neurodegenerative and gastrointestinal 
disorders, diabetes, aging and cancer [14]. Interestingly, exogenous antioxidants are able to reinforce 
the endogenous antioxidant defense system acting as radical scavengers, hydrogen and electron 
donors, peroxide decomposers, singlet oxygen quenchers, enzyme inhibitors and inducers, or metal-
chelating agents. 
 
2.1. Cardiovascular and neurodegenerative diseases, cancer, diabetes and aging are linked to 
oxidative stress and inflammation 
 Disruption of the steady-state cellular homeostasis by redox signaling may cause long-term 
damage, altered cellular responses, and mucosal injury that have been implicated as underlying 
causes of numerous degenerative diseases. 
Cardiovascular diseases (CVD) have become the leading cause of morbidity and mortality 
worldwide, equally affecting both men and women. Besides the growing body of evidence connecting 
increased levels of ROS with the etiopathogenesis of CVD, ROS-induced oxidative stress further 
affects to various CVD-related conditions including hypertension, atherosclerosis, ischemic heart 
disease, cardiomyopathies, cardiac hypertrophy, and congestive heart failure. Uncoupling of the 
mitochondrial oxidative phosphorylation and the nitric oxide synthesis, the xanthine-oxidoreductase 
deregulation, and the activation of the nicotinamide adenine dinucleotide phosphate hydrogen 
(NAD(P)H) oxidase system by a variety of mediators have been proposed as the main mechanisms 
involved on these alterations [11]. Likewise, oxidative processes have been shown to participate in the 
development of neurodegenerative Alzheimer´s and Parkinson´s diseases. Although the origin of 
these disorders appears to be multifactorial, the underlying factors are clearly ROS-increased either
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Figure 1. Schematic illustration on the factors leading to ROS generation, the induction of 
oxidative stress and its patho-physiological effects 
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by direct modification on the protein side-chains of the pathological depositions, or indirectly by the 
lipid peroxidation products [15]. Moreover, nervous tissues are particularly vulnerable to the oxidative 
damage due to the elevated rate of oxygen consumption at the nervous system, the presence of 
redox-active metals (Fe, Cu), and the high content of oxidisable polyunsaturated fatty acids in the 
brain. The cancer stages of initiation, promotion and progression have been also associated to 
oxidative stress as consequence of the increased DNA mutations, damage to macromolecules, 
genome instability, and cellular proliferation. In fact, ROS are able to interact with a variety of 
transcriptional factors such as nuclear factor (NF)-κB, activator protein-1 (AP-1), p53, hypoxia-
inducible factor (HIF)-1α, peroxisome proliferator activated receptor (PPAR)-γ, β-catenin/Wnt, and 
nuclear factor-erythroid 2-related factor (Nrf2) leading to the expression of multiple genes related to 
the control of growth factors, inflammatory cytokines, and apoptosis and cell cycle regulatory agents 
[16]. Related to the metabolic disorders, diabetes mellitus is considered as one of the most common 
alterations and major health problems worldwide. Chronic overproduction of reactive species 
contributes to both the onset and evolution of diabetes and its complications, by inducing insulin 
resistance, β-cell dysfunction, impaired glucose tolerance, and abnormal mitochondrial activity [17]. 
Above-mentioned findings are all related to the process of aging and chronic diseases, absolutely 
linked to the harmful consequences of free radicals through lipid peroxidation, DNA damage, and 
protein oxidation. 
 
2.2. Gastrointestinal disorders associated to oxidative stress and inflammation 
 There is a growing body of evidence into the physiology and etiopathogenesis of oxidative 
stress and inflammation that establish an intricate relationship between both processes. ROS are key 
molecules that regulate the beginning and the progression of many inflammatory disorders. On the 
other hand, it is well known the implication of inflammatory states in the generation of large amounts of 
reactive species [16, 18].  
 The gastrointestinal tract represents a complex interface system between the body and the 
external environment. Therefore, it has developed several protective mechanisms such as the 
mucosal gel layer, peristalsis, pH modulation, and the gut-associated lymphoid tissue. Despite this 
protective barrier, the gut mucosa is prone to ROS attack as continually exposed to a high 
concentration of reactive species with origin from endogenous compounds at the luminal surface as 
well as from exogenous sources and intestinal microbiota [19, 20]. ROS are able to cause 
inflammation through activation of epithelium, neutrophils, macrophages, and pro-inflammatory 
cytokines. Inflammation induces oxidative stress by stimulation of ROS-generating systems in the 
gastrointestinal tract, such as NAD(P)H oxidase, xanthine oxidoreductase, inducible nitric oxide 
synthase (iNOS), and myeloperoxidase release from inflammatory cells [18]. Moreover, disruption of 
redox homeostasis is related to the infiltration of inflammatory agents across the gut mucosa and the 
stimulation of signaling pathways, especially the redox-sensitive transcription factor NF-κB [21]. All 
these factors contribute to a variety of gastrointestinal alterations, and ultimately lead to the initiation 
and promotion of several pathophysiological conditions at this organism level. Therefore, a large 
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amount of evidence has highlighted the implication of redox imbalance and chronic inflammation on 
the development of various gastrointestinal diseases [22, 23].  
The highly selective and regulated gastrointestinal epithelial barrier allows nutrients, ions, and 
water to be absorbed, but hampers the passage of harmful molecules, pathogens, and endotoxins. 
Inflammatory processes accompanied by the attack of free radicals are able to impair the epithelial 
barrier and disrupt the gut mucosa, leading to the alteration termed as increased intestinal 
permeability. As a consequence, decreased transcellular electrical resistance, increased paracellular 
permeability, affected epithelial tight junctions, and increased apoptosis rate have been shown at the 
epithelium level [24]. Integrity of gut mucosa may be compromised by both direct and indirect 
disorders. Excessive ROS lead to the formation of oxidative products such as lipid peroxides and 
protein carbonyl groups, which cause damage to the intercellular junctions [25]. On the other hand, 
redox imbalances are implicated in the activation of the apoptotic c-Jun N-terminal kinases (JNKs) and 
p38 mitogen-activated protein kinases (MAPKs) signaling pathways [16, 26]. Regarding to increased 
intestinal permeability, it has been associated with Crohn´s disease and ulcerative colitis, celiac 
disease, gastrointestinal infections, and food allergies [24]. 
 Inflammatory bowel disease (IBD), including both Crohn´s disease and ulcerative colitis, is a 
relapsing and remitting condition that involves chronic inflammation of the gastrointestinal tract. 
Despite the exact etiology remains to be elucidated, it is known to be mediated by several factors 
associated with an inflammatory-oxidative state [22, 23], leading to uncontrolled and abnormal 
immune reactions in the gut mucosa. Oxidative injury from free radicals as well as reduced antioxidant 
levels, accompanied by perpetuate inflammation with endothelial dysfunction and tissue damage, are 
causative findings that have been found in both IBD experimental animals and human subjects [27-
29]. Evidences of IBD human patients are marked by increased levels of reactive species and 
oxidative biomarkers (lipid peroxidation products, and protein carbonyls) in colonic mucosa, correlated 
with disease severity and progression [30], and depletion of mucosal defensive agents (GSH and 
related-enzymatic systems, superoxide dismutase, catalase, paraoxonase-1, and metallothionein) 
[29], as well as at the peripheral systemic level [31]. 
 Persistent oxidative stress and chronic inflammation contribute to tissue dysplasia. ROS are 
able to attack cellular molecules such as, proteins, lipids, DNA, and organelles, and trigger cytotoxic 
effects, altered phenotypic patterns, and the uncontrolled transformation of epithelium. Colorectal 
cancer in IBD patients has been found to progress from low-grade dysplasia to indefinite dysplasia, 
and then high-grade dysplasia with invasive adenocarcinoma as an ending step [23]. Besides, 
interleukin (IL)-6, IL-8, transforming growth factor (TGF)-β1, cyclooxygenase (COX)-2 mediators, and 
inflammation-induced protein kinase B and NF-κB activation, and JNKs and p38 inhibition may 
perpetuate this process [16]. In the literature, some population-based studies and meta-analysis have 
demonstrated an increased risk of developing gastrointestinal cancers in IBD populations [32-35].  
To sum up, many gastrointestinal disorders have been associated to the inflammatory-
oxidative pathophysiology, such as, gastroesophageal reflux, Barrett´s esophagus, esophageal 
adenocarcinoma, esophageal squamous cell cancer, gastritis, peptic ulcers, gastric adenocarcinoma, 
IBD, enteric infections, ischemic intestinal injury, and colorectal cancer, among others. Because of the 
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continuous and direct interaction between food and the digestive tract, dietary compounds may 
fortunately represent an interesting source of protective antioxidant and anti-inflammatory agents for 
gastrointestinal health [36].  
 
3. Antioxidant and anti-inflammatory compounds from soybean  
Over the past decades, accumulating evidence of experimental, epidemiological and clinical 
studies have linked consumption of soy foods with low incidences of several diseases, such as 
gastrointestinal disorders, cardiovascular diseases, metabolic disorders and cancers. These kind of 
diseases accompanied oxidative stress and inflammatory response in physiological changes [37-39]. 
The majority of soy components with antioxidant and anti-inflammatory properties include phenolic 
compounds, isoflavones, phospholipids, oligosaccharides, protein hydrolyzates, protease inhibitors 
and lunasin, which play protective roles in individuals who frequently consume soy foods [40]. This 
section summarizes the antioxidant and anti-inflammatory effects of soybean phytochemicals (Figure 
2). Their properties and mechanisms of action will be also included. 
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Figure 2. The schema of the health effects of phytochemicals in soybean with antioxidative and anti-
inflammatory properties 
 
 
3.1. Non-protein compounds: polyphenols, isoflavones, oligosaccharides, and phospholipids 
The health benefits of soy consumption have received rising interest worldwide. Soybean contains 
several bioactive compounds, including isoflavones, phytate, saponins, phytosterol, vitamins, and 
minerals which exert beneficial effects on human health such as adjustment of cholesterol levels and 
metabolic changes. Components and amounts of phytochemicals in soy depend on environmental 
factors. Generally, the contents of major phytochemicals in soybean are phytic acid (1.0-2.2%), 
saponins (0.2-6.2%), phytosterols (0.23-0.46%), and isoflavones (0.1-0.3%) [41].  
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3.1.1. Polyphenols 
Polyphenols are plant’s compounds that show an extensive variety of chemical structures with 
multiple bioactivities and beneficial health effects. They are classified into two major types: flavonoids 
and non-flavonoids [42]. Ekor and coworkers have demonstrated that rats with acute toxic injury 
induced by cisplatin, and then fed the phenolic extract of soybean, improved the activities of the 
antioxidant enzymes such as superoxide dismutase, catalase, and GSH-S-transferase, suggesting 
prevention of GSH depletion and decrease of malondialdehyde levels in liver and kidney [43]. The 
data indicated that phenolic extract conducted antioxidant and anti-inflammatory effects, thereby, 
providing protective benefits against toxic injury in rats. Furthermore, antimicrobial activity of dietary 
phenolic compounds against gut microbes has been also reported by in vitro and in vivo studies [42]. 
 
3.1.2. Isoflavonoids 
Isoflavones have been suggested as the major bioactive components in soy, receiving a growing 
body of considerable interest. The three major isoflavones, genistein, daidzein and glycitein have been 
extensively studied [44, 45]. Their structure and function are similar to 17-estradiol, the most potent 
mammalian estrogen, thus, they are called phytoestrogens [45]. Soy isoflavones exert both estrogenic 
and/or anti-estrogenic effects depending on the compounds and target tissues, interacting with 
estrogen receptor, blocking the binding of potent estrogens and/or regulating target genes expression 
[46]. This effect resulted in beneficial properties for chronic renal disease [47]. Moreover, the extracted 
isoflavone from soy decreased interferon (IFN)γ secretion of mitogen-stimulated T cells and 
autoantibodies of serum that contributed to delay inflammation in kidney [48].  
Besides, non-hormonal mechanisms of isoflavones are believed to participate in their antioxidant, 
anti-inflammatory, and anti-proliferative properties [44, 49]. The chemical structure of soy isoflavones 
contributes to their antioxidative effects resulting in a decrease of lipid peroxidation and oxidative-DNA 
damage [44]. This antioxidative activity was demonstrated for soymilk fermented by probiotic 
Lactobacillus spp. which polyphenols inhibited oxidative reaction and increased proteolysis improving 
soymilk digestion by humans. In addition, isoflavone aglycones increased the antioxidative activity in 
soymilk during fermentation, suggesting health benefits [50]. Evidence has found that neither soyfoods 
nor soy isoflavones affect inflammatory mediators such as IL-6 or TNF-α expression [49]. In addition, 
growing literature suggests that isoflavones may have an additionally beneficial role in lipid and 
glucose metabolism [45]. In summary, isoflavones have beneficial effects in several chronic diseases 
through their anti-oxidative and anti-inflammatory activities, and more clinical trials are needed to 
prove these effects. 
 
3.1.3. Phospholipids 
Dietary phospholipids are contained in different food sources, such as soy, egg yolk, milk and 
marine sources, with demonstrated health benefits. Low phospholipid levels have been associated 
with various illnesses and symptoms, such as CVD, inflammation and cancer [51]. Phospholipids 
effectively deliver the fatty acid residues for incorporation into the membranes of cells. The altered 
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composition of membrane might be modulated by the activity of proteins affecting the microstructure 
and characteristics of membranes, or the biosynthesis of derived lipid second messengers. The 
essential phospholipids purified from soybeans influenced membrane-associated cellular functions 
and showed antioxidant, anti-inflammatory, apoptosis and regenerative, membrane repairing and 
protective, and cell signaling properties both in in vitro and in vivo studies [52]. Therefore, soy 
phospholipids might be considered as a potential therapeutic treatment and/or prevention of chronic 
diseases. 
 
3.1.4. Oligosaccharides 
Soybean oligosaccharides have been approved as potential prebiotic material and a safe 
ingredient by the Food and Drug Administration (FDA) in the US [53]. They have been shown to be a 
potential candidate for prevention/therapy of various diseases such as cancer, atherosclerosis and 
menopausal disorders [54, 55]. Their antioxidative properties have been shown in a rat model of 
myocardium ischemia reperfusion injury. Rats pretreated with soybean oligosaccharides showed a 
reduction in infarct size, and decrease in creatine kinase, aspartate transaminase and lactate 
dehydrogenase levels [55]. Moreover, in rats fed a high fat diet, soybean oligosaccharides were able 
to modify abnormal blood lipid prolife and decrease oxidative stress status [54]. In a clinical study, 
soybean oligosaccharides increased anti-oxidative enzyme activities, reduced malondialdehyde level 
in serum, and alleviated insulin resistance in women with gestational diabetes mellitus [56], suggesting 
that these promising compounds are beneficial to control multiple disease complications.  
 
3.1.5. Anthocyanins 
Anthocyanins are well known antioxidant and anti-inflammatory compounds. Treatment of 
anthocyanins in immortalized epidermal keratinocytes and human neonatal dermal fibroblasts resulted 
in an increase of vascular endothelial growth factor levels and wound healing, whereas 
thrombospondin 1 was decreased, and the translocation of NF-κB (p65) and its phosphorylation were 
inhibited. This data indicated that anthocyanins enhance wound healing, angiogenesis, and exert anti-
inflammatory effects [57]. Recently, dietary anthocyanins supplement was found to reduce the 
expression of cytosolic β-catenin, COX-2 and phospholipase A2 in intestinal mucosa cells, contributing 
to lower the development of intestinal tumors in APC Min/+ mice [58]. The therapeutic effects of 
anthocyanins extracted from black soybean coats have been also shown to participate in the 
suppression of Th17 inflammatory signals, and to retard oxidative stress, and then to inhibit the 
arthritis process in an autoimmune mice model [59]. These findings showed that the anthocyanins’ 
properties might provide support for their application as anti-inflammatory-related diseases agents. 
 
3.2. Protein compounds: protein hydrolyzates, protease inhibitors and lunasin  
In 2006, the American Cancer Society declared that soy-derived foods are excellent dietary 
protein sources and a good alternative to meat proteins [60]. The following section summarizes the 
soy proteins and peptides with antioxidative and anti-inflammatory bioactivities, including their 
mechanisms of action. 
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3.2.1. Protein hydrolyzates 
Several soy-derived peptides and peptide-rich hydrolysates have been demonstrated to exert 
biological activities by both in vivo and in vitro studies. Soy protein hydrolysates prepared by several 
proteases such as alcalase, flavourzyme, trypsin, and papain, have been demonstrated to exert more 
potent antioxidant and anti-inflammatory activities than the intact protein [61]. As an example, glycinin 
and β-conglycinin of soy protein have shown radicals-scavenging activity about 3-5 times higher after 
enzymatic digestion by protease S from Bacillus spp. [62].  
Soybean peptides are involved in the production of anti-inflammatory mediators by intestinal 
epithelial and immune cells, reduce myeloperoxidase activity, increase the suppressor T cells, and 
retardate the tissue damage, suggesting that these peptides might exert benefits against IBD [63, 64]. 
Vernaza and co-workers analyzed the oxidative and inflammatory markers of germinated Brazilian 
soybean protein extracts. The protein hydrolysates produced from those extracts for 18 and 72 hours 
showed a significant inhibition of markers nitric oxide, iNOS, prostaglandin E2 (PGE2), COX-2, and 
TNF-α in RAW 264.7 macrophages stimulated by lipopolysaccharide (LPS), suggesting that 
germination and hydrolysis executed more potential bioactivities compared with original soybean, 
mainly due to the release of bioactive sequences such as RQRK and VIK [65]. Soymilks hydrolyzed by 
pepsin-pancreatin have been shown to inhibit of LPS-induced inflammation in RAW 264.7 cells, 
indicating that soy products might be considered to maintain healthy status under inflammatory stress 
[66]. 
 
3.2.2. Protease inhibitors (BBI and KTI) 
Accumulating evidence has revealed that protease inhibitors found in plant tissues, mainly from 
legumes, act by targeting different enzymes or molecules, being involved in various biological 
processes. The most popular inhibitor, known as Bowman-Birk protease inhibitor (BBI), contains 71 
amino acid residues, was isolated from soybean and characterized by its ability to inhibit trypsin and 
chymotrypsin [67]. Both soybean BBI and its concentrate (BBIC) are nontoxic, safe, and have been 
reported to exert anti-inflammatory and anti-carcinogenic activities by in vitro and in vivo assays [67]. 
BBIC was granted as “Investigational New Drug” status under the FDA policies, and there are several 
completed and ongoing human trials on its properties [68]. Arbogast and co-workers have reported 
that BBIC treatment retarded ROS and serine protease activity in vitro. In addition, animal fed 
supplement with BBIC protected skeletal muscle during prolonged unloading and promoted redox 
homeostasis in muscle fibers [69]. Moreover, oral administration of BBIC and BBI both ameliorated 
inflammation and demyelination in the spinal cord of the treated groups [70, 71]. It has been 
demonstrated the anti-inflammatory and immune regulatory effects of BBI in the experimental 
autoimmune encephalomyelitis model, suggesting that therapeutic effects of BBI against multiple 
sclerosis might be considered [71]. BBI treatment significantly inhibited IL-1β, IL-6, TNF-α and ROS 
productions in LPS-induced macrophages [72]. 
Kunitz trypsin inhibitor (KTI) is another soybean-derived protease inhibitor found to exert anti-
carcinogenesis properties mainly attributed to its ability to inhibit tumor invasion and metastasis [73]. 
Moreover, the suppressive effects have been also shown after intraperitoneal injection or oral 
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administration of this inhibitor in C57BL/6 mice, where a significant reduction of the LPS-induced 
lethality was mediated through inhibition of MAP kinases activation and pro-inflammatory cytokines 
expression [74].  
Accumulating evidence has showed that these protease inhibitors are safe and low cost. Moreover, 
they not only act as anti-proteolytic proteins, but also are good candidates for oral administration 
exerting physiological bioactivities without additional side effects [75, 76].  
 
3.3.3. Lunasin 
Lunasin, SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD, is a 43 amino acid 
peptide firstly identified in soybean in 1999 [77]. Lunasin is resistant to gastrointestinal digestion 
through protection by soybean protease inhibitors, such as BBI and KTI, being bioavailable to reach 
target tissues in an intact and active form [78]. Lunasin is considered as one of the most promising 
naturally agent that has been extensively studied in the last two decades on the basis of its potential 
against chronic diseases, such as cancer, cardiovascular and immunological disorders. 
Hernández-Ledesma and co-workers firstly demonstrated that lunasin exerts antioxidant and anti-
inflammation properties [79], which might contribute on its chemopreventive properties. Lunasin acts 
as a free radical scavenger and an inhibitor of ROS production in active RAW 264.7 cells [79]. 
Moreover, the ability of lunasin to protect human hepatic HepG2 and epithelial intestinal Caco2 cells 
from oxidative stress induced by tert-butylhydroperoxide has been also reported [80, 81]. In Solanum 
nigrum L., purified-lunasin protected DNA oxidation by blocking fenton reaction and then, suppressing 
the generation of hydroxyl radical [82].  
The anti-inflammatory properties of lunasin were initially revealed to be mediated through 
inhibition of pro-inflammatory mediators IL-6, TNF-α, and PGE2 production in RAW 264.7 cells 
stimulated by LPS [79]. Subsequently, blocking signaling pathways of COX-2 and iNOS, and 
suppression of NF-κB pathway have also been demonstrated for this peptide [83, 84]. It has revealed 
that lunasin treatment inhibited the NF-κB-dependent inflammatory mediators through down-regulation 
of Akt phosphorylation and p65 protein expression in human LPS-challenged THP-1 macrophages by 
[85]. These findings indicate that the antioxidant and anti-inflammatory properties of lunasin could 
contribute on its protective effects against several related disorders. 
 
4. Effects of soybean processing on antioxidant activity  
4.1. Fermentation  
A large number of studies have shown that the fermentative activities of different 
microorganisms are not only determinant on the sensorial, technological and nutritional characteristics 
of foods, but also may increase the functional value of natural products. Soybean fermentation has 
presented improved health benefits mainly due to the enhanced content in free isoflavones and 
peptides. Fermented soybean products have been consumed in many Asian countries for centuries. 
They mainly result from the microbial effect of bacteria (Bacillus spp., lactic acid bacteria), fungi 
(Aspergillus spp., Mucor spp., and Rhizopus spp.), or a combined action of both microbes, such as the 
example of the soybean paste termed doenjang [86]. Table 1 summarizes the recent evidence on the 
Table 1. Antioxidant activity of fermented soybean products 
Method of preparation Time 
(h) 
Antioxidant activity 
assays 
Other analysis Antioxidant outcomes Reference 
Soy germ + Aspergillus niger 
M46 
7 d Radical (DPPH, peroxyl, 
hydroxyl, superoxide) 
scavenging 
 
Total polyphenolic 
content 
Total flavonoid 
content 
Flavonoid analysis 
α-amilase and β-
glucosidase activity 
Higher radical scavenging activity compared 
with unfermented soy germ 
β-glucosidase and α-amylase were mainly 
responsible for the mobilization of phenolics 
during fermentation 
[87]  
Soybean + Aspergillus oryzae 
NL 5 
7 d Radical (DPPH) 
scavenging 
Ferric reducing power 
Antioxidant effects in 
hepatoma hepa1c1c7 cells 
Isoflavone analysis Antioxidant activity was proportional to the 
concentration of free isoflavones, and was 
significantly influenced by total isoflavone 
content of soybean variety and fermentation 
period 
[88]  
Soybean + Aspergillus oryzae 5 d Radical (DPPH and ABTS) 
scavenging 
Ferric reducing power 
Antioxidant activity in 
stimulated- HepG2 cells 
Lipid peroxidation and 
antioxidant enzyme 
activities in animals 
Biomarkers gene 
expression 
Protein content 
Isoflavone analysis 
Histopathological 
assays 
Antioxidant and hepatoprotective effects on 
tert-butyl hydroperoxide-induced oxidative 
stress in HepG2 cells and in the rat liver 
[90]  
Soybean fermented paste with 
Aspergillus oryzae 
72  Lipid peroxidation in mice 
Antioxidant enzyme 
activities 
Hepatic glucose 
regulating enzyme 
Diet supplementation of fermented paste 
inhibited oxidative stress via regulation of 
antioxidant enzymes 
[89]  
Black soybean + Rhizopus 
oligosporous NTU-5 
48 Radical (DPPH) 
scavenging 
 
Isoflavone 
quantification 
Polyphenol 
quantification 
Cytotoxicity 
Identification of 
bioactive compounds 
High antioxidant activity that does not 
correspond to total polyphenol or isoflavone 
content 
An unknown compound, FBE5-A, with strong 
antioxidant activity was isolated 
[106]  
Fermented soybean paste 
(Doenjang) with Aspergillus 
oryzae J, Mucor racemosus 15, 
--- Radical (DPPH) 
scavenging 
Nitrite radical scavenging 
Total phenolic 
content 
Tyrosinase inhibitory 
The starter culture Doenjang samples 
demonstrated considerable in vitro antioxidant, 
α-glucosidase inhibitory, and tyrosinase 
[107]  
Mucor racemosus 42, and 
Bacillus subtilis TKSP 24 
Ferric reducing power 
 
activity 
α-glucosidase 
inhibitory activity 
inhibitory effects  
Soybean and soy meal + 
Bacillus natto js-1 
48 Radical (DPPH, 
superoxide) scavenging 
Ferric reducing power 
Lipid peroxidation inhibition 
in rats liver 
Antioxidant enzyme 
activities and 
malondialdehyde in rats 
Total flavonoid 
content 
Inhibition of 
erythrocyte 
haemolysis in rat 
blood 
In vitro and in vivo antioxidant effects of 
fermented soy meal 
[93]  
Soybean + Bacillus subtilis 120 Radical (DPPH) 
scavenging 
Ferric reducing power 
Nitrite scavenging 
Total phenolic 
content 
Total flavonoid 
content 
HPLC of free 
phenolic acid 
Tyrosinase inhibitory 
activity 
Conjugated diene 
inhibitory activity 
Anti-inflammatory 
activity 
Lower antioxidant activity compared to 
fermented sword beans 
[91]  
Soybean + Bacillus subtilis 
MTCC5480 and MTCC1747 
24 Radical (DPPH, 
superoxide) scavenging 
Ferric reducing power 
Total antioxidant activity 
Total phenolic 
content 
Degree of protein 
hydrolysis Protein 
extractability 
Free amino acid 
analysis 
Fermentation increased radical scavenging 
activity, total antioxidant activity and reducing 
power in comparison with unfermented 
soybean Higher degree of protein hydrolysis 
increase in free phenolics and free amino acid 
contents on hydrolysis 
[92]  
Soy whey + Lactobacillus 
plantarum B1-6 
24 Radical (ABTS, hydroxyl, 
superoxide) scavenging 
Ferric reducing power 
Assessment of DNA 
damage 
 
Total phenolic 
content 
Flavonoid analysis 
 
 
Higher antioxidant activity of fermented soy 
whey compared with unfermented samples 
Higher total pehnolic and isoflavone aglycone 
contents 
[108]  
Soybean protein meal + 
Lactobacillus plantarum LP6 
72 Radical (DPPH and 
hydroxyl) scavenging 
Ferric reducing power 
Amino acid 
composition 
Release of antioxidant peptides and amino 
acids by fermentation 
[109]  
Metal chelating 
Soymilk + Lactobacillus 
rhamnosus CRL981 
24 Antioxidant enzyme 
activities in mice 
Biochemical analysis Fermented soymilk significantly decreased 
glucose levels, total cholesterol 
concentrations, triacylglycerols and increase 
antioxidant enzyme activities compared to 
animals that received unfermented soymilk 
[94]  
Soymilk fermented with 
Streptococcus thermophilus 
grx02 
--- Radical (DPPH) 
scavenging 
Lipid peroxidation inhibition 
Reduced glutation content 
and antioxidant enzyme 
activities in mice 
--- In vitro and in vivo antioxidant effects of 
fermented soymilk 
[95]  
Soybeans and derived-products 
(Soy sauce, Cheonggukjang, 
Meju, Doenjang, Makjang) 
--- Radical (DPPH) 
scavenging 
 
Total phenolic 
content 
Total flavonoid 
content 
Protein content 
Other biological 
activities 
Identification of 
bioactive compounds 
Antioxidant activity increased as fermentation 
time increased.  
Total phenolic and protein contents showed 
strong negative correlations with antioxidant 
activity 
[96]  
Fermented soy products --- Radical (DPPH) 
scavenging 
Ferric reducing power 
 
Total phenolic 
content 
Total flavonoid 
content 
Flavonoid analysis 
Amino acid analysis 
Higher antioxidant activity in fermented 
products compared with unfermented samples 
Increase of total phenolics and flavonoid 
during fermentation 
Changes in isoflavone profiles 
Increase of essential amino acids content 
[97]  
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antioxidant effects of fermented soybean products, including the type of fermented preparation, the 
antioxidant properties demonstrated, and the analyses carried out to evaluate the chemo-preventive 
attributes of these food-derived compounds. 
Aspergillus spp. have been widely used in the fermentation of soybean. Sheih and coworkers 
found that the radical 1,1-Diphenyl-2-picryl-hydrazyl, peroxyl, hydroxyl, and superoxide scavenging 
activity of fermented soy germ with Aspergillus niger M46 was higher than that demonstrated for the 
unfermented source [87]. Similarly, it was shown that Aspergillus oryzae NL 5 was able to improve the 
radical scavenging and ferric reducing power and the antioxidant defense systems of liver HepG2 
cells, being these activities directly related to the content of free isoflavones on the soybean fermented 
preparation [88]. Moreover, this Aspergillus specie has proved functionality in in vivo models on 
biological markers at lipid peroxidation and enzymatic antioxidant levels [89, 90]. From a bacterial 
origin, recent studies have reported the potential of Bacillus subtilis to enhance the in vitro anti-radical 
activities of soybean [91], which were related to the increase in free phenolics and amino acids 
contents on fermentation-hydrolyzed products [92]. Similar results have been shown for different lactic 
acid bacteria spp. (Table 1). Moreover, biochemical analysis on the antioxidant profiles of serum and 
liver tissue proved the in vivo protective effects provided by soybean fermentation with Bacillus natto 
js-1 [93], Lactobacillus rhamnosus CRL981 [94], and Streptococcus thermophilus grx02 [95].  
Interestingly, integrative studies have been recently published aiming to connect the 
determination of bioactive phytochemicals and their proved biological effects, related to the 
fermentation process. Chai and coworkers found an enhanced antioxidant radical scavenging activity 
as the fermentation time increased, as well as it was promoted the protein and the total phenolic 
contents [96]. Xu and coworkers also found a higher antioxidant activity, and total phenolic and 
flavonoid contents in commercially fermented soy products marketed in China, compared with the 
unfermented samples [97]. However, these authors hardly established a correlation between 
bioactivities and the observed changes in phytochemicals levels. Therefore, further studies are 
needed to systematically assess the bioactive compounds and antioxidant properties of commercially 
fermented soybean products and to clearly elucidate relationships with the presence of beneficial food 
components. 
 
4.2. Germination and roasting 
 Germination has been recognized as an economical and efficient technology for the 
breakdown of macromolecules, increase of digestibility, and enhancement of nutritive values of 
soybean. Moreover, germinated beans are thought to contain more functional compounds, and also to 
eliminate or reduce anti-nutritional factors by activating the formation of enzymes, showing health 
benefits as compared to non-germinated beans [98]. However, many factors such as the bean cultivar, 
time of germination and soaking, humidity, and temperature might influence the germination process 
and then the contents and composition of nutrients in germinated beans [99]. Furthermore, it has been 
demonstrated that soybean seeds presented increased phenolic amounts correlated with antioxidant 
in vitro activities, when germinated in presence of light as compared to the dark-growth sprouts [100]. 
Combination of germination and fermentation was also an interesting strategy for the production of the 
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soybean paste doenjang, which showed greater antioxidant, and angiotensin converting enzyme- and 
fibrinolytic-inhibitory activities than the regular soybean doenjang [101]. In a systematic review of 
germinated soybean products, it was recently found that the contents of L-ascorbic acid, phenolics, 
isoflavones, and antioxidants were significantly improved by biochemical reactions during germination, 
being 4 days at 25 ºC the recommendation for optimal germination of soybean with additional 
functional values [102]. 
 In food processing, roasting has been used to neutralize the anti-nutritional factors of soybean 
and to provide characteristic sensorial features to the final product. However, few studies have been 
focused on the impact of roasting conditions in the antioxidant properties of soybean. By in vitro 
assays, it has been demonstrated that the contents of isoflavone aglycones, glycosides, total 
phenolics and flavonoids were increased after roasting, ultimately leading to a general improved 
antioxidant capacity [103, 104]. Likewise, these findings were also reported by Kim and coworkers, 
showing further protection through suppressive effects of ROS production in rat PC12 cells stressed 
by H2O2 [105]. 
 
5. Concluding remarks 
Soybean is one of the most cultivated plants in the world and ranked as one of the top sources 
of different functional ingredients, including some excellent proteins and peptides, phospholipids, 
oligosaccharides, phytosterols, along with phytoestrogens like genistein and daidzein. This chapter 
has summarized the evidence on the role played by the antioxidant and anti-inflammatory activity of 
soybean’s compounds as responsible for its protective effects against intestinal and other chronic 
disorders related to oxidative stress and inflammation. Although soybean has been recognized as a 
functional food, there is still a lot to be learned about it and its beneficial properties. More researchs on 
the bioactivities of different soybean compounds and further elucidation of their mechanisms of action 
are needed. In addition, other aspects worthy of research are the bioavailability of those bioactives, 
the possible synergisms among them, and the influence of soybean processing on their biological 
effects.  
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